Título	link	data	tipo	doi	issn	ISSN	Periódico	Qualis	FI (JCR)	H-index	media_citacao_3_anos	Resumo	Categorias	categories
Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients	https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and	29/09/2020	Press release	https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and	-	-	-	-	-	-	-	-	['REGN-COV2']	['REGN-COV2']
Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial	https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery	14/09/2020	Press release	https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery	-	-	-	-	-	-	-	-	['Baricitinibe', 'Remdesivir']	['Baricitinib', 'Remdesivir']
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severerespiratory complications of COVID-19	https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf	16/06/2020	Press release	https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf	-	-	-	-	-	-	-	-	[]	[]
Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19	https://www.businesswire.com/news/home/20200429005424/en/	29/04/2020	Press release	https://www.businesswire.com/news/home/20200429005424/en/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis.	https://www.researchsquare.com/article/rs-119202/v1	12/01/2021	Preprint	https://www.researchsquare.com/article/rs-119202/v1	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Efficacy of propolis as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial.	https://doi.org/10.1101/2021.01.08.20248932	09/01/2021	Preprint	10.1101/2021.01.08.20248932	-	-	-	-	-	-	-	-	['Própolis']	['Propolis']
Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial.	https://doi.org/10.21203/rs.3.rs-139942/v1	08/01/2021	Preprint	10.21203/rs.3.rs-139942/v1	-	-	-	-	-	-	-	-	['Ácido ascórbico']	['Ascorbic acid']
Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.	https://doi.org/10.1101/2020.07.09.20143339	07/08/2020	Preprint	10.1101/2020.07.09.20143339	-	-	-	-	-	-	-	-	['Fluoxetina', 'Fluoxetina', 'Venlafaxina', 'Venlafaxina']	['Fluoxetine', 'Fluoxetine', 'Venlafaxine', 'Venlafaxine']
The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis.	https://doi.org/10.1101/2021.01.04.21249219	05/01/2021	Preprint	10.1101/2021.01.04.21249219	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos.	https://doi.org/10.1101/2021.01.05.21249131	06/01/2021	Preprint	10.1101/2021.01.05.21249131	-	-	-	-	-	-	-	-	['Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin']
Lack of Association of Baseline 25-Hydroxyvitamin D Levels and Cholecalciferol Treatment With Disease Severity and Mortality in Indian Patients Hospitalized for Covid-19.	https://doi.org/10.21203/rs.3.rs-129238/v1	28/12/2020	Preprint	10.21203/rs.3.rs-129238/v1	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Prophylactic use of Hydroxychloroquine among Physicians working in Pandemic Hospitals.	https://doi.org/10.21203/rs.3.rs-107937/v1	16/12/2020	Preprint	10.21203/rs.3.rs-107937/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trials.	https://doi.org/10.1101/2020.12.06.20244798	08/12/2020	Preprint	10.1101/2020.12.06.20244798	-	-	-	-	-	-	-	-	['Dexametasona', 'Dexametasona', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Dexamethasone', 'Dexamethasone', 'Hydroxychloroquine', 'Hydroxychloroquine']
Exposure to Renin-Angiotensin System Inhibitors Is Associated with Reduced Mortality of Older Hypertensive Covid-19 Patients.	https://www.medrxiv.org/content/10.1101/2020.12.15.20247999v1	17/12/2020	Preprint	10.1101/2020.12.15.20247999v1	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Efficacy and Safety of Indomethacin in Covid -19 patients.	https://doi.org/10.1101/2020.12.14.20245266	16/12/2020	Preprint	10.1101/2020.12.14.20245266	-	-	-	-	-	-	-	-	['Indometacina']	['Indomethacin']
A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152.	https://doi.org/10.1101/2020.12.11.20210419	15/12/2020	Preprint	10.1101/2020.12.11.20210419	-	-	-	-	-	-	-	-	['Covaxin']	['Covaxin']
Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States.	https://doi.org/10.1101/2020.12.09.20246579	11/12/2020	Preprint	10.1101/2020.12.09.20246579	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Anticoagulantes']	['Anticoagulants', 'Anticoagulants']
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans.	https://doi.org/10.1101/2020.12.09.20245175	11/12/2020	Preprint	10.1101/2020.12.09.20245175	-	-	-	-	-	-	-	-	['Vacina BNT162', 'Vacina BNT162']	['BNT162 vaccine', 'BNT162 vaccine']
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial.	https://doi.org/10.21203/rs.3.rs-116547/v1	07/12/2020	Preprint	10.21203/rs.3.rs-116547/v1	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Galectin antagonist use in mild cases of SARS-CoV-2 cases; pilot feasibility randomised, open label, controlled trial.	https://doi.org/10.1101/2020.12.03.20238840	09/12/2020	Preprint	10.1101/2020.12.03.20238840	-	-	-	-	-	-	-	-	['Prolactina-M']	['Prolactin-M']
A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial.	https://doi.org/10.1101/2020.12.03.20243709	04/12/2020	Preprint	10.1101/2020.12.03.20243709	-	-	-	-	-	-	-	-	['Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina (SCB-2019)']	['Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine (SCB-2019)']
Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis.	https://doi.org/10.1101/2020.12.03.20239863	04/12/2020	Preprint	10.1101/2020.12.03.20239863	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Convalescent Plasma', 'Convalescent Plasma', 'Convalescent Plasma' ']
Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)	https://doi.org/10.1101/2020.11.22.20236448	24/11/2020	Preprint	10.1101/2020.11.22.20236448	-	-	-	-	-	-	-	-	['Bromexina', 'Bromexina', 'Bromexina', 'Bromexina', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Bromhexine', 'Bromhexine', 'Bromhexine', 'Bromhexine', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.	https://doi.org/10.1101/2020.12.01.20239574	02/12/2020	Preprint	10.1101/2020.12.01.20239574	-	-	-	-	-	-	-	-	['Itolizumabe']	['Itolizumab']
Convalescent Plasma in COVID-19. Mortality-Safety First Results of the Prospective Multicenter FALP 001-2020 Trial.	https://doi.org/10.1101/2020.11.30.20218560	02/12/2020	Preprint	10.1101/2020.11.30.20218560	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19: A Meta-Analysis of 27 Studies and 44,684 Patients.	https://doi.org/10.21203/rs.3.rs-107101/v1	02/12/2020	Preprint	10.21203/rs.3.rs-107101/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Clinical Efficacy of Eucaloric Ketogenic Nutrition in the COVID-19 Cytokine Storm: a Retrospective Analysis of Mortality and ICU Admission.	https://www.researchsquare.com/article/rs-103541/v2	21/11/2020	Preprint	https://www.researchsquare.com/article/rs-103541/v2	-	-	-	-	-	-	-	-	['Dieta eucalórica e cetogênica']	['Eucaloric and ketogenic diet']
The efficacy and safety of hydroxychloroquine in COVID19 patients: a multicenter national retrospective cohort.	https://doi.org/10.1101/2020.11.25.20234914	30/11/2020	Preprint	10.1101/2020.11.25.20234914	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine	https://www.medrxiv.org/content/10.1101/2020.11.26.20239418v1	30/11/2020	Preprint	10.1101/2020.11.26.20239418v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial.	https://doi.org/10.21203/rs.3.rs-109670/v1	24/11/2020	Preprint	10.21203/rs.3.rs-109670/v1	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients.	https://doi.org/10.1101/2020.03.22.20034041	24/03/2020	Preprint	10.1101/2020.03.22.20034041	-	-	-	-	-	-	-	-	['Danoprevir']	['Damageprevir']
Prevention of severe COVID-19 in the elderly by early high-titer plasma.	https://doi.org/10.1101/2020.11.20.20234013	21/11/2020	Preprint	10.1101/2020.11.20.20234013	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente']	['Convalescent Plasma', 'Convalescent Plasma']
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19.	https://doi.org/10.1101/2020.11.19.20234153	20/11/2020	Preprint	10.1101/2020.11.19.20234153	-	-	-	-	-	-	-	-	['Dexametasona', 'Remdesivir']	['Dexamethasone', 'Remdesivir']
5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men.	https://doi.org/10.1101/2020.11.16.20232512	18/11/2020	Preprint	10.1101/2020.11.16.20232512	-	-	-	-	-	-	-	-	['Dutasterida']	['Dutasteride']
Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in 2 Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized 3 Controlled Trial.	https://doi.org/10.1101/2020.11.16.20232397	17/11/2020	Preprint	10.1101/2020.11.16.20232397	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Peginterferon-lambda for the treatment of COVID-19 in outpatients.	https://doi.org/10.1101/2020.11.09.20228098	12/11/2020	Preprint	10.1101/2020.11.09.20228098	-	-	-	-	-	-	-	-	['Interferon', 'Interferon']	['Interferon', 'Interferon']
Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic.	https://doi.org/10.21203/rs.3.rs-100956/v1	01/11/2020	Preprint	10.21203/rs.3.rs-100956/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Ivermectina']	['Hydroxychloroquine', 'Ivermectin']
Vitamin D status and seroconversion for COVID-19 in UK healthcare workers who isolated for COVID-19 like symptoms during the 2020 pandemic.	https://www.medrxiv.org/content/10.1101/2020.10.05.20206706v1	06/10/2020	Preprint	10.1101/2020.10.05.20206706v1	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Mathematical analysis of Córdoba calcifediol trial suggests strong role for Vitamin D in reducing ICU admissions of hospitalized COVID-19 patients.	https://doi.org/10.1101/2020.11.08.20222638	12/11/2020	Preprint	10.1101/2020.11.08.20222638	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Corticosteroids are associated with increased survival in elderly presenting severe SARS-Cov2 infection.	https://doi.org/10.1101/2020.11.10.20226886	13/11/2020	Preprint	10.1101/2020.11.10.20226886	-	-	-	-	-	-	-	-	['Dexametasona', 'Hidrocortisona', 'Prednisolona', 'Prednisona']	['Dexamethasone', 'Hydrocortisone', 'Prednisolone', 'Prednisone']
Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency.	https://www.medrxiv.org/content/10.1101/2020.11.08.20224790v1	10/11/2020	Preprint	10.1101/2020.11.08.20224790v1	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Evaluating the Efficacy of Tocilizumab in Moderate to Severe COVID-19 with Progressive Illness despite Steroids: Identifying the Optimal Timing of its Administration in C3G study.	https://www.medrxiv.org/content/10.1101/2020.11.07.20226837v1	10/11/2020	Preprint	10.1101/2020.11.07.20226837v1	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Reducing the use of empiric antibiotic therapy in patients on admission to the hospital with COVID-19.	https://doi.org/10.21203/rs.3.rs-94854/v1	20/10/2020	Preprint	10.21203/rs.3.rs-94854/v1	-	-	-	-	-	-	-	-	['Amoxicilina', 'Azitromicina', 'Cefdinir', 'Cefepima', 'Ceftriaxona', 'Doxiciclina', 'Levofloxacina', 'Metronidazol', 'Vancomicina']	['Amoxicillin', 'Azithromycin', 'Cefdinir', 'Cefepime', 'Ceftriaxone', 'Doxycycline', 'Levofloxacin', 'Metronidazole', 'Vancomycin']
Repurposing of drugs for Covid-19: asystematic review and meta-analysis	https://www.medrxiv.org/content/10.1101/2020.06.07.20124677v1	09/06/2020	Preprint	10.1101/2020.06.07.20124677v1	-	-	-	-	-	-	-	-	[]	[]
A systematic review of Anakinra, Sarilumab, Siltuximab with meta-analysis of Tocilizumab for Covid-19.	https://doi.org/10.1101/2020.04.23.20076612	06/09/2020	Preprint	10.1101/2020.04.23.20076612	-	-	-	-	-	-	-	-	['Anakinra', 'Anakinra', 'Sarilumabe', 'Sarilumabe', 'Siltuximabe', 'Siltuximabe', 'Tocilizumabe', 'Tocilizumabe']	['Anakinra', 'Anakinra', 'Sarilumab', 'Sarilumab', 'Siltuximab', 'Siltuximab', 'Tocilizumab', 'Tocilizumab']
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study	https://doi.org/10.1101/2020.10.30.20215301	03/11/2020	Preprint	10.1101/2020.10.30.20215301	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy	https://doi.org/10.1101/2020.07.29.20162917	29/10/2020	Preprint	10.1101/2020.07.29.20162917	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With SARS-CoV-2	https://doi.org/10.1101/2020.10.27.20211433	28/10/2020	Preprint	10.1101/2020.10.27.20211433	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study	https://doi.org/10.1101/2020.10.29.20222661	03/11/2020	Preprint	10.1101/2020.10.29.20222661	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Hidroxicloroquina', 'Ivermectina']	['Ascorbic acid', 'Hydroxychloroquine', 'Ivermectin']
The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020	https://doi.org/10.1101/2020.10.29.20222505	03/11/2020	Preprint	10.1101/2020.10.29.20222505	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial.	https://www.medrxiv.org/content/10.1101/2020.10.25.20219337v1.article-info	27/10/2020	Preprint	10.1101/2020.10.25.20219337v1.article-info	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study	https://doi.org/10.21203/rs.3.rs-94509/v1	26/10/2020	Preprint	10.21203/rs.3.rs-94509/v1	-	-	-	-	-	-	-	-	['Zinco']	['Zinc']
Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients	https://doi.org/10.1101/2020.11.01.20223958	04/11/2020	Preprint	10.1101/2020.11.01.20223958	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
The Role of Vitamin D in The Age of COVID-19: A Systematic Review and Meta-Analysis	https://doi.org/10.1101/2020.06.05.20123554	26/10/2020	Preprint	10.1101/2020.06.05.20123554	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)']
Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers	https://doi.org/10.1101/2020.08.17.254375	21/08/2020	Preprint	10.1101/2020.08.17.254375	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Phase II Clinical trial for Evaluation of BCG as potential therapy for COVID-19	https://doi.org/10.1101/2020.10.28.20221630	03/11/2020	Preprint	10.1101/2020.10.28.20221630	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Safety, Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis	https://doi.org/10.1101/2020.11.03.20224998	04/11/2020	Preprint	10.1101/2020.11.03.20224998	-	-	-	-	-	-	-	-	['Ad5-nCoV', 'CoronaVac', 'Vacina BNT162', 'Vacina de vírus inativado', 'Vacina NVX-CoV2373']	['Ad5-nCoV', 'CoronaVac', 'BNT162 vaccine', 'Inactivated virus vaccine', 'NVX-CoV2373 vaccine']
Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients	https://doi.org/10.21203/rs.3.rs-52778/v2	10/08/2020	Preprint	10.21203/rs.3.rs-52778/v2	-	-	-	-	-	-	-	-	['Ácido ascórbico']	['Ascorbic acid']
Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia	https://doi.org/10.1101/2020.10.21.20210203	23/10/2020	Preprint	10.1101/2020.10.21.20210203	-	-	-	-	-	-	-	-	['Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial	https://doi.org/10.1101/2020.10.21.20217208	23/10/2020	Preprint	10.1101/2020.10.21.20217208	-	-	-	-	-	-	-	-	['Nitazoxanida']	['Nitazoxanide']
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management	https://doi.org/10.1101/2020.07.07.20145979	08/07/2020	Preprint	10.1101/2020.07.07.20145979	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin']
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq	https://doi.org/10.1101/2020.10.26.20219345	27/10/2020	Preprint	10.1101/2020.10.26.20219345	-	-	-	-	-	-	-	-	['Doxiciclina', 'Ivermectina']	['Doxycycline', 'Ivermectin']
Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial	https://www.researchgate.net/publication/344877090_Hydroxychloroquine_nitazoxanide_and_ivermectin_have_similar_effects_in_early_COVID-19_-_a_head-to-head_comparison_of_the_Pre-AndroCoV_Trial	26/10/2020	Preprint	https://www.researchgate.net/publication/344877090_Hydroxychloroquine_nitazoxanide_and_ivermectin_have_similar_effects_in_early_COVID-19_-_a_head-to-head_comparison_of_the_Pre-AndroCoV_Trial	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Ivermectina', 'Nitazoxanida']	['Hydroxychloroquine', 'Ivermectin', 'Nitazoxanide']
Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population	https://doi.org/10.1101/2020.10.26.20219154	27/10/2020	Preprint	10.1101/2020.10.26.20219154	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina']	['Corticosteroids', 'Hydroxychloroquine']
Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study	https://doi.org/10.1101/2020.10.23.20218172	27/10/2020	Preprint	10.1101/2020.10.23.20218172	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
Intravenous Mesenchymal Stem Cells in Extracorporeal Oxygenation Patients with Severe COVID-19 Acute Respiratory Distress Syndrome	https://doi.org/10.1101/2020.10.15.20122523	20/10/2020	Preprint	10.1101/2020.10.15.20122523	-	-	-	-	-	-	-	-	['Terapia celular']	['Cell Therapy']
Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial	https://doi.org/10.1101/2020.10.15.20213553	21/10/2020	Preprint	10.1101/2020.10.15.20213553	-	-	-	-	-	-	-	-	['Terapia celular']	['Cell Therapy']
Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial	https://doi.org/10.21203/rs.3.rs-91430/v1	19/10/2020	Preprint	10.21203/rs.3.rs-91430/v1	-	-	-	-	-	-	-	-	['Umifenovir']	['Umifenovir']
Large population study identifies drugs associated with reduced COVID-19 severity	https://doi.org/10.1101/2020.10.13.20211953	18/10/2020	Preprint	10.1101/2020.10.13.20211953	-	-	-	-	-	-	-	-	['Ezetimiba', 'Flecainida', 'Rosuvastatina', 'Ubiquinona']	['Ezetimibe', 'Flecainide', 'Rosuvastatin', 'Ubiquinone']
Tocilizumab is associated with reduction in inflammation and improvement in P/F ratio in critically sick COVID19 patients	https://www.medrxiv.org/content/10.1101/2020.10.20.20210195v1	21/10/2020	Preprint	10.1101/2020.10.20.20210195v1	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Pharmacological treatment for patients with coronavirus disease 2019: systematic review of randomized controlled trials	https://doi.org/10.21203/rs.3.rs-90401/v1	09/10/2020	Preprint	10.21203/rs.3.rs-90401/v1	-	-	-	-	-	-	-	-	['Dexametasona', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Dexamethasone', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results	https://doi.org/10.1101/2020.10.15.20209817	15/10/2020	Preprint	10.1101/2020.10.15.20209817	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Interferon beta', 'Interferon beta' , 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Interferon beta', 'Lopinavir', 'Lopinavir', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir' , 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', ' Ritonavir', 'Ritonavir', 'Ritonavir']
Melatonin is significantly associated with survival of intubated COVID-19 patients	https://doi.org/10.1101/2020.10.15.20213546	18/10/2020	Preprint	10.1101/2020.10.15.20213546	-	-	-	-	-	-	-	-	['Melatonina']	['Melatonin']
A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19	https://doi.org/10.1101/2020.10.19.20214940	21/10/2020	Preprint	10.1101/2020.10.19.20214940	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY	https://doi.org/10.1101/2020.10.16.20214130	20/10/2020	Preprint	10.1101/2020.10.16.20214130	-	-	-	-	-	-	-	-	['Antagonista de β-adrenérgico', 'Anticoagulantes', 'Corticosteroides', 'Hidroxicloroquina', 'Remdesivir']	['β-Adrenergic Antagonist', 'Anticoagulants', 'Corticosteroids', 'Hydroxychloroquine', 'Remdesivir']
Tocilizumab in Treatment of Severe COVID-19 Patients: A Systematic Review and Meta-Analysis of Cohort Studies	https://www.authorea.com/doi/full/10.22541/au.160071232.27950965	21/09/2020	Preprint	10.22541/au.160071232.27950965	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Enoxaparin is associated with lower rates of thrombosis, kidney injury, and mortality than Unfractionated Heparin in hospitalized COVID patients	https://doi.org/10.1101/2020.10.06.20208025	11/10/2020	Preprint	10.1101/2020.10.06.20208025	-	-	-	-	-	-	-	-	['Enoxaparina', 'Heparina']	['Enoxaparin', 'Heparin']
Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19	https://doi.org/10.1101/2020.07.20.20147769	26/07/2020	Preprint	10.1101/2020.07.20.20147769	-	-	-	-	-	-	-	-	['Enoxaparina', 'Heparina']	['Enoxaparin', 'Heparin']
Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia	https://doi.org/10.1101/2020.10.08.20202606	09/10/2020	Preprint	10.1101/2020.10.08.20202606	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Montelukast in Hospitalized Patients Diagnosed with COVID-19	https://doi.org/10.21203/rs.3.rs-52430/v1	05/08/2020	Preprint	10.21203/rs.3.rs-52430/v1	-	-	-	-	-	-	-	-	['Montelucaste']	['Montelukast']
COVID-19: Ivermectin prophylaxis in adult contacts. Report on First Cases of Prophylaxis for Healthcare Personnel and PostExposure Prophylaxis	http://dx.doi.org/10.13140/RG.2.2.11985.35680/2	31/07/2020	Preprint	10.13140/RG.2.2.11985.35680/2	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients	https://doi.org/10.1101/2020.10.03.20206375	06/10/2020	Preprint	10.1101/2020.10.03.20206375	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru	https://doi.org/10.1101/2020.10.06.20208066	08/10/2020	Preprint	10.1101/2020.10.06.20208066	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin']
Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving the Partial Pressure of Arterial Oxygen and Fraction of Inspired Oxygen Ratio among COVID-19	https://doi.org/10.1101/2020.10.06.20171579	08/10/2020	Preprint	10.1101/2020.10.06.20171579	-	-	-	-	-	-	-	-	['Dexametasona', 'Prednisona']	['Dexamethasone', 'Prednisone']
An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial	https://doi.org/10.1101/2020.10.05.20206870	06/10/2020	Preprint	10.1101/2020.10.05.20206870	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Espironolactona', 'Espironolactona', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Ivermectina', 'Ivermectina', 'Nitazoxanida', 'Nitazoxanida']	['Azithromycin', 'Azithromycin', 'Spironolactone', 'Spironolactone', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Ivermectin', 'Ivermectin', 'Nitazoxanide', 'Nitazoxanide']
Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial)	https://www.researchsquare.com/article/rs-88952/v1	08/10/2020	Preprint	https://www.researchsquare.com/article/rs-88952/v1	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Dutasterida', 'Dutasterida', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Ivermectina', 'Ivermectina', 'Nitazoxanida', 'Nitazoxanida']	['Azithromycin', 'Azithromycin', 'Dutasteride', 'Dutasteride', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Ivermectin', 'Ivermectin', 'Nitazoxanide', 'Nitazoxanide']
Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19	https://doi.org/10.1101/2020.10.06.20207092	08/10/2020	Preprint	10.1101/2020.10.06.20207092	-	-	-	-	-	-	-	-	['Azitromicina', 'Betaferon', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Betaferon', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Anakinra After Corticosteroid and/or Tocilizumab Treatment in Patients with Severe COVID-19 Pneumonia and Moderate Hyperinflammation. A Retrospective Cohort Study	https://doi.org/10.21203/rs.3.rs-88775/v1	09/10/2020	Preprint	10.21203/rs.3.rs-88775/v1	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies	https://doi.org/10.1101/2020.08.20.20178699	23/09/2020	Preprint	10.1101/2020.08.20.20178699	-	-	-	-	-	-	-	-	['Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Convalescent plasma treatment of severe COVID-19: A matched control study	https://doi.org/10.1101/2020.05.20.20102236	12/06/2020	Preprint	10.1101/2020.05.20.20102236	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality	https://doi.org/10.1101/2020.10.02.20206029	05/10/2020	Preprint	10.1101/2020.10.02.20206029	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19	https://doi.org/10.1101/2020.04.24.20077735	29/04/2020	Preprint	10.1101/2020.04.24.20077735	-	-	-	-	-	-	-	-	['Novaferon']	['Novaferon']
Hydroxychloroquine as Post-Exposure Prophylaxis for Covid-19: Why simple data analysis can lead to the wrong conclusions from well-designed studies	https://www.researchgate.net/publication/344369617_Hydroxychloroquine_as_Post-Exposure_Prophylaxis_for_Covid-19_Why_simple_data_analysis_can_lead_to_the_wrong_conclusions_from_well-designed_studies	24/09/2020	Preprint	https://www.researchgate.net/publication/344369617_Hydroxychloroquine_as_Post-Exposure_Prophylaxis_for_Covid-19_Why_simple_data_analysis_can_lead_to_the_wrong_conclusions_from_well-designed_studies	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers - a Retrospective cohort	https://doi.org/10.1101/2020.06.09.20116806	01/10/2020	Preprint	10.1101/2020.06.09.20116806	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital	https://doi.org/10.1101/2020.09.25.20199562	06/10/2020	Preprint	10.1101/2020.09.25.20199562	-	-	-	-	-	-	-	-	['Glutationa', 'Inosina', 'Potássio']	['Glutathione', 'Inosine', 'Potassium']
A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far?	https://doi.org/10.21203/rs.3.rs-83677/v1	29/09/2020	Preprint	10.21203/rs.3.rs-83677/v1	-	-	-	-	-	-	-	-	['Favipiravir', 'Hidroxicloroquina']	['Favipiravir', 'Hydroxychloroquine']
Corticosteroid pulses for hospitalized patients with COVID-19: Effects on mortality and in-hospital stay	https://doi.org/10.1101/2020.09.30.20204719	05/10/2020	Preprint	10.1101/2020.09.30.20204719	-	-	-	-	-	-	-	-	['Corticosteroides', 'Prednisona']	['Corticosteroids', 'Prednisone']
Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments	https://www.medrxiv.org/content/10.1101/2020.08.13.20174060v1	14/08/2020	Preprint	10.1101/2020.08.13.20174060v1	-	-	-	-	-	-	-	-	['Cloroquina', 'Corticosteroides', 'Danoprevir', 'Favipiravir', 'Hidroxicloroquina', 'Imunoglobulina', 'Lopinavir', 'Meplazumabe', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Chloroquine', 'Corticosteroids', 'Danoprevir', 'Favipiravir', 'Hydroxychloroquine', 'Immunoglobulin', 'Lopinavir', 'Meplazumab', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', ' Umifenovir']
Impact of tocilizumab administration on mortality in severe COVID-19	https://doi.org/10.1101/2020.07.30.20114959	02/08/2020	Preprint	10.1101/2020.07.30.20114959	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial	https://doi.org/10.21203/rs.3.rs-68403/v1	10/09/2020	Preprint	10.21203/rs.3.rs-68403/v1	-	-	-	-	-	-	-	-	['Solução salina eletrolisada']	['Electrolyzed saline solution']
Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized	https://doi.org/10.21203/rs.3.rs-66909/v1	09/09/2020	Preprint	10.21203/rs.3.rs-66909/v1	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients	https://doi.org/10.21203/rs.3.rs-38896/v1	14/07/2020	Preprint	10.21203/rs.3.rs-38896/v1	-	-	-	-	-	-	-	-	['Azitromicina', 'Doxiciclina', 'Hidroxicloroquina', 'Ivermectina']	['Azithromycin', 'Doxycycline', 'Hydroxychloroquine', 'Ivermectin']
Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients	https://doi.org/10.21203/rs.3.rs-65224/v1	31/08/2020	Preprint	10.21203/rs.3.rs-65224/v1	-	-	-	-	-	-	-	-	['Interferon supercomposto recombinante (rSIFN-co)']	['Recombinant supercompound interferon (rSIFN-co)']
Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial	https://doi.org/10.1101/2020.07.30.20165365	04/08/2020	Preprint	10.1101/2020.07.30.20165365	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis	https://doi.org/10.1101/2020.09.30.20204693	30/09/2020	Preprint	10.1101/2020.09.30.20204693	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19	https://doi.org/10.1101/2020.09.29.20203869	01/10/2020	Preprint	10.1101/2020.09.29.20203869	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-analysis	https://doi.org/10.1101/2020.09.28.20203463	30/09/2020	Preprint	10.1101/2020.09.28.20203463	-	-	-	-	-	-	-	-	['Famotidina']	['Famotidine']
The Impact of Colchicine on The COVID-19 Patients: A Clinical Trial Study	https://doi.org/10.21203/rs.3.rs-69374/v1	21/09/2020	Preprint	10.21203/rs.3.rs-69374/v1	-	-	-	-	-	-	-	-	['Colchicina']	['Colchicine']
Pulmonary radiological change of COVID-19 patients with 99mTc-MDP treatment	https://doi.org/10.1101/2020.04.07.20054767	14/04/2020	Preprint	10.1101/2020.04.07.20054767	-	-	-	-	-	-	-	-	['Radiofármaco (99mTc-MDP)']	['Radiopharmaceutical (99mTc-MDP)']
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial	https://doi.org/10.1101/2020.09.23.20199604	25/09/2020	Preprint	10.1101/2020.09.23.20199604	-	-	-	-	-	-	-	-	['Vacina', 'Vacina', 'Vacina']	['Vaccine', 'Vaccine', 'Vaccine']
High-dose vitamin C infusion for the treatment ofcritically ill COVID-19	https://doi.org/10.21203/rs.3.rs-52778/v1	10/08/2020	Preprint	10.21203/rs.3.rs-52778/v1	-	-	-	-	-	-	-	-	[]	[]
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia	https://doi.org/10.1101/2020.08.27.20183442	12/09/2020	Preprint	10.1101/2020.08.27.20183442	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial	https://doi.org/10.1101/2020.09.17.20196212	18/09/2020	Preprint	10.1101/2020.09.17.20196212	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Pentoxifylline and Covid-19: A Systematic Review	https://www.medrxiv.org/content/10.1101/2020.09.14.20194381v1	18/09/2020	Preprint	10.1101/2020.09.14.20194381v1	-	-	-	-	-	-	-	-	['Pentoxifilina', 'Pentoxifilina']	['Pentoxifylline', 'Pentoxifylline']
The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: A randomised placebo-controlled double-blind clinical trial	https://www.researchsquare.com/article/rs-40899/v2	04/09/2020	Preprint	https://www.researchsquare.com/article/rs-40899/v2	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial	https://doi.org/10.1101/2020.09.18.20197327	21/09/2020	Preprint	10.1101/2020.09.18.20197327	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial	https://www.researchsquare.com/article/rs-72132/v1	21/09/2020	Preprint	https://www.researchsquare.com/article/rs-72132/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients	https://doi.org/10.1101/2020.09.23.20199463	24/09/2020	Preprint	10.1101/2020.09.23.20199463	-	-	-	-	-	-	-	-	['Famotidina']	['Famotidine']
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.	https://doi.org/10.1101/2020.09.16.20194571	18/08/2020	Preprint	10.1101/2020.09.16.20194571	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', ' Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine' , 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine']
Clinical Outcomes and Plasma Concentrations 1 of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial	https://doi.org/10.1101/2020.04.29.20085761	05/05/2020	Preprint	10.1101/2020.04.29.20085761	-	-	-	-	-	-	-	-	['Baloxavir marboxil', 'Favipiravir']	['Baloxavir marboxil', 'Favipiravir']
Effect of Arbidol on COVID-19: A Randomized Controlled Trial	https://doi.org/10.21203/rs.3.rs-78316/v1	16/09/2020	Preprint	10.21203/rs.3.rs-78316/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Combination of Tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: A spanish, multicenter, cohorty study	https://doi.org/10.1101/2020.09.07.20189357	10/09/2020	Preprint	10.1101/2020.09.07.20189357	-	-	-	-	-	-	-	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']
Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses	https://doi.org/10.1101/2020.09.03.20187526	10/09/2020	Preprint	10.1101/2020.09.03.20187526	-	-	-	-	-	-	-	-	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in Baghdad, Iraq	https://doi.org/10.1101/2020.06.24.20121905	30/06/2020	Preprint	10.1101/2020.06.24.20121905	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19	https://doi.org/10.1101/2020.09.10.20191619	15/09/2020	Preprint	10.1101/2020.09.10.20191619	-	-	-	-	-	-	-	-	['Ácido acetilsalicílico', 'Dexametasona', 'Enoxaparina', 'Ivermectina']	['Acetylsalicylic acid', 'Dexamethasone', 'Enoxaparin', 'Ivermectin']
Early viral clearance among COVID-19 patients when gargling with Povidone-iodine and essential oils – a clinical trial	https://doi.org/10.1101/2020.09.07.20180448	09/09/2020	Preprint	10.1101/2020.09.07.20180448	-	-	-	-	-	-	-	-	['Iodopovidona']	['povidone iodine']
The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study	https://doi.org/10.1101/2020.09.09.20184143	13/09/2020	Preprint	10.1101/2020.09.09.20184143	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study	https://doi.org/10.1101/2020.09.04.20187781	09/09/2020	Preprint	10.1101/2020.09.04.20187781	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.	https://doi.org/10.1101/2020.09.03.20187112	15/09/2020	Preprint	10.1101/2020.09.03.20187112	-	-	-	-	-	-	-	-	['CIGB-325 (Peptídeo anti-CK2)']	['CIGB-325 (Anti-CK2 Peptide)']
Role of Drugs used for chronic disease management on Susceptibility and Severity of COVID-19: A Large Case-Control Study	https://www.medrxiv.org/content/10.1101/2020.04.24.20077875v2	07/09/2020	Preprint	10.1101/2020.04.24.20077875v2	-	-	-	-	-	-	-	-	['Anti-hipertensivos', 'Antidiabéticos', 'Corticosteroides']	['Anti-hypertensives', 'Antidiabetics', 'Corticosteroids']
Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19	https://doi.org/10.1101/2020.09.10.20191486	15/09/2020	Preprint	10.1101/2020.09.10.20191486	-	-	-	-	-	-	-	-	['CPI-006']	['CPI-006']
The link between vitamin D deficiency and Covid-19 in a large population	https://doi.org/10.1101/2020.09.04.20188268	07/09/2020	Preprint	10.1101/2020.09.04.20188268	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Beneficial and Harmful Outcomes of Tocilizumab in Severe COVID-19:A Systematic Review and Meta-Analysis	https://doi.org/10.1101/2020.09.05.20188912	08/09/2020	Preprint	10.1101/2020.09.05.20188912	-	-	-	-	-	-	-	-	[]	[]
Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis	https://doi.org/10.1101/2020.07.10.20150680	03/09/2020	Preprint	10.1101/2020.07.10.20150680	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy	https://doi.org/10.1101/2020.07.29.20162917	10/09/2020	Preprint	10.1101/2020.07.29.20162917	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)	https://doi.org/10.1101/2020.09.03.20187252	08/09/2020	Preprint	10.1101/2020.09.03.20187252	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Convalescent plasma as potential therapy for severe COVID-19 pneumonia	https://doi.org/10.1101/2020.09.01.20184390	07/09/2020	Preprint	10.1101/2020.09.01.20184390	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis	https://doi.org/10.1101/2020.09.03.20187393	04/09/2020	Preprint	10.1101/2020.09.03.20187393	-	-	-	-	-	-	-	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
COVID-19 mortality risk factors in older people in a long-term care center	https://doi.org/10.21203/rs.3.rs-70219/v1	02/09/2020	Preprint	10.21203/rs.3.rs-70219/v1	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Hydroxychloroquine is Effective and Safe for the Treatment of COVID-19, and May be Universally Effective When Used Early Before Hospitalization: A Systematic Review	https://www.palmerfoundation.com.au/hydroxychloroquine-is-effective-and-safe-for-the-treatment-of-covid-19-and-may-be-universally-effective-when-used-early-before-hospitalization-a-systematic-review/	04/09/2020	Preprint	https://www.palmerfoundation.com.au/hydroxychloroquine-is-effective-and-safe-for-the-treatment-of-covid-19-and-may-be-universally-effective-when-used-early-before-hospitalization-a-systematic-review/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients	https://doi.org/10.1101/2020.09.03.20158121	09/09/2020	Preprint	10.1101/2020.09.03.20158121	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Hydroxicloroquine for pre-exposure prophylaxis for SARS-CoV-2	https://doi.org/10.1101/2020.08.31.20185314	02/09/2020	Preprint	10.1101/2020.08.31.20185314	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia	https://doi.org/10.1101/2020.08.30.20182451	01/08/2020	Preprint	10.1101/2020.08.30.20182451	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three Month Experience	https://doi.org/10.1101/2020.08.12.20169359	12/08/2020	Preprint	10.1101/2020.08.12.20169359	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial	https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v2	01/09/2020	Preprint	10.1101/2020.08.26.20182444v2	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
A COVID-19 vaccine candidate 1 using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses	https://doi.org/10.1101/2020.08.31.275701	31/08/2020	Preprint	10.1101/2020.08.31.275701	-	-	-	-	-	-	-	-	['Vacina RBD-SpyVLP']	['RBD-SpyVLP vaccine']
Immune response to vaccine candidates based on different types of nanoscaffolded RBD domain of the SARS-CoV-2 spike protein	https://doi.org/10.1101/2020.08.28.244269	28/08/2020	Preprint	10.1101/2020.08.28.244269	-	-	-	-	-	-	-	-	['Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2', 'Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2', 'Diferentes estruturas de proteínas de ligação ao receceptor (ACE2) do SARS-CoV-2']	['Different structures of receptor-binding proteins (ACE2) of SARS-CoV-2', 'Different structures of receptor-binding proteins (ACE2) of SARS-CoV-2', 'Different structures of receptor-binding proteins (ACE2) of SARS-CoV-2']
Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis	http://medrxiv.org/content/early/2020/08/25/2020.08.24.20180638.abstract	25/08/2020	Preprint	http://medrxiv.org/content/early/2020/08/25/2020.08.24.20180638.abstract	-	-	-	-	-	-	-	-	['Antibióticos', 'Antivirais', 'Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Imunoglobulina', 'Interferon', 'Terapia de substituição renal', 'Tocilizumabe']	['Antibiotics', 'Antivirals', 'Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Immunoglobulin', 'Interferon', 'Kidney Replacement Therapy', 'Tocilizumab']
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study	https://doi.org/10.1101/2020.08.20.20178772	25/08/2020	Preprint	10.1101/2020.08.20.20178772	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study	https://doi.org/10.1101/2020.08.17.20176651	20/08/2020	Preprint	10.1101/2020.08.17.20176651	-	-	-	-	-	-	-	-	['Vacina de RNA']	['RNA vaccine']
An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2	https://doi.org/10.1101/2020.08.19.258244	20/08/2020	Preprint	10.1101/2020.08.19.258244	-	-	-	-	-	-	-	-	['Vacina C-Vac']	['C-Vac vaccine']
Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: randomized clinical trial, in vitro and in silico preliminary evidences	https://doi.org/10.1101/2020.08.11.244996	17/08/2020	Preprint	10.1101/2020.08.11.244996	-	-	-	-	-	-	-	-	['Lactoferrina']	['Lactoferrin']
Anti-C5a antibody (IFX-1) treatment of severe Covid-19: an exploratory phase 2 randomized controlled trial	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3658226	30/07/2020	Preprint	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3658226	-	-	-	-	-	-	-	-	['Vilobelimabe']	['Vilobelimab']
OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?	http://medrxiv.org/content/early/2020/08/14/2020.08.12.20171405.abstract	12/08/2020	Preprint	http://medrxiv.org/content/early/2020/08/14/2020.08.12.20171405.abstract	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine	https://www.medrxiv.org/content/10.1101/2020.08.14.20173369v1.article-info	15/08/2020	Preprint	10.1101/2020.08.14.20173369v1.article-info	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study	https://doi.org/10.1101/2020.08.11.20167353	14/08/2020	Preprint	10.1101/2020.08.11.20167353	-	-	-	-	-	-	-	-	['Acetato de icatibanto', 'Inibidor de C1 esterase/calicreína']	['Icatibant acetate', 'C1 esterase/kallikrein inhibitor']
Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach	https://doi.org/10.1101/2020.08.01.20166678	04/08/2020	Preprint	10.1101/2020.08.01.20166678	-	-	-	-	-	-	-	-	['Aprepitanto']	['Aprepitant']
Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience	https://doi.org/10.1101/2020.08.05.20151027	11/08/2020	Preprint	10.1101/2020.08.05.20151027	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report	https://doi.org/10.1101/2020.08.04.20167205	13/08/2020	Preprint	10.1101/2020.08.04.20167205	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists']
Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial	https://doi.org/10.1101/2020.08.06.20169573	12/08/2020	Preprint	10.1101/2020.08.06.20169573	-	-	-	-	-	-	-	-	['Azitromicina', 'Colchicina', 'Hidroxicloroquina', 'Prednisona']	['Azithromycin', 'Colchicine', 'Hydroxychloroquine', 'Prednisone']
Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis	http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172189.abstract	11/08/2020	Preprint	http://medrxiv.org/content/early/2020/08/11/2020.08.10.20172189.abstract	-	-	-	-	-	-	-	-	['Inibidores de Janus Kinase (JAK)', 'Interferon recombinante tipo 1']	['Janus Kinase (JAK) Inhibitors', 'Recombinant Interferon Type 1']
Effectiveness of booster BCG vaccination in preventing Covid-19 infection	https://doi.org/10.1101/2020.08.10.20172288	11/08/2020	Preprint	10.1101/2020.08.10.20172288	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial	http://dx.doi.org/10.1101/2020.07.31.20161216	10/08/2020	Preprint	10.1101/2020.07.31.20161216	-	-	-	-	-	-	-	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Avoiding COVID-19 complications with diabetic patients could be achieved by multi-dose Bacillus Calmette–Guérin vaccine: A case study of beta cells regeneration by serendipity	https://www.preprints.org/manuscript/202004.0134/v1	09/04/2020	Preprint	https://www.preprints.org/manuscript/202004.0134/v1	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine	http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168435.abstract	06/08/2020	Preprint	http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168435.abstract	-	-	-	-	-	-	-	-	['Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Vaccine NVX-CoV2373', 'Vaccine NVX-CoV2373']
Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery	https://doi.org/10.1101/2020.07.28.20157974	04/08/2020	Preprint	10.1101/2020.07.28.20157974	-	-	-	-	-	-	-	-	['Interferon alfa']	['Interferon alpha']
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19	https://doi.org/10.1101/2020.07.20.20157503	26/07/2020	Preprint	10.1101/2020.07.20.20157503	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS?	http://medrxiv.org/content/early/2020/07/28/2020.07.22.20154542.abstract	22/07/2020	Preprint	http://medrxiv.org/content/early/2020/07/28/2020.07.22.20154542.abstract	-	-	-	-	-	-	-	-	['Tetraciclinas']	['Tetracyclines']
Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA	https://doi.org/10.1101/2020.07.29.20164251	29/07/2020	Preprint	10.1101/2020.07.29.20164251	-	-	-	-	-	-	-	-	['Interferon alfa', 'Interferon gama']	['Interferon alpha', 'Interferon gamma']
Efficacy and tolerability of bevacizumab 2 in patients with severe Covid -19	https://doi.org/10.1101/2020.07.26.20159756	29/07/2020	Preprint	10.1101/2020.07.26.20159756	-	-	-	-	-	-	-	-	['Bevacizumabe', 'Bevacizumabe', 'Bevacizumabe']	['Bevacizumab', 'Bevacizumab', 'Bevacizumab']
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19	https://doi.org/10.1101/2020.07.24.20153833	30/07/2020	Preprint	10.1101/2020.07.24.20153833	-	-	-	-	-	-	-	-	['Itolizumabe']	['Itolizumab']
Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial	https://doi.org/10.1101/2020.07.20.20157891	25/07/2020	Preprint	10.1101/2020.07.20.20157891	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease	https://doi.org/10.1101/2020.07.20.20157651	26/07/2020	Preprint	10.1101/2020.07.20.20157651	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic	https://doi.org/10.1101/2020.07.29.20164277	30/07/2020	Preprint	10.1101/2020.07.29.20164277	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
A meta-review of systematic reviews and an updated metaanalysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection	https://www.medrxiv.org/content/10.1101/2020.07.28.20164012v1	30/07/2020	Preprint	10.1101/2020.07.28.20164012v1	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)	https://doi.org/10.1101/2020.07.21.20151423	29/07/2020	Preprint	10.1101/2020.07.21.20151423	-	-	-	-	-	-	-	-	['Cobre', 'Resveratrol']	['Copper', 'Resveratrol']
Association between NSAIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: A nationwide study	http://medrxiv.org/content/early/2020/06/16/2020.06.01.20119768.abstract	02/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/16/2020.06.01.20119768.abstract	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Effectiveness and Safety of Chloroquine or hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis	https://doi.org/10.1101/2020.07.25.20162073	28/07/2020	Preprint	10.1101/2020.07.25.20162073	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
COVID-19 Severity in Europe and the USA: Could the Seasonal Influenza Vaccination Play a Role?	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3621446	16/06/2020	Preprint	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3621446	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']
Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine	https://doi.org/10.1101/2020.07.17.20140533	20/07/2020	Preprint	10.1101/2020.07.17.20140533	-	-	-	-	-	-	-	-	['Vacina de RNA', 'Vacina de RNA']	['RNA vaccine', 'RNA vaccine']
Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US	https://doi.org/10.1101/2020.07.22.20159855	24/07/2020	Preprint	10.1101/2020.07.22.20159855	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
ISARIC Clinical Data Report 8 June 2020	https://www.medrxiv.org/content/10.1101/2020.07.17.20155218v1	25/07/2020	Preprint	10.1101/2020.07.17.20155218v1	-	-	-	-	-	-	-	-	['Agentes anti-interleucinas', 'Agentes anti-interleucinas', 'Antibióticos', 'Antibióticos', 'Antifúngicos', 'Antifúngicos', 'Antivirais', 'Antivirais', 'Corticosteroides', 'Corticosteroides', 'Inotrópicos', 'Inotrópicos', 'Plasma convalescente', 'Plasma convalescente']	['Anti-interleukin agents', 'Anti-interleukin agents', 'Antibiotics', 'Antibiotics', 'Antifungals', 'Antifungals', 'Antivirals', 'Antivirals', 'Corticosteroids', 'Corticosteroids', 'Inotropics' , 'Inotropics', 'Convalescent Plasma', 'Convalescent Plasma']
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study	https://doi.org/10.1101/2020.07.20.20156398	26/07/2020	Preprint	10.1101/2020.07.20.20156398	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Second Week Methyl-Prednisolone Pulses Improve Prognosis In Patients With Severe Coronavirus Disease 2019 Pneumonia: An Observational Comparative Study Using Routine Care Data.	https://doi.org/10.1101/2020.07.16.20152868	23/07/2020	Preprint	10.1101/2020.07.16.20152868	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid	https://doi.org/10.1101/2020.07.17.20155960	21/07/2020	Preprint	10.1101/2020.07.17.20155960	-	-	-	-	-	-	-	-	['Azitromicina', 'Ceftriaxona', 'Dexametasona', 'Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Oseltamivir', 'Prednisona', 'Ritonavir']	['Azithromycin', 'Ceftriaxone', 'Dexamethasone', 'Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Oseltamivir', 'Prednisone', 'Ritonavir']
Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study	https://doi.org/10.1101/2020.07.18.20157008	21/07/2020	Preprint	10.1101/2020.07.18.20157008	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Do low TB prevalence or lack of BCG Vaccination Contribute to Emergence Multisystem Inflammatory Syndrome?	https://doi.org/10.1101/2020.07.18.20156893	21/07/2020	Preprint	10.1101/2020.07.18.20156893	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study	https://doi.org/10.1101/2020.07.13.20149328	15/07/2020	Preprint	10.1101/2020.07.13.20149328	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial	https://doi.org/10.1101/2020.07.15.20151852	16/07/2020	Preprint	10.1101/2020.07.15.20151852	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Treatment response to hydroxychloroquine and antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea	https://doi.org/10.1101/2020.07.04.20146548	07/07/2020	Preprint	10.1101/2020.07.04.20146548	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)	https://doi.org/10.1101/2020.07.08.20148841	10/07/2020	Preprint	10.1101/2020.07.08.20148841	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Addition of Tocilizumab to standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis	https://doi.org/10.1101/2020.07.10.20150680	11/07/2020	Preprint	10.1101/2020.07.10.20150680	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab	https://doi.org/10.1007/s15010-020-01476-7	08/07/2020	Preprint	10.1007/s15010-020-01476-7	-	-	-	-	-	-	-	-	['Baricitinibe']	['Baricitinib']
Association between angiotensin-converting enzyme inhibitors and angiotensin II 2 receptor blockers use and the risk of infection and clinical outcome of COVID-19: a 3 comprehensive systematic review and meta-analysis	https://doi.org/10.1101/2020.07.02.20144717	03/07/2020	Preprint	10.1101/2020.07.02.20144717	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review	https://doi.org/10.1101/2020.05.29.20116483	07/07/2020	Preprint	10.1101/2020.05.29.20116483	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations	https://doi.org/10.1101/2020.07.05.20146878	07/07/2020	Preprint	10.1101/2020.07.05.20146878	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Tocilizumabe']	['Hydroxychloroquine', 'Lopinavir', 'Tocilizumab']
COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes	https://doi.org/10.1101/2020.04.20.20072421	24/04/2020	Preprint	10.1101/2020.04.20.20072421	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Strong Correlation Between Prevalence of Severe Vitamin D Deficiency and Population Mortality Rate from COVID-19 in Europe	https://doi.org/10.1101/2020.06.24.20138644	01/07/2020	Preprint	10.1101/2020.06.24.20138644	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities	http://medrxiv.org/content/early/2020/05/22/2020.05.18.20066902.abstract	22/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/22/2020.05.18.20066902.abstract	-	-	-	-	-	-	-	-	['Doxiciclina', 'Hidroxicloroquina']	['Doxycycline', 'Hydroxychloroquine']
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France	https://doi.org/10.1101/2020.06.16.20132597	19/06/2020	Preprint	10.1101/2020.06.16.20132597	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies	https://doi.org/10.1101/2020.06.17.20133884	19/06/2020	Preprint	10.1101/2020.06.17.20133884	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials	http://medrxiv.org/content/early/2020/06/29/2020.06.22.20136531.abstract	29/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/29/2020.06.22.20136531.abstract	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multicenter Observational Study	https://doi.org/10.1101/2020.06.24.20133249	01/07/2020	Preprint	10.1101/2020.06.24.20133249	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19	https://doi.org/10.1101/2020.06.30.20143289	03/07/2020	Preprint	10.1101/2020.06.30.20143289	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study	https://www.preprints.org/manuscript/202005.0057/v2	05/05/2020	Preprint	https://www.preprints.org/manuscript/202005.0057/v2	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19	https://www.preprints.org/manuscript/202005.0486/v1	31/05/2020	Preprint	https://www.preprints.org/manuscript/202005.0486/v1	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Convalescent Plasma for COVID-19. A randomized clinical trial	https://doi.org/10.1101/2020.07.01.20139857	03/07/2020	Preprint	10.1101/2020.07.01.20139857	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia	https://doi.org/10.1101/2020.06.08.20125369	14/07/2020	Preprint	10.1101/2020.06.08.20125369	-	-	-	-	-	-	-	-	['Lenzilumabe']	['Lenzilumab']
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report	https://doi.org/10.1101/2020.06.30.20142570	01/07/2020	Preprint	10.1101/2020.06.30.20142570	-	-	-	-	-	-	-	-	['Vacina de RNA', 'Vacina de RNA']	['RNA vaccine', 'RNA vaccine']
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection	http://medrxiv.org/content/early/2020/06/29/2020.06.26.20056507.abstract	29/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/29/2020.06.26.20056507.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19	https://doi.org/10.1101/2020.06.06.20124461	10/06/2020	Preprint	10.1101/2020.06.06.20124461	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Influenza Vaccination and COVID19 Mortality in the USA	https://doi.org/10.1101/2020.06.24.201298177	26/06/2020	Preprint	10.1101/2020.06.24.201298177	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']
The Association Between the Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of Covid-19 Confirmed Cases and Deaths in the United States: Geospatial Study	https://doi.org/10.1101/2020.05.31.20118802	20/06/2020	Preprint	10.1101/2020.05.31.20118802	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study	http://medrxiv.org/content/early/2020/06/12/2020.06.11.20125849.abstract	12/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/12/2020.06.11.20125849.abstract	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists']
Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest	https://doi.org/10.1101/2020.06.19.20135830	22/06/2020	Preprint	10.1101/2020.06.19.20135830	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia	https://doi.org/10.1101/2020.06.17.20134031	25/06/2020	Preprint	10.1101/2020.06.17.20134031	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Tocilizumab for treatment of mechanically ventilated patients with COVID-19	https://doi.org/10.1101/2020.05.29.20117358	03/06/2020	Preprint	10.1101/2020.05.29.20117358	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Observational Study of Metformin and Risk of Mortality in Persons Hospitalized with Covid-19	https://doi.org/10.1101/2020.06.19.20135095	01/06/2020	Preprint	10.1101/2020.06.19.20135095	-	-	-	-	-	-	-	-	['Metformina']	['Metformin']
Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report	http://medrxiv.org/content/early/2020/06/22/2020.06.22.20137273.abstract	22/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/22/2020.06.22.20137273.abstract	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
Pre exposure Hydroxychloroquine Prophylaxis for COVID-19 in healthcare workers: a retrospective cohort	https://doi.org/10.1101/2020.06.09.20116806	12/06/2020	Preprint	10.1101/2020.06.09.20116806	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis	http://atm.amegroups.com/article/view/43126/html	08/05/2020	Preprint	http://atm.amegroups.com/article/view/43126/html	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a primary care population.	https://doi.org/10.1101/2020.06.19.20135475	20/06/2020	Preprint	10.1101/2020.06.19.20135475	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study.	https://doi.org/10.1093/qjmed/hcaa206	19/06/2020	Preprint	10.1093/qjmed/hcaa206	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study.	http://medrxiv.org/content/early/2020/06/22/2020.06.19.20136093.abstract	22/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/22/2020.06.19.20136093.abstract	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Clozapine treatment and risk of COVID-19.	http://medrxiv.org/content/early/2020/06/20/2020.06.17.20133595.abstract	20/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/20/2020.06.17.20133595.abstract	-	-	-	-	-	-	-	-	['Clozapina']	['Clozapine']
Effect of hydroxychloroquine on SARS-CoV-2 viral load in patients with COVID-19.	https://doi.org/10.1101/2020.06.16.20133066	19/06/2020	Preprint	10.1101/2020.06.16.20133066	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.	https://doi.org/10.1101/2020.06.16.20133298	19/06/2020	Preprint	10.1101/2020.06.16.20133298	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia.	https://doi.org/10.1101/2020.06.17.20133579	18/06/2020	Preprint	10.1101/2020.06.17.20133579	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review.	http://medrxiv.org/content/early/2020/06/16/2020.06.15.20131227.abstract	16/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/16/2020.06.15.20131227.abstract	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late.	https://doi.org/10.1101/2020.06.13.20130088	16/06/2020	Preprint	10.1101/2020.06.13.20130088	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Explore the Possible Impact of BCG Vaccination Policy on the Morbidity, Mortality, and Recovery Rates due to COVID-19 Infection.	https://doi.org/10.1101/2020.06.14.20131268	16/06/2020	Preprint	10.1101/2020.06.14.20131268	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Hydroxychloroquine-Induced Stevens-Johnson Syndrome in COVID-19: A rare Case Report.	https://www.researchsquare.com/article/rs-26196/v1	01/05/2020	Preprint	https://www.researchsquare.com/article/rs-26196/v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A 78-year Old Urothelial Cancer Patient with Faster Recovery from COVID-19: Potential Benefit from Adjuvant Active Immunotherapy.	https://ssrn.com/abstract=3609259	04/06/2020	Preprint	https://ssrn.com/abstract=3609259	-	-	-	-	-	-	-	-	['OncoTherad']	['OncoTherad']
Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review.	https://doi.org/10.1101/2020.05.29.20116483	30/05/2020	Preprint	10.1101/2020.05.29.20116483	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study.	http://medrxiv.org/content/early/2020/06/09/2020.06.06.20122341.abstract	09/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/09/2020.06.06.20122341.abstract	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience.	https://doi.org/10.1101/2020.05.29.20109199	09/06/2020	Preprint	10.1101/2020.05.29.20109199	-	-	-	-	-	-	-	-	['Interferon alfa']	['Interferon alpha']
Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study.	https://doi.org/10.1101/2020.06.08.20125245	09/06/2020	Preprint	10.1101/2020.06.08.20125245	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs tested positive for SARS-CoV-2: a danish nationwide cohort study.	https://doi.org/10.1101/2020.06.08.20115683	09/06/2020	Preprint	10.1101/2020.06.08.20115683	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.	http://medrxiv.org/content/early/2020/06/08/2020.06.05.20122622.abstract	08/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/08/2020.06.05.20122622.abstract	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Association of Vitamin D Deficiency and Treatment with COVID-19 Incidence.	https://doi.org/10.1101/2020.05.08.20095893	13/05/2020	Preprint	10.1101/2020.05.08.20095893	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Tobaiqy M, Helmi N, Majrashi M, Majrashi M, Al-Dahery S, Mujallad A. COVID-19 therapeutics outcome: systematic review and data analysis. Research Square. 2020. Disponível em: https://doi.org/10.21203/rs.3.rs-33391/v1	https://doi.org/10.21203/rs.3.rs-33391/v1	05/06/2020	Preprint	10.21203/rs.3.rs-33391/v1	-	-	-	-	-	-	-	-	['Azitromicina', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Moxifloxacina', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Azithromycin', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Moxifloxacin', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis.	https://doi.org/10.1101/2020.05.02.20088872	08/06/2020	Preprint	10.1101/2020.05.02.20088872	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Association of Renin-Angiotensin-Aldosterone System Inhibition with Risk of COVID-19, Inflammation Level, Severity and Death in Patients With COVID-19: A Rapid Systematic Review and Meta-Analysis.	https://doi.org/10.1101/2020.05.20.20108399	08/06/2020	Preprint	10.1101/2020.05.20.20108399	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis.	http://medrxiv.org/content/early/2020/06/08/2020.06.03.20120261.abstract	08/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/08/2020.06.03.20120261.abstract	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A shred of evidence that BCG vaccine may protect against COVID-19: Comparing cohorts in Spain and Italy.	http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123539.abstract	07/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123539.abstract	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Tocilizumab is associated with reduced risk of ICU admission and mortality in patients with SARS-CoV-2 infection.	https://doi.org/10.1101/2020.06.05.20113738	05/06/2020	Preprint	10.1101/2020.06.05.20113738	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries.	http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121624.abstract	05/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121624.abstract	-	-	-	-	-	-	-	-	['Vacina BCG', 'Vacina BCG', 'Vacina influenza', 'Vacina influenza', 'Vacina pneumocócica', 'Vacina pneumocócica']	['BCG vaccine', 'BCG vaccine', 'Influenza vaccine', 'Influenza vaccine', 'Pneumococcal vaccine', 'Pneumococcal vaccine']
Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117994v2	01/06/2020	Preprint	10.1101/2020.06.03.20117994v2	-	-	-	-	-	-	-	-	['Ozonioterapia']	['Ozone Therapy']
Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study.	https://doi.org/10.1101/2020.05.29.20114223	02/06/2020	Preprint	10.1101/2020.05.29.20114223	-	-	-	-	-	-	-	-	['Leflunomida']	['Leflunomide']
A SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP TREATMENTS FOR COVID-19.	http://medrxiv.org/content/early/2020/06/02/2020.05.27.20115238.abstract	02/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/02/2020.05.27.20115238.abstract	-	-	-	-	-	-	-	-	['Favipiravir', 'Hidroxicloroquina', 'Lopinavir', 'Meplazumabe', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Favipiravir', 'Hydroxychloroquine', 'Lopinavir', 'Meplazumab', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials.	http://medrxiv.org/content/early/2020/06/01/2020.06.01.20118901.abstract	01/06/2020	Preprint	http://medrxiv.org/content/early/2020/06/01/2020.06.01.20118901.abstract	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a 2 retrospective cohort study	https://doi.org/10.1101/2020.05.18.20105650	22/05/2020	Preprint	10.1101/2020.05.18.20105650	-	-	-	-	-	-	-	-	[]	[]
Impact of glucocorticoid treatment in Sars-CoV-2 infection mortality: a retrospective controlled Cohort Study	https://doi.org/10.1101/2020.05.22.20110544	26/05/2020	Preprint	10.1101/2020.05.22.20110544	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Renin-angiotensin-aldosterone system inhibitors and mortality in patients with hypertension hospitalized for COVID19: systematic review &meta-analysis	https://doi.org/10.1101/2020.05.21.20107003	26/05/2020	Preprint	10.1101/2020.05.21.20107003	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis	https://doi.org/10.1101/2020.05.24.20111799	26/05/2020	Preprint	10.1101/2020.05.24.20111799	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Use of inhibitors of the renin angiotensin system and COVID-19 prognosis: a systematic review and meta-analysis	http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106799.abstract	26/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106799.abstract	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study	http://medrxiv.org/content/early/2020/05/25/2020.05.21.20109207.abstract	21/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/25/2020.05.21.20109207.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis	https://doi.org/10.1101/2020.05.20.20103804	22/05/2020	Preprint	10.1101/2020.05.20.20103804	-	-	-	-	-	-	-	-	['Antibióticos', 'Antivirais', 'Corticosteroides', 'Oxigenoterapia']	['Antibiotics', 'Antivirals', 'Corticosteroids', 'Oxygen Therapy']
A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2	http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108365.abstract	20/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108365.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', ' Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab' ]
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques	http://biorxiv.org/content/early/2020/05/13/2020.05.13.093195	13/05/2020	Preprint	http://biorxiv.org/content/early/2020/05/13/2020.05.13.093195	-	-	-	-	-	-	-	-	['Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 Vaccine', 'ChAdOx1 nCoV-19 Vaccine']
Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients	http://medrxiv.org/content/early/2020/05/21/2020.05.19.20106971	21/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/21/2020.05.19.20106971	-	-	-	-	-	-	-	-	['Inibidores da BRAF', 'Inibidores da MEK', 'Inibidores de PD-1']	['BRAF inhibitors', 'MEK inhibitors', 'PD-1 inhibitors']
Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically 2 ventilated COVID-19 patients: A case series	https://doi.org/10.1101/2020.05.13.20087734	15/05/2020	Preprint	10.1101/2020.05.13.20087734	-	-	-	-	-	-	-	-	['Albuterol', 'Dornase alfa']	['Albuterol', 'Dornase alpha']
Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea	https://doi.org/10.1101/2020.05.13.20094193	18/05/2020	Preprint	10.1101/2020.05.13.20094193	-	-	-	-	-	-	-	-	['Antibióticos', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Antibiotics', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients	https://doi.org/10.1101/2020.05.02.20080036	08/05/2020	Preprint	10.1101/2020.05.02.20080036	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Zinc']
Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study	https://www.medrxiv.org/content/10.1101/2020.05.14.20099234v1	18/05/2020	Preprint	10.1101/2020.05.14.20099234v1	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Sarilumab use in severe SARS-CoV-2 pneumonia	http://medrxiv.org/content/early/2020/05/18/2020.05.14.20094144.abstract	18/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/18/2020.05.14.20094144.abstract	-	-	-	-	-	-	-	-	['Sarilumabe']	['Sarilumab']
Hydroxychloroquine in COVID-19: A systematic review and meta-analysis	https://doi.org/10.1101/2020.05.14.20101774	19/05/2020	Preprint	10.1101/2020.05.14.20101774	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration	https://www.medrxiv.org/content/10.1101/2020.05.13.20100081v1	13/05/2020	Preprint	10.1101/2020.05.13.20100081v1	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients	https://doi.org/10.1101/2020.05.12.20099879	14/05/2020	Preprint	10.1101/2020.05.12.20099879	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust	https://doi.org/10.1101/2020.04.07.20056788	11/04/2020	Preprint	10.1101/2020.04.07.20056788	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in COVID-19	http://medrxiv.org/content/early/2020/05/12/2020.05.07.20093831.abstract	12/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/12/2020.05.07.20093831.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-making	https://doi.org/10.1101/2020.05.07.20093989	12/05/2020	Preprint	10.1101/2020.05.07.20093989	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Steroid-responsive encephalitis in Covid-19 disease	http://medrxiv.org/content/early/2020/05/09/2020.04.12.20062646.abstract	17/04/2020	Preprint	http://medrxiv.org/content/early/2020/05/09/2020.04.12.20062646.abstract	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender	https://www.medrxiv.org/content/10.1101/2020.03.26.20040709v1	27/04/2020	Preprint	10.1101/2020.03.26.20040709v1	-	-	-	-	-	-	-	-	['Anticorpo IgG']	['IgG antibody']
The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19	https://doi.org/10.1101/2020.05.05.20091785	09/05/2020	Preprint	10.1101/2020.05.05.20091785	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Does BCG protect against SARS-CoV-2 infection ?: elements of proof	https://doi.org/10.1101/2020.05.01.20087437	06/05/2020	Preprint	10.1101/2020.05.01.20087437	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective?	https://doi.org/10.1101/2020.05.01.20087411	06/05/2020	Preprint	10.1101/2020.05.01.20087411	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Evidence Supports a Causal Model for Vitamin D in COVID-19 Outcomes	http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087965.abstract	06/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087965.abstract	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)']
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs	https://www.medrxiv.org/content/10.1101/2020.04.30.20086090v1	05/05/2020	Preprint	10.1101/2020.04.30.20086090v1	-	-	-	-	-	-	-	-	['Abatacept', 'Adalimumabe', 'Anakinra', 'Baricitinibe', 'Certolizumabe Pegol', 'Etanercepte', 'Golimumabe', 'Infliximabe', 'Inibidores da fosfodiesterase-4', 'Ixequizumab', 'Ruxolitinibe', 'Sarilumabe', 'Secuquinumabe', 'Tocilizumabe', 'Tofacitinibe', 'Ustekinumabe']	['Abatacept', 'Adalimumab', 'Anakinra', 'Baricitinib', 'Certolizumab Pegol', 'Etanercept', 'Golimumab', 'Infliximab', 'Phosphodiesterase-4 inhibitors', 'Ixequizumab', 'Ruxolitinib', 'Sarilumab', 'Secukinumab', 'Tocilizumab', 'Tofacitinib', 'Ustekinumab']
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study	https://doi.org/10.1101/2020.04.27.20082180	02/05/2020	Preprint	10.1101/2020.04.27.20082180	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Ocular toxicity and Hydroxychloroquine: A Rapid Meta-Analysis	http://medrxiv.org/content/early/2020/05/03/2020.04.28.20083378	12/05/2020	Preprint	http://medrxiv.org/content/early/2020/05/03/2020.04.28.20083378	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study	https://www.medrxiv.org/content/10.1101/2020.04.25.20079079v1	29/04/2020	Preprint	10.1101/2020.04.25.20079079v1	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir', 'Umifenovir']	['Lopinavir', 'Ritonavir', 'Umifenovir']
The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis	https://doi.org/10.1101/2020.04.23.20076661	28/04/2020	Preprint	10.1101/2020.04.23.20076661	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections	https://doi.org/10.1101/2020.04.23.20076612	26/04/2020	Preprint	10.1101/2020.04.23.20076612	-	-	-	-	-	-	-	-	['Anakinra', 'Inibidores de interleucina-6']	['Anakinra', 'Interleukin-6 Inhibitors']
Intravenous Immunoglobulin of COVID-19 Effectiveness of Intravenous Immunoglobulin for Children with Severe COVID-19: A Rapid Review	https://doi.org/10.1101/2020.04.17.20064444	22/04/2020	Preprint	10.1101/2020.04.17.20064444	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis	https://doi.org/10.1101/2020.04.17.20069773	22/04/2020	Preprint	10.1101/2020.04.17.20069773	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Hydroxychloroquine for the management of COVID-19: Hope or Hype? A Systematic review of the current evidence	http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068205.abstract	22/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068205.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases	https://www.biorxiv.org/content/10.1101/2020.04.21.053017v2	21/04/2020	Preprint	https://www.biorxiv.org/content/10.1101/2020.04.21.053017v2	-	-	-	-	-	-	-	-	['Enisamium']	['Enisamium']
A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2	http://biorxiv.org/content/early/2020/04/21/2020.04.10.036335.1	12/04/2020	Preprint	http://biorxiv.org/content/early/2020/04/21/2020.04.10.036335.1	-	-	-	-	-	-	-	-	['Silenciadores de RNA', 'Silenciadores de RNA']	['RNA silencers', 'RNA silencers']
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease	https://doi.org/10.1101/2020.04.20.051581	20/04/2020	Preprint	10.1101/2020.04.20.051581	-	-	-	-	-	-	-	-	['Inibidores de protease']	['Protease inhibitors']
Heparin therapy improving hypoxia in COVID-19 patients - a case series	https://doi.org/10.1101/2020.04.15.20067017	20/04/2020	Preprint	10.1101/2020.04.15.20067017	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019（COVID-19).	http://medrxiv.org/content/early/2020/04/21/2020.04.15.20066266.abstract	15/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/21/2020.04.15.20066266.abstract	-	-	-	-	-	-	-	-	['Ácido alfa lipóico']	['Alpha lipoic acid']
Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis	https://www.biorxiv.org/content/10.1101/2020.04.20.051557v1	20/04/2020	Preprint	https://www.biorxiv.org/content/10.1101/2020.04.20.051557v1	-	-	-	-	-	-	-	-	['Vacina contra SARS-CoV-2']	['SARS-CoV-2 vaccine']
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19	https://doi.org/10.1101/2020.04.16.20065920	21/04/2020	Preprint	10.1101/2020.04.16.20065920	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Rapid development of an inactivated vaccine for SARS-CoV-2	https://doi.org/10.1101/2020.04.17.046375	19/04/2020	Preprint	10.1101/2020.04.17.046375	-	-	-	-	-	-	-	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis	https://doi.org/10.1101/2020.04.13.20064436	17/04/2020	Preprint	10.1101/2020.04.13.20064436	-	-	-	-	-	-	-	-	['Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Umifenovir', 'Umifenovir', 'Umifenovir']	['Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', ' Umifenovir', 'Umifenovir', 'Umifenovir']
Steroid-responsive severe encephalopathy in SARS-CoV-2 infection	https://doi.org/10.1101/2020.04.12.20062646	17/04/2020	Preprint	10.1101/2020.04.12.20062646	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2	http://biorxiv.org/content/early/2020/04/15/2020.04.15.043166	15/04/2020	Preprint	http://biorxiv.org/content/early/2020/04/15/2020.04.15.043166	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
The FDA-approved gold drug Auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells	http://biorxiv.org/content/early/2020/04/15/2020.04.14.041228	14/04/2020	Preprint	http://biorxiv.org/content/early/2020/04/15/2020.04.14.041228	-	-	-	-	-	-	-	-	['Auranofina']	['Auranofin']
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A multicenter retrospective cohort study	http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061739	11/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061739	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial	http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060558.abstract	10/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060558.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial	https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1	10/04/2020	Preprint	10.1101/2020.04.10.20060699v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Currently available intravenous immunoglobulin (Gamunex®-C and Flebogamma® DIF) contains antibodies reacting against SARS-CoV-2 antigens	https://doi.org/10.1101/2020.04.07.029017	10/04/2020	Preprint	10.1101/2020.04.07.029017	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro	http://biorxiv.org/content/early/2020/04/09/2020.04.07.028589.abstract	07/04/2020	Preprint	http://biorxiv.org/content/early/2020/04/09/2020.04.07.028589.abstract	-	-	-	-	-	-	-	-	['Merimepodib']	['Merimepodib']
Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression	http://medrxiv.org/content/early/2020/04/11/2020.04.06.20054890.abstract	06/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/11/2020.04.06.20054890.abstract	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust	https://doi.org/10.1101/2020.04.07.20056788	11/04/2020	Preprint	10.1101/2020.04.07.20056788	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis	https://doi.org/10.1101/2020.04.08.20057539	10/04/2020	Preprint	10.1101/2020.04.08.20057539	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Cloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Interferon alfa', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Angiotensin II Receptor Antagonists', 'Chloroquine', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Interferon alpha', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Interferon-α2b treatment for COVID-19	https://doi.org/10.1101/2020.04.06.20042580	10/04/2020	Preprint	10.1101/2020.04.06.20042580	-	-	-	-	-	-	-	-	['Interferon alfa', 'Interferon alfa', 'Interferon alfa']	['Interferon alpha', 'Interferon alpha', 'Interferon alpha']
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical	https://doi.org/10.1101/2020.03.17.20037432	20/03/2020	Preprint	10.1101/2020.03.17.20037432	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
COVID-19 infection during pregnancy: A systematic review to summarize possible symptoms, treatments, and pregnancy outcomes	https://doi.org/10.1101/2020.03.31.20049304	03/04/2020	Preprint	10.1101/2020.03.31.20049304	-	-	-	-	-	-	-	-	['Antibióticos', 'Antibióticos', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Oxigenoterapia', 'Oxigenoterapia']	['Antibiotics', 'Antibiotics', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Oxygen Therapy', 'Oxygen Therapy']
BCG protects against COVID-19? A word of caution	http://medrxiv.org/content/early/2020/04/11/2020.04.09.20056903.abstract	09/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/11/2020.04.09.20056903.abstract	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences	https://doi.org/10.1101/2020.04.07.20056440	11/04/2020	Preprint	10.1101/2020.04.07.20056440	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Human monoclonal antibodies block the binding of SARS CoV 2 spike protein	https://doi.org/10.1101/2020.04.06.20055475	11/04/2020	Preprint	10.1101/2020.04.06.20055475	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population	https://www.medrxiv.org/content/10.1101/2020.04.08.20057893v1	10/04/2020	Preprint	10.1101/2020.04.08.20057893v1	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study	https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v2	10/04/2020	Preprint	10.1101/2020.04.08.20054551v2	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study)	https://doi.org/10.1101/2020.04.07.20056424	11/04/2020	Preprint	10.1101/2020.04.07.20056424	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review	https://www.medrxiv.org/content/10.1101/2020.03.22.20040964v2	27/03/2020	Preprint	10.1101/2020.03.22.20040964v2	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Differential COVID-19-attributable mortality and BCG vaccine use in countries	http://medrxiv.org/content/early/2020/04/06/2020.04.01.20049478.abstract	01/01/2020	Preprint	http://medrxiv.org/content/early/2020/04/06/2020.04.01.20049478.abstract	-	-	-	-	-	-	-	-	['Vacina BCG', 'Vacina BCG']	['BCG vaccine', 'BCG vaccine']
Association of BCG vaccination policy with prevalence and mortality of COVID-19	https://doi.org/10.1101/2020.03.30.20048165	06/04/2020	Preprint	10.1101/2020.03.30.20048165	-	-	-	-	-	-	-	-	['Vacina BCG', 'Vacina BCG']	['BCG vaccine', 'BCG vaccine']
Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome	https://www.medrxiv.org/content/10.1101/2020.04.02.20051565v2	01/01/2020	Preprint	10.1101/2020.04.02.20051565v2	-	-	-	-	-	-	-	-	['Doxazosina', 'Prazosina', 'Silodosina', 'Tansulosina', 'Terazosina']	['Doxazosin', 'Prazosin', 'Silodosin', 'Tansulosin', 'Terazosin']
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial	https://doi.org/10.1101/2020.03.22.20040758	30/03/2020	Preprint	10.1101/2020.03.22.20040758	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Lack of Antiviral Activity of Darunavir against SARS-CoV-2	https://doi.org/10.1101/2020.04.03.20052548	08/04/2020	Preprint	10.1101/2020.04.03.20052548	-	-	-	-	-	-	-	-	['Darunavir']	['Darunavir']
Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking	https://www.medrxiv.org/content/10.1101/2020.04.05.20054254v2	07/04/2020	Preprint	10.1101/2020.04.05.20054254v2	-	-	-	-	-	-	-	-	['Amprenavir', 'Atazanavir', 'Darunavir', 'Fosamprenavir', 'Indinavir', 'Lopinavir', 'Paritaprevir', 'Ritonavir', 'Saquinavir', 'Tipranavir']	['Amprenavir', 'Atazanavir', 'Darunavir', 'Fosamprenavir', 'Indinavir', 'Lopinavir', 'Paritaprevir', 'Ritonavir', 'Saquinavir', 'Tipranavir']
Kamal MA, Helmi N. Therapeutic Management of COVID-19 Patients: A systematic review	https://www.medrxiv.org/content/10.1101/2020.04.02.20051029v1	06/04/2020	Preprint	10.1101/2020.04.02.20051029v1	-	-	-	-	-	-	-	-	['Corticosteroides', 'Lopinavir', 'Moxifloxacina', 'Oseltamivir', 'Ritonavir', 'Tigeciclina', 'Umifenovir']	['Corticosteroids', 'Lopinavir', 'Moxifloxacin', 'Oseltamivir', 'Ritonavir', 'Tigecycline', 'Umifenovir']
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support	https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v1?versioned=true	03/04/2020	Preprint	10.1101/2020.04.01.20048561v1?versioned=true	-	-	-	-	-	-	-	-	['Siltuximabe']	['Siltuximab']
The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin	http://medrxiv.org/content/early/2020/04/03/2020.04.02.20047050.abstract	03/04/2020	Preprint	http://medrxiv.org/content/early/2020/04/03/2020.04.02.20047050.abstract	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis	https://doi.org/10.1101/2020.03.30.20048058	03/04/2020	Preprint	10.1101/2020.03.30.20048058	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Clinical features, Diagnosis, and Treatment of COVID-19: A systematic review of case reports and case series	https://doi.org/10.1101/2020.03.28.20046151	03/04/2020	Preprint	10.1101/2020.03.28.20046151	-	-	-	-	-	-	-	-	['Lopinavir', 'Lopinavir', 'Meropenem', 'Meropenem', 'Moxifloxacina', 'Moxifloxacina', 'Oseltamivir', 'Oseltamivir', 'Umifenovir', 'Umifenovir']	['Lopinavir', 'Lopinavir', 'Meropenem', 'Meropenem', 'Moxifloxacin', 'Moxifloxacin', 'Oseltamivir', 'Oseltamivir', 'Umifenovir', 'Umifenovir']
DEVELOPMENT OF A HYPERIMMUNE EQUINE SERUM THERAPY FOR COVID-19 IN ARGENTINA	http://www.medicinabuenosaires.com/PMID/32658841.pdf	26/06/2020	Estudo pré-clínico	http://www.medicinabuenosaires.com/PMID/32658841.pdf	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2	https://doi.org/10.1016/j.cell.2020.08.026	19/08/2020	Estudo pré-clínico	10.1016/j.cell.2020.08.026	0092-8674	00928674	CELL (CAMBRIDGE)	A1	25.716	814	42.41	-	['Vacina ChAd-SARS-CoV-2-S']	['ChAd-SARS-CoV-2-S vaccine']
Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients’ characteristics: a review of the literature and simulations	https://www.tandfonline.com/doi/full/10.1080/00498254.2020.1824301	16/09/2020	Estudo pré-clínico	10.1080/00498254.2020.1824301	0049-8254	00498254	XENOBIOTICA (LONDON. PRINT)	B1	0.403	82	1.83	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine’s Prophylactic Effect Against Infection With SARS-CoV-2	https://www.frontiersin.org/articles/10.3389/fmed.2020.00490/full	13/08/2020	Estudo pré-clínico	10.3389/fmed.2020.00490/full	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge	https://doi.org/10.1038/s41467-020-17972-1	14/08/2020	Estudo pré-clínico	10.1038/s41467-020-17972-1	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.	['Ad5-nCoV']	['Ad5-nCoV']
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques	https://www.nature.com/articles/s41467-020-18077-5.pdf?origin=ppub	21/08/2020	Estudo pré-clínico	https://www.nature.com/articles/s41467-020-18077-5.pdf?origin=ppub	-	-	-	-	-	-	-	-	['Vacina de adenovírus']	['Adenovirus vaccine']
A Thermostable mRNA Vaccine against COVID-19	https://doi.org/10.1016/j.cell.2020.07.024	23/07/2020	Estudo pré-clínico	10.1016/j.cell.2020.07.024	0092-8674	00928674	CELL (CAMBRIDGE)	A1	25.716	814	42.41	-	['Vacina mRNA-LNP']	['mRNA-LNP vaccine']
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19	https://doi.org/10.1038/s41541-020-00221-3	27/07/2020	Estudo pré-clínico	10.1038/s41541-020-00221-3	2059-0105	20590105	npj Vaccines	-	2.953	30	8.19	 Abstract Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.	['Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 vaccine']
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice	https://doi.org/10.1016/j.immuni.2020.07.019	30/07/2020	Estudo pré-clínico	10.1016/j.immuni.2020.07.019	1074-7613	10747613	IMMUNITY (CAMBRIDGE, MASS.)	A1	14.075	417	26.14	-	['Vacina mRNA-LNP', 'Vacina mRNA-LNP', 'Vacina mRNA-LNP', 'Vacina mRNA-LNP']	['mRNA-LNP vaccine', 'mRNA-LNP vaccine', 'mRNA-LNP vaccine', 'mRNA-LNP vaccine']
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques	https://doi.org/10.1038/s41586-020-2607-z	30/07/2020	Estudo pré-clínico	10.1038/s41586-020-2607-z	0028-0836	00280836	NATURE (LONDON)	A1	17.897	1276	19.35	-	['Vacina (Ad26.COV2.S)', 'Vacina (Ad26.COV2.S)']	['Vaccine (Ad26.COV2.S)', 'Vaccine (Ad26.COV2.S)']
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates	https://www.nejm.org/doi/full/10.1056/NEJMoa2024671	28/07/2020	Estudo pré-clínico	10.1056/NEJMoa2024671	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2	http://science.sciencemag.org/content/early/2020/05/12/science.abc2241.abstract	13/05/2020	Estudo pré-clínico	http://science.sciencemag.org/content/early/2020/05/12/science.abc2241.abstract	-	-	-	-	-	-	-	-	['Anticorpos']	['Antibodies']
A human monoclonal antibody blocking SARS-CoV-2 infection	https://doi.org/10.1038/s41467-020-16256-y	04/05/2020	Estudo pré-clínico	10.1038/s41467-020-16256-y	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.	['Anticorpos']	['Antibodies']
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis	https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00305-4	20/04/2020	Estudo pré-clínico	https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00305-4	1749-7922	17497922	WORLD JOURNAL OF EMERGENCY SURGERY	A1	1.736	51	7.7	 Abstract  Background COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO 2/FiO 2 (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS). It is unclear to what extent tPA may impact population-based survival during the current US COVID-19 pandemic.  Methods A decision analytic Markov state transition model was created to simulate the life critically ill COVID-19 patients as they transitioned to either recovery or death. Two patient groups were simulated (50,000 patients in each group); (1) Patients received tPA immediately upon diagnosis of ARDS and (2) patients received standard therapy for ARDS. Base case critically ill COVID-19 patients were defined as having a refractory PaO 2/FiO 2 of &lt; 60 mmHg (salvage use criteria). Transition from severe to moderate to mild ARDS, recovery, and death were estimated. Markov model parameters were extracted from existing ARDS/COVID-19 literature.  Results The use of tPA was associated with reduced mortality (47.6% [tTPA] vs. 71.0% [no tPA]) for base case patients. When extrapolated to the projected COVID-19 eligible for salvage use tPA in the USA, peak mortality (deaths/100,000 patients) was reduced for both optimal social distancing (70.5 [tPA] vs. 75.0 [no tPA]) and no social distancing (158.7 [tPA] vs. 168.8 [no tPA]) scenarios.  Conclusions Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic.	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MSE analysis	https://pubmed.ncbi.nlm.nih.gov/32307268/	08/04/2020	Estudo pré-clínico	PUBMED_ID:32307268/	-	-	-	-	-	-	-	-	['Medicina Tradicional Chinesa', 'Medicina Tradicional Chinesa']	['Traditional Chinese Medicine', 'Traditional Chinese Medicine']
In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus	https://www.sciencedirect.com/science/article/pii/S2095496420300157	20/02/2020	Estudo pré-clínico	https://www.sciencedirect.com/science/article/pii/S2095496420300157	-	-	-	-	-	-	-	-	['Medicina Tradicional Chinesa']	['Traditional Chinese medicine']
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study	https://pubs.acs.org/doi/abs/10.1021/acs.jcim.0c00179	21/04/2020	Estudo pré-clínico	10.1021/acs.jcim.0c00179	1549-9596	15499596	JOURNAL OF CHEMICAL INFORMATION AND MODELING	A1	1.223	169	5.91	-	['Carfilzomibe', 'Elbasvir', 'Eravaciclina', 'Estreptomicina', 'Lopinavir', 'Valrubicina']	['Carfilzomib', 'Elbasvir', 'Eravacycline', 'Streptomycin', 'Lopinavir', 'Valrubicin']
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody	https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1729069	17/02/2020	Estudo pré-clínico	10.1080/22221751.2020.1729069	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	['Anticorpos']	['Antibodies']
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)	https://www.sciencedirect.com/science/article/pii/S104366182030743X	20/03/2020	Estudo pré-clínico	https://www.sciencedirect.com/science/article/pii/S104366182030743X	-	-	-	-	-	-	-	-	['Lianhua Qingwen (Medicina Tradicional Chinesa)']	['Lianhua Qingwen (Traditional Chinese Medicine)']
Peptide-like and small-molecule inhibitors against Covid-19	https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1757510	20/04/2020	Estudo pré-clínico	10.1080/07391102.2020.1757510	0739-1102	07391102	JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS	A3	0.561	73	3.78	-	['Apicidina', 'Carfilzomibe', 'Darunavir', 'Dobutamina', 'Lopinavir', 'Nelfinavir', 'Ritonavir', 'Saquinavir', 'Teniposídeo']	['Apicidin', 'Carfilzomib', 'Darunavir', 'Dobutamine', 'Lopinavir', 'Nelfinavir', 'Ritonavir', 'Saquinavir', 'Teniposide']
Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus	https://pubmed.ncbi.nlm.nih.gov/32308266/	31/03/2020	Estudo pré-clínico	PUBMED_ID:32308266/	-	-	-	-	-	-	-	-	['Azelastina', 'Conivaptano', 'Idelalisibe', 'Loxapina', 'Olaparibe', 'Perampanel', 'Ponatinibe', 'Sonidegibe', 'Suvorexant', 'Tolvaptano']	['Azelastine', 'Conivaptan', 'Idelalisibe', 'Loxapine', 'Olaparib', 'Perampanel', 'Ponatinib', 'Sonidegibe', 'Suvorexant', 'Tolvaptan']
Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus	https://academic.oup.com/bioinformatics/article/36/11/3295/5814924	01/04/2020	Estudo pré-clínico	https://academic.oup.com/bioinformatics/article/36/11/3295/5814924	-	-	-	-	-	-	-	-	['Ácido folínico', 'Composto ITX5061', 'Oberadilol', 'Poziotinibe', 'Vidupiprant', 'Ziprasidona']	['Folinic acid', 'Compound ITX5061', 'Oberadilol', 'Poziotinib', 'Vidupiprant', 'Ziprasidone']
Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment	https://doi.org/10.1111/vox.12937	20/04/2020	Estudo pré-clínico	10.1111/vox.12937	0042-9007	00429007	VOX SANGUINIS (BASEL. 1956)	B1	0.643	86	2.47	-	['Luz ultravioleta', 'Riboflavina']	['Ultraviolet Light', 'Riboflavin']
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease	https://doi.org/10.1016/j.tmaid.2020.101646	12/04/2020	Estudo pré-clínico	10.1016/j.tmaid.2020.101646	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Adeflavin', 'Coenzima A', 'Indinavir', 'Narcissoside', 'Remdesivir', 'Saquinavir', 'Zanamivir']	['Adeflavin', 'Coenzyme A', 'Indinavir', 'Narcissoside', 'Remdesivir', 'Saquinavir', 'Zanamivir']
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	https://doi.org/10.1016/j.lfs.2020.117477	28/02/2020	Estudo pré-clínico	10.1016/j.lfs.2020.117477	0024-3205	00243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Cinamaldeído', 'Guanosina trifosfato', 'IDX-184', 'Remdesivir', 'Ribavirina', 'Sofosbuvir', 'Timoquinona']	['Cinmaldehyde', 'Guanosine triphosphate', 'IDX-184', 'Remdesivir', 'Ribavirin', 'Sofosbuvir', 'Thymoquinone']
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites	https://www.sciencedirect.com/science/article/pii/S0166354220302072	10/04/2020	Estudo pré-clínico	https://www.sciencedirect.com/science/article/pii/S0166354220302072	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes	http://www.ncbi.nlm.nih.gov/pubmed/32306862	26/04/2020	Estudo pré-clínico	http://www.ncbi.nlm.nih.gov/pubmed/32306862	-	-	-	-	-	-	-	-	['Composto ZINC000000702323', 'Composto ZINC000012481889', 'Composto ZINC000015988935', 'Composto ZINC000103558522', 'Loprazolam', 'Lurasidona', 'Rubitecan', 'Talampicilina']	['ZINC Compound000000702323', 'ZINC Compound000012481889', 'ZINC Compound000015988935', 'ZINC Compound000103558522', 'Loprazolam', 'Lurasidone', 'Rubitecan', 'Talampicillin']
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	https://doi.org/10.1016/j.apsb.2020.02.008	27/02/2020	Estudo pré-clínico	10.1016/j.apsb.2020.02.008	2211-3835	22113835	ACTA PHARMACEUTICA SINICA B	A1	2.200	65	13.74	-	['Cassine xylocarpa', 'Cloroquina', 'Derivados de andrografolideo', 'Gluconato de clorexidina', 'Limeciclina', 'Lopinavir', 'Platycodon grandiflorus', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Scutellaria baicalensis', 'Valganciclovir']	['Cassine xylocarpa', 'Chloroquine', 'Andrografolide derivatives', 'Chlorhexidine gluconate', 'Limecycline', 'Lopinavir', 'Platycodon grandiflorus', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Scutellaria baicalensis ', 'Valganciclovir']
Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms	https://pubmed.ncbi.nlm.nih.gov/32293875/	16/04/2020	Estudo pré-clínico	PUBMED_ID:32293875/	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data	https://msystems.asm.org/content/5/2/e00297-20	14/04/2020	Estudo pré-clínico	https://msystems.asm.org/content/5/2/e00297-20	-	-	-	-	-	-	-	-	['Didanosina']	['Didanosine']
Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach	https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1751298	13/04/2020	Estudo pré-clínico	10.1080/07391102.2020.1751298	0739-1102	07391102	JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS	A3	0.561	73	3.78	-	['Darunavir', 'Derivados cumarínicos e flavonas (origem natural)', 'Remdesivir', 'Saquinavir']	['Darunavir', 'Coumarin derivatives and flavones (natural origin)', 'Remdesivir', 'Saquinavir']
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency	https://www.jbc.org/cgi/doi/10.1074/jbc.RA120.013679	13/04/2020	Estudo pré-clínico	10.1074/jbc.RA120.013679	0021-9258	00219258	THE JOURNAL OF BIOLOGICAL CHEMISTRY (PRINT)	A1	1.871	528	5.02	-	['Remdesivir']	['Remdesivir']
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	https://www.sciencedirect.com/science/article/pii/S2001037020300490	30/03/2020	Estudo pré-clínico	https://www.sciencedirect.com/science/article/pii/S2001037020300490	-	-	-	-	-	-	-	-	['Atazanavir', 'Atazanavir', 'Dolutegravir', 'Dolutegravir', 'Efavirenz', 'Efavirenz', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir']	['Atazanavir', 'Atazanavir', 'Dolutegravir', 'Dolutegravir', 'Efavirenz', 'Efavirenz', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir']
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach	https://www.sciencedirect.com/science/article/pii/S0024320520304008	09/04/2020	Estudo pré-clínico	https://www.sciencedirect.com/science/article/pii/S0024320520304008	-	-	-	-	-	-	-	-	['Asunaprevir', 'Indinavir', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Asunaprevir', 'Indinavir', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease	https://doi.org/10.1016/j.lfs.2020.117627	03/04/2020	Estudo pré-clínico	10.1016/j.lfs.2020.117627	0024-3205	00243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Agentes anti-tuberculose', 'Agentes anti-tuberculose', 'Antineoplásicos', 'Antineoplásicos', 'Antivirais', 'Antivirais', 'Nicotinamida', 'Nicotinamida', 'Ribavirina', 'Ribavirina', 'Telbivudina', 'Telbivudina', 'Vitamina B12', 'Vitamina B12', 'Vitaminas', 'Vitaminas']	['Anti-tuberculosis agents', 'Anti-tuberculosis agents', 'Antineoplastics', 'Antineoplastics', 'Antivirals', 'Antivirals', 'Nicotinamide', 'Nicotinamide', 'Ribavirin', 'Ribavirin', 'Telbivudine' , 'Telbivudine', 'Vitamin B12', 'Vitamin B12', 'Vitamins', 'Vitamins']
Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of Novel Coronavirus Pneumonia by network pharmacology	http://jtp.cnki.net/bilingual/detail/html/ZCYO20200216002	16/02/2020	Estudo pré-clínico	http://jtp.cnki.net/bilingual/detail/html/ZCYO20200216002	-	-	-	-	-	-	-	-	['Medicina Tradicional Chinesa']	['Traditional Chinese medicine']
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model	https://journals.lww.com/cmj/fulltext/2020/05050/repurposing_of_clinically_approved_drugs_for.8.aspx	12/04/2020	Estudo pré-clínico	https://journals.lww.com/cmj/fulltext/2020/05050/repurposing_of_clinically_approved_drugs_for.8.aspx	-	-	-	-	-	-	-	-	['Mefloquina', 'Selamectina']	['Mefloquine', 'Selamectin']
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice	https://stm.sciencemag.org/content/12/541/eabb5883	08/04/2020	Estudo pré-clínico	https://stm.sciencemag.org/content/12/541/eabb5883	-	-	-	-	-	-	-	-	['Molnupiravir']	['Molnupiravir']
Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase	https://doi.org/10.26434/chemrxiv.11888730.v1	25/02/2020	Estudo pré-clínico	10.26434/chemrxiv.11888730.v1	-	-	-	-	-	-	-	-	['Bictegravir', 'Dolutegravir', 'Paritaprevir', 'Raltegravir']	['Bictegravir', 'Dolutegravir', 'Paritaprevir', 'Raltegravir']
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	https://doi.org/10.1016/j.antiviral.2020.104786	03/04/2020	Estudo pré-clínico	10.1016/j.antiviral.2020.104786	0166-3542	01663542	ANTIVIRAL RESEARCH	A1	2.213	134	9.13	-	['Emetine', 'Homoharringtonina (HHT)', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Emetine', 'Homoharringtonine (HHT)', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development	https://doi.org/10.1016/j.ebiom.2020.1027433	02/04/2020	Estudo pré-clínico	10.1016/j.ebiom.2020.1027433	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
A vaccine for SARS-CoV-2: goals and promises	https://doi.org/10.1016/j.eclinm.2020.100494	19/08/2020	Editorial	10.1016/j.eclinm.2020.100494	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Ad5-nCoV', 'Ad5-nCoV']	['Ad5-nCoV', 'Ad5-nCoV']
Does vitamin D status impact mortality from SARS-CoV-2 infection?	https://pubmed.ncbi.nlm.nih.gov/32352080/	29/04/2020	Editorial	PUBMED_ID:32352080/	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Covid-19 treatment update: follow the scientific evidence	https://link.springer.com/article/10.1007/s11239-020-02120-9	27/04/2020	Editorial	https://link.springer.com/article/10.1007/s11239-020-02120-9	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19	https://doi.org/10.1016/j.onehlt.2020.100131	04/04/2020	Editorial	10.1016/j.onehlt.2020.100131	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Standing out from the crowd in treating COVID-19	https://doi.org/10.1016/j.medidd.2020.100034	03/04/2020	Editorial	10.1016/j.medidd.2020.100034	2590-0986	25900986	Medicine in Drug Discovery	-	0.306	5	3.33	-	['Resiniferatoxina']	['Resiniferatoxin']
G6PD and chloroquine: selecting the treatment against SARS-CoV-2?	https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15312	12/04/2020	Editorial	10.1111/jcmm.15312	1582-1838	15821838	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (PRINT)	A2	1.081	138	5.41	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
COVID-19: Important Therapy Considerations and Approaches in this Hour of Need	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2396	08/04/2020	Editorial	10.1002/phar.2396	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?	https://link.springer.com/article/10.1007/s00204-020-02734-1	08/04/2020	Editorial	https://link.springer.com/article/10.1007/s00204-020-02734-1	0340-5761	03405761	ARCHIVES OF TOXICOLOGY	A1	1.100	121	5.03	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence.	https://iris.paho.org/bitstream/handle/10665.2/52719/PAHOIMSEIHCOVID-19200030_eng.pdf?sequence=17&isAllowed=y	18/12/2020	Documento institucional	https://iris.paho.org/bitstream/handle/10665.2/52719/PAHOIMSEIHCOVID-19200030_eng.pdf?sequence=17&isAllowed=y	-	-	-	-	-	-	-	-	['Corticosteroides', 'Favipiravir', 'Hidroxicloroquina', 'Ivermectina', 'Plasma convalescente']	['Corticosteroids', 'Favipiravir', 'Hydroxychloroquine', 'Ivermectin', 'Convalescent Plasma']
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews	https://iris.paho.org/handle/10665.2/52097	22/09/2020	Documento institucional	https://iris.paho.org/handle/10665.2/52097	-	-	-	-	-	-	-	-	['Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Cloroquina', 'Corticosteroides', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Meplazumabe', 'Nelfinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Steroidal', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Chloroquine', 'Corticosteroids', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Interferon alpha', 'Ivermectin', 'Lopinavir', 'Meplazumab', 'Nelfinavir', ' Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
DRAFT landscape of COVID-19 candidate vaccines – 03 November 2020	https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-191cf012d2866d4102b9430ef02369d152.pdf?sfvrsn=f52877c4_3&download=true	11/11/2020	Documento institucional	https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-191cf012d2866d4102b9430ef02369d152.pdf?sfvrsn=f52877c4_3&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
HCQ is effective for COVID-19 when used early: analysis of 118 studies	https://www.palmerfoundation.com.au/hcq-is-effective-for-covid-19-when-used-early-analysis-of-118-studies/	20/10/2020	Documento institucional	https://www.palmerfoundation.com.au/hcq-is-effective-for-covid-19-when-used-early-analysis-of-118-studies/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
DRAFT landscape of COVID-19 candidate vaccines – 19 October 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19cc0232c16129498983a6a0e30ca94000.pdf?sfvrsn=87aa8dc9_1&download=true	19/10/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19cc0232c16129498983a6a0e30ca94000.pdf?sfvrsn=87aa8dc9_1&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews	https://iris.paho.org/handle/10665.2/52719	13/10/2020	Documento institucional	https://iris.paho.org/handle/10665.2/52719	-	-	-	-	-	-	-	-	['Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Cloroquina', 'Corticosteroides', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Meplazumabe', 'Nelfinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Steroidal', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Chloroquine', 'Corticosteroids', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Interferon alpha', 'Ivermectin', 'Lopinavir', 'Meplazumab', 'Nelfinavir', ' Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
DRAFT landscape of COVID-19 candidate vaccines – 02 October 2020	https://www.who.int/docs/default-source/inaugural-who-partners-forum/novel-coronavirus-landscape-covid-19-(6).pdf?sfvrsn=3086971d_1&download=true	02/10/2020	Documento institucional	https://www.who.int/docs/default-source/inaugural-who-partners-forum/novel-coronavirus-landscape-covid-19-(6).pdf?sfvrsn=3086971d_1&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews	https://iris.paho.org/handle/10665.2/52097	08/05/2020	Documento institucional	https://iris.paho.org/handle/10665.2/52097	-	-	-	-	-	-	-	-	['Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Cloroquina', 'Corticosteroides', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Meplazumabe', 'Nelfinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Steroidal', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Chloroquine', 'Corticosteroids', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Interferon alpha', 'Ivermectin', 'Lopinavir', 'Meplazumab', 'Nelfinavir', ' Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
DRAFT landscape of COVID-19 candidate vaccines – 28 September 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19e6f0a2cece4247158bf7fd7020907c82.pdf?sfvrsn=ef8b7cdb_1&download=true	28/09/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19e6f0a2cece4247158bf7fd7020907c82.pdf?sfvrsn=ef8b7cdb_1&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 21 September 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(5).pdf?sfvrsn=ba27da1f_1&download=true	21/09/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(5).pdf?sfvrsn=ba27da1f_1&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 23 September 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(5).pdf?sfvrsn=ba27da1f_3&download=true	23/09/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(5).pdf?sfvrsn=ba27da1f_3&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 17 September 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	17/09/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 9 September 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3)4b6debde1bdc4a85ae67d4ce578be1bf.pdf?sfvrsn=57c0b234_1&download=truee	09/09/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3)4b6debde1bdc4a85ae67d4ce578be1bf.pdf?sfvrsn=57c0b234_1&download=truee	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 8 September 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3)4b6debde1bdc4a85ae67d4ce578be1bf.pdf?sfvrsn=57c0b234_1&download=true	08/09/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3)4b6debde1bdc4a85ae67d4ce578be1bf.pdf?sfvrsn=57c0b234_1&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 28 August 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	28/08/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 25 August 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	25/08/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Tocilizumab en infección por COVID-19	http://docs.bvsalud.org/biblioref/2020/08/1116521/iecs-irr-782-va-tocilizumab-en-covid-19.pdf	01/06/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/08/1116521/iecs-irr-782-va-tocilizumab-en-covid-19.pdf	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Remdesivir en pacientes con COVID-19	http://docs.bvsalud.org/biblioref/2020/08/1116426/iecs-irr-777.pdf	12/06/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/08/1116426/iecs-irr-777.pdf	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
DRAFT landscape of COVID-19 candidate vaccines – 20 August 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-1939812896bcff49719d21643afa5dfa4e.pdf?sfvrsn=9c18d69c_3&download=true	20/08/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-1939812896bcff49719d21643afa5dfa4e.pdf?sfvrsn=9c18d69c_3&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
INTERFERON PARA PROFILAXIA E TRATAMENTO DE COVID-19. Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/08/14/interferon-para-profilaxia-e-tratamento-de-covid-19-revisao-sistematica-rapida/	14/08/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/08/14/interferon-para-profilaxia-e-tratamento-de-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Interferon']	['Interferon']
Uso de dexametasona en pacientes internados con COVID-19	http://docs.bvsalud.org/biblioref/2020/08/1116529/dexametasona-en-covid19-redarets-08-2020.pdf	18/08/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/08/1116529/dexametasona-en-covid19-redarets-08-2020.pdf	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
Lopinavir-Ritonavir para infecção por SARS-CoV-2 (Covid-19). Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/08/05/lopinavir-ritonavir-para-covid-19-revisao-sistematica-rapida/	05/08/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/08/05/lopinavir-ritonavir-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática de ensaios clínicos randomizados	https://oxfordbrazilebm.com/index.php/2020/08/12/hidroxicloroquina-e-cloroquina-para-covid-19-revisao-sistematica-rapida/	12/08/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/08/12/hidroxicloroquina-e-cloroquina-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
REPORTE BREVE Nº 30 USO DE ANAKINRA PARA EL TRATAMIENTO DE PACIENTES CON EL DIAGNOSTICO DE COVID-19, 2020.  SEGURO SOCIAL DE SALUD - ESSALUD INSTITUTO DE EVALUACION DE TECNOLOGIAS EN SALUD E INVESTIGACIÓN	http://docs.bvsalud.org/biblioref/2020/07/1104042/rb30_anakinra.pdf	06/06/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/07/1104042/rb30_anakinra.pdf	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Uso de dexametasona en pacientes internados con COVID-19 - Informe de Evaluación de Tecnología Sanitaria	http://docs.bvsalud.org/biblioref/2020/08/1116529/dexametasona-en-covid19-redarets-08-2020.pdf	16/08/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/08/1116529/dexametasona-en-covid19-redarets-08-2020.pdf	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
DRAFT landscape of COVID-19 candidate vaccines – 10 August 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	13/08/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Drug vignettes: Remdesivir	https://www.cebm.net/covid-19/drug-vignettes-remdesivir	10/08/2020	Documento institucional	https://www.cebm.net/covid-19/drug-vignettes-remdesivir	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Drug vignettes: Interferons	https://www.cebm.net/covid-19/drug-vignettes-interferons/	06/08/2020	Documento institucional	https://www.cebm.net/covid-19/drug-vignettes-interferons/	-	-	-	-	-	-	-	-	['Interferon']	['Interferon']
DRAFT landscape of COVID-19 candidate vaccines – 31 July 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	31/07/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 27 July 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acesso: 28/07/2020	27/07/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acesso: 28/07/2020	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 21 July 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acesso em: 23/07/2020	21/07/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Acesso em: 23/07/2020	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 15 July 2020	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	15/07/2020	Documento institucional	https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(3).pdf?sfvrsn=9c18d69c_7&download=true	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 13 July 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	13/07/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Eficácia da Ivermectina para o Tratamento da Covid-19. Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/05/07/ivermectina-para-o-tratamento-de-pacientes-com-covid-19-revisao-sistematica-rapida2/	08/07/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/07/ivermectina-para-o-tratamento-de-pacientes-com-covid-19-revisao-sistematica-rapida2/	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Emergence of institutional antithrombotic protocols for coronavirus 2019	https://doi.org/10.1002/rth2.12358	28/04/2020	Documento institucional	10.1002/rth2.12358	2475-0379	24750379	RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS	C	1.817	24	4.32	-	['Betrixabana', 'Betrixabana', 'Clopidogrel', 'Clopidogrel', 'Enoxaparina', 'Enoxaparina', 'Heparina', 'Heparina', 'Lopinavir', 'Lopinavir', 'Prasugrel', 'Prasugrel', 'Ritonavir', 'Ritonavir', 'Rivaroxabana', 'Rivaroxabana', 'Ticagrelor', 'Ticagrelor']	['Betrixabana', 'Betrixabana', 'Clopidogrel', 'Clopidogrel', 'Enoxaparin', 'Enoxaparin', 'Heparin', 'Heparin', 'Lopinavir', 'Lopinavir', 'Prasugrel', 'Prasugrel', ' Ritonavir', 'Ritonavir', 'Rivaroxaban', 'Rivaroxaban', 'Ticagrelor', 'Ticagrelor']
DRAFT landscape of COVID-19 candidate vaccines – 06 July 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	06/07/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Associação hidroxicloroquina/ cloroquina e azitromicina para Covid-19	https://oxfordbrazilebm.com/index.php/2020/06/02/associacao-hidroxicloroquina-cloroquina-e-azitromicina-para-covid-19-revisao-sistematica-rapida/	29/06/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/06/02/associacao-hidroxicloroquina-cloroquina-e-azitromicina-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Tocilizumabe para infecção por SARS-CoV-2 (COVID-19) Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/06/30/tocilizumabe-para-pacientes-com-covid-19/	29/06/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/06/30/tocilizumabe-para-pacientes-com-covid-19/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Corticoides para infecção por SARS-CoV-2 (Covid-19) Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/05/18/corticoides-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica-rapida/	29/06/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/18/corticoides-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
DRAFT landscape of COVID-19 candidate vaccines – 24 June 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	28/06/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 22 June 2020.	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	22/06/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines – 18 June 2020.	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	18/06/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19	https://www.who.int/publications/m/item/targeted-update-safety-and-efficacy-of-hydroxychloroquine-or-chloroquine-for-treatment-of-covid-19	17/06/2020	Documento institucional	https://www.who.int/publications/m/item/targeted-update-safety-and-efficacy-of-hydroxychloroquine-or-chloroquine-for-treatment-of-covid-19	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Uso de plasma de pacientes recuperados no tratamento de COVID-19. Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/04/15/plasma-de-pacientes-recuperados-no-tratamento-de-covid-19/	14/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/15/plasma-de-pacientes-recuperados-no-tratamento-de-covid-19/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Heparina para Covid-19. Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/04/17/heparinas-para-infeccao-por-sars-cov-2-covid-19/	01/05/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/17/heparinas-para-infeccao-por-sars-cov-2-covid-19/	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Eficácia, segurança e prognóstico associados ao uso de Inibidores da Enzima Conversora de Angiotensina (IECA) e Bloqueadores do Receptor de Angiotensina 2 (BRA) para COVID-19. Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/06/17/inibidores-da-enzima-conversora-de-angiotensina-ieca-e-bloqueadores-do-receptor-de-angiotensina-2-bra-para-covid-19-revisao-sistematica-rapida/	15/06/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/06/17/inibidores-da-enzima-conversora-de-angiotensina-ieca-e-bloqueadores-do-receptor-de-angiotensina-2-bra-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
DRAFT landscape of COVID-19 candidate vaccines - 16 June 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	17/06/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
DRAFT landscape of COVID-19 candidate vaccines - 9 June 2020	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	09/06/2020	Documento institucional	https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Nitazoxanida no tratamento de covid-19. Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/04/22/nitazoxanida-para-tratamento-de-covid-19/	22/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/22/nitazoxanida-para-tratamento-de-covid-19/	-	-	-	-	-	-	-	-	['Nitazoxanida']	['Nitazoxanide']
Tocilizumabe para infecção por SARS-CoV-2 (COVID-19) Revisão sistemática rápida.	https://oxfordbrazilebm.com/index.php/2020/04/14/tocilizumabe-para-pacientes-com-covid-19/	08/06/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/14/tocilizumabe-para-pacientes-com-covid-19/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Remdesivir para infecção por SARS-CoV-2 (COVID-19). Revisão sistemática.	https://oxfordbrazilebm.com/index.php/2020/05/02/remdesivir-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica2.	29/05/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/02/remdesivir-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica2.	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Hidroxicloroquina e cloroquina para Covid-19. Revisão sistemática rápida	http://docs.bvsalud.org/biblioref/2020/06/1099475/rs_rapida_hidroxicloroquina_covid19_atualizacao_21_05_20.pdf	21/05/2020	Documento institucional	http://docs.bvsalud.org/biblioref/2020/06/1099475/rs_rapida_hidroxicloroquina_covid19_atualizacao_21_05_20.pdf	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 8 May 2020	https://iris.paho.org/handle/10665.2/52097	08/05/2020	Documento institucional	https://iris.paho.org/handle/10665.2/52097	-	-	-	-	-	-	-	-	['Ácido alfa lipóico', 'Cloroquina', 'Corticosteroides', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Meplazumabe', 'Nelfinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Alpha Lipoic Acid', 'Chloroquine', 'Corticosteroids', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Interferon alpha', 'Ivermectin', 'Lopinavir', 'Meplazumab ', 'Nelfinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
DRAFT landscape of COVID-19 candidate vaccines - 15 May 2020	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	15/05/2020	Documento institucional	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Corticoides para infecção por SARS-CoV-2 (Covid-19) Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/05/18/corticoides-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica-rapida/	02/05/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/18/corticoides-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Associação hidroxicloroquina/cloroquina e azitromicina para Covid-19.	https://oxfordbrazilebm.com/index.php/2020/05/18/associacao-hidroxicloroquina-cloroquina-e-azitromicina-para-covid-19-revisao-sistematica-rapida/	18/05/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/18/associacao-hidroxicloroquina-cloroquina-e-azitromicina-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Uso de Tocilizumab para el tratamiento de pacientes con COVID-19. Reporte breve n° 01.	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_03_Tocilizumab_v18Mar.pdf	18/03/2020	Documento institucional	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_03_Tocilizumab_v18Mar.pdf	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Uso de Oseltamivir para el tratamiento de pacientes con COVID-19. Reporte breve n° 01.	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_01_Oseltamivir_v18Mar.pdf	14/03/2020	Documento institucional	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_01_Oseltamivir_v18Mar.pdf	-	-	-	-	-	-	-	-	['Oseltamivir']	['Oseltamivir']
Uso de atazanavir para el tratamiento de pacientes con diagnóstico de COVID-19. Reporte breve n° 02.	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_02_atazanavir_v17Mar.pdf	17/03/2020	Documento institucional	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB_02_atazanavir_v17Mar.pdf	-	-	-	-	-	-	-	-	['Atazanavir']	['Atazanavir']
Uso de AINES en pacientes con diagnóstico de COVID-19. Reporte breve n° 013.	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/AINES_RB_13_editado_270320_lm.pdf	27/03/2020	Documento institucional	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/AINES_RB_13_editado_270320_lm.pdf	-	-	-	-	-	-	-	-	['Ibuprofeno']	['Ibuprofen']
Draft landscape of COVID 19 candidate vaccines - 11 May 2020	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	11/05/2020	Documento institucional	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
COVID-19 Informal consultation on the dose of chloroquine and hydroxychloroquine for the SOLIDARITY Clinical Trial	https://www.who.int/publications/m/item/informal-consultation-on-the-dose-of-chloroquine-and-hydroxychloroquine-for-the-solidarity-clinical-trial---8-april-2020	08/04/2020	Documento institucional	https://www.who.int/publications/m/item/informal-consultation-on-the-dose-of-chloroquine-and-hydroxychloroquine-for-the-solidarity-clinical-trial---8-april-2020	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
DRAFT landscape of COVID-19 candidate vaccines - 5 May 2020	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	05/05/2020	Documento institucional	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
What is the evidence for using macrolide antibiotics to treat COVID-19?	https://www.cebm.net/covid-19/what-is-the-evidence-for-use-of-macrolide-antobiotics-for-treatmetnof-covid-19/	28/04/2020	Documento institucional	https://www.cebm.net/covid-19/what-is-the-evidence-for-use-of-macrolide-antobiotics-for-treatmetnof-covid-19/	-	-	-	-	-	-	-	-	['Azitromicina']	['Azithromycin']
Drug vignettes: Tocilizumab	https://www.cebm.net/covid-19/tocilizumab/	01/05/2020	Documento institucional	https://www.cebm.net/covid-19/tocilizumab/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Heparinas para infecção por SARS-CoV-2 (COVID-19). Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/04/17/heparinas-para-infeccao-por-sars-cov-2-covid-19/	13/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/17/heparinas-para-infeccao-por-sars-cov-2-covid-19/	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Remdesivir parainfecção por SARS-CoV-2 (COVID-19). Revisão sistemática	https://oxfordbrazilebm.com/index.php/2020/05/02/remdesivir-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica2	01/05/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/05/02/remdesivir-para-infeccao-por-sars-cov-2-covid-19-revisao-sistematica2	-	-	-	-	-	-	-	-	[]	[]
Vitamin D: A rapid review of the evidence for treatment or prevention in COVID-19	https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/	01/05/2020	Documento institucional	https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
A rapid review of the evidence for treatment or prevention in COVID-19	https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/	01/05/2020	Documento institucional	https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-of-the-evidence-for-treatment-or-prevention-in-covid-19/	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
DRAFT landscape of COVID-19 candidate vaccines - 20 April 2020	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	30/04/2020	Documento institucional	https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews	https://iris.paho.org/handle/10665.2/52025	22/04/2020	Documento institucional	https://iris.paho.org/handle/10665.2/52025	-	-	-	-	-	-	-	-	['Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Esteroides', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Cloroquina', 'Corticosteroides', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Meplazumabe', 'Nelfinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Steroidal', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Ssteroids', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Chloroquine', 'Corticosteroids', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Interferon alpha', 'Ivermectin', 'Lopinavir', 'Meplazumab', 'Nelfinavir', ' Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19	https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/	11/04/2020	Documento institucional	https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
DRAFT landscape of COVID-19 candidate vaccines - 23 April 2020	https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf	23/04/2020	Documento institucional	https://www.who.int/blueprint/priority-diseases/key-action/draft-landscape-COVID-19-candidate-vaccines-23-April-2020.pdf	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Nitazoxanida para tratamento de COVID-19: Revisão Sistemática Rápida	https://oxfordbrazilebm.com/index.php/2020/04/22/nitazoxanida-para-tratamento-de-covid-19/	17/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/22/nitazoxanida-para-tratamento-de-covid-19/	-	-	-	-	-	-	-	-	['Nitazoxanida']	['Nitazoxanide']
Atazanavir para COVID-19. Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/04/15/atazanavir-para-covid-19-revisao-sistematica-rapida/	13/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/15/atazanavir-para-covid-19-revisao-sistematica-rapida/	-	-	-	-	-	-	-	-	['Atazanavir']	['Atazanavir']
Uso de plasma de pacientes recuperados no tratamento de COVID-19. Revisão sistemática rápida	https://oxfordbrazilebm.com/index.php/2020/04/15/plasma-de-pacientes-recuperados-no-tratamento-de-covid-19/	13/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/15/plasma-de-pacientes-recuperados-no-tratamento-de-covid-19/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Inibidores da janus associated kinases para COVID-19.	https://oxfordbrazilebm.com/index.php/2020/04/14/inibidores-das-janus-associated-kinases-para-covid-19/	14/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/14/inibidores-das-janus-associated-kinases-para-covid-19/	-	-	-	-	-	-	-	-	['Inibidores de Janus Kinase (JAK)']	['Janus Kinase (JAK) Inhibitors']
Antagonistas do receptor da endotelina para o tratamento de pacientes com COVID-19	https://oxfordbrazilebm.com/index.php/2020/04/14/antagonistas-do-receptor-de-endotelina-para-o-tratamento-de-pacientes-com-covid-19/	08/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/14/antagonistas-do-receptor-de-endotelina-para-o-tratamento-de-pacientes-com-covid-19/	-	-	-	-	-	-	-	-	['Antagonistas do receptor de endotelina']	['Endothelin receptor antagonists']
Antagonistas do receptor da ivermectina para o tratamento de pacientes com COVID-19	https://oxfordbrazilebm.com/index.php/2020/04/14/ivermectina-para-o-tratamento-de-pacientes-com-covid-19/	07/04/2020	Documento institucional	https://oxfordbrazilebm.com/index.php/2020/04/14/ivermectina-para-o-tratamento-de-pacientes-com-covid-19/	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
DRAFT landscape of COVID-19 candidate vaccines – 4 April 2020	https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf?ua=1	04/04/2020	Documento institucional	https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf?ua=1	-	-	-	-	-	-	-	-	['Vacinas']	['Vaccines']
Remdesivir for severe covid-19: a clinical practice guideline	http://www.bmj.com/content/370/bmj.m2924.abstract	30/07/2020	Diretriz para prática clínica	http://www.bmj.com/content/370/bmj.m2924.abstract	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology	https://doi.org/10.5935/0103-507X.20200039	18/05/2020	Diretriz para prática clínica	10.5935/0103-507X.20200039	0103-507X	0103507X	REVISTA BRASILEIRA DE TERAPIA INTENSIVA (IMPRESSO)	A4	0.521	23	1.54	-	['Antibióticos', 'Cloroquina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumabe']	['Antibiotics', 'Chloroquine', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumab']
Interim Guidelines on Antiviral Therapy for COVID-19	https://pubmed.ncbi.nlm.nih.gov/32342676/	23/04/2020	Diretriz para prática clínica	PUBMED_ID:32342676/	-	-	-	-	-	-	-	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.12897	21/09/2020	Comunicação breve	10.1111/cts.12897	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Metformina']	['Metformin']
Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study	https://onlinelibrary.wiley.com/doi/10.1111/ajt.16314	18/09/2020	Comunicação breve	10.1111/ajt.16314	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection	https://www.eymj.org/DOIx.php?id=10.3349/ymj.2020.61.9.826	27/08/2020	Comunicação breve	https://www.eymj.org/DOIx.php?id=10.3349/ymj.2020.61.9.826	-	-	-	-	-	-	-	-	['Cobicistato', 'Darunavir']	['Cobicistat', 'Darunavir']
Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics	https://doi.org/10.1016/j.jfma.2020.08.022	25/09/2020	Comunicação breve	10.1016/j.jfma.2020.08.022	0929-6646	09296646	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (PRINT)	A1	0.779	59	2.92	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Towards evidence-based Emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2: Hydroxychloroquine in the treatment of COVID-19	https://emj.bmj.com/content/37/7/451	02/07/2020	Comunicação breve	https://emj.bmj.com/content/37/7/451	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Use of Darunavir-Cobicistat as a Treatment Optionfor Critically Ill Patients with SARS-CoV-2 Infection	https://doi.org/10.3349/ymj.2020.61.9.826	27/08/2020	Comunicação breve	10.3349/ymj.2020.61.9.826	0513-5796	05135796	Yonsei Medical Journal	-	0.570	66	2.83	-	[]	[]
A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort	https://doi.org/10.1007/s10096-020-04016-1	27/08/2020	Comunicação breve	10.1007/s10096-020-04016-1	0934-9723	09349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Ceftriaxona', 'Doxiciclina', 'Hidroxicloroquina', 'Lopinavir']	['Ceftriaxone', 'Doxycycline', 'Hydroxychloroquine', 'Lopinavir']
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients	https://www.frontiersin.org/articles/10.3389/fphar.2020.01124/full	06/08/2020	Comunicação breve	10.3389/fphar.2020.01124/full	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS‐CoV‐2 infection	https://doi.org/10.1111/jth.15032	29/07/2020	Comunicação breve	10.1111/jth.15032	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Anticoagulantes', 'Enoxaparina', 'Varfarina']	['Anticoagulants', 'Enoxaparin', 'Warfarin']
Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19)	https://www.sciencedirect.com/science/article/pii/S245184762030110X	18/08/2020	Comunicação breve	https://www.sciencedirect.com/science/article/pii/S245184762030110X	-	-	-	-	-	-	-	-	['Metformina']	['Metformin']
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island	https://doi.org/10.1016/j.jgar.2020.08.001	20/08/2020	Comunicação breve	10.1016/j.jgar.2020.08.001	2213-7165	22137165	JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE	B1	0.763	33	3.07	-	['Azitromicina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Corticosteroid Therapy in COVID-19 Disease	https://doi.org/10.37678/dcybd.2020.2349	22/06/2020	Comunicação breve	10.37678/dcybd.2020.2349	2717-6428	27176428	Journal of Critical and Intensive Care	-	0.131	5	0.41	-	['Corticosteroides']	['Corticosteroids']
Susceptibility to COVID-19 in patients treated with antimalarials: a population based study in Emilia-Romagna, Northern Italy	https://doi.org/10.1002/art.41475	06/08/2020	Comunicação breve	10.1002/art.41475	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? International Journal of Antimicrobial Agents	https://www.sciencedirect.com/science/article/pii/S092485792030145X	17/04/2020	Comunicação breve	https://www.sciencedirect.com/science/article/pii/S092485792030145X	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19	https://www.journalofhospitalmedicine.com/jhospmed/article/225402/hospital-medicine/effect-systemic-glucocorticoids-mortality-or-mechanical	22/07/2020	Comunicação breve	https://www.journalofhospitalmedicine.com/jhospmed/article/225402/hospital-medicine/effect-systemic-glucocorticoids-mortality-or-mechanical	-	-	-	-	-	-	-	-	[]	[]
Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported.	https://www.sciencedirect.com/science/article/pii/S1567576920314946	08/08/2020	Comunicação breve	https://www.sciencedirect.com/science/article/pii/S1567576920314946	-	-	-	-	-	-	-	-	['Oxigênio-ozônio (O2-O3)']	['Oxygen-Ozone (O2-O3)']
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631	01/05/2020	Comunicação breve	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19	https://smw.ch/article/doi/smw.2020.20262	20/04/2020	Comunicação breve	https://smw.ch/article/doi/smw.2020.20262	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan	http://www.sciencedirect.com/science/article/pii/S168411822030092X	03/04/2020	Comunicação breve	http://www.sciencedirect.com/science/article/pii/S168411822030092X	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Mortality of COVID-19 with preadmission metformin use in patients with diabetes: a meta-analysis	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26498	09/09/2020	Carta do editor	10.1002/jmv.26498	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Metformina', 'Metformina']	['Metformin', 'Metformin']
Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia	https://pubmed.ncbi.nlm.nih.gov/32874012/	27/08/2020	Carta do editor	PUBMED_ID:32874012/	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension	https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1746200	31/03/2020	Carta do editor	10.1080/22221751.2020.1746200	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study	https://doi.org/10.1186/s13054-020-03215-8	08/08/2020	Carta do editor	10.1186/s13054-020-03215-8	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Plasmaferese']	['Plasmapheresis']
Efficacy of tocilizumab treatment in severely ill COVID-19 patients	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03224-7	27/07/2020	Carta do editor	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03224-7	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Azitromicina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Prednisona', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Prednisone', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
Argatroban for therapeutic anticoagulation for heparin resistanceassociated with Covid-19 infection	https://link.springer.com/article/10.1007/s11239-020-02251-z	24/08/2020	Carta do editor	https://link.springer.com/article/10.1007/s11239-020-02251-z	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	[]	[]
“Toxic erythema” and eosinophilia associated to tocilizumab therapy in a COVID-19 patient	https://onlinelibrary.wiley.com/doi/10.1111/jdv.16620	09/05/2020	Carta do editor	10.1111/jdv.16620	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Tocilizumabe']	['Tocilizumab']
Drug-induced vasculitis in a patient with COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16588	07/05/2020	Carta do editor	10.1111/jdv.16588	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Anti-histamínicos', 'Corticosteroides', 'Prednisolona']	['Antihistamines', 'Corticosteroids', 'Prednisolone']
Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16781	05/05/2020	Carta do editor	10.1111/bjh.16781	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Teicoplanina']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Teicoplanin']
IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma	https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16787	05/05/2020	Carta do editor	10.1111/bjh.16787	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']
A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia	https://doi.org/10.1038/s41392-020-0158-2	28/04/2020	Carta do editor	10.1038/s41392-020-0158-2	2059-3635	20593635	Signal Transduction and Targeted Therapy	-	5.157	53	17.87	-	['Prednisona']	['Prednisone']
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	https://doi.org/10.1016/j.jinf.2020.04.017	23/04/2020	Carta do editor	10.1016/j.jinf.2020.04.017	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Baricitinibe']	['Baricitinib']
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167302/	20/04/2020	Carta do editor	PMC:PMC7167302/	-	-	-	-	-	-	-	-	['Azitromicina']	['Azithromycin']
Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection	https://doi.org/10.1002/jmv.25897	16/04/2020	Carta do editor	10.1002/jmv.25897	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19	https://doi.org/10.1016/S2352-3026(20)30109-5	09/04/2020	Carta do editor	10.1016/S2352-3026(20)30109-5	2352-3026	23523026	THE LANCET HAEMATOLOGY	A1	5.189	71	8.49	-	['Profilaxia para tromboembolismo']	['Prophylaxis for thromboembolism']
Safety of hydroxychloroquine for treatment or prevention of SARS‐CoV‐2 infection: A rapid systematic review and meta‐analysis of randomized clinical trials.	https://onlinelibrary.wiley.com/doi/10.1002/iid3.374	26/11/2020	Artigo de opinião	10.1002/iid3.374	2050-4527	20504527	IMMUNITY, INFLAMMATION AND DISEASE	B3	0.562	22	2.33	-	['Hidroxicloroquina']	['Hydroxychloroquine']
L’hydroxy-chloroquine pour traiter les patients infectes du ´COVID-19: quelques lec¸ons d’an-thropologie medicale et d’histoire de la m ´ edecine	https://doi.org/10.1016/j.jemep.2020.100587	27/08/2020	Artigo de opinião	10.1016/j.jemep.2020.100587	2352-5525	23525525	Ethics, Medicine and Public Health	-	0.175	9	0.49	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Amiodarone in the COVID‑19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?	https://doi.org/10.1007/s40256-020-00429-7	01/08/2020	Artigo de opinião	10.1007/s40256-020-00429-7	1175-3277	11753277	AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS	A2	1.010	54	3.47	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients	https://doi.org/10.1186/s13054-020-03227-4	12/08/2020	Artigo de opinião	10.1186/s13054-020-03227-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir', 'Nafamostato']	['Favipiravir', 'Nafamostat']
An Inactivated Virus Candidate Vaccine to Prevent COVID-19	https://doi.org/10.1001/jama.2020.15539	13/08/2020	Artigo de opinião	10.1001/jama.2020.15539	0098-7484	00987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic	https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keaa388/5878163	29/07/2020	Artigo de opinião	10.1093/rheumatology/keaa388/5878163	-	-	-	-	-	-	-	-	['Corticosteroides', 'Drogas antirreumáticas modificadoras de doenças', 'Sarilumabe', 'Tocilizumabe']	['Corticosteroids', 'Disease-modifying anti-rheumatic drugs', 'Sarilumab', 'Tocilizumab']
The use of dexamethasone in the treatment of COVID-19	https://doi.org/10.1016/j.amsu.2020.07.004	09/07/2020	Artigo de opinião	10.1016/j.amsu.2020.07.004	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Dexametasona']	['Dexamethasone']
Anakinra in COVID-19: important considerations for clinical trials	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30160-0/fulltext	21/05/2020	Artigo de opinião	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30160-0/fulltext	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy	https://doi.org/10.1016/j.clim.2020.108550	31/07/2020	Artigo de opinião	10.1016/j.clim.2020.108550	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals	https://jamanetwork.com/journals/jama/fullarticle/2766940	03/06/2020	Artigo de opinião	https://jamanetwork.com/journals/jama/fullarticle/2766940	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01445/full	16/06/2020	Artigo de opinião	10.3389/fimmu.2020.01445/full	-	-	-	-	-	-	-	-	['Etoposídeo', 'Plasmaferese', 'Ruxolitinibe', 'Tocilizumabe']	['Etoposide', 'Plasmapheresis', 'Ruxolitinib', 'Tocilizumab']
Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388856/	29/07/2020	Artigo de opinião	PMC:PMC7388856/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Vitamin D for COVID-19: a case to answer?	https://doi.org/10.1016/S2213-8587(20)30268-0	03/08/2020	Artigo de opinião	10.1016/S2213-8587(20)30268-0	2213-8587	22138587	THE LANCET DIABETES & ENDOCRINOLOGY	A1	9.767	132	11.05	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Practical considerations in prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19	https://doi.org/10.1093/ajhp/zxaa245	06/07/2020	Artigo de opinião	10.1093/ajhp/zxaa245	1079-2082	10792082	American Journal of Health-System Pharmacy	-	0.483	99	1.59	 Abstract                                   Purpose                   There are increasing reports in the literature of high rates of coagulopathy and venous thromboembolism (VTE) among hospitalized patients with coronavirus disease 2019 (COVID-19). Understanding of these abnormalities is continually evolving, but these conditions may pose a risk to patients with COVID-19 beyond the risk typically seen in critically ill patients.                                                  Summary                   There are currently no widely accepted evidence-based guidelines regarding specifics related to treatment and prevention of COVID-19–related coagulopathies. Areas of management requiring clinical equipoise include agent selection and dosing, continuation vs interruption of home oral anticoagulant therapy during hospital admission, and postdischarge VTE prophylaxis. Clinicians may wish to consider use of a stratified, 3-tiered approach of low-intensity anticoagulation, intermediate-intensity anticoagulation, and therapeutic-dose anticoagulation. Patients can be categorized by tier depending on their risk factors for VTE, acuity of illness, and laboratory values such as D-dimer level.                                                  Conclusion                   Practical guidance on anticoagulation considerations and dosing suggestions are provided to assist clinicians faced with challenging anticoagulation-related situations in caring for hospitalized patients with COVID-19 until formal evidence-based guidelines become available.               	['Enoxaparina']	['Enoxaparin']
Hydroxychloroquine and Azithromycin as Treatments for COVID-19	http://dx.doi.org/10.12996/gmj.2020.82	19/05/2020	Artigo de opinião	10.12996/gmj.2020.82	2147-2092	21472092	Gazi Medical Journal	-	0.112	7	0.13	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Rituximab: a safe therapeutic option during the COVID-19 pandemic? Journal of Dermatological Treatment. 22 de julho de 2020;1–3. DOI: 10	https://www.tandfonline.com/doi/abs/10.1080/09546634.2020.1800565?journalCode=ijdt20	22/07/2020	Artigo de opinião	10.1080/09546634.2020.1800565?journalCode=ijdt20	-	-	-	-	-	-	-	-	['Rituximabe']	['Rituximab']
Hypercoagulable state in COVID-19 with diabetes mellitus and obesity: Is therapeutic-dose or higher-dose anticoagulant thromboprophylaxis necessary?	https://pubmed.ncbi.nlm.nih.gov/32683322/	15/07/2020	Artigo de opinião	PUBMED_ID:32683322/	-	-	-	-	-	-	-	-	['Anticoagulantes']	['Anticoagulants']
The effect of BCG vaccine in the era of COVID-19 pandemic	https://onlinelibrary.wiley.com/doi/abs/10.1111/sji.12947	22/07/2020	Artigo de opinião	10.1111/sji.12947	0300-9475	03009475	SCANDINAVIAN JOURNAL OF IMMUNOLOGY (PRINT)	A4	0.811	90	3.31	-	['Vacina BCG']	['BCG vaccine']
How should we treat pregnant women infected with SARS-CoV-2?	https://doi.org/10.1111/1471-0528.16270	23/04/2020	Artigo de opinião	10.1111/1471-0528.16270	1470-0328	14700328	BJOG: An International Journal of Obstetrics and Gynaecology	-	2.449	170	2.95	-	['Cloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Chloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Anakinra for patients with COVID-19	https://covid19.elsevierpure.com/en/publications/anakinra-for-patients-with-covid-19	01/07/2020	Artigo de opinião	https://covid19.elsevierpure.com/en/publications/anakinra-for-patients-with-covid-19	-	-	-	-	-	-	-	-	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']
Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making	http://jme.bmj.com/content/early/2020/07/08/medethics-2020-106306.abstract	20/06/2020	Artigo de opinião	http://jme.bmj.com/content/early/2020/07/08/medethics-2020-106306.abstract	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality	https://doi.org/10.1016/j.vaccine.2020.06.083	03/07/2020	Artigo de opinião	10.1016/j.vaccine.2020.06.083	0264-410X	0264410X	VACCINE (GUILDFORD)	A2	1.392	191	4.02	-	['Cloroquina', 'Hidroxicloroquina', 'Vacina BCG']	['Chloroquine', 'Hydroxychloroquine', 'BCG Vaccine']
Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03143-7	09/07/2020	Artigo de opinião	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03143-7	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Angiotensina II']	['Angiotensin II']
Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19?	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa320/5811417	24/03/2020	Artigo de opinião	10.1093/cid/ciaa320/5811417	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0271	03/06/2020	Artigo de opinião	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0271	0002-9637	00029637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Ivermectina']	['Ivermectin']
Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses	https://doi.org/10.1016/j.antiviral.2020.104805	21/04/2020	Artigo de opinião	10.1016/j.antiviral.2020.104805	0166-3542	01663542	ANTIVIRAL RESEARCH	A1	2.213	134	9.13	-	['Ivermectina', 'Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin', 'Ivermectin']
New international guidance on quality, safety and efﬁcacy of DNA vaccines	https://doi.org/10.1038/s41541-020-0199-0	18/06/2020	Artigo de opinião	10.1038/s41541-020-0199-0	2059-0105	20590105	npj Vaccines	-	2.953	30	8.19	-	['Vacina de DNA', 'Vacina de RNA', 'Vacina de vírus inativado']	['DNA vaccine', 'RNA vaccine', 'Inactivated virus vaccine']
COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution	https://doi.org/10.1016/j.onehlt.2020.100148	24/06/2020	Artigo de opinião	10.1016/j.onehlt.2020.100148	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Ivermectina']	['Ivermectin']
Rapid advice guidelines for management of children with COVID-19	https://atm.amegroups.com/article/view/43612/html	08/05/2020	Artigo de opinião	https://atm.amegroups.com/article/view/43612/html	-	-	-	-	-	-	-	-	['Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Antibióticos', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Antibiotics', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', ' Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin' , 'Immunoglobulin', 'Immunoglobulin', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir' , 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', ' Remdesivir', 'Ribaviri na', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin	https://doi.org/10.1016/j.tmaid.2020.101819	03/07/2020	Artigo de opinião	10.1016/j.tmaid.2020.101819	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Ivermectin: potential candidate for the treatment of Covid 19	http://www.ncbi.nlm.nih.gov/pubmed/32615072	28/06/2020	Artigo de opinião	http://www.ncbi.nlm.nih.gov/pubmed/32615072	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
BCG is a Good Immunotherapeutic Agent for Viral and Autoimmune Diseases: Is it a New Weapon against Coronavirus (COVID-19)?	https://doi.org/10.29333/ejgm/7892	06/04/2020	Artigo de opinião	10.29333/ejgm/7892	2516-3507	25163507	Electronic Journal of General Medicine	-	0.297	21	1.74	-	['Vacina BCG']	['BCG vaccine']
Does zinc improve symptoms of viral upper respiratory tract infection? Evidence-Based Pract	https://journals.lww.com/ebp/Fulltext/2020/01000/Does_zinc_improve_symptoms_of_viral_upper.32.aspx	31/01/2020	Artigo de opinião	https://journals.lww.com/ebp/Fulltext/2020/01000/Does_zinc_improve_symptoms_of_viral_upper.32.aspx	-	-	-	-	-	-	-	-	['Zinco']	['Zinc']
Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models	https://www.nejm.org/doi/10.1056/NEJMp2020076	01/07/2020	Artigo de opinião	10.1056/NEJMp2020076	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Modelos de Infecção Humana Controlada (CHIM)']	['Models of Controlled Human Infection (CHIM)']
Ensuring Uptake of Vaccines against SARS-CoV-2	https://doi.org/10.1056/NEJMp2020926	26/06/2020	Artigo de opinião	10.1056/NEJMp2020926	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina']	['Vaccine']
Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?	https://pubmed.ncbi.nlm.nih.gov/32582439/	29/06/2020	Artigo de opinião	PUBMED_ID:32582439/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Chloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Covid-19: Oxford team begins vaccine trials in Brazil and South Africa to determine efficacy	https://doi.org/10.1136/bmj.m2612	29/06/2020	Artigo de opinião	10.1136/bmj.m2612	1756-1833	17561833	BMJ, The	-	2.291	453	4.44	-	['Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 vaccine']
Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.	https://doi.org/10.6061/clinics/2020/e2022	08/06/2020	Artigo de opinião	10.6061/clinics/2020/e2022	1807-5932	18075932	CLINICS (USP, IMPRESSO)	A3	0.604	67	2.64	-	['Corticosteroides']	['Corticosteroids']
COVID-19 in patients with rheumatological diseases treated with anti-TNF.	http://dx.doi.org/10.1136/annrheumdis-2020-218171	16/06/2020	Artigo de opinião	10.1136/annrheumdis-2020-218171	0003-4967	00034967	ANNALS OF THE RHEUMATIC DISEASES	A1	5.366	257	8.59	-	['Antagonistas de TNF', 'Azitromicina', 'Corticosteroides']	['TNF Antagonists', 'Azithromycin', 'Corticosteroids']
Amplifying RNA Vaccine Development.	https://www.nejm.org/doi/10.1056/NEJMcibr2009737	18/06/2020	Artigo de opinião	10.1056/NEJMcibr2009737	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina de RNA']	['RNA vaccine']
Hydroxychloroquine for covid-19: the end of the line?	https://doi.org/10.1136/bmj.m2378	15/06/2020	Artigo de opinião	10.1136/bmj.m2378	1756-1833	17561833	BMJ, The	-	2.291	453	4.44	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Monoclonal Antibodies for Prevention and Treatment of COVID-19.	https://jamanetwork.com/journals/jama/fullarticle/2767383	15/06/2020	Artigo de opinião	https://jamanetwork.com/journals/jama/fullarticle/2767383	-	-	-	-	-	-	-	-	['Anticorpos']	['Antibodies']
Convalescent Plasma and COVID-19.	https://doi.org/10.1001/jama.2020.10699	12/06/2020	Artigo de opinião	10.1001/jama.2020.10699	0098-7484	00987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Plasma convalescente']	['Convalescent Plasma']
COVID-19 vaccines for all?	https://europepmc.org/article/med/32534638	11/06/2020	Artigo de opinião	https://europepmc.org/article/med/32534638	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Can existing live vaccines prevent COVID-19?	https://science.sciencemag.org/content/368/6496/1187/tab-article-info	12/06/2020	Artigo de opinião	https://science.sciencemag.org/content/368/6496/1187/tab-article-info	-	-	-	-	-	-	-	-	['Vacina de vírus inativado', 'Vacina de vírus inativado', 'Vacina de vírus inativado']	['Inactivated virus vaccine', 'Inactivated virus vaccine', 'Inactivated virus vaccine']
COVID-19 vaccine development pipeline gears up.	https://doi.org/10.1016/S0140-6736(20)31252-6	06/06/2020	Artigo de opinião	10.1016/S0140-6736(20)31252-6	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina']	['Vaccine']
Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?	https://pubmed.ncbi.nlm.nih.gov/32378647/	04/06/2020	Artigo de opinião	PUBMED_ID:32378647/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26078	28/05/2020	Artigo de opinião	10.1002/jmv.26078	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed	http://www.sciencedirect.com/science/article/pii/S1876034120304718	11/05/2020	Artigo de opinião	http://www.sciencedirect.com/science/article/pii/S1876034120304718	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails	https://www.jaad.org/article/S0190-9622(20)30929-4/pdf	26/05/2020	Artigo de opinião	https://www.jaad.org/article/S0190-9622(20)30929-4/pdf	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Precision Medicine in COVID-19: IL-1β a Potential Target	https://pubmed.ncbi.nlm.nih.gov/32313848/	18/04/2020	Artigo de opinião	PUBMED_ID:32313848/	-	-	-	-	-	-	-	-	['Inibidor de IL-1β']	['IL-1β inhibitor']
SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment	https://www.frontiersin.org/articles/10.3389/fmed.2020.00184/full	24/04/2020	Artigo de opinião	10.3389/fmed.2020.00184/full	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome	https://doi.org/10.1007/s10928-020-09689-x	13/05/2020	Artigo de opinião	10.1007/s10928-020-09689-x	1567-567X	1567567X	Journal of Pharmacokinetics and Pharmacodynamics	-	0.579	64	2.34	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Drug vignettes: Azithromycin	https://www.cebm.net/covid-19/drug-vignettes-azithromycin/	13/05/2020	Artigo de opinião	https://www.cebm.net/covid-19/drug-vignettes-azithromycin/	-	-	-	-	-	-	-	-	['Azitromicina']	['Azithromycin']
A recommendation for the use of chloroquine, hydroxychloroquine, primaquine or tafenoquine for prophylaxis againts the 2019 novel coronavirus (COVD-19) with note to the ophthalmic considerations	https://www.eyereports.org/index.php/eyereports/article/view/99	14/05/2020	Artigo de opinião	https://www.eyereports.org/index.php/eyereports/article/view/99	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina', 'Primaquina', 'Tafenoquina']	['Chloroquine', 'Hydroxychloroquine', 'Primaquine', 'Tafenoquine']
Covid‐19 and drug therapy, what we learned	https://doi.org/10.1007/s11096-020-01049-6	07/05/2020	Artigo de opinião	10.1007/s11096-020-01049-6	2210-7703	22107703	INTERNATIONAL JOURNAL OF CLINICAL PHARMACY	A4	0.501	63	2.41	-	['Antagonistas do Receptor da Angiotensina II', 'Azitromicina', 'Camostato', 'Cloroquina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Angiotensin II Receptor Antagonists', 'Azithromycin', 'Camostat', 'Chloroquine', 'Hydroxychloroquine', 'Interferon alfa', 'Ivermectin', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir' , 'Tocilizumab', 'Umifenovir']
The FDA has authorised remdesivir for use in COVID-19 patients: but there’s no good evidence it reduces mortality	https://www.cebm.net/covid-19/the-fda-has-authorised-remdesivir-for-use-in-covid-19-patients-but-theres-no-good-evidence-it-reduces-mortality/	12/05/2020	Artigo de opinião	https://www.cebm.net/covid-19/the-fda-has-authorised-remdesivir-for-use-in-covid-19-patients-but-theres-no-good-evidence-it-reduces-mortality/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Metformin in COVID-19: A possible role beyond diabetes	https://doi.org/10.1016/j.diabres.2020.108183	29/04/2020	Artigo de opinião	10.1016/j.diabres.2020.108183	0168-8227	01688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Metformina']	['Metformin']
NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?	https://doi.org/10.1016/j.phrs.2020.104849	29/04/2020	Artigo de opinião	10.1016/j.phrs.2020.104849	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Emergency Use Authorization of remdesivir by the US Food and Drug Administration	https://www.cebm.net/covid-19/emergency-use-authorization-of-remdesivir-by-the-us-food-and-drug-administration/	06/05/2020	Artigo de opinião	https://www.cebm.net/covid-19/emergency-use-authorization-of-remdesivir-by-the-us-food-and-drug-administration/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Can melatonin reduce the severity of COVID-19 pandemic?	https://www.tandfonline.com/doi/full/10.1080/08830185.2020.1756284	29/04/2020	Artigo de opinião	10.1080/08830185.2020.1756284	0883-0185	08830185	INTERNATIONAL REVIEWS OF IMMUNOLOGY (PRINT)	A4	1.072	71	4.74	-	['Melatonina', 'Melatonina', 'Melatonina']	['Melatonin', 'Melatonin', 'Melatonin']
Headache medication and the COVID-19 pandemic	https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-01106-5	25/04/2020	Artigo de opinião	https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-020-01106-5	1129-2369	11292369	Journal of Headache and Pain	-	1.924	70	7.37	 Abstract The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.	['Ibuprofeno', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Ibuprofen', 'Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
COVID-19 therapeutic options for patients with kidney disease	https://doi.org/10.1016/j.kint.2020.03.015	30/03/2020	Artigo de opinião	10.1016/j.kint.2020.03.015	0085-2538	00852538	KIDNEY INTERNATIONAL	A1	4.063	288	7.69	-	['Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', ' Tocilizumab', 'Tocilizumab']
The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement	https://doi.org/10.1016/j.micinf.2020.04.005	17/04/2020	Artigo de opinião	10.1016/j.micinf.2020.04.005	1286-4579	12864579	MICROBES AND INFECTION	A2	1.586	148	6.22	-	['Células Th17']	['Th17 Cells']
Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?	https://www.ahajournals.org/doi/full/10.1161/JAHA.120.016509	01/04/2020	Artigo de opinião	10.1161/JAHA.120.016509	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties	https://link.springer.com/article/10.1007/s40262-020-00891-1	18/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s40262-020-00891-1	0312-5963	03125963	CLINICAL PHARMACOKINETICS	A1	1.274	169	5.4	-	['Cloroquina', 'Cloroquina', 'Cloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine']
Angiotensin Receptor Blockers and 2019-nCoV	https://doi.org/10.1016/j.phrs.2020.104832	15/04/2020	Artigo de opinião	10.1016/j.phrs.2020.104832	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists']
Challenges of Convalescent Plasma Therapy on COVID-19	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146649/	10/04/2020	Artigo de opinião	PMC:PMC7146649/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and reninangiotensin system blockers in SARS-CoV-2 infections	https://onlinelibrary.wiley.com/doi/full/10.1002/ddr.21672	17/04/2020	Artigo de opinião	10.1002/ddr.21672	0272-4391	02724391	DRUG DEVELOPMENT RESEARCH (PRINT)	A4	0.552	62	4.75	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action	https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16727	18/04/2020	Artigo de opinião	10.1111/bjh.16727	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Anticoagulantes']	['Anticoagulants']
Inaccurate conclusions by Tang and colleagues	https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14857	18/04/2020	Artigo de opinião	10.1111/jth.14857	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Anticoagulantes']	['Anticoagulants']
Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine	https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13380	06/04/2020	Artigo de opinião	10.1111/dth.13380	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes	https://pubmed.ncbi.nlm.nih.gov/32267301/	06/04/2020	Artigo de opinião	PUBMED_ID:32267301/	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients	https://link.springer.com/article/10.1007/s11739-020-02331-1	15/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s11739-020-02331-1	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Acenocoumarol', 'Apixabana', 'Dabigatrana', 'Darunavir', 'Edoxabana', 'Heparina', 'Lopinavir', 'Ritonavir', 'Rivaroxabana', 'Varfarina']	['Acenocoumarol', 'Apixaban', 'Dabigatran', 'Darunavir', 'Edoxaban', 'Heparin', 'Lopinavir', 'Ritonavir', 'Rivaroxaban', 'Warfarin']
Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19	https://ard.bmj.com/content/annrheumdis/early/2020/04/15/annrheumdis-2020-217460.full.pdf	15/04/2020	Artigo de opinião	https://ard.bmj.com/content/annrheumdis/early/2020/04/15/annrheumdis-2020-217460.full.pdf	-	-	-	-	-	-	-	-	['Antirreumáticos', 'Antirreumáticos', 'Corticosteroides', 'Corticosteroides']	['Anti-rheumatics', 'Anti-rheumatics', 'Corticosteroids', 'Corticosteroids']
Finding Effective Treatments for COVID-19: Scientific Integrity and Public Confidence in a Time of Crisis	https://jamanetwork.com/journals/jama/fullarticle/2764823	16/04/2020	Artigo de opinião	https://jamanetwork.com/journals/jama/fullarticle/2764823	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments	https://link.springer.com/article/10.1007/s10654-020-00628-1	15/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s10654-020-00628-1	0393-2990	03932990	EUROPEAN JOURNAL OF EPIDEMIOLOGY	A1	3.920	120	10.4	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
EMA advice on renin-angiotensin system medicines during covid-19 pandemic	https://dtb.bmj.com/content/58/6/85	15/04/2020	Artigo de opinião	https://dtb.bmj.com/content/58/6/85	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology	https://doi.org/10.1016/j.clim.2020.108414	06/04/2020	Artigo de opinião	10.1016/j.clim.2020.108414	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	[]	[]
Reply to "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy	https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14852	17/04/2020	Artigo de opinião	10.1111/jth.14852	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	[]	[]
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?	https://pubmed.ncbi.nlm.nih.gov/32302707/	14/04/2020	Artigo de opinião	PUBMED_ID:32302707/	-	-	-	-	-	-	-	-	['Anticorpos neutralizantes direcionados a IL-17']	['IL-17-targeted neutralizing antibodies']
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19	https://pubmed.ncbi.nlm.nih.gov/32300051/	19/04/2020	Artigo de opinião	PUBMED_ID:32300051/	-	-	-	-	-	-	-	-	['Sarilumabe', 'Siltuximabe', 'Tocilizumabe']	['Sarilumab', 'Siltuximab', 'Tocilizumab']
Potential of Heparin and Nafamostat Combination Therapy for COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14858	17/04/2020	Artigo de opinião	10.1111/jth.14858	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Heparina', 'Nafamostato']	['Heparin', 'Nafamostat']
Amiodarone as a possible therapy for coronavirus infection	https://journals.sagepub.com/doi/full/10.1177/2047487320919233	16/04/2020	Artigo de opinião	10.1177/2047487320919233	2047-4873	20474873	EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY	A1	1.689	106	3.07	-	['Amiodarona']	['Amiodarone']
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view	https://www.medrxiv.org/content/10.1101/2020.04.11.20061804v2	17/04/2020	Artigo de opinião	10.1101/2020.04.11.20061804v2	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153514/	13/04/2020	Artigo de opinião	PMC:PMC7153514/	-	-	-	-	-	-	-	-	['Nitazoxanida']	['Nitazoxanide']
Importance of inclusion of pregnant and breastfeeding women in COVID-19 therapeutic trials	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa444/5820683	15/04/2020	Artigo de opinião	10.1093/cid/ciaa444/5820683	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Remdesivir']	['Hydroxychloroquine', 'Remdesivir']
Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19	https://www.sciencedirect.com/science/article/pii/S1876382020303899	03/04/2020	Artigo de opinião	https://www.sciencedirect.com/science/article/pii/S1876382020303899	-	-	-	-	-	-	-	-	['Medicina Tradicional Chinesa']	['Traditional Chinese medicine']
Why tocilizumab could be an efective treatment for severe COVID-19?	https://doi.org/10.1186/s12967-020-02339-3	14/04/2020	Artigo de opinião	10.1186/s12967-020-02339-3	1479-5876	14795876	JOURNAL OF TRANSLATIONAL MEDICINE (ONLINE)	A2	1.570	121	7.38	 Abstract A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.	['Tocilizumabe']	['Tocilizumab']
Coronavirus Vaccines: Light at the End of the Tunnel	https://www.researchgate.net/publication/340679212_Coronavirus_Vaccine_Light_at_the_End_of_the_Tunnel	15/04/2020	Artigo de opinião	https://www.researchgate.net/publication/340679212_Coronavirus_Vaccine_Light_at_the_End_of_the_Tunnel	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia	https://www.nature.com/articles/s41392-020-0127-9	21/02/2020	Artigo de opinião	https://www.nature.com/articles/s41392-020-0127-9	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Hydroxychloroquine prophylaxis for COVID-19 contacts in India	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30313-3/fulltext	17/04/2020	Artigo de opinião	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30313-3/fulltext	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19	https://doi.org/10.1016/S1473-3099(20)30296-6	17/04/2020	Artigo de opinião	10.1016/S1473-3099(20)30296-6	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use	https://www.mdpi.com/2073-4409/9/4/924	09/04/2020	Artigo de opinião	https://www.mdpi.com/2073-4409/9/4/924	-	-	-	-	-	-	-	-	['Terapia celular']	['Cell Therapy']
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base	http://dx.doi.org/10.1016/S2213-2600(20)30172-7	15/04/2020	Artigo de opinião	10.1016/S2213-2600(20)30172-7	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)?	https://journals.lww.com/jtrauma/Fulltext/publishahead/Is_There_a_Role_for_Tissue_Plasminogen_Activator.97967.aspx	15/04/2020	Artigo de opinião	https://journals.lww.com/jtrauma/Fulltext/publishahead/Is_There_a_Role_for_Tissue_Plasminogen_Activator.97967.aspx	-	-	-	-	-	-	-	-	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces	http://ijpr.sbmu.ac.ir/article_1101020.html	15/04/2020	Artigo de opinião	http://ijpr.sbmu.ac.ir/article_1101020.html	-	-	-	-	-	-	-	-	['Talidomida']	['Thalidomide']
Pharmaceutical are of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19)	https://onlinelibrary.wiley.com/doi/full/10.1002/agm2.12104	06/04/2020	Artigo de opinião	10.1002/agm2.12104	2475-0360	24750360	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Drug Evaluation during the Covid-19 Pandemic	https://doi.org/10.1056/NEJMp2009457	14/04/2020	Artigo de opinião	10.1056/NEJMp2009457	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?	https://doi.org/10.1016/j.jaad.2020.04.017	10/04/2020	Artigo de opinião	10.1016/j.jaad.2020.04.017	0190-9622	01909622	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	A1	1.948	217	4.29	-	['Hidroxicloroquina', 'Ivermectina']	['Hydroxychloroquine', 'Ivermectin']
Chloroquine and hydroxychloroquine in covid-19.	https://www.bmj.com/content/369/bmj.m1432	08/04/2020	Artigo de opinião	https://www.bmj.com/content/369/bmj.m1432	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Type 1 interferons as a potential treatment against COVID-19	https://www.sciencedirect.com/science/article/pii/S0166354220302059	07/04/2020	Artigo de opinião	https://www.sciencedirect.com/science/article/pii/S0166354220302059	-	-	-	-	-	-	-	-	['Interferon recombinante tipo 1']	['Type 1 recombinant interferon']
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy	https://pubmed.ncbi.nlm.nih.gov/32253068/	02/04/2020	Artigo de opinião	PUBMED_ID:32253068/	-	-	-	-	-	-	-	-	['Anakinra', 'Baricitinibe', 'Hidroxicloroquina', 'Sarilumabe', 'Tocilizumabe']	['Anakinra', 'Baricitinib', 'Hydroxychloroquine', 'Sarilumab', 'Tocilizumab']
Therapeutic Potential for Tetracyclines in the Treatment of COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.2395	08/04/2020	Artigo de opinião	10.1002/phar.2395	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Tetraciclinas']	['Tetracyclines']
Considerations for statin therapy in patients with COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2397	08/04/2020	Artigo de opinião	10.1002/phar.2397	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Estatina']	['Statin']
Regulators split on antimalarials for COVID-19	https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30817-5.pdf	11/04/2020	Artigo de opinião	https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30817-5.pdf	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
SARS-CoV-2 Vaccines: Status Report	http://www.sciencedirect.com/science/article/pii/S1074761320301205	06/04/2020	Artigo de opinião	http://www.sciencedirect.com/science/article/pii/S1074761320301205	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment	https://doi.org/10.1161/CIRCULATIONAHA.120.047521	08/04/2020	Artigo de opinião	10.1161/CIRCULATIONAHA.120.047521	0009-7322	00097322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients	https://doi.org/10.1093/cid/ciaa394	07/04/2020	Artigo de opinião	10.1093/cid/ciaa394	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.	['Hidroxicloroquina']	['Hydroxychloroquine']
Comunicado a la opinión pública uso de Hidroxicloroquina / Public opinion on the use of Hydroxychloroquine	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1053244	08/04/2020	Artigo de opinião	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1053244	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Macrolide treatment for COVID-19: Will this be the way forward?	https://pubmed.ncbi.nlm.nih.gov/32249257/	05/04/2020	Artigo de opinião	PUBMED_ID:32249257/	-	-	-	-	-	-	-	-	['Azitromicina']	['Azithromycin']
The versatile heparin in COVID-19. Journal of thrombosis and haemostasis	https://onlinelibrary.wiley.com/doi/10.1111/jth.14821	02/04/2020	Artigo de opinião	10.1111/jth.14821	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Heparina']	['Heparin']
Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial.	https://doi.org/10.1183/13993003.03725-2020	14/01/2021	Artigo completo publicado em periódico científico	10.1183/13993003.03725-2020	0903-1936	09031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background Nitazoxanide is widely available and exerts broad-spectrum antiviral activity  in vitro. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.  Methods In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation and hospitalisation rate. Adverse events were also assessed.  Results From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median (interquartile range) time from symptom onset to first dose of study drug was 5 (4–5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm  versus 18.2% in the placebo arm (p=0.009). Viral load was reduced after nitazoxanide compared to placebo (p=0.006). The percentage viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.  Conclusions In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.	['Nitazoxanida']	['Nitazoxanide']
Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.	https://onlinelibrary.wiley.com/doi/full/10.1111/trf.16177	30/10/2020	Artigo completo publicado em periódico científico	10.1111/trf.16177	0041-1132	00411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.	https://doi.org/10.1186/s12879-021-05773-w	14/01/2021	Artigo completo publicado em periódico científico	10.1186/s12879-021-05773-w	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.                                Methods                 We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.                                Results                 Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.                                Conclusions                 In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.              	['Hidroxicloroquina']	['Hydroxychloroquine']
Corticosteroid treatment has no efect on hospital mortality in COVID‐19 patients.	https://doi.org/10.1038/s41598-020-80654-x	13/01/2021	Artigo completo publicado em periódico científico	10.1038/s41598-020-80654-x	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract Since the start of the novel coronavirus 2019 (COVID-19) pandemic, corticosteroid use has been the subject of debate. The available evidence is uncertain, and knowledge on the subject is evolving. The aim of our cohort study was to evaluate the association between corticosteroid therapy and hospital mortality, in patients hospitalized with COVID-19 after balancing for possible confounders. One thousand four hundred forty four patients were admitted to our hospital with a positive RT-PCR test for SARS-CoV-2, 559 patients (39%) were exposed to corticosteroids during hospital stay, 844 (61%) were not exposed to corticosteroids. In the cohort of patients exposed to corticosteroids, 171 (30.6%) died. In the cohort of patients not exposed to corticosteroids, 183 (21.7%) died (unadjusted  p &lt; 0.001). Nonetheless, exposure to corticosteroids was not associated with in-hospital mortality after balancing with overlap weight propensity score (adjusted  p = 0.25). Patients in the corticosteroids cohort had a reduced risk of ICU admission (adjusted  p &lt; 0.001). Treatment with corticosteroids did not affect hospital mortality in patients with COVID-19 after balancing for confounders. A possible advantage of corticosteroid therapy was to reduce Intensive Care Unit admission, which could be useful in reducing pressure on Intensive Care Units in times of limited resources, as during the COVID-19 pandemic.	['Corticosteroides']	['Corticosteroids']
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.	https://www.nejm.org/doi/full/10.1056/NEJMoa2034201	13/01/2021	Artigo completo publicado em periódico científico	10.1056/NEJMoa2034201	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina (Ad26.COV2.S)', 'Vacina (Ad26.COV2.S)']	['Vaccine (Ad26.COV2.S)', 'Vaccine (Ad26.COV2.S)']
The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.	https://doi.org/10.1371/journal.pone.0244128	31/12/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244128	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Purpose To evaluate the efficacy and safety of methylprednisolone in treating the coronavirus disease 2019 (COVID-19) patients.<jats:sec id="sec002"> Methods A retrospective cohort study was conducted, and all COVID-19 patients were recruited who were admitted to the Yichang Third People’s Hospital from February 1 st to March 31 st, 2020. One-to-one propensity score matching (PSM) was used for minimizing confounding effects. The primary outcome was hospital mortality, with the secondary outcomes being the time needed for a positive SARS-CoV-2 nucleic acid test to turn negative and the length of hospital stay.<jats:sec id="sec003"> Results Totaling 367 patients with COVID-19 hospitalized at the Yichang Third People’s Hospital were identified, of whom 276 were mild or stable COVID-19, and 67 were serious or critically ill. Among them, 255 patients were treated using methylprednisolone, and 188 did not receive any corticosteroid-related treatment. After PSM, no statistically significant difference was found in the baseline characteristics between the two groups. Regarding the outcomes, there also were no statistically significant difference between the two groups. Patients without the use of methylprednisolone were more quickly to obtain negative results of their nasopharyngeal swab tests of SARS-CoV-2 nucleic acid after treatment, compared to those receiving methylprednisolone.<jats:sec id="sec004"> Conclusion Methylprednisolone could not improve the prognosis of patients with COVID-19, and the efficacy and safety of the use of methylprednisolone in patients with COVID-19 still remain uncertain, thus the use of corticosteroids clinically in patients with COVID-19 should be with cautions.	['Prednisona']	['Prednisone']
Efficacy Evaluation of Intravenous Immunoglobulin in Non-severe Patients with COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.	https://doi.org/10.1016/j.ijid.2021.01.009	09/01/2021	Artigo completo publicado em periódico científico	10.1016/j.ijid.2021.01.009	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Imunoglobulina']	['Immunoglobulin']
Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study.	https://dx.doi.org/10.3390/jcm10010028	24/12/2020	Artigo completo publicado em periódico científico	https://dx.doi.org/10.3390/jcm10010028	2077-0383	20770383	JOURNAL OF CLINICAL MEDICINE	A1	1.040	75	4.84	 Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p &lt; 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible.	['Plasma convalescente']	['Convalescent Plasma']
Impact of oral anticoagulation on clinical outcomes of COVID‐19: a nationwide cohort study of hospitalized patients in Germany.	https://doi.org/10.1007/s00392-020-01783-x	08/01/2021	Artigo completo publicado em periódico científico	10.1007/s00392-020-01783-x	1861-0684	18610684	CLINICAL RESEARCH IN CARDIOLOGY (PRINT)	A2	1.772	75	4.86	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes']	['Vitamin K antagonists (VKA)', 'Anticoagulants']
Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.	https://dx.doi.org/10.3390/ijerph18010102	25/12/2020	Artigo completo publicado em periódico científico	https://dx.doi.org/10.3390/ijerph18010102	1660-4601	16604601	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH	A2	0.814	138	4.7	 Introduction: The Coronavirus disease 2019 (COVID-19) outbreak is a whole Earth health emergency related to a highly pathogenic human coronavirus responsible for severe acute respiratory syndrome (SARS-CoV-2). Despite the fact that the majority of infected patients were managed in outpatient settings, little is known about the clinical characteristics of COVID-19 patients not requiring hospitalization. The aim of our study was to describe the clinical comorbidity and the pharmacological therapies of COVID-19 patients managed in outpatient settings. Materials and Methods: We performed an observational, retrospective analysis of laboratory-confirmed COVID-19 patients managed in outpatient settings in Naples, Italy between 9 March and 1 May 2020. Data were sourced from the prospectively maintained Health Search (HS)/Thales database, shared by 128 primary care physicians (PCPs) in Naples, Italy. The clinical features and pharmacological therapies of COVID-19 patients not requiring hospitalization and managed in outpatient settings have been described. Results: A total of 351 laboratory-confirmed COVID-19 patients (mean age 54 ± 17 years; 193 males) with outpatient management were evaluated. Hypertension was the most prevalent comorbidity (35%). The distribution of cardiovascular comorbidities showed no gender-related differences. A total of 201 patients (57.3%) were treated with at least one experimental drug for COVID-19. Azithromycin, alone (42.78%) or in combination (27.44%), was the most widely used experimental anti-COVID drug in outpatient settings. Low Molecular Weight Heparin and Cortisone were prescribed in 24.87% and 19.4% of the study population, respectively. At multivariate regression model, diabetes (risk ratio (RR): 3.74; 95% CI 1.05 to 13.34; p = 0.04) and hypertension (RR: 1.69; 95% CI 1.05 to 2.7; p = 0.03) were significantly associated with the experimental anti-COVID drug administration. Moreover, only diabetes (RR: 2.43; 95% CI 1.01 to 5.8; p = 0.03) was significantly associated with heparin administration. Conclusions: Our data show a high prevalence of hypertension, more likely treated with renin–angiotensin–aldosterone system (RASS) inhibitors, among COVID-19 patients not requiring hospitalization. Experimental COVID-19 therapies have been prescribed to COVID-19 patients considered at risk for increased venous thromboembolism based on concomitant comorbidities, in particular diabetes and hypertension.	['Azitromicina', 'Corticosteroides', 'Heparina', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Azithromycin', 'Corticosteroids', 'Heparin', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.	https://doi.org/10.1016/j.onehlt.2021.100214	05/01/2021	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2021.100214	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Tocilizumabe']	['Tocilizumab']
Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.	https://doi.org/10.1371/journal.pone.0244853	07/01/2021	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244853	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Background Cytokine release syndrome (CRS) plays a pivotal role in the pathophysiology and progression of Coronavirus disease-2019 (COVID-19). Therapeutic plasma exchange (TPE) by removing the pathogenic cytokines is hypothesized to dampen CRS.<jats:sec id="sec002"> Objective To evaluate the outcomes of the patients with COVID-19 having CRS being treated with TPE compared to controls on the standard of care.<jats:sec id="sec003"> Methodology Retrospective propensity score-matched analysis in a single centre from 1st April to 31st July 2020. We retrospectively analyzed data of 280 hospitalized patients developing CRS initially. PSM was used to minimize bias from non-randomized treatment assignment. Using PSM 1:1, 90 patients were selected and assigned to 2 equal groups. Forced matching was done for disease severity, routine standard care and advanced supportive care. Many other Co-variates were matched. Primary outcome was 28 days overall survival. Secondary outcomes were duration of hospitalization, CRS resolution time and timing of viral clearance on Polymerase chain reaction testing.<jats:sec id="sec004"> Results After PS-matching, the selected cohort had a median age of 60 years (range 32–73 in TPE, 37–75 in controls), p = 0.325 and all were males. Median symptoms duration was 7 days (range 3–22 days’ TPE and 3–20 days controls), p = 0.266. Disease severity in both groups was 6 (6.6%) moderate, 40 (44.4%) severe and 44 (49%) critical. Overall, 28-day survival was significantly superior in the TPE group (91.1%), 95% CI 78.33–97.76; as compared to PS-matched controls (61.5%), 95% CI 51.29–78.76 (log rank 0.002), p&lt;0.001. Median duration of hospitalization was significantly reduced in the TPE treated group (10 days vs 15 days) (p&lt; 0.01). CRS resolution time was also significantly reduced in the TPE group (6 days vs. 12 days) (p&lt; 0.001). In 71 patients who underwent TPE, the mortality was 0 (n = 43) if TPE was done within the first 12 days of illness while it was 17.9% (deaths 5, n = 28 who received it after 12 th day (p = 0.0045).<jats:sec id="sec005"> Conclusion An earlier use of TPE was associated with improved overall survival, early CRS resolution and time to discharge compared to SOC for COVID-19 triggered CRS in this selected cohort of PS-matched male patients from one major hospital in Pakistan.	['Plasma convalescente']	['Convalescent Plasma']
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.	https://pubmed.ncbi.nlm.nih.gov/33078604/	17/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33078604/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.	https://doi.org/10.1016/j.cct.2021.106272	07/01/2021	Artigo completo publicado em periódico científico	10.1016/j.cct.2021.106272	1551-7144	15517144	CONTEMPORARY CLINICAL TRIALS	A3	0.867	65	2.26	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients—initial experience.	10.5603/ARM.a2020.0139	11/01/2020	Artigo completo publicado em periódico científico	10.5603/ARM.a2020.0139	2543-6031	25436031	Advances in Respiratory Medicine	-	0.251	20	0.87	-	['Cloroquina']	['Chloroquine']
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738873/	01/01/2021	Artigo completo publicado em periódico científico	PMC:PMC7738873/	-	-	-	-	-	-	-	-	['colchicina', 'daclastavir', 'interferon', 'plasma convalescente', 'Sofosbuvir']	['colchicine', 'daclastavir', 'interferon', 'convalescent plasma', 'Sofosbuvir']
Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.	https://doi.org/10.1186/s13054-020-03422-3	04/01/2021	Artigo completo publicado em periódico científico	10.1186/s13054-020-03422-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Critically ill patients with coronavirus disease 19 (COVID-19) have a high fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate this inappropriate response, although there are still some concerns regarding its use, timing, and dose.                                Methods                 This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in Spain from 12th March to 29th June 2020. Using a multivariable Cox model with inverse probability weighting, we compared relevant outcomes between patients treated with early corticosteroids (before or within the first 48 h of ICU admission) with those who did not receive early corticosteroids (delayed group) or any corticosteroids at all (never group). Primary endpoint was ICU mortality. Secondary endpoints included 7-day mortality, ventilator-free days, and complications.                                Results                 A total of 691 patients out of 882 (78.3%) received corticosteroid during their hospital stay. Patients treated with early-corticosteroids (n = 485) had lower ICU mortality (30.3% vs. never 36.6% and delayed 44.2%) and lower 7-day mortality (7.2% vs. never 15.2%) compared to non-early treated patients. They also had higher number of ventilator-free days, less length of ICU stay, and less secondary infections than delayed treated patients. There were no differences in medical complications between groups. Of note, early use of moderate-to-high doses was associated with better outcomes than low dose regimens.                                Conclusion                 Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality than no or delayed use, and fewer complications than delayed use.              	['Corticosteroides']	['Corticosteroids']
The Role of Vitamin C as Adjuvant Therapy in COVID-19.	https://www.cureus.com/articles/45284-the-role-of-vitamin-c-as-adjuvant-therapy-in-covid-19	30/11/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/45284-the-role-of-vitamin-c-as-adjuvant-therapy-in-covid-19	-	-	-	-	-	-	-	-	['Ácido ascórbico']	['Ascorbic acid']
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30558-0/fulltext	07/01/2021	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30558-0/fulltext	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists' 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors' Angiotensin Converting Enzyme 2 (ACEI 2)', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.	https://doi.org/10.1016/j.intimp.2020.107329	26/12/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107329	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon', 'Lopinavir', 'Ritonavir']	['Interferon', 'Lopinavir', 'Ritonavir']
Association of ACEI/ARB, inflammatory cytokines, and antiviral drugs with liver dysfunction in patients with hypertension and COVID-19.	https://www.tandfonline.com/doi/full/10.1080/10641963.2020.1867160	26/12/2020	Artigo completo publicado em periódico científico	10.1080/10641963.2020.1867160	1064-1963	10641963	CLINICAL AND EXPERIMENTAL HYPERTENSION (1993, PRINT)	B1	0.481	50	1.96	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.	https://www.nejm.org/doi/full/10.1056/NEJMoa2033700	06/01/2021	Artigo completo publicado em periódico científico	10.1056/NEJMoa2033700	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Plasma convalescente']	['Convalescent Plasma']
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.	https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472	05/01/2021	Artigo completo publicado em periódico científico	10.1002/sctm.20-0472	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 ± 20 × 106 UC-MSCs; controls received two infusions of vehicle solution. Both groups received best standard of care. Primary endpoint was safety (adverse events [AEs]) within 6 hours; cardiac arrest or death within 24 hours postinfusion). Secondary endpoints included patient survival at 31 days after the first infusion and time to recovery. No difference was observed between groups in infusion-associated AEs. No serious adverse events (SAEs) were observed related to UC-MSC infusions. UC-MSC infusions in COVID-19 ARDS were found to be safe. Inflammatory cytokines were significantly decreased in UC-MSC-treated subjects at day 6. Treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS.	['Acetato de icatibanto', 'Ácido alfa lipóico', 'Ácido ascórbico', 'Aprepitanto', 'Auxora', 'Azitromicina', 'Azivudina', 'Baloxavir marboxil', 'Bromexina', 'Cloroquina', 'Cobicistato', 'Colchicina', 'Corticosteroides', 'Daclatasvir', 'Darunavir', 'Dexametasona', 'Difosfonato de metila (99-mTc)', 'Fator estimulador de colônias de granulócitos humano recombinante', 'Favipiravir', 'Hidroxicloroquina', 'Imunoglobulina', 'Inibidor de C1 esterase/calicreína', 'Interferon alfa', 'Interferon beta', 'Interferon gama', 'Lincocin', 'Lopinavir', 'N-acetilcisteína', 'Novaferon', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sofosbuvir', 'Solução salina eletrolisada', 'Terapia celular', 'Tocilizumabe', 'Triazavirina', 'Umifenovir', 'Vilobelimabe', 'Vitamina D (25-hidroxivitamina D)']	['Icatibant acetate', 'Alpha lipoic acid', 'Ascorbic acid', 'Aprepitant', 'Auxora', 'Azithromycin', 'Azivudine', 'Baloxavir marboxil', 'Bromhexine', 'Chloroquine', 'Cobicistat' , 'Colchicine', 'Corticosteroids', 'Daclatasvir', 'Darunavir', 'Dexamethasone', 'Methyl diphosphonate (99-mTc)', 'Recombinant human granulocyte colony stimulating factor', 'Favipiravir', 'Hydroxychloroquine' , 'Immunoglobulin', 'C1 esterase/kallikrein inhibitor', 'Interferon alpha', 'Interferon beta', 'Interferon gamma', 'Lincocin', 'Lopinavir', 'N-acetylcysteine', 'Novaferon', 'Convalescent plasma ', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sofosbuvir', 'Electrolyzed saline', 'Cell therapy', 'Tocilizumab', 'Triazavirin', 'Umifenovir', 'Vilobelimab', 'Vitamin D (25 -hydroxyvitamin D)']
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.	https://doi.org/10.2147/IDR.S289037	29/12/2020	Artigo completo publicado em periódico científico	10.2147/IDR.S289037	1178-6973	11786973	INFECTION AND DRUG RESISTANCE	A1	0.944	44	4.55	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone' , 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', ' Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.	https://pubmed.ncbi.nlm.nih.gov/33402859/	14/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33402859/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.	https://pubmed.ncbi.nlm.nih.gov/33402523/	01/01/2021	Artigo completo publicado em periódico científico	PUBMED_ID:33402523/	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Anticoagulantes']	['Anticoagulants', 'Anticoagulants']
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.	https://doi.org/10.1093/cid/ciaa677	05/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa677	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   In patients with severe coronavirus disease 2019 (COVID-19), data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.                                                  Methods                   We performed a retrospective longitudinal cohort study on consecutive patients with newly diagnosed severe COVID-19. Independent predictors were assessed through receiver operating characteristic analysis, time-series analysis, logistic regression analysis, and multilevel modeling for repeated measures.                                                  Results                   On the 149 patients included in the study 30% (44/149) were treated with ACEI/ARB. ACEI/ARB use was independently associated with the following biochemical variations: phosphorus &amp;gt;40 mg/L (odds ratio [OR], 3.35, 95% confidence interval [CI], 1.83–6.14), creatinine &amp;gt;10.1 mg/L (OR, 3.22, 2.28–4.54), and urea nitrogen (UN) &amp;gt;0.52 g/L (OR, 2.65, 95% CI, 1.89–3.73). ACEI/ARB use was independently associated with acute kidney injury stage ≥1 (OR, 3.28, 95% CI, 2.17–4.94). The daily dose of ACEI/ARB was independently associated with altered kidney markers with an increased risk of +25 to +31% per each 10 mg increment of lisinopril-dose equivalent. In multivariable multilevel modeling, UN &amp;gt;0.52 g/L was independently associated with the risk of acute respiratory failure (OR, 3.54, 95% CI, 1.05–11.96).                                                  Conclusions                   Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719003/	05/12/2020	Artigo completo publicado em periódico científico	PMC:PMC7719003/	-	-	-	-	-	-	-	-	['Corticosteroides', 'Prednisolona']	['Corticosteroids', 'Prednisolone']
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy.	https://doi.org/10.1016/j.jacl.2020.12.008	21/12/2020	Artigo completo publicado em periódico científico	10.1016/j.jacl.2020.12.008	1933-2874	19332874	JOURNAL OF CLINICAL LIPIDOLOGY	A1	1.281	62	3.57	-	['Estatina']	['Statin']
Low vitamin D status is associated with coronavirus disease 2019 outcomes: A systematic review and meta-analysis	https://doi.org/10.1016/j.ijid.2020.12.077	01/01/2021	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.12.077	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study.	https://doi.org/10.1016/j.diabres.2020.108619	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.diabres.2020.108619	0168-8227	01688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Metformina']	['Metformin']
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035389	30/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2035389	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.	https://doi.org/10.1016/j.eclinm.2020.100689	23/12/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100689	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Vacina INO-4800', 'Vacina INO-4800']	['INO-4800 vaccine', 'INO-4800 vaccine']
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.	https://doi.org/10.1016/j.diabet.2020.101220	23/12/2020	Artigo completo publicado em periódico científico	10.1016/j.diabet.2020.101220	1262-3636	12623636	DIABETES & METABOLISM	A2	1.834	94	4.51	-	['Estatina']	['Statin']
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection.	https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.04.260	30/12/2020	Artigo completo publicado em periódico científico	https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.04.260	2153-8174	21538174	-	-	-	-	-	-	['Azitromicina', 'Ceftriaxona', 'Doxiciclina', 'Hidroxicloroquina', 'Ivermectina', 'Zinco']	['Azithromycin', 'Ceftriaxone', 'Doxycycline', 'Hydroxychloroquine', 'Ivermectin', 'Zinc']
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir.	https://doi.org/10.1016/j.jiph.2020.12.017	29/12/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.12.017	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Favipiravir', 'Hidroxicloroquina']	['Favipiravir', 'Hydroxychloroquine']
Tocilizumab in the Management of COVID-19: A Preliminary Report.	https://doi.org/10.1016/j.amjms.2020.11.005	08/11/2020	Artigo completo publicado em periódico científico	10.1016/j.amjms.2020.11.005	0002-9629	00029629	THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES (PRINT)	A2	0.628	92	1.74	-	['Tocilizumabe']	['Tocilizumab']
No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.	https://www.ijidonline.com/article/S1201-9712(20)32583-2/fulltext	23/12/2020	Artigo completo publicado em periódico científico	https://www.ijidonline.com/article/S1201-9712(20)32583-2/fulltext	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773971	10/12/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773971	-	-	-	-	-	-	-	-	['Azitromicina', 'Estatina', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Azithromycin', 'Statin', 'Hydroxychloroquine', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Safety and Efficacy of Convalescent Plasma for Severe COVID‐19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.	https://www.researchgate.net/profile/Abdul_Rehman_Zaidi/publication/347933502_Safety_and_Efficacy_of_Convalescent_Plasma_for_Severe_COVID-19_Interim_Report_of_a_Multicenter_Phase_II_Study_from_Saudi_Arabia/links/5fe848bd299bf140884ab6ed/Safety-and-Efficacy-of-Convalescent-Plasma-for-Severe-COVID-19-Interim-Report-of-a-Multicenter-Phase-II-Study-from-Saudi-Arabia.pdf	26/12/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/profile/Abdul_Rehman_Zaidi/publication/347933502_Safety_and_Efficacy_of_Convalescent_Plasma_for_Severe_COVID-19_Interim_Report_of_a_Multicenter_Phase_II_Study_from_Saudi_Arabia/links/5fe848bd299bf140884ab6ed/Safety-and-Efficacy-of-Convalescent-Plasma-for-Severe-COVID-19-Interim-Report-of-a-Multicenter-Phase-II-Study-from-Saudi-Arabia.pdf	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Effects of Tocilizumab in COVID-19 patients: a cohort study.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	22/12/2020	Artigo completo publicado em periódico científico	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2.                                Methods                 A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020.                                Results                 Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1–21) after initial symptoms and 2 days (range 0–12) after hospital admission. Within 30 days from receiving tocilizumab, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. After tocilizumab was administered, there was a slight increase in PaO 2/FiO 2 and an initial reduction in CRP, but this effect was not sustained beyond day 10.                                Conclusions                 Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this.              	['Tocilizumabe']	['Tocilizumab']
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2033130	22/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2033130	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Bamlanivimabe', 'Bamlanivimabe']	['Bamlanivimab', 'Bamlanivimab']
Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting Real-World Data from a Multicenter Observational Study Targeting Inflammatory & Infectious Dermatoses.	https://onlinelibrary.wiley.com/doi/10.1111/dth.14694	22/12/2020	Artigo completo publicado em periódico científico	10.1111/dth.14694	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Tetraciclinas']	['Tetracyclines']
Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia.	https://journals.lww.com/ccejournal/Fulltext/2020/12000/Effects_of_Inhaled_Epoprostenol_and_Prone.21.aspx	16/12/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/ccejournal/Fulltext/2020/12000/Effects_of_Inhaled_Epoprostenol_and_Prone.21.aspx	-	-	-	-	-	-	-	-	['Epoprostenol']	['Epoprostenol']
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai	https://pubmed.ncbi.nlm.nih.gov/33342929/	18/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33342929/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Early Clinical Outcomes with Tocilizumab for Severe Covid-19: A Two-Center Retrospective Study.	https://www.sciencedirect.com/science/article/pii/S0924857920304854?via%3Dihub	15/12/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0924857920304854?via%3Dihub	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.	https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13767	15/10/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13767	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases.	https://pubmed.ncbi.nlm.nih.gov/33344594/	06/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33344594/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Corticosteroid therapy in critically ill patients with COVID‑19: a multicenter, retrospective study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	18/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Corticoid therapy has been recommended in the treatment of critically ill patients with COVID-19, yet its efficacy is currently still under evaluation. We investigated the effect of corticosteroid treatment on 90-day mortality and SARS-CoV-2 RNA clearance in severe patients with COVID-19.                                Methods                 294 critically ill patients with COVID-19 were recruited between December 30, 2019 and February 19, 2020. Logistic regression, Cox proportional-hazards model and marginal structural modeling (MSM) were applied to evaluate the associations between corticosteroid use and corresponding outcome variables.                                Results                 Out of the 294 critically ill patients affected by COVID-19, 183 (62.2%) received corticosteroids, with methylprednisolone as the most frequently administered corticosteroid (175 accounting for 96%). Of those treated with corticosteroids, 69.4% received corticosteroid prior to ICU admission. When adjustments and subgroup analysis were not performed, no significant associations between corticosteroids use and 90-day mortality or SARS-CoV-2 RNA clearance were found. However, when stratified analysis based on corticosteroid initiation time was performed, there was a significant correlation between corticosteroid use (≤ 3 day after ICU admission) and 90-day mortality (logistic regression adjusted for baseline: OR 4.49, 95% CI 1.17–17.25,  p = 0.025; Cox adjusted for baseline and time varying variables: HR 3.89, 95% CI 1.94–7.82,  p &lt; 0.001; MSM adjusted for baseline and time-dependent variants: OR 2.32, 95% CI 1.16–4.65,  p = 0.017). No association was found between corticosteroid use and SARS-CoV-2 RNA clearance even after stratification by initiation time of corticosteroids and adjustments for confounding factors (corticosteroids use ≤ 3 days initiation vs no corticosteroids use) using MSM were performed.                                Conclusions                 Early initiation of corticosteroid use (≤ 3 days after ICU admission) was associated with an increased 90-day mortality. Early use of methylprednisolone in the ICU is therefore not recommended in patients with severe COVID-19.              	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.	https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa138/6041623	18/12/2020	Artigo completo publicado em periódico científico	10.1093/ehjcvp/pvaa138/6041623	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A systematic review and meta‑analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID‑19 treatment	https://www.nature.com/articles/s41598-020-77748-x	17/12/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41598-020-77748-x	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa501/6041772	18/12/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa501/6041772	-	-	-	-	-	-	-	-	['Daclatasvir', 'Daclatasvir', 'Sofosbuvir', 'Sofosbuvir']	['Daclatasvir', 'Daclatasvir', 'Sofosbuvir', 'Sofosbuvir']
Convalescent plasma may be a possible treatment for COVID-19: A systematic review.	https://www.sciencedirect.com/science/article/pii/S1567576920337292?via%3Dihub	05/12/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1567576920337292?via%3Dihub	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035002	17/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2035002	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['REGN-COV2']	['REGN-COV2']
Tocilizumab in the Treatment of Critical COVID-19 Pneumonia: A Retrospective Cohort Study of Mechanically Ventilated Patients.	https://doi.org/10.1016/j.ijid.2020.12.021	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.12.021	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']
Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study.	https://www.frontiersin.org/articles/10.3389/fmed.2020.569567/full	27/11/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.569567/full	-	-	-	-	-	-	-	-	['Enoxaparina', 'Fondaparinux']	['Enoxaparin', 'Fondaparinux']
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243961	16/12/2020	Artigo completo publicado em periódico científico	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243961	-	-	-	-	-	-	-	-	['Anakinra', 'Corticosteroides']	['Anakinra', 'Corticosteroids']
Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.	https://pubmed.ncbi.nlm.nih.gov/32407459/	19/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32407459/	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']	['Corticosteroids', 'Corticosteroids', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']
Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: A systematic review with meta-analysis.	https://doi.org/10.18632/aging.202195	16/11/2020	Artigo completo publicado em periódico científico	10.18632/aging.202195	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Plasma convalescente']	['Convalescent Plasma']
Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort.	https://www.mdpi.com/2072-6643/12/12/3773	09/12/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/12/3773	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Coagulation dysfunction in ICU patients with coronavirus disease 2019 in Wuhan, China: A retrospective observational study of 75 fatal cases.	https://doi.org/10.18632/aging.202223	09/12/2020	Artigo completo publicado em periódico científico	10.18632/aging.202223	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Anticoagulantes']	['Anticoagulants']
Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel.	https://media.marinomed.com/8b/7a/c7/nota-journal-of-biomedical-research-safety-adn-efficacy-iota-carrageenan-and-ivermectin.pdf	17/11/2020	Artigo completo publicado em periódico científico	https://media.marinomed.com/8b/7a/c7/nota-journal-of-biomedical-research-safety-adn-efficacy-iota-carrageenan-and-ivermectin.pdf	-	-	-	-	-	-	-	-	['Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin']
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. A Randomized Trial.	https://www.acpjournals.org/doi/10.7326/M20-6519	08/12/2020	Artigo completo publicado em periódico científico	10.7326/M20-6519	0003-4819	00034819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w	14/12/2020	Artigo completo publicado em periódico científico	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.                                Methods                 Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.                                Results                 The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days;  P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) ( P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.                                Conclusion                 Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.                                Trial registration                 <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://irct.ir/search/result?query=Evaluation+of+the+effect+of+Arbidol+drug+in+the+treatment+of+hospitalized+patients+with+COVID-19">IRCT20180725040596N2</jats:ext-link> on 18 April 2020.              	['Umifenovir']	['Umifenovir']
Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.	https://journals.sagepub.com/doi/full/10.1177/0300060520979151	15/12/2020	Artigo completo publicado em periódico científico	10.1177/0300060520979151	0300-0605	03000605	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH	B1	0.366	61	1.58	  Objective  Association of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) use with coronavirus disease 2019 (COVID-19) remains controversial. We aimed to investigate the impact of ACEI/ARB use on all-cause mortality in severe COVID-19 patients with hypertension.   Methods  We enrolled 650 COVID-19 patients from Changsha and Wuhan city between 17 January 2020 and 8 March 2020. Demographic, clinical characteristics, and outcomes were collected. Multivariable analysis and propensity-score matching were performed to assess the impact of ACEI/ARB therapy on mortality.   Results  Among the 650 patients, 126 who had severe COVID-19 concomitant with hypertension were analyzed. The average age was 66 years and 56 (44.4%) were men. There were 37 ACEI/ARB users and 21 in-hospital deaths (mortality rate, 16.7%). Male sex (odds ratio [OR], 5.13; 95% confidence interval [CI], 1.75 to 17.8), but not ACEI/ARB use (OR, 1.09; 95%CI, 0.31 to 3.43), was an independent risk factor for mortality in severe COVID-19 patients with hypertension. After propensity-score matching, 60 severe COVID-19 patients were included and no significant correlation between use of ACEI/ARB and mortality was observed.   Conclusions  There was no significant association of ACEI/ARB use with mortality in severe COVID-19 patients with hypertension. These findings support the continuation of ACEI/ARB therapy for such patients. 	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study.	https://doi.org/10.1080/11101849.2020.1842087	03/11/2020	Artigo completo publicado em periódico científico	10.1080/11101849.2020.1842087	1110-1849	11101849	Egyptian Journal of Anaesthesia	-	0.249	14	0.57	-	['Plasma convalescente']	['Convalescent Plasma']
A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?	https://doi.org/10.1002/prp2.666	20/10/2020	Artigo completo publicado em periódico científico	10.1002/prp2.666	2052-1707	20521707	Pharmacology Research and Perspectives	-	0.851	32	2.8	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors' , 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study.	https://www.researchgate.net/publication/347308382_Ivermectin_as_Pre-exposure_Prophylaxis_for_COVID-19_among_Healthcare_Providers_in_a_Selected_Tertiary_Hospital_in_Dhaka_-An_Observational_Study	15/12/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/347308382_Ivermectin_as_Pre-exposure_Prophylaxis_for_COVID-19_among_Healthcare_Providers_in_a_Selected_Tertiary_Hospital_in_Dhaka_-An_Observational_Study	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Ivermectin use associated with reduced duration of COVID-19 febrile illness in a community setting.	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478	15/12/2020	Artigo completo publicado em periódico científico	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.	https://www.frontiersin.org/articles/10.3389/fphar.2020.561674/full	06/11/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.561674/full	-	-	-	-	-	-	-	-	['Celecoxibe']	['Celecoxib']
COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome.	https://pubmed.ncbi.nlm.nih.gov/33317261/	15/12/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33317261/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Blockage of interleukin‑1β with canakinumab in patients ith Covid‑19.	https://www.nature.com/articles/s41598-020-78492-y	11/12/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41598-020-78492-y	-	-	-	-	-	-	-	-	['Canaquinumabe']	['Canakinumab']
Corticosteroid use in COVID‑19 patients: a systematic review and meta‑analysis on clinical outcomes.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03400-9	14/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03400-9	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommending corticosteroids in COVID-19. However, the effectiveness and safety of corticosteroids still remain uncertain, and reliable data to further shed light on the benefit and harm are needed.                                Objectives                 The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of corticosteroids in COVID-19.                                Methods                 A systematic literature search of RCTS and observational studies on adult patients was performed across Medline/PubMed, Embase and Web of Science from December 1, 2019, until October 1, 2020, according to the PRISMA guidelines. Primary outcomes were short-term mortality and viral clearance (based on RT-PCR in respiratory specimens). Secondary outcomes were: need for mechanical ventilation, need for other oxygen therapy, length of hospital stay and secondary infections.                                Results                 Forty-four studies were included, covering 20.197 patients. In twenty-two studies, the effect of corticosteroid use on mortality was quantified. The overall pooled estimate (observational studies and RCTs) showed a significant reduced mortality in the corticosteroid group (OR 0.72 (95%CI 0.57–0.87). Furthermore, viral clearance time ranged from 10 to 29 days in the corticosteroid group and from 8 to 24 days in the standard of care group. Fourteen studies reported a positive effect of corticosteroids on need for and duration of mechanical ventilation. A trend toward more infections and antibiotic use was present.                                Conclusions                 Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for mechanical ventilation. And although data in the studies were too sparse to draw any firm conclusions, there might be a signal of delayed viral clearance and an increase in secondary infections.              	['Corticosteroides']	['Corticosteroids']
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System.	https://www.ahajournals.org/doi/10.1161/JAHA.120.019669	14/12/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.019669	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">Previous reports suggest that the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may upregulate angiotensin‐converting enzyme 2 receptors and increase severe acute respiratory syndrome coronavirus 2 infectivity. We evaluated the association between ACEI or ARB use and coronavirus disease 2019 (COVID‐19) infection among patients with hypertension.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              We identified patients with hypertension as of March 1, 2020 (index date) from Kaiser Permanente Southern California. Patients who received ACEIs, ARBs, calcium channel blockers, beta blockers, thiazide diuretics (TD), or no therapy were identified using outpatient pharmacy data covering the index date. Outcome of interest was a positive reverse transcription polymerase chain reaction test for COVID‐19 between March 1 and May 6, 2020. Patient sociodemographic and clinical characteristics were identified within 1 year preindex date. Among 824 650 patients with hypertension, 16 898 (2.0%) were tested for COVID‐19. Of those tested, 1794 (10.6%) had a positive result. Overall, exposure to ACEIs or ARBs was not statistically significantly associated with COVID‐19 infection after propensity score adjustment (odds ratio [OR], 1.06; 95% CI, 0.90–1.25) for ACEIs versus calcium channel blockers/beta blockers/TD; OR, 1.10; 95% CI, 0.91–1.31 for ARBs versus calcium channel blockers/beta blockers/TD). The associations between ACEI use and COVID‐19 infection varied in different age groups (               P              ‐interaction=0.03). ACEI use was associated with lower odds of COVID‐19 among those aged ≥85 years (OR, 0.30; 95% CI, 0.12–0.77). Use of no antihypertensive medication was significantly associated with increased odds of COVID‐19 infection compared with calcium channel blockers/beta blockers/TD (OR, 1.32; 95% CI, 1.11–1.56).                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">Neither ACEI nor ARB use was associated with increased likelihood of COVID‐19 infection. Decreased odds of COVID‐19 infection among adults ≥85 years using ACEIs warrants further investigation.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.	https://www.annsaudimed.net/doi/pdf/10.5144/0256-4947.2020.462	03/12/2020	Artigo completo publicado em periódico científico	10.5144/0256-4947.2020.462	0256-4947	02564947	Annals of Saudi Medicine	-	0.354	48	1.57	 ABSTRACT                        BACKGROUND:             Venous thromboembolism or extensive thrombosis is relatively common in patients with severe COVID-19 infection and has been associated with increased mortality. During the current COVID-19 pandemic, several prophylactic doses and types of low-molecular-weight heparin (LMWH) are being used worldwide; however, there are no high-quality studies or recommendations for an optimal prophylactic LMWH dose.                                  OBJECTIVES:             Investigate the relationship between coagulation parameters and the LMWH dose, and mortality and ICU admission in hospitalized patients with severe COVID-19 pneumonia.                                  DESIGN:             Retrospective.                                  SETTING:             Tertiary care hospital.                                  PATIENTS AND METHODS:             Data on clinical features, coagulation parameters and anticoagulant medications of inpatients with severe COVID-19 were collected for the period between 11 March 2020 and 31 April 2020.                                  MAIN OUTCOME MEASURES:             Mortality and ICU admission for prophylactic dose LMWH (0.5 mg/kg twice daily) and therapeutic dose LMWH (1 mg/kg twice daily).                                  SAMPLE SIZE:             154 cases.                                  RESULTS:                           Ninety-eight (63.6%) patients were treated with the LMWH prophylactic dose and 56 (36.4%) patients were treated with the therapeutic dose. Forty-four (44.9%) of 98 patients using the prophylactic dose LMWH died, while 10 (17.9%) of 56 patients using the therapeutic dose LMWH died (               P              =.001). Mortality was 6.4-fold higher in the prophylactic dose LMWH users than in the therapeutic dose LMWH users (OR=6.5, 95% CI: 2.4–17.6,               P              &lt;.001).                                              CONCLUSIONS:             Therapeutic dosing of LMWH may decrease mortality in patients with severe COVID-19 infected pneumonia. More aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.                                  LIMITATIONS:             Lack of information about bleeding complications. LMWH was not compared with other anticoagulant therapies. There was no comparison between our two groups on the APACHE score. Used different doses of LMWH in different clinics in our hospital. Single-center, retrospective study.                                  CONFLICT OF INTEREST:             None.          	['Heparina']	['Heparin']
Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxicloroquina	https://www.sciencedirect.com/science/article/pii/S0025775320307570?via%3Dihub	06/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0025775320307570?via%3Dihub	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil.	https://ebm.bmj.com/content/early/2020/12/10/bmjebm-2020-111549.citation-tools	11/12/2020	Artigo completo publicado em periódico científico	https://ebm.bmj.com/content/early/2020/12/10/bmjebm-2020-111549.citation-tools	-	-	-	-	-	-	-	-	['Vacina influenza', 'Vacina influenza']	['Influenza vaccine', 'Influenza vaccine']
Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype.	https://journal.chestnet.org/article/S0012-3692(20)35352-6/pdf	30/11/2020	Artigo completo publicado em periódico científico	https://journal.chestnet.org/article/S0012-3692(20)35352-6/pdf	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.	https://www.sciencedirect.com/science/article/pii/S0022073620306075?via%3Dihub	28/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0022073620306075?via%3Dihub	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients.	https://www.nature.com/articles/s41421-020-00221-6	29/10/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41421-020-00221-6	-	-	-	-	-	-	-	-	['Antagonista de β-adrenérgico', 'Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Diuréticos', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['β-Adrenergic Antagonist', 'Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Diuretics', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Sars-Cov-2 Associated Coagulopathy and Thromboembolism Prophylaxis in Children: a Single Centre Observational Study.	https://onlinelibrary.wiley.com/doi/10.1111/jth.15216	11/12/2020	Artigo completo publicado em periódico científico	10.1111/jth.15216	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Anticoagulantes']	['Anticoagulants']
Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.	https://doi.org/10.1016/j.ajem.2020.12.014	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ajem.2020.12.014	0735-6757	07356757	American Journal of Emergency Medicine	-	0.823	93	2.31	-	['Hidroxicloroquina']	['Hydroxychloroquine']
The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis.	https://doi.org/10.47102/annals-acadmed.sg.2020370	31/10/2020	Artigo completo publicado em periódico científico	10.47102/annals-acadmed.sg.2020370	0304-4602	03044602	Annals of the Academy of Medicine, Singapore	-	0.514	64	2.23	 Objective: A systematic review and meta-analysis was carried out to examine the role of hydroxychloroquine (HCQ) in the treatment of COVID-19. Methods: We performed a systematic search in PubMed, Scopus, Embase, Cochrane- Library, Web of Science, Google-Scholar, and medRxiv pre-print databases using available MeSH terms for COVID-19 and hydroxychloroquine. Data from all studies that focused on the effectiveness of HCQ with or without the addition of azithromycin (AZM) in confirmed COVID-19 patients, which were published up to 12 September 2020, were collated for analysis using CMA v.2.2.064. Results: Our systematic review retrieved 41 studies. Among these, 37 studies including 45,913 participants fulfilled the criteria for subsequent meta-analysis. The data showed no significant difference in treatment efficacy between the HCQ and control groups (RR: 1.02, 95% CI, 0.81–1.27). Combination of HCQ with AZM also did not lead to improved treatment outcomes (RR: 1.26, 95% CI, 0.91–1.74). Furthermore, the mortality difference was not significant, neither in HCQ treatment group (RR: 0.86, 95% CI, 0.71–1.03) nor in HCQ+AZM treatment group (RR: 1.28, 95% CI, 0.76–2.14) in comparison to controls. Meta-regression analysis showed that age was the factor that significantly affected mortality (P&lt;0.00001). Conclusion: The meta-analysis found that there was no clinical benefit of using either HCQ by itself or in combination with AZM for the treatment of COVID-19 patients. Hence, it may be prudent for clinicians and researchers to focus on other therapeutic options that may show greater promise in this disease. Keywords: Azithromycin, coronavirus outbreaks, pandemic, 2019-nCoV disease	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients.	https://www.ijp-online.com/text.asp?2020/52/5/414/302510	05/12/2020	Artigo completo publicado em periódico científico	https://www.ijp-online.com/text.asp?2020/52/5/414/302510	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study.	https://www.mdpi.com/2072-6643/12/12/3799	11/12/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/12/3799	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.	https://www.nejm.org/doi/10.1056/NEJMoa2031994	11/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2031994	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Baricitinibe', 'Baricitinibe', 'Baricitinibe']	['Baricitinib', 'Baricitinib', 'Baricitinib']
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study	https://doi.org/10.1016/j.cmi.2020.12.003	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.12.003	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systemic Review of Clinical Trials.	https://www.ijccm.org/doi/IJCCM/pdf/10.5005/jp-journals-10071-23664	11/11/2020	Artigo completo publicado em periódico científico	https://www.ijccm.org/doi/IJCCM/pdf/10.5005/jp-journals-10071-23664	0972-5229	09725229	INDIAN JOURNAL OF CRITICAL CARE MEDICINE	B2	0.340	33	1.17	-	['Anticorpos', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon alfa', 'Plasma convalescente']	['Antibodies', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon alpha', 'Convalescent plasma']
First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.	https://www.frontiersin.org/articles/10.3389/fmed.2020.596916/full	16/11/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.596916/full	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243705	10/12/2020	Artigo completo publicado em periódico científico	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243705	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
Corticosteroids in patients hospitalised for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30731-X/fulltext	07/12/2020	Artigo completo publicado em periódico científico	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30731-X/fulltext	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Association between seasonal flu vaccination and COVID-19 among healthcare workers.	https://academic.oup.com/occmed/advance-article/doi/10.1093/occmed/kqaa197/6029444	10/12/2020	Artigo completo publicado em periódico científico	10.1093/occmed/kqaa197/6029444	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Anakinra treatment in critically ill COVID‑19 patients: a prospective cohort study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	10/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.                                Methods                 In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment.                                Results                 Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) ( p = 0.0002), ferritin ( p = 0.009), and temperature ( p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature ( p = 0.03), white blood cell counts ( p = 0.02), and plasma levels of ferritin ( p = 0.003), procalcitonin ( p = 0.001), creatinine ( p = 0.01), and bilirubin ( p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results.                                Conclusions                 Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.              	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.	https://www.nejm.org/doi/10.1056/NEJMoa2034577	10/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2034577	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162']	['BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine']
Repurposed Tocilizumab in Patients with Severe COVID-19.	https://doi.org/10.4049/jimmunol.2000981	09/12/2020	Artigo completo publicado em periódico científico	10.4049/jimmunol.2000981	0022-1767	00221767	THE JOURNAL OF IMMUNOLOGY (1950)	A1	1.964	387	5.25	-	['Tocilizumabe']	['Tocilizumab']
Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A meta-Analysis of Randomized Clinical Trials.	https://www.jcvaonline.com/article/S1053-0770(20)31292-1/fulltext	28/11/2020	Artigo completo publicado em periódico científico	https://www.jcvaonline.com/article/S1053-0770(20)31292-1/fulltext	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids', 'Corticosteroids']
Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19.	https://link.springer.com/article/10.1007/s00508-020-01780-0	09/12/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s00508-020-01780-0	0043-5325	00435325	Wiener Klinische Wochenschrift	-	0.497	54	1.65	-	['Oseltamivir']	['Oseltamivir']
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial.	https://doi.org/10.1016/j.eimc.2020.10.023	09/12/2020	Artigo completo publicado em periódico científico	10.1016/j.eimc.2020.10.023	0213-005X	0213005X	ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA (ED. IMPRESA)	B3	0.277	44	0.91	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.	https://www.clinexprheumatol.org/abstract.asp?a=16290	03/12/2020	Artigo completo publicado em periódico científico	https://www.clinexprheumatol.org/abstract.asp?a=16290	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.	https://www.europeanreview.org/article/23854	30/11/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/23854	-	-	-	-	-	-	-	-	['Interferon alfa', 'Lopinavir', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ritonavir']
Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID‐19.	https://doi.org/10.29271/jcpsp.2020.Supp2.S153	31/10/2020	Artigo completo publicado em periódico científico	10.29271/jcpsp.2020.Supp2.S153	1022-386X	1022386X	Journal of the College of Physicians and Surgeons--Pakistan : JCPSP	-	0.217	35	0.71	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave.	https://www.sciencedirect.com/science/article/pii/S1876034120307516?via%3Dihub	09/12/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1876034120307516?via%3Dihub	-	-	-	-	-	-	-	-	['Antivirais', 'Antivirais', 'Antivirais', 'Antivirais', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Antivirals', 'Antivirals', 'Antivirals', 'Antivirals', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids']
Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study.	https://www.frontiersin.org/articles/10.3389/fmed.2020.584870/full	17/11/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.584870/full	-	-	-	-	-	-	-	-	['Estatina', 'Estatina']	['Statin', 'Statin']
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.	https://doi.org/10.1016/S0140-6736(20)32661-1	08/12/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32661-1	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 Vaccine', 'ChAdOx1 nCoV-19 Vaccine', 'ChAdOx1 nCoV-19 Vaccine']
The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.	https://doi.org/10.1111/eci.13412	20/09/2020	Artigo completo publicado em periódico científico	10.1111/eci.13412	0014-2972	00142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Prednisona']	['Prednisone']
COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.	https://doi.org/10.1016/j.ijid.2020.11.198	26/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.198	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']
Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.	https://www.sciencedirect.com/science/article/pii/S1567576920336766?via%3Dihub	26/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1567576920336766?via%3Dihub	-	-	-	-	-	-	-	-	['Pentoxifilina']	['Pentoxifylline']
Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study.	https://bmjopen.bmj.com/content/10/12/e044421.citation-tools	04/12/2020	Artigo completo publicado em periódico científico	https://bmjopen.bmj.com/content/10/12/e044421.citation-tools	-	-	-	-	-	-	-	-	['Estatina']	['Statin']
Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Final Results of a Pilot Study.	https://www.redjournal.org/article/S0360-3016(20)34605-8/pdf	26/11/2020	Artigo completo publicado em periódico científico	https://www.redjournal.org/article/S0360-3016(20)34605-8/pdf	-	-	-	-	-	-	-	-	['Radioterapia']	['Radiotherapy']
Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases.	https://www.resmedjournal.com/article/S0954-6111(20)30415-7/fulltext	28/11/2020	Artigo completo publicado em periódico científico	https://www.resmedjournal.com/article/S0954-6111(20)30415-7/fulltext	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid‑19.	https://www.nature.com/articles/s41598-020-78039-1	04/12/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41598-020-78039-1	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients’ Retrospective Study.	https://www.frontiersin.org/articles/10.3389/fmed.2020.575439/full	12/11/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.575439/full	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID‐19.	https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.13896	05/12/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13896	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand.	https://content.sciendo.com/view/journals/abm/14/3/article-p107.xml?language=en	10/09/2020	Artigo completo publicado em periódico científico	https://content.sciendo.com/view/journals/abm/14/3/article-p107.xml?language=en	-	-	-	-	-	-	-	-	['Favipiravir', 'Favipiravir']	['Favipiravir', 'Favipiravir']
An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19.	https://doi.org/10.1016/j.eclinm.2020.100547	20/09/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100547	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Interferon kappa', 'TTF2']	['Interferon kappa', 'TTF2']
Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.	https://onlinelibrary.wiley.com/doi/10.1111/joim.13223	03/12/2020	Artigo completo publicado em periódico científico	10.1111/joim.13223	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Ciclosporina', 'Esteroides']	['Cyclosporin', 'Steroidal']
A systematic review of corticosteroid treatment for noncritically ill patients with COVID‑19.	https://www.nature.com/articles/s41598-020-78054-2	01/12/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41598-020-78054-2	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.	https://doi.org/10.1016/S2666-7568(20)30033-7	03/12/2020	Artigo completo publicado em periódico científico	10.1016/S2666-7568(20)30033-7	2666-7568	26667568	Lancet Healthy Longevity, The	-	4.366	10	7.42	-	['Metformina']	['Metformin']
Synergistic Effect of Quercetin and Vitamin C Against COVID-19: Is A Possible Guard for Front liners?	https://ssrn.com/abstract=3682517	16/11/2020	Artigo completo publicado em periódico científico	https://ssrn.com/abstract=3682517	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Quercetina']	['Ascorbic acid', 'Quercetin']
Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.	https://www.sciencedirect.com/science/article/pii/S0924857920304672?via%3Dihub	28/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0924857920304672?via%3Dihub	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.	https://www.medscimonit.com/abstract/index/idArt/928755	02/12/2020	Artigo completo publicado em periódico científico	https://www.medscimonit.com/abstract/index/idArt/928755	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
INFLUENCE OF TOCILIZUMAB ON THE OUTCOME OF PATIENTS WITH COVID-19. RETROSPECTIVE OBSERVATIONAL STUDY.	https://doi.org/10.31925/farmacia.2020.5.4	01/09/2020	Artigo completo publicado em periódico científico	10.31925/farmacia.2020.5.4	0014-8237	00148237	Farmacia	-	0.265	27	1.27	-	['Tocilizumabe']	['Tocilizumab']
Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users.	https://doi.org/10.1093/ofid/ofaa455	25/09/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa455	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   The preventive effect that tenofovir/emtricitabine (FTC) could have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human immunodeficiency virus-negative people is unknown. The objective of this study was to analyze the seroprevalence and clinical manifestations of COVID-19 among users of pre-exposure prophylaxis (PrEP), disoproxil fumarate/FTC (TDF/FTC), or tenofovir alafenamide (TAF)/FTC and to compare it to that of a control group.                                                  Methods                   An observational descriptive study of the seroprevalence of antibodies for SARS-CoV-2 among men who have sex with men and transgender women without use of PrEP (Group 1; n = 250) and PrEP users with TDF/FTC (n = 409) or TAF/FTC (n = 91) (Group 2; n = 500) was conducted from May11, 2020 to June 27, 2020. All participants were provided with a structured questionnaire that collected information on the variables to be analyzed, and testing for immunoglobulin G antibodies to SARS-CoV-2 (chemiluminescent microparticle immunoassay) was then carried out.                                                  Results                   The seroprevalence of SARS-CoV-2 was 9.2% (95% confidence interval [CI], 5.9–13.5) in the group without PrEP and 15.0% (95% CI, 12.0–18.4) in the group with PrEP (P = .026). Among users of TDF/FTC it was 14.7% (95% CI, 11.4–18.5), and in users of TAF/FTC it was 16.5% (95% CI, 9.5–25.7) (P = .661). In those who tested positive for SARS-CoV-2 and receiving PrEP, 57.4% manifested symptoms, compared with 78.3% in the control group (P = .070). In users of TDF/FTC the figure was 53.3% and in users of TAF/FTC the figure was 73.3% (P = .100). The duration of symptoms was 11.5 days in the control group, 9.0 days in PrEP users (P = .116), 7.0 days in users of TDF/FTC, and 13.0 days in users of TAF/FTC (P = .100).                                                  Conclusions                   Users of PrEP, TDF/FTC, or TAF/FTC presented a higher seroprevalence to SARS-CoV-2 than the control group. No statistically significant differences were found in relation to clinical manifestations. The PrEP users should use the same prevention measures as those indicated for the general population.               	['Tenofovir']	['Tenofovir']
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.	https://doi.org/10.1016/j.ijid.2020.11.191	02/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.191	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin']
Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore.	https://ideas.repec.org/a/adm/journl/v9y2020i11p31-34.html	11/11/2020	Artigo completo publicado em periódico científico	https://ideas.repec.org/a/adm/journl/v9y2020i11p31-34.html	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1,4 million patient nation-wide registry analysis.	https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2060	22/11/2020	Artigo completo publicado em periódico científico	10.1002/ejhf.2060	1388-9842	13889842	EUROPEAN JOURNAL OF HEART FAILURE	A1	5.231	144	6.95	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Systematic review on current antiviral therapy in COVID-19 pandemic.	https://pubmed.ncbi.nlm.nih.gov/33219182/	06/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33219182/	-	-	-	-	-	-	-	-	['Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Assessment of schistosomiasis endemicity and preventive treatment on coronavirus disease 2019 outcomes in Africa.	https://www.sciencedirect.com/science/article/pii/S2052297520301736?via%3Dihub	21/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2052297520301736?via%3Dihub	-	-	-	-	-	-	-	-	['Praziquantel']	['Praziquantel']
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.	https://doi.org/10.1016/j.ijantimicag.2020.106248	28/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106248	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Ivermectina']	['Ivermectin']
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.	https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1856655	30/11/2020	Artigo completo publicado em periódico científico	10.1080/17512433.2021.1856655	1751-2433	17512433	EXPERT REVIEW OF CLINICAL PHARMACOLOGY	A3	0.927	46	3.94	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.	https://onlinelibrary.wiley.com/doi/10.1002/cti2.1218	25/11/2020	Artigo completo publicado em periódico científico	10.1002/cti2.1218	2050-0068	20500068	Clinical and Translational Immunology	-	1.771	39	5.9	-	['Itolizumabe']	['Itolizumab']
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext	17/11/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext	-	-	-	-	-	-	-	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes.	https://www.sciencedirect.com/science/article/pii/S1550413120306471?via%3Dihub	23/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1550413120306471?via%3Dihub	-	-	-	-	-	-	-	-	['Insulina']	['Insulin']
Comparison of clinical and laboratory features and treatment options of 237 symptomatic and asymptomatic children infected with SARS-CoV-2 in the early phase of the COVID-19 pandemic in Turkey.	https://pubmed.ncbi.nlm.nih.gov/33250495/	30/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33250495/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Tocilizumab and COVID-19: A Meta-Analysis of 2120 Patients with Severe Disease 1 and Implications for Clinical Trial Methodologies.	doi: 10.3906/sag-2010-131	27/11/2020	Artigo completo publicado em periódico científico	doi: 10.3906/sag-2010-131	1303-6165	13036165	Turkish Journal of Medical Sciences	-	0.440	32	2.32	-	['Tocilizumabe']	['Tocilizumab']
Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial.	https://pubmed.ncbi.nlm.nih.gov/32703797/	23/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32703797/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.	https://journals.sagepub.com/doi/10.1177/0036933020949219	17/08/2020	Artigo completo publicado em periódico científico	10.1177/0036933020949219	0036-9330	00369330	Scottish Medical Journal	-	0.293	27	1.26	  The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients with Coronavirus 2019 (COVID-19) has been controversial. We performed a meta-analysis of all published studies that reported the outcomes of ACEIs/ARBs in patients with COVID-19. We included four observational studies (3,267 patients). The use of ACEIs/ARBs was associated with a similar risk of all-cause death (OR: 0.75, 95% CI [0.36, 1.57], p = 0.45). Sensitivity analysis including only hypertensive patients demonstrated a lower risk of death with ACEIs/ARBs use (OR: 0.57, 95% CI [0.32-0.98], p = 0.04). In conclusion, hypertensive patients with COVID-19 treated with ACEIs/ARBS have a lower mortality but further research is needed. 	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers.	https://link.springer.com/article/10.1007/s10875-020-00925-0	26/11/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10875-020-00925-0	0271-9142	02719142	JOURNAL OF CLINICAL IMMUNOLOGY	A3	1.522	101	4.54	-	['Vacina influenza', 'Vacina influenza']	['Influenza vaccine', 'Influenza vaccine']
Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study.	https://pubmed.ncbi.nlm.nih.gov/33251522/	25/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33251522/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.	https://academic.oup.com/jid/article/222/8/1256/5875659	23/07/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/jid/article/222/8/1256/5875659	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Tocilizumab administration is associated with reduction in biomarkers of coronavirus disease 2019 (COVID-19) infection.	https://doi.org/10.1002/jmv.26698	26/11/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26698	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers.	https://www.mdpi.com/2077-0383/9/11/3785	23/11/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/11/3785	-	-	-	-	-	-	-	-	['Receptor para os produtos finais de glicação avançada (RAGE)']	['Receptor for advanced glycation end products (RAGE)']
Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.	https://www.tandfonline.com/doi/full/10.1080/17476348.2021.1856659	11/11/2020	Artigo completo publicado em periódico científico	10.1080/17476348.2021.1856659	1747-6348	17476348	EXPERT REVIEW OF RESPIRATORY MEDICINE	A3	0.939	47	3.79	-	['Corticosteroides']	['Corticosteroids']
The effectiveness of early anticoagulant treatment in Covid-19 patients.	https://journals.sagepub.com/doi/abs/10.1177/0268355520975595	27/11/2020	Artigo completo publicado em periódico científico	10.1177/0268355520975595	0268-3555	02683555	PHLEBOLOGY (LONDON)	A4	0.504	52	1.79	  Objectives  Coronavirus disease 2019 (Covid-19) is an emerging, fast-spreading and worldwide infectious disease that would be deteriorated with the precipitation of systemic or local thrombosis. The aim of current study was evaluating the effects of early anticoagulant treatment in hospitalized Covid-19 patients.   Method  The present retrospective and comparative cohort study investigated 413 hospitalized Covid-19 patients treated with or without Low Molecular Weight Heparin (LMWH) (n = 187 and 226, respectively) in the Covid Clinics of Gulhane Education and Research Hospital in Ankara, Turkey, between March 18 and May 03, 2020. The treatment groups were consisted of the patients evaluated before and after The Covid-19 Treatment Guide update on April 12, 2020 that included the anticoagulant treatment thereafter.   Results  The mean age of all 413 patients (204 male and 209 female) at disease onset was 50.6 ± 16.7 years. The LMWH-treated patients had significantly higher coagulation markers such as d-dimer and platelet count than LMWH-untreated patients (p values &lt; 0.05). The inflammatory markers, ferritin, interleukin-6 and procalcitonin were significantly increased in LMWH-untreated patients (p values &lt; 0.05). The presence of any comorbidity was significantly more common in LMWH-treated patients compared to LMWH-untreated group (39.6% vs 19.9%, respectively; p &lt; 0.001). Hypertension and diabetes mellitus were the most frequent comorbidities in both groups. The number of intensive care unit (ICU) transfer and longer length of hospital stay were more commonly observed in LMWH-untreated patients (p values &lt;0.05).   Conclusions  Early anticoagulant treatment with relatively higher doses of LMWH may improve the clinical outcome of Covid-19 patients and shorten the length of hospital stay. 	['Heparina']	['Heparin']
Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial	https://doi.org/10.1007/s12011-020-02512-1	27/11/2020	Artigo completo publicado em periódico científico	10.1007/s12011-020-02512-1	0163-4984	01634984	BIOLOGICAL TRACE ELEMENT RESEARCH	A3	0.649	88	4.18	-	['Hidroxicloroquina', 'Zinco']	['Hydroxychloroquine', 'Zinc']
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.	https://doi.org/10.1055/s-0040-1720962	23/11/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1720962	2512-9465	25129465	-	-	-	-	-	 Abstract           Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality remain unacceptably high in patients with severe novel coronavirus disease 2019 (COVID-19) disease. Direct oral anticoagulants (DOACs), such as apixaban, have numerous purported benefits although the safety and efficacy of their use in intensive care unit (ICU) patients with severe COVID-19 has yet to be evaluated.           Materials and Methods Single-center, retrospective cohort study of 21 ICU patients with severe COVID-19 respiratory disease treated with apixaban for atrial fibrillation (AFib), venous thromboembolism (VTE), catheter-induced thrombosis, and/or COVID-19-induced coagulopathy. The primary objective was to evaluate the incidence of bleeding events and secondary objectives included thromboembolic events, coagulation parameters, and mortality.           Results Ninety percent of patients were non-White, 43% were obese, 90% had acute respiratory distress syndrome, and 76% required mechanical ventilation. Nearly half of (47.6%) also experienced renal dysfunction and required renal replacement therapy. Eighty-six percent of patients received prophylaxis or treatment with UFH or LMWH within the 24-hour period prior to apixaban initiation. Patients were initiated on apixaban for the treatment of suspected or confirmed VTE (67%) or AFib (33%). All coagulation parameters remained abnormal but stable throughout the 10-day monitoring period. No patients experienced any major bleeding events or thrombosis throughout the study period. There were four deaths during the follow-up period, all deemed unrelated to coagulopathy or bleeding.           Conclusion Apixaban appeared safe and efficacious in ICU patients with severe COVID-19 disease. These data encourage future trials seeking to optimize anticoagulation strategies in patients with severe COVID-19.	['Apixabana']	['Apixaban']
Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality.	https://academic.oup.com/ajcp/advance-article/doi/10.1093/ajcp/aqaa252/6000689	25/11/2020	Artigo completo publicado em periódico científico	10.1093/ajcp/aqaa252/6000689	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.	https://doi.org/10.1093/ofid/ofaa519	27/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa519	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   There is growing concern about the potential harmful effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19) and cardiovascular diseases (CVDs). The aim of this study was to evaluate the association between recent exposure to ACEIs/ARBs and in-hospital mortality in patients with COVID-19.                                                  Methods                   We used data from a nationwide cohort of patients with COVID-19 from the health insurance claims data of South Korea, which were released for research purposes for public health by the Ministry of Health and Welfare of South Korea. Patients with COVID-19 were identified using the relevant diagnostic code. Propensity score matching (1:1) was carried out among patients with CVD according to the type of medication (ACEIs/ARBs vs other), and the risk of death was assessed.                                                  Results                   A total of 4936 patients with COVID-19 were analyzed, of whom 1048 (21.2%) had CVD. Of the 1048 patients with CVD, 864 (82.4%) received at least 1 antihypertensive medication before the diagnosis of COVID-19, including 359 (41.6%) who received ACEIs/ARBs and 505 (58.4%) who received drugs other than ACEIs/ARBs. Using the propensity scores for ACEI/ARB use, we matched 305 pairs of patients receiving ACEIs/ARBs and patients receiving other drugs. Recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality in unadjusted analysis (odds ratio [OR], 0.62; 95% CI, 0.33–1.14) or propensity score matching analysis (OR, 1.00; 95% CI, 0.46–2.16).                                                  Conclusions                   In patients with COVID-19 and underlying CVDs, the recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality. These findings do not support stopping or modifying ACEIs/ARBs in patients during the current COVID-19 pandemic.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.	https://doi.org/10.1093/ofid/ofaa486	14/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa486	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                This is a retrospective cohort study of hospitalized adults with coronavirus disease 2019 (COVID-19). Fifty-seven patients received treatment alone, and 35 patients received treatment with adjunctive prednisolone. A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.	['Antivirais', 'Corticosteroides']	['Antivirals', 'Corticosteroids']
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.	https://pubmed.ncbi.nlm.nih.gov/33231487/	24/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33231487/	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.	https://ejhp.bmj.com/content/early/2020/11/24/ejhpharm-2020-002449	25/11/2020	Artigo completo publicado em periódico científico	https://ejhp.bmj.com/content/early/2020/11/24/ejhpharm-2020-002449	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.	https://pubmed.ncbi.nlm.nih.gov/33237663/	25/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33237663/	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.	https://www.nejm.org/doi/full/10.1056/NEJMoa2031304	24/11/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2031304	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Plasma convalescente']	['Convalescent Plasma']
Evidence for treatment with estradiol for women with SARS-CoV-2 infection.	https://doi.org/10.1186/s12916-020-01851-z	25/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01851-z	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract                  Background                 Given that an individual’s age and gender are strongly predictive of coronavirus disease 2019 (COVID-19) outcomes, do such factors imply anything about preferable therapeutic options?                                Methods                 An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in 5-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15–49 years) and peri-/post-menopausal (&gt; 50 years).                                Results                 The incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is higher in women than men (by about + 15%) and, in contrast, the fatality rate is higher in men (about + 50%). Interestingly, the relationships between these quantities are linked to age: pre-adolescent girls and boys had the same risk of infection and fatality rate, while adult premenopausal women had a significantly higher risk of infection than men in the same 5-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in peri- and postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50 years, there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17ß-estradiol influences expression of the human angiotensin-converting enzyme 2 (ACE2) protein, which plays a role in SARS-CoV-2 cellular entry, propensity score matching was performed for the women’s sub-cohort, comparing users vs. non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women &gt; 50 years receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95% CI [0.18, 0.62] and the hazard ratio (HR) was 0.29, 95% CI [0.11,0.76]. For younger, pre-menopausal women (15–49 years), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels.                                Conclusions                 As of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.              	['Estradiol', 'Estradiol', 'Estradiol']	['Estradiol', 'Estradiol', 'Estradiol']
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2021801	24/11/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021801	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort.	https://doi.org/10.1016/j.thromres.2020.10.031	05/11/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.10.031	0049-3848	00493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Anticoagulantes']	['Anticoagulants']
Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.	https://doi.org/10.18632/aging.202172	24/11/2020	Artigo completo publicado em periódico científico	10.18632/aging.202172	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Corticosteroides']	['Corticosteroids']
Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.	https://doi.org/10.1016/j.rmed.2020.106188	07/11/2020	Artigo completo publicado em periódico científico	10.1016/j.rmed.2020.106188	0954-6111	09546111	RESPIRATORY MEDICINE	A2	1.112	127	3.99	-	['Plasma convalescente']	['Convalescent Plasma']
Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.	https://doi.org/10.1111/ijcp.13856	24/11/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13856	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine']
Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671875/	16/11/2020	Artigo completo publicado em periódico científico	PMC:PMC7671875/	-	-	-	-	-	-	-	-	['Imunoglobulina', 'Prednisona']	['Immunoglobulin', 'Prednisone']
Therapeutic potential of ivermectin as add-on treatment in COVID 19: A systematic review and meta-analysis.	https://doi.org/10.18433/jpps31457	23/11/2020	Artigo completo publicado em periódico científico	10.18433/jpps31457	1482-1826	14821826	JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCES	A3	0.547	81	3.2	 The current management of COVID-19 is mostly limited to general supportive care and symptomatic treatment. Ivermectin is a broad-spectrum anti-parasitic drug used widely for the treatment of onchocerciasis and lymphatic filariasis. Apart from its anti-parasitic effect it also exhibits antiviral activity against a number of viruses both in vitro and in vivo. Hence, we conducted this systematic review and meta-analysis to assess the currently available data on the therapeutic potential of ivermectin for the treatment of COVID‐19 as add on therapy. A total of 629 patients were included in the 4 studies and all were COVID-19 RT-PCR positive. Among them, 397 patients received ivermectin along with usual therapy. The random effect model showed the overall pooled OR to be 0.53 (95%CI: 0.29 to0.96) for the primary outcome (all-cause mortality) which was statistically significant (P=0.04). Similarly, the random effect model revealed that adding ivermectin led to significant clinical improvement compared to usual therapy (OR=1.98, 95% CI: 1.11 to 3.53, P=0.02).  However, this should be inferred cautiously as the quality of evidence is very low. Currently, many clinical trials are on-going, and definitive evidence for repurposing this drug for COVID-19 patients will emerge only in the future.	['Ivermectina']	['Ivermectin']
A Propensity-Matched Cohort Study of Tocilizumab in Patients With Coronavirus Disease 2019.	https://journals.lww.com/ccejournal/Fulltext/2020/11000/A_Propensity_Matched_Cohort_Study_of_Tocilizumab.15.aspx	16/11/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/ccejournal/Fulltext/2020/11000/A_Propensity_Matched_Cohort_Study_of_Tocilizumab.15.aspx	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality	https://doi.org/10.1055/s-0040-1720978	13/11/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1720978	0340-6245	03406245	THROMBOSIS AND HAEMOSTASIS	A1	1.745	195	5.58	 Abstract           Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.           Objective We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.           Methods This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48 hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admission, and time period, all determined during the first 48 hours.           Results Adjusted logistic regression analyses demonstrated a significant decrease in mortality with prophylactic use of apixaban (odds ratio [OR] 0.46, p = 0.001) and enoxaparin (OR = 0.49, p = 0.001). Therapeutic apixaban was also associated with decreased mortality (OR 0.57, p = 0.006) but was not more beneficial than prophylactic use when analyzed over the entire cohort or within D-dimer stratified categories. Higher D-dimer levels were associated with increased mortality (p &lt; 0.0001). When adjusted for these same comorbidities within D-dimer strata, patients with D-dimer levels &lt; 1 µg/mL did not appear to benefit from anticoagulation while patients with D-dimer levels &gt; 10 µg/mL derived the most benefit. There was no increase in transfusion requirement with any of the anticoagulants used.           Conclusion We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.	['Apixabana', 'Enoxaparina']	['Apixaban', 'Enoxaparin']
linical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran.	http://www.aimjournal.ir/Article/aim-17382	01/11/2020	Artigo completo publicado em periódico científico	http://www.aimjournal.ir/Article/aim-17382	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
The effects of favipiravir on hematological parameters of covıd-19 patients.	http://dx.doi.org/10.1590/1806-9282.66.S2.65	21/09/2020	Artigo completo publicado em periódico científico	10.1590/1806-9282.66.S2.65	1806-9282	18069282	-	-	-	-	-	 SUMMARY  INTRODUCTION  This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections.  METHODS  Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment.  RESULTS  The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005).  CONCLUSION  We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.	['Favipiravir']	['Favipiravir']
The effect of IL-6 inhibitors on mortality among hospitalized COVID-19 patients: a multicenter study.	https://read.qxmd.com/read/33216906/the-effect-of-il-6-inhibitors-on-mortality-among-hospitalized-covid-19-patients-a-multicenter-study	20/11/2020	Artigo completo publicado em periódico científico	https://read.qxmd.com/read/33216906/the-effect-of-il-6-inhibitors-on-mortality-among-hospitalized-covid-19-patients-a-multicenter-study	-	-	-	-	-	-	-	-	['Sarilumabe', 'Tocilizumabe']	['Sarilumab', 'Tocilizumab']
Renin–angiotensin system inhibitors and mortality in patients with COVID‐19.	https://doi.org/10.1007/s15010-020-01550-0	22/11/2020	Artigo completo publicado em periódico científico	10.1007/s15010-020-01550-0	0300-8126	03008126	INFECTION	A4	1.119	80	4.01	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.	https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13458	20/11/2020	Artigo completo publicado em periódico científico	10.1111/eci.13458	0014-2972	00142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Prednisona']	['Prednisone']
Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19.	https://doi.org/10.1016/j.eclinm.2020.100645	20/11/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100645	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine']
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa441/5998282	21/11/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa441/5998282	-	-	-	-	-	-	-	-	['Darunavir', 'Hidroxicloroquina', 'Lopinavir']	['Darunavir', 'Hydroxychloroquine', 'Lopinavir']
Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID‐19: a retrospective cohort study.	https://doi.org/10.1038/s41598-020-76915-4	20/11/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-76915-4	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10–4.38;  P = 0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02–6.51;  P = 0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15–8.15;  P = 0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all,  P &lt; 0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis.	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14660	20/11/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14660	0306-5251	03065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	[]	[]
Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19.	https://doi.org/10.1002/art.41593	13/11/2020	Artigo completo publicado em periódico científico	10.1002/art.41593	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital.	https://doi.org/10.1016/j.clnu.2020.10.055	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.clnu.2020.10.055	0261-5614	02615614	CLINICAL NUTRITION (EDINBURGH)	A1	1.553	150	6.65	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.	https://doi.org/10.1016/j.jaci.2020.11.006	06/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.11.006	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Anakinra', 'Prednisona']	['Anakinra', 'Prednisone']
Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.	https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1853508	19/11/2020	Artigo completo publicado em periódico científico	10.1080/03007995.2020.1853508	0300-7995	03007995	CURRENT MEDICAL RESEARCH AND OPINION	A1	0.689	111	2.34	-	['Corticosteroides', 'Glicirrizinato de amônio', 'Imunoglobulina', 'Timosina']	['Corticosteroids', 'Ammonium Glycyrrhizinate', 'Immunoglobulin', 'Thymosin']
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers.	https://doi.org/10.1172/JCI145157	19/11/2020	Artigo completo publicado em periódico científico	10.1172/JCI145157	0021-9738	00219738	THE JOURNAL OF CLINICAL INVESTIGATION	A1	5.527	505	14.12	-	['Vacina BCG']	['BCG vaccine']
Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study.	https://doi.org/10.1093/ofid/ofaa563	19/11/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa563	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract  Background This study was conducted to evaluate the impact of low-molecular-weight heparin (LMWH) on the outcome of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.  Methods This is a prospective observational study including consecutive patients with laboratory-confirmed SARS-CoV-2 pneumonia admitted to the University Hospital of Pisa (March 4–April 30, 2020). Demographic, clinical, and outcome data were collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe acute respiratory distress syndrome (ARDS). Low-molecular-weight heparin, hydroxychloroquine, doxycycline, macrolides, antiretrovirals, remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox regression analysis, in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent propensity score (PS) was calculated and a PS matching was performed for each treatment variable.  Results Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) received hydroxychloroquine, 201 (63.8%) received proteases inhibitors, 150 (47.6%) received doxycycline, 141 (44.8%) received steroids, 42 (13.3%) received macrolides, 40 (12.7%) received baricitinib, 13 (4.1%) received tocilizumab, and 13 (4.1%) received remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.21–0.6; P &amp;lt; .001) and composite endpoint (HR, 0.61; 95% CI, 0.39–0.95; P = .029). The PS-matched cohort of 55 couples confirmed the same results for both primary and secondary endpoint.  Conclusions This study suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in coronavirus disease 2019. Randomized controlled trials are warranted to confirm these preliminary findings.	['Heparina']	['Heparin']
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients	https://doi.org/10.1371/journal.pone.0242184	11/11/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0242184	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	 Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.	['Ivermectina']	['Ivermectin']
The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.	https://doi.org/10.1016/j.intimp.2020.107143	31/10/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107143	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Timosina']	['Thymosin']
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.	https://doi.org/10.1186/s12979-020-00207-8	14/11/2020	Artigo completo publicado em periódico científico	10.1186/s12979-020-00207-8	1742-4933	17424933	IMMUNITY & AGEING	A2	1.697	50	7.3	 Abstract                  Background                 Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities have been the most risky population. Although most patients present a mild to moderate disease, some have developed severe symptoms. One of the possible mechanisms underlying rapid disease progression is a cytokine storm, in which interleukin (IL) -6 seems to be a major mediator. Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody (MAb), with the ability of reducing serum interferon gamma (INF-γ), tumour necrosis factor alpha (TNFα) and IL-6. Based on these previous results in patients with psoriasis and rheumatoid arthritis, an expanded access clinical trial was approved by the Cuban regulatory agency for COVID-19 critically, severely and moderately ill patients.                                Results                 We show here a short kinetic of IL-6 serum concentration in the first 24 COVID-19 patients treated with itolizumab. Most of patients were elderly with multiple comorbidities. We found that with one itolizumab dose, the circulating IL-6 decreased in critically and severely ill patients, whereas in moderately ill patients the values didn’t rise as compared to their low baseline levels.                                Conclusion                 These findings suggest that itolizumab could be an attractive therapeutic option to decrease the negative outcome of the cytokine storm in COVID-19 patients.                                Trial registration                 CECMED IIC RD-EC 179, RPCEC00000311. Registered 4 May 2020 - Retrospectively registered, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp">http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp</jats:ext-link> or <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rpcec.sld.cu/trials/RPCEC00000311-En">http://rpcec.sld.cu/trials/RPCEC00000311-En</jats:ext-link>              	['Itolizumabe']	['Itolizumab']
Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.	https://doi.org/10.1016/j.medcli.2020.07.004	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.07.004	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial.	https://doi.org/10.1016/S0140-6736(20)32466-1	18/11/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32466-1	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 vaccine']
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.	https://doi.org/10.1093/ofid/ofaa481	13/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa481	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   Remdesivir has been associated with accelerated recovery of severe coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients requiring mechanical ventilation is uncertain.                                                  Methods                   All consecutive intensive care unit (ICU) patients requiring mechanical ventilation due to COVID-19 were enrolled. Univariate and multivariable Cox models were used to explore the possible association between in-hospital death or hospital discharge, considered competing-risk events, and baseline or treatment-related factors, including the use of remdesivir. The rate of extubation and the number of ventilator-free days were also calculated and compared between treatment groups.                                                  Results                   One hundred thirteen patients requiring mechanical ventilation were observed for a median of 31 days of follow-up; 32% died, 69% were extubated, and 66% were discharged alive from the hospital. Among 33 treated with remdesivir (RDV), lower mortality (15.2% vs 38.8%) and higher rates of extubation (88% vs 60%), ventilator-free days (median [interquartile range], 11 [0–16] vs 5 [0–14.5]), and hospital discharge (85% vs 59%) were observed. Using multivariable analysis, RDV was significantly associated with hospital discharge (hazard ratio [HR], 2.25; 95% CI, 1.27–3.97; P = .005) and with a nonsignificantly lower mortality (HR, 0.73; 95% CI, 0.26–2.1; P = .560). RDV was also independently associated with extubation (HR, 2.10; 95% CI, 1.19–3.73; P = .011), which was considered a competing risk to death in the ICU in an additional survival model.                                                  Conclusions                   In our cohort of mechanically ventilated patients, RDV was not associated with a significant reduction of mortality, but it was consistently associated with shorter duration of mechanical ventilation and higher probability of hospital discharge, independent of other risk factors.               	['Remdesivir']	['Remdesivir']
Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study.	https://doi.org/10.1111/cpr.12947	17/11/2020	Artigo completo publicado em periódico científico	10.1111/cpr.12947	0960-7722	09607722	CELL PROLIFERATION (PRINT)	A2	1.421	80	7.54	-	['Terapia celular']	['Cell Therapy']
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years	https://doi.org/10.1016/S1473-3099(20)30843-4	17/11/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30843-4	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['CoronaVac']	['CoronaVac']
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.	https://doi.org/10.1016/j.ijid.2020.11.142	08/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.142	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Favipiravir', 'Favipiravir', 'Favipiravir']	['Favipiravir', 'Favipiravir', 'Favipiravir']
Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.	https://doi.org/10.1016/j.jsps.2020.11.003	13/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jsps.2020.11.003	1319-0164	13190164	SAUDI PHARMACEUTICAL JOURNAL	A2	0.613	57	4.71	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.	https://onlinelibrary.wiley.com/doi/full/10.1111/imj.15002	16/11/2020	Artigo completo publicado em periódico científico	10.1111/imj.15002	1444-0903	14440903	INTERNAL MEDICINE JOURNAL (PRINT)	A4	0.590	74	1.53	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections.	https://www.frontiersin.org/articles/10.3389/fmed.2020.583897/full	28/10/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.583897/full	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.	https://www.tandfonline.com/doi/full/10.1080/14787210.2021.1848545	13/11/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2021.1848545	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']
Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.	https://doi.org/10.1002/jmv.26674	17/11/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26674	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.	https://doi.org/10.1016/j.amsu.2020.11.027	10/11/2020	Artigo completo publicado em periódico científico	10.1016/j.amsu.2020.11.027	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Dexametasona', 'Prednisona']	['Dexamethasone', 'Prednisone']
Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.	https://doi.org/10.1007/s10072-020-04887-4	13/11/2020	Artigo completo publicado em periódico científico	10.1007/s10072-020-04887-4	1590-1874	15901874	NEUROLOGICAL SCIENCES (TESTO STAMPATO)	A3	0.847	76	2.69	-	['Heparina']	['Heparin']
Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19.	https://www.aging-us.com/article/104019/text	16/11/2020	Artigo completo publicado em periódico científico	https://www.aging-us.com/article/104019/text	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO).	https://www.frontiersin.org/articles/10.3389/fcvm.2020.585866/full	09/10/2020	Artigo completo publicado em periódico científico	10.3389/fcvm.2020.585866/full	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.	https://doi.org/10.1186/s12916-020-01832-2	16/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01832-2	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract  Background Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay.  Methods We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference &gt; 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100.  Results A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.  Conclusions In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.	['Metformina']	['Metformin']
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.	https://doi.org/10.1183/13993003.01811-2020	01/07/2020	Artigo completo publicado em periódico científico	10.1183/13993003.01811-2020	0903-1936	09031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients.  Methods Among all (n=349) patients hospitalised for COVID-19 in a university hospital in a French region with a high rate of COVID-19, we analysed patients who underwent CTPA for clinical signs of severe disease (oxygen saturation measured by pulse oximetry ≤93% or breathing rate ≥30 breaths·min −1) or rapid clinical worsening. Multivariable analysis was performed using Firth penalised maximum likelihood estimates.  Results 162 (46.4%) patients underwent CTPA (mean± sd age 65.6±13.0 years; 67.3% male (95% CI 59.5–75.5%). PE was diagnosed in 44 (27.2%) patients. Most PEs were segmental and the rate of PE-related right ventricular dysfunction was 15.9%. By multivariable analysis, the only two significant predictors of CTPA-confirmed PE were D-dimer level and the lack of any anticoagulant therapy (OR 4.0 (95% CI 2.4–6.7) per additional quartile and OR 4.5 (95% CI 1.1–7.4), respectively). Receiver operating characteristic curve analysis identified a D-dimer cut-off value of 2590 ng·mL −1 to best predict occurrence of PE (area under the curve 0.88, p&lt;0.001, sensitivity 83.3%, specificity 83.8%). D-dimer level &gt;2590 ng·mL −1 was associated with a 17-fold increase in the adjusted risk of PE.  Conclusion Elevated D-dimers (&gt;2590 ng·mL −1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19.	['Heparina']	['Heparin']
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.	https://peerj.com/articles/10322/	02/11/2020	Artigo completo publicado em periódico científico	https://peerj.com/articles/10322/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19.	https://doi.org/10.1128/AAC.01061-20	20/08/2020	Artigo completo publicado em periódico científico	10.1128/AAC.01061-20	0066-4804	00664804	Antimicrobial Agents and Chemotherapy	-	1.546	269	5.16	 To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group received IFN β-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-μg/ml (12 million IU/ml) dose of interferon β-1a was subcutaneously injected three times weekly for two consecutive weeks.	['Atazanavir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Ritonavir']	['Atazanavir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Ritonavir']
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.	https://doi.org/10.1016/j.clim.2020.108631	12/11/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108631	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Tocilizumabe']	['Tocilizumab']
Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.	https://doi.org/10.1093/cid/ciaa1703	09/11/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1703	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   We evaluated an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for immunogenicity and safety in adults aged 18–59 years.                                                  Methods                   In this randomized, double-blinded, controlled trial, healthy adults received a medium dose (MD) or a high dose (HD) of the vaccine at an interval of either 14 days or 28 days. Neutralizing antibody (NAb) and anti-S and anti-N antibodies were detected at different times, and adverse reactions were monitored for 28 days after full immunization.                                                  Results                   A total of 742 adults were enrolled in the immunogenicity and safety analysis. Among subjects in the 0, 14 procedure, the seroconversion rates of NAb in MD and HD groups were 89% and 96% with geometric mean titers (GMTs) of 23 and 30, respectively, at day 14 and 92% and 96% with GMTs of 19 and 21, respectively, at day 28 after immunization. Anti-S antibodies had GMTs of 1883 and 2370 in the MD group and 2295 and 2432 in the HD group. Anti-N antibodies had GMTs of 387 and 434 in the MD group and 342 and 380 in the HD group. Among subjects in the 0, 28 procedure, seroconversion rates for NAb at both doses were both 95% with GMTs of 19 at day 28 after immunization. Anti-S antibodies had GMTs of 937 and 929 for the MD and HD groups, and anti-N antibodies had GMTs of 570 and 494 for the MD and HD groups, respectively. No serious adverse events were observed during the study period.                                                  Conclusions                   Adults vaccinated with inactivated SARS-CoV-2 vaccine had NAb as well as anti-S/N antibody and had a low rate of adverse reactions.                                                  Clinical Trials Registration                   NCT04412538.               	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Prophylactic or therapeutic doses of heparins for COVID‐19 infection? A retrospective study.	https://doi.org/10.1007/s40520-020-01750-6	16/11/2020	Artigo completo publicado em periódico científico	10.1007/s40520-020-01750-6	1720-8319	17208319	AGING CLINICAL AND EXPERIMENTAL RESEARCH	A4	0.911	78	4.02	-	['Heparina']	['Heparin']
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.	https://doi.org/10.1016/j.ijid.2020.11.149	16/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.149	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.	https://doi.org/10.1016/j.intimp.2020.107205	13/11/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107205	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Imunoglobulina', 'Imunoglobulina']	['Immunoglobulin', 'Immunoglobulin']
Utility of Ivermectin and Doxycycline combination for the treatment of SARS- CoV-2.	http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf	10/11/2020	Artigo completo publicado em periódico científico	http://iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf	-	-	-	-	-	-	-	-	['Doxiciclina', 'Ivermectina']	['Doxycycline', 'Ivermectin']
Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh	https://doi.org/10.1016/j.diabres.2020.108538	12/11/2020	Artigo completo publicado em periódico científico	10.1016/j.diabres.2020.108538	0168-8227	01688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Azitromicina', 'Dexametasona', 'Hidroxicloroquina']	['Azithromycin', 'Dexamethasone', 'Hydroxychloroquine']
Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.	https://doi.org/10.1007/s10875-020-00911-6	14/11/2020	Artigo completo publicado em periódico científico	10.1007/s10875-020-00911-6	0271-9142	02719142	JOURNAL OF CLINICAL IMMUNOLOGY	A3	1.522	101	4.54	-	['Tocilizumabe']	['Tocilizumab']
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study).	https://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065	12/11/2020	Artigo completo publicado em periódico científico	https://pmj.bmj.com/content/early/2020/11/12/postgradmedj-2020-139065	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.	https://doi.org/10.1007/s11739-020-02543-5	09/11/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02543-5	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', ' Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People.	https://academic.oup.com/jn/advance-article/doi/10.1093/jn/nxaa332/5981721	13/11/2020	Artigo completo publicado em periódico científico	10.1093/jn/nxaa332/5981721	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.	https://doi.org/10.1016/j.ijantimicag.2020.106216	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106216	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Artemisinina', 'Piperaquina']	['Artemisinin', 'Piperaquine']
Comparison between Prophylactic versus Therapeutic Doses of Low-Molecular-Weight Heparin in Severely Ill Coronavirus Disease 2019 Patients in Relation to Disease Progression and Outcome.	https://www.karger.com/Article/Abstract/511163	26/10/2020	Artigo completo publicado em periódico científico	https://www.karger.com/Article/Abstract/511163	-	-	-	-	-	-	-	-	['Enoxaparina']	['Enoxaparin']
Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7808 patients in France.	https://onlinelibrary.wiley.com/doi/10.1111/apt.16040	09/09/2020	Artigo completo publicado em periódico científico	10.1111/apt.16040	-	-	-	-	-	-	-	-	['Adalimumabe', 'Etanercepte', 'Infliximabe', 'Ustekinumabe', 'Vedolizumab']	['Adalimumab', 'Etanercept', 'Infliximab', 'Ustekinumab', 'Vedolizumab']
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study, Mayo Clinic Proceedings	https://doi.org/10.1016/j.mayocp.2020.08.038	14/06/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.08.038	0025-6196	00256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Lenzilumabe']	['Lenzilumab']
Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak.	https://covid19.elsevierpure.com/en/publications/clinical-characteristics-in-545-patients-with-severe-asthma-on-bi	01/01/2021	Artigo completo publicado em periódico científico	https://covid19.elsevierpure.com/en/publications/clinical-characteristics-in-545-patients-with-severe-asthma-on-bi	-	-	-	-	-	-	-	-	['Benralizumabe', 'Dupilumabe', 'Mepolizumabe', 'Omalizumabe', 'Reslizumabe']	['Benralizumab', 'Dupilumab', 'Mepolizumab', 'Omalizumab', 'Reslizumab']
Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria	https://doi.org/10.7705/biomedica.5478	30/10/2020	Artigo completo publicado em periódico científico	10.7705/biomedica.5478	2590-7379	25907379	-	-	-	-	-	 Introducción. Recientemente, investigadores chinos y franceses reportaron la eficacia de la cloroquina y la hidroxicloroquina para inhibir la replicación in vitro del virus SARS-CoV-2. La diseminación oportuna de la información científica es clave en tiempos de pandemia. Es urgente contar con una revisión sistemática sobre el efecto y la seguridad de estos medicamentos en la COVID-19.Objetivo. Describir el estado actual de la literatura científica publicada hasta el 25 de marzo de 2020 sobre el uso de la cloroquina o sus derivados en el manejo de pacientes con COVID-19.Materiales y métodos. Se hizo una revisión sistemática exploratoria en PubMed, Embase, Lilacs y 15 bases de datos de la Plataforma de Registros Internacionales de Ensayos Clínicos de la Organización Mundial de la Salud (OMS). Se incluyeron publicaciones empíricas y teóricas en inglés, español, italiano, francés o portugués, y se hizo una síntesis narrativa de los resultados.Resultados. Se incluyeron 19 documentos y 24 registros de ensayos clínicos (n=43) de 18.059 pacientes. El 66 % (16/24) de los ensayos están registrados en China. Nueve ensayos evalúan la cloroquina exclusivamente y ocho, la hidroxicloroquina. Los documentos son comentarios (n=9), estudios in vitro (n=3), revisiones narrativas (n=2), guías de práctica clínica (n=2), así como una revisión sistemática, un consenso de expertos y un ensayo controlado.Conclusiones. Un ensayo clínico pequeño (n=26), no aleatorizado y defectuoso, respalda el uso de la hidroxicloroquina en pacientes con COVID-19. Se requiere de manera urgente tener acceso a los resultados de otros ensayos clínicos para determinar la efectividad y la seguridad de la cloroquina y sus derivados en pacientes con COVID-19.	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience	https://doi.org/10.1093/ofid/ofaa319	08/06/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa319	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract  Background The US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19.  Methods We utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir on in-hospital death by day 28 and time to recovery, clinical improvement, and discharge. We utilized Cox proportional hazards models and stratified log-rank tests.  Results Two hundred twenty-four patients were included in the study. The median age was 59 years; 67.0% were male; 17/125 patients (13.6%) who received supportive care and 7/99 patients (7.1%) who received remdesivir died. The unadjusted risk for 28-day in-hospital death was lower for patients who received remdesivir compared with patients who received supportive care (hazard ratio [HR], 0.42; 95% CI, 0.16–1.08). Although this trend remained the same after adjusting for age, sex, race, and oxygen requirements on admission (adjusted HR [aHR], 0.49; 95% CI, 0.19–1.28), as well as chronic comorbidities and use of corticosteroids (aHR, 0.44; 95% CI, 0.16–1.23), it did not reach statistical significance. The use of remdesivir was not associated with an increased risk of acute kidney injury (AKI) or liver test abnormalities. Although not statistically significant, the rate ratios for time to recovery, clinical improvement, and discharge were higher in women and black or African American patients.  Conclusions Patients on remdesivir had lower, albeit not significant, all-cause in-hospital mortality, and the use of remdesivir did not increase the risk for AKI. Promising signals from this study need to be confirmed by future placebo-controlled randomized clinical trials.	['Remdesivir']	['Remdesivir']
The efect of tocilizumab on cytokine release syndrome in COVID‐19 patients.	https://doi.org/10.1007/s43440-020-00186-z	09/11/2020	Artigo completo publicado em periódico científico	10.1007/s43440-020-00186-z	1734-1140	17341140	PHARMACOLOGICAL REPORTS	A3	0.625	87	3.5	-	['Tocilizumabe']	['Tocilizumab']
The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.	https://doi.org/10.1016/j.jelectrocard.2020.10.015	06/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jelectrocard.2020.10.015	0022-0736	00220736	JOURNAL OF ELECTROCARDIOLOGY (PRINT)	B1	0.419	63	1.34	-	['Favipiravir']	['Favipiravir']
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.	https://doi.org/10.1016/j.ijid.2020.11.008	04/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.008	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Favipiravir', 'Interferon beta']	['Favipiravir', 'Interferon beta']
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial.	https://jamanetwork.com/journals/jama/fullarticle/2773108	12/11/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2773108	-	-	-	-	-	-	-	-	['Fluvoxamina']	['Fluvoxamine']
Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.	https://www.sciencedirect.com/science/article/pii/S2049080120304179?via%3Dihub	05/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2049080120304179?via%3Dihub	-	-	-	-	-	-	-	-	['Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext	12/11/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext	-	-	-	-	-	-	-	-	['Interferon beta']	['Interferon beta']
Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.	https://www.journal-of-cardiology.com/article/S0914-5087(20)30353-1/fulltext	02/11/2020	Artigo completo publicado em periódico científico	https://www.journal-of-cardiology.com/article/S0914-5087(20)30353-1/fulltext	-	-	-	-	-	-	-	-	['Antagonista de β-adrenérgico', 'Antagonista de β-adrenérgico', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Anti-hipertensivos', 'Anti-hipertensivos', 'Bloqueadores do Canal de Cálcio', 'Bloqueadores do Canal de Cálcio', 'Diuréticos', 'Diuréticos', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['β-Adrenergic Antagonist', 'β-Adrenergic Antagonist', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Antihypertensives', 'Antihypertensives', 'Antihypertensives' Calcium Channel', 'Calcium Channel Blockers', 'Diuretics', 'Diuretics', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.	https://doi.org/10.1186/s13054-020-03340-4	10/11/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03340-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without.  Methods In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality.  Results A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0–3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0–80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0–12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85;  p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort.  Conclusion In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.	['Dexametasona', 'Prednisolona', 'Prednisona']	['Dexamethasone', 'Prednisolone', 'Prednisone']
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.	https://doi.org/10.1016/j.eclinm.2020.100590	04/11/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100590	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Eculizumabe']	['Eculizumab']
Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19.	http://dx.doi.org/10.1590/1806-9282.66.S2.71	21/09/2020	Artigo completo publicado em periódico científico	10.1590/1806-9282.66.S2.71	1806-9282	18069282	-	-	-	-	-	 SUMMARY  OBJECTIVE  Coronavirus disease 2019 (COVID-19) is an emerging health threat caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Previous studies have noted hypertension is associated with increased mortality due to COVID-19; however, it is not clear whether the increased risk is due to hypertension itself or antihypertensive agents. We aimed to evaluate the impact of antihypertensive agents on the clinical outcomes of hypertensive patients with COVID-19.  METHODS  Our study included 169 consecutive hypertensive patients hospitalized due to COVID-19 between March 20 and April 10, 2020. The demographic characteristics, clinical data, and type of antihypertensive agents being used were reviewed.  RESULTS  The mean age of patients was 65.8±11.7 years.30 patients(17.7%) died during hospitalization. A total of 142 patients(84%) were using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), 91 (53.8%) were using diuretics, 69 (40.8%) were using calcium channel blockers (CCBs), 66 (39.1%) were using beta-blockers, 12 (7.1%) were using alpha-blockers, and 5 (2.9%) were using mineralocorticoid receptor antagonists (MRAs). There was no significant difference between survivors and non-survivors based on the type of antihypertensive agents being used. Binary logistic regression analysis showed that the type of the antihypertensive agent being used had no effect on mortality [OR=0.527 (0.130-2.138), p=0.370 for ACEIs/ARBs; OR=0.731 (0.296-1.808), p=0.498 for CCBs; OR=0.673 (0.254-1.782), p=0.425 for diuretics; OR=1.846 (0.688-4.950), p=0.223 for beta-blockers; OR=0.389 (0.089-1.695), p=0.208 for alpha-blockers; and OR=1.372 (0.107-17.639), p=0.808 for MRAs].  CONCLUSION  The type of antihypertensive agent being used had no effect on the clinical course and mortality in hypertensive patients with COVID-19. The use of these agents should be maintained for the treatment of hypertension during hospitalization.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03328-0	02/11/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03328-0	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 COVID-19-related ARDS has unique features when compared with ARDS from other origins, suggesting a distinctive inflammatory pathogenesis. Data regarding the host response within the lung are sparse. The objective is to compare alveolar and systemic inflammation response patterns, mitochondrial alarmin release, and outcomes according to ARDS etiology (i.e., COVID-19 vs. non-COVID-19).                                Methods                 Bronchoalveolar lavage fluid and plasma were obtained from 7 control, 7 non-COVID-19 ARDS, and 14 COVID-19 ARDS patients. Clinical data, plasma, and epithelial lining fluid (ELF) concentrations of 45 inflammatory mediators and cell-free mitochondrial DNA were measured and compared.                                Results                 COVID-19 ARDS patients required mechanical ventilation (MV) for significantly longer, even after adjustment for potential confounders. There was a trend toward higher concentrations of plasma CCL5, CXCL2, CXCL10, CD40 ligand, IL-10, and GM-CSF, and ELF concentrations of CXCL1, CXCL10, granzyme B, TRAIL, and EGF in the COVID-19 ARDS group compared with the non-COVID-19 ARDS group. Plasma and ELF CXCL10 concentrations were independently associated with the number of ventilator-free days, without correlation between ELF CXCL-10 and viral load. Mitochondrial DNA plasma and ELF concentrations were elevated in all ARDS patients, with no differences between the two groups. ELF concentrations of mitochondrial DNA were correlated with alveolar cell counts, as well as IL-8 and IL-1β concentrations.                                Conclusion                 CXCL10 could be one key mediator involved in the dysregulated immune response. It should be evaluated as a candidate biomarker that may predict the duration of MV in COVID-19 ARDS patients. Targeting the CXCL10-CXCR3 axis could also be considered as a new therapeutic approach.                                Trial registration                 ClinicalTrials.gov, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03955887">NCT03955887</jats:ext-link>              	['CXCL10']	['CXCL10']
Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG.	https://www.sciencedirect.com/science/article/pii/S0002944020304892	04/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0002944020304892	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience.	https://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2020;volume=22;issue=3;spage=98;epage=104;aulast=Mathai	06/11/2020	Artigo completo publicado em periódico científico	https://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2020;volume=22;issue=3;spage=98;epage=104;aulast=Mathai	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.	https://www.sciencedirect.com/science/article/pii/S2213398420301949	05/09/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2213398420301949	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Therapeutic Plasma Exchange followed by Convalescent Plasma transfusion in critical COVID-19- an exploratory study.	https://doi.org/10.1016/j.ijid.2020.10.085	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.085	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']
Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?	https://www.sciencedirect.com/science/article/pii/S1262363620301592?via%3Dihub	04/11/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1262363620301592?via%3Dihub	-	-	-	-	-	-	-	-	['Metformina']	['Metformin']
Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.	https://www.ejinme.com/article/S0953-6205(20)30406-4/abstract	03/11/2020	Artigo completo publicado em periódico científico	https://www.ejinme.com/article/S0953-6205(20)30406-4/abstract	-	-	-	-	-	-	-	-	['Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.	https://doi.org/10.1038/s41598-020-76258-0	05/11/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-76258-0	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract               Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm.	https://journaljpri.com/index.php/JPRI/article/view/30780	22/09/2020	Artigo completo publicado em periódico científico	https://journaljpri.com/index.php/JPRI/article/view/30780	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Imunoglobulina', 'Imunoglobulina', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Ribavirina', 'Ribavirina', 'Ritonavir', 'Ritonavir', 'Umifenovir', 'Umifenovir']	['Azithromycin', 'Azithromycin', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Immunoglobulin', 'Immunoglobulin', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', ' Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Ribavirin', 'Ribavirin', 'Ritonavir', 'Ritonavir', 'Umifenovir', 'Umifenovir']
Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide.	https://peerj.com/articles/10112/	01/10/2020	Artigo completo publicado em periódico científico	https://peerj.com/articles/10112/	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']
The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.	https://doi.org/10.1016/j.mayocpiqo.2020.10.005	19/10/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocpiqo.2020.10.005	2542-4548	25424548	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.	https://doi.org/10.1016/j.lfs.2020.118663	26/10/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.118663	0024-3205	00243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19.	https://jamanetwork.com/journals/jama/fullarticle/2772922	09/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2772922	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1578/5938528	24/09/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1578/5938528	-	-	-	-	-	-	-	-	['Antivirais', 'Antivirais']	['Antivirals', 'Antivirals']
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.	https://doi.org/10.1016/j.imlet.2020.10.009	05/11/2020	Artigo completo publicado em periódico científico	10.1016/j.imlet.2020.10.009	0165-2478	01652478	IMMUNOLOGY LETTERS	A4	0.869	97	4.04	-	['Tocilizumabe']	['Tocilizumab']
Asociación entre el tratamiento esteroideo a dosis alta, la función respiratoria y el tiempo hasta el alta en pacientes con COVID-19: Estudio de cohortes.	https://www.x-mol.com/paper/1309585002089123840	25/09/2020	Artigo completo publicado em periódico científico	https://www.x-mol.com/paper/1309585002089123840	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
The Association between Influenza Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and Death: A Systematic Review of the Literature.	https://www.mdpi.com/1660-4601/17/21/7870	27/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1660-4601/17/21/7870	-	-	-	-	-	-	-	-	['Vacina influenza', 'Vacina influenza']	['Influenza vaccine', 'Influenza vaccine']
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.	https://www.sciencedirect.com/science/article/pii/S0924857920304234	24/10/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0924857920304234	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584850/	30/09/2020	Artigo completo publicado em periódico científico	PMC:PMC7584850/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.	https://onlinelibrary.wiley.com/doi/10.1111/fcp.12613	28/10/2020	Artigo completo publicado em periódico científico	10.1111/fcp.12613	0767-3981	07673981	FUNDAMENTAL & CLINICAL PHARMACOLOGY	A4	0.534	77	2.61	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Investigation of the frequency of COVID-19 in patients treated with intravesical BCG.	https://pubmed.ncbi.nlm.nih.gov/32965364/	21/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32965364/	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.	https://pubmed.ncbi.nlm.nih.gov/33167571/	05/11/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33167571/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Protection against SARS‐CoV‐2 by BCG vaccination is not supported by epidemiological analyses	https://www.nature.com/articles/s41598-020-75491-x	27/10/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41598-020-75491-x	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.	https://www.jamda.com/article/S1525-8610(20)30787-8/abstract	09/09/2020	Artigo completo publicado em periódico científico	https://www.jamda.com/article/S1525-8610(20)30787-8/abstract	-	-	-	-	-	-	-	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.	https://link.springer.com/article/10.1007/s40121-020-00363-w	02/11/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00363-w	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Anti-inflamatórios não esteroidais', 'Anti-inflamatórios não esteroidais', 'Ibuprofeno', 'Ibuprofeno']	['Non-steroidal anti-inflammatory drugs', 'Non-steroidal anti-inflammatory drugs', 'Ibuprofen', 'Ibuprofen']
Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.	https://www.mdpi.com/2077-0383/9/11/3472	28/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/11/3472	-	-	-	-	-	-	-	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.	https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.202008-940OC	09/09/2020	Artigo completo publicado em periódico científico	10.1513/AnnalsATS.202008-940OC	2329-6933	23296933	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study	https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13303	24/10/2020	Artigo completo publicado em periódico científico	10.1111/jcpt.13303	0269-4727	02694727	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (PRINT)	B1	0.517	76	2.22	-	['Tocilizumabe']	['Tocilizumab']
Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis	https://doi.org/10.1002/rmv.2187	31/10/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2187	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Remdesivir']	['Remdesivir']
Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial	https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13185	09/10/2020	Artigo completo publicado em periódico científico	10.1111/joim.13185	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Plasma convalescente']	['Convalescent Plasma']
Blood ozonization in patients with mild to moderate COVID‑19 pneumonia: a single centre experience	https://doi.org/10.1007/s11739-020-02542-6	01/11/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02542-6	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Ozonioterapia']	['Ozone Therapy']
Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study	https://link.springer.com/article/10.1007/s00394-020-02411-0	30/10/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s00394-020-02411-0	1436-6207	14366207	EUROPEAN JOURNAL OF NUTRITION (PRINT)	A1	1.061	103	5.34	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Metformin is associated with Decreased 30-day Mortality among Nursing Home Residents Infected with SARS-CoV2	https://doi.org/10.1016/j.jamda.2020.10.031	23/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jamda.2020.10.031	1525-8610	15258610	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (PRINT)	A1	2.023	102	5.45	-	['Metformina']	['Metformin']
Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients	https://www.frontiersin.org/articles/10.3389/fphar.2020.582348/full	08/10/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.582348/full	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19	https://doi.org/10.1007/s42770-020-00395-x	27/10/2020	Artigo completo publicado em periódico científico	10.1007/s42770-020-00395-x	1517-8382	15178382	Brazilian Journal of Microbiology	-	0.497	70	2.8	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907	26/10/2020	Artigo completo publicado em periódico científico	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Effect of Statin Therapy on SARS-CoV-2 Infection-Related Mortality in Hospitalized Patients	https://doi.org/10.1093/ehjcvp/pvaa128	02/11/2020	Artigo completo publicado em periódico científico	10.1093/ehjcvp/pvaa128	2055-6837	20556837	European Heart Journal - Cardiovascular Pharmacotherapy	-	1.662	30	4.27	 Abstract                                   Aim                   Assessing the effect of statin therapy (ST) at hospital admission for COVID-19 on in-hospital mortality.                                                  Methods and results                    Retrospective observational study. Patients taking statins were 11 years older and had significantly more comorbidities than patients who were not taking statins. A genetic matching (GM) procedure was performed prior to analysis of the mortality risk. A Cox proportional hazards model was used for the cause-specific hazard (CSH) function, and a competing-risks Fine and Gray (FG) model was also used to study the direct effects of statins on risk. Data from reverse transcription-polymerase chain reaction-confirmed 2157 SARS-CoV-2-infected patients [1234 men, 923 women; age: 67 y/o (IQR 54–78)] admitted to the hospital were retrieved from the clinical records in anonymized manner. Three hundred and fifty-three deaths occurred. Five hundred and eighty-one patients were taking statins. Univariate test after GM showed a significantly lower mortality rate in patients on ST than the matched non-statin group (19.8% vs. 25.4%, χ2 with Yates continuity correction: P = 0.027). The mortality rate was even lower in patients (n = 336) who maintained their statin treatments during hospitalization compared with the GM non-statin group (17.4%; P = 0.045). The Cox model applied to the CSH function [HR = 0.58(CI: 0.39–0.89); P = 0.01] and the competing-risks FG model [HR = 0.60 (CI: 0.39–0.92); P = 0.02] suggest that statins are associated with reduced COVID-19-related mortality.                                                  Conclusions                    A lower SARS-CoV-2 infection-related mortality was observed in patients treated with ST prior to hospitalization. Statin therapy should not be discontinued due to the global concern of the pandemic or in patients hospitalized for COVID-19.               	['Atorvastatina', 'Rosuvastatina']	['Atorvastatin', 'Rosuvastatin']
Statin Use and In-Hospital Mortality in Diabetics with COVID-19	Doi: 10.1161/jaha.120.018475	23/10/2020	Artigo completo publicado em periódico científico	Doi: 10.1161/jaha.120.018475	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years;               P              &lt;0.01), had lower inflammatory markers (C‐reactive protein, 10.2; interquartile range, 4.5–18.4 versus 12.9; interquartile range, 5.9–21.4 mg/dL;               P              &lt;0.01) and reduced cumulative in‐hospital mortality (24% versus 39%;               P              &lt;0.01) than those not on a statin (n=1283). No difference in hospital mortality was noted in patients without diabetes mellitus on or off statin (20% versus 21%;               P              =0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94;               P              &lt;0.01) and inverse probability treatment weighting (HR, 0.88; 95% CI, 0.84–0.92;               P              &lt;0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers.                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era.          	['Estatina']	['Statin']
Zinc and vitamin A deficiency predisposes to the need for intubation and ICU admission in patients with COVID-19. An observational study	https://europepmc.org/article/ppr/ppr230396	25/10/2020	Artigo completo publicado em periódico científico	https://europepmc.org/article/ppr/ppr230396	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Dosagem de micronutrientes', 'Vitamina A', 'Vitamina B6', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina E', 'Zinco']	['Ascorbic acid', 'Micronutrient dosage', 'Vitamin A', 'Vitamin B6', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin E', 'Zinc']
Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study	https://www.mdpi.com/2077-0383/9/11/3406	23/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/11/3406	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis	https://doi.org/10.1016/j.chest.2020.10.054	21/10/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.10.054	0012-3692	00123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Corticosteroides', 'Dexametasona', 'Prednisolona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Prednisolone', 'Prednisone']
Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome	https://www.jci.org/articles/view/140617/ga	03/11/2020	Artigo completo publicado em periódico científico	https://www.jci.org/articles/view/140617/ga	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection	https://doi.org/10.1155/2020/8865954	27/10/2020	Artigo completo publicado em periódico científico	10.1155/2020/8865954	1918-1493	19181493	Canadian Journal of Infectious Diseases and Medical Microbiology	-	0.590	41	2.59	 Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M1">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.002</mn>                     </math>                  </jats:inline-formula>), a lower percentage of intubations (52.8% versus 73.6%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M2">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.006</mn>                     </math>                  </jats:inline-formula>), and a higher discharge rate (50.9% versus 27.1%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M3">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.002</mn>                     </math>                  </jats:inline-formula>), in the patients who received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group) had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3% versus 35.2%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M4">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.015</mn>                     </math>                  </jats:inline-formula>). HTN (71.8% versus 52.9%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M5">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.053</mn>                     </math>                  </jats:inline-formula>) and DM (51.3% versus 32.4%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M6">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.064</mn>                     </math>                  </jats:inline-formula>) were also more prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a lower mortality than the control group (47.1% versus 80.8%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M7">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.0003</mn>                     </math>                  </jats:inline-formula>), lower rate of intubations (47.1% versus 87.2%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M8">                        <mi>P</mi>                        <mo>&lt;</mo>                        <mn>0.0001</mn>                     </math>                  </jats:inline-formula>), and a higher discharge rate (52.9% versus 19.2%, <jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M9">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.0003</mn>                     </math>                  </jats:inline-formula>). Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (<jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M10">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.037</mn>                     </math>                  </jats:inline-formula>), CRP (<jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M11">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.014</mn>                     </math>                  </jats:inline-formula>), and ferritin (<jats:inline-formula>                     <math xmlns="http://www.w3.org/1998/Math/MathML" id="M12">                        <mi>P</mi>                        <mo>=</mo>                        <mn>0.012</mn>                     </math>                  </jats:inline-formula>). Conclusions. Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.	['Colchicina']	['Colchicine']
COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients	https://www.sciencedirect.com/science/article/pii/S1525861020307878	09/09/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1525861020307878	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of HealthWorkers	https://www.mdpi.com/2076-393X/8/4/611	15/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-393X/8/4/611	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']
VITAMIN D TREATMENT IS ASSOCIATED WITH REDUCED RISK OF MORTALITY IN PATIENTS WITH COVID-19: A CROSS-SECTIONAL MULTI-CENTRE OBSERVATIONAL STUDY	https://ssrn.com/abstract=3690902	20/10/2020	Artigo completo publicado em periódico científico	https://ssrn.com/abstract=3690902	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India	http://dx.doi.org/10.2139/ssrn.3689618	20/10/2020	Artigo completo publicado em periódico científico	10.2139/ssrn.3689618	1556-5068	15565068	-	-	-	-	-	-	['Hidroxicloroquina', 'Vacina BCG']	['Hydroxychloroquine', 'BCG Vaccine']
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial	https://doi.org/10.1186/s12967-020-02573-9	21/10/2020	Artigo completo publicado em periódico científico	10.1186/s12967-020-02573-9	1479-5876	14795876	JOURNAL OF TRANSLATIONAL MEDICINE (ONLINE)	A2	1.570	121	7.38	 Abstract                  Background                 Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.                                Methods                 A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.                                Results                 In the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6–24.0,  P = 0.52) and 22.4% (97.5% CI: 17.2–28.3,  P &lt; 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.                                Conclusions                 Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.                  Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).              	['Tocilizumabe']	['Tocilizumab']
The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review	https://journals.sagepub.com/doi/full/10.1177/1076029620960797	20/10/2020	Artigo completo publicado em periódico científico	10.1177/1076029620960797	1076-0296	10760296	CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS	B1	0.758	55	2.76	  The incidence of venous thromboembolism (VTE) events in patients with COVID-19 treated with a standard thromboprophylaxis dose of anticoagulants remains high. We conducted a systematic review in order to explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. A systematic search was carried out using the electronic databases of PubMed, EuropePMC, and the Cochrane Central Database, using specific keywords. All articles that fulfilled the inclusion criteria were included in the qualitative analysis. There were 8 observational studies included in the final qualitative analysis. Quality assessment using the Newcastle-Ottawa Scale (NOS) showed a mean score of 7.5 ± 1.06, indicating moderate to high quality of the studies. Three retrospective cohort studies reported a reduction in the mortality rate, while 6 other studies showed no mortality benefits among patients with COVID-19 treated with therapeutic-dose anticoagulation. There was a slight tendency toward a reduction in the mortality rate among mechanically-ventilated patients with COVID-19 receiving therapeutic-dose anticoagulation. Bleeding events and thrombotic complications among patients receiving therapeutic-dose anticoagulation were reported in 3 studies. Although it is too soon to draw any conclusions, this systematic review draws attention to current evidence regarding the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19. 	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes', 'Heparina']	['Vitamin K (VKA) antagonists', 'Anticoagulants', 'Heparin']
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa418/5924537	16/10/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa418/5924537	-	-	-	-	-	-	-	-	['Daclatasvir', 'Sofosbuvir']	['Daclatasvir', 'Sofosbuvir']
OZONE AS ADJUVANT SUPPORT IN THE TREATMENT OF COVID-19: A PRELIMINARY REPORT OF PROBIOZOVID TRIAL	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26636	28/10/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26636	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Ozonioterapia']	['Ozone Therapy']
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study	https://doi.org/10.1016/j.ijid.2020.10.062	27/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.062	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19	https://doi.org/10.1111/1440-1681.13425	22/10/2020	Artigo completo publicado em periódico científico	10.1111/1440-1681.13425	0305-1870	03051870	CLINICAL & EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY	A4	0.584	107	2.82	-	['Interferon', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	['Interferon', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']
Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277	20/10/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1583/5932277	-	-	-	-	-	-	-	-	['Leronlimab']	['Leronlimab']
The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1592/5932274	20/10/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1592/5932274	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
The Use of Renin–Angiotensin–Aldosterone System (RAAS) Inhibitors is Associated with a Lower Risk of Mortality in Hypertensive COVID-19 Patients: A Systematic Review and Meta-analysis	https://doi.org/10.1002/jmv.26625	23/10/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26625	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis	https://doi.org/10.1016/j.tmaid.2020.101906	27/11/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101906	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina', 'Nitazoxanida', 'Oseltamivir', 'Prednisona', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin', 'Nitazoxanide', 'Oseltamivir', 'Prednisone', 'Zinc']
COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin a retrospective case series study	https://doi.org/10.1016/j.ijantimicag.2020.106214	26/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106214	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina', 'Hidroxicloroquina', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Zinc']
Safely Administering Potential QTc Prolonging Therapy Across a Large Healthcare System in the COVID-19 Era	https://doi.org/10.1161/CIRCEP.120.008937	01/10/2020	Artigo completo publicado em periódico científico	10.1161/CIRCEP.120.008937	1941-3149	19413149	CIRCULATION. ARRHYTHMIA AND ELECTROPHYSIOLOGY	A1	2.471	113	5.0	              Background:             The severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) has resulted in a global pandemic. Hydroxychloroquine±azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy. The incidence of torsade de pointes remains unknown. Widespread use of these medications forced overwhelmed health care systems to search for ways to effectively monitor these patients while simultaneously trying to minimize health care provider exposure and use of personal protective equipment.                                  Methods:             Patients with COVID-19 positive who received hydroxychloroquine±azithromycin across 13 hospitals between March 1 and April 15 were included in this study. A comprehensive search of the electronic medical records was performed using a proprietary python script to identify any mention of QT prolongation, ventricular tachy-arrhythmias and cardiac arrest.                                  Results:             The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 6476 hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin. Sixty-seven (1.03%) had hydroxychloroquine±azithromycin held or discontinued due to an average QT prolongation of 60.5±40.5 ms from a baseline QTc of 473.7±35.9 ms to a peak QTc of 532.6±31.6 ms. Of these patients, hydroxychloroquine±azithromycin were discontinued in 58 patients (86.6%), while one or more doses of therapy were held in the remaining nine (13.4%). A simplified approach to monitoring for QT prolongation and arrythmia was implemented on April 5. There were no deaths related to the medications with the simplified monitoring approach and health care provider exposure was reduced.                                  Conclusions:             The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy.          	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554375/	24/06/2020	Artigo completo publicado em periódico científico	PMC:PMC7554375/	-	-	-	-	-	-	-	-	['Corticosteroides', 'Dexametasona', 'Hidrocortisona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Hydrocortisone', 'Prednisone']
Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.	https://doi.org/10.1007/s42399-020-00515-6	19/10/2020	Artigo completo publicado em periódico científico	10.1007/s42399-020-00515-6	2523-8973	25238973	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and Intensive Care Unit admission in patients with COVID-19 according to patients' oxygen requirements.	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26635	27/11/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26635	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Corticosteroides']	['Corticosteroids']
Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19	https://journals.lww.com/anesthesia-analgesia/Abstract/9000/Aspirin_Use_is_Associated_with_Decreased.95423.aspx	21/10/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/anesthesia-analgesia/Abstract/9000/Aspirin_Use_is_Associated_with_Decreased.95423.aspx	-	-	-	-	-	-	-	-	['Ácido acetilsalicílico']	['Acetylsalicylic acid']
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2029849	28/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2029849	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Bamlanivimabe']	['Bamlanivimab']
Vitamin D and survival in COVID-19 patients: A quasi-experimental study	https://doi.org/10.1016/j.jsbmb.2020.105771	13/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jsbmb.2020.105771	0960-0760	09600760	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY	A2	1.072	133	4.92	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)	https://doi.org/10.1016/j.eclinm.2020.100591	15/10/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100591	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Ciclosporina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Cyclosporin', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness	https://doi.org/10.1016/j.ijid.2020.09.1486	06/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1486	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Corticosteroides', 'Prednisona', 'Tocilizumabe']	['Corticosteroids', 'Prednisone', 'Tocilizumab']
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study	https://www.mdpi.com/1424-8247/13/10/317	17/10/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1424-8247/13/10/317	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial	https://doi.org/10.1016/j.intimp.2020.107102	13/10/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107102	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Tocilizumabe']	['Tocilizumab']
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19	https://pubmed.ncbi.nlm.nih.gov/33080002/	20/10/2020	Artigo completo publicado em periódico científico	PUBMED_ID:33080002/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Efficacy and safety of tocilizumab in COVID-19 patients	https://doi.org/10.18632/aging.103988	08/10/2020	Artigo completo publicado em periódico científico	10.18632/aging.103988	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Tocilizumabe']	['Tocilizumab']
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2028836	21/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2028836	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Tocilizumabe']	['Tocilizumab']
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187	20/10/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2772187	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies	https://doi.org/10.1007/s00228-020-03017-5	13/10/2020	Artigo completo publicado em periódico científico	10.1007/s00228-020-03017-5	0031-6970	00316970	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.732	114	2.61	-	['Tocilizumabe']	['Tocilizumab']
Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence	https://www.cureus.com/articles/42647-use-of-tocilizumab-in-covid-19-a-systematic-review-and-meta-analysis-of-current-evidence	09/10/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/42647-use-of-tocilizumab-in-covid-19-a-systematic-review-and-meta-analysis-of-current-evidence	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis	https://doi.org/10.1111/ejh.13533	11/10/2020	Artigo completo publicado em periódico científico	10.1111/ejh.13533	0902-4441	09024441	EUROPEAN JOURNAL OF HAEMATOLOGY	A3	1.057	88	3.2	-	['Argatrobana', 'Enoxaparina', 'Fondaparinux', 'Heparina']	['Argatroban', 'Enoxaparin', 'Fondaparinux', 'Heparin']
Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study	https://doi.org/10.1016/j.ancard.2020.09.030	29/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ancard.2020.09.030	0003-3928	00033928	Annales de Cardiologie et d'Angeiologie	-	0.166	18	0.36	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1002/cti2.1192	14/10/2020	Artigo completo publicado em periódico científico	10.1002/cti2.1192	2050-0068	20500068	Clinical and Translational Immunology	-	1.771	39	5.9	-	['Imunoglobulina']	['Immunoglobulin']
Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study	https://doi.org/10.1007/s40119-020-00201-7	14/10/2020	Artigo completo publicado em periódico científico	10.1007/s40119-020-00201-7	2193-8261	21938261	Cardiology and Therapy	-	0.789	17	2.8	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients	https://doi.org/10.1016/j.ijid.2020.10.031	10/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.031	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Hidroxicloroquina']	['Hydroxychloroquine']
QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study	https://doi.org/10.1111/ijcp.13767	15/10/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13767	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics	https://doi.org/10.1038/s41467-020-19056-6	20/10/2020	Artigo completo publicado em periódico científico	10.1038/s41467-020-19056-6	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.	['Hidroxicloroquina']	['Hydroxychloroquine']
The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis	https://doi.org/10.1155/2020/4312519	13/10/2020	Artigo completo publicado em periódico científico	10.1155/2020/4312519	1916-7245	19167245	Canadian Respiratory Journal	-	0.552	56	2.4	 Background. The pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19. Purpose. To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19. Data Source. PubMed, Cochrane CENTRAL, LITCOVID, Web of Science, SCOPUS, BioRxiv, Embase, MedRxiv, and Wiley online library were searched from 2019/12/30 to 2020/05/23. Study Selection. Three investigators assessed the quality of the studies. Data Extraction. Data about study characteristics, effect estimates, and the quality of the studies were extracted by two independent reviewers and cross-checked by the third reviewer. Data Synthesis. The data of 6,782 (HCQ group, 3623; HCQ + AZ group, 1,020; control group, 2139) participants were included. HCQ was compared with standard care for virologic efficacy, disease progression, mortality, and adverse effects. HCQ was also compared with HCQ + AZ for QTc prolongation, admission to the intensive care unit, and mortality. The study found HCQ did not alter the rate of virologic cure (OR = 0.78; 95% CI: 0.39–1.56) and the risk of mortality (OR = 1.26; 95% CI: 0.66–2.39). The pooled prevalence for mortality was 5.8% (95% CI: 0.9%–10.8%). Moreover, HCQ did not impact disease progression (OR = 0.9; 95% CI: 0.36–2.29) but resulted in a higher risk of adverse effects (OR = 2.35; 95% CI: 1.15–4.8). HCQ was also compared against HCQ + AZ, and no difference was observed in QTc prolongation above 500 ms (OR = 1.11; 95% CI: 0.54–2.28), admission to the intensive care unit (OR = 0.92; 95% CI: 0.52–1.63), and mortality (OR = 0.88; 95% CI: 0.55–1.43). However, in the analysis of single-arm studies, about 11.2% (95% CI: 7.0%–15.5%) of patients have developed an absolute increase of QTc greater than 500 ms, and 4.1% (95% CI: 1.1%–7.1%) of patients discontinued their medication. Conclusion. This meta-analysis and systematic review, which included a limited number of poorly designed studies of patients with COVID-19, revealed HCQ is intolerable, unsafe, and not efficacious. Similarly, HCQ + AZ combination was not different from HCQ alone in curbing mortality and ICU admission.	['Hidroxicloroquina']	['Hydroxychloroquine']
Statin use is associated with lower disease severity in COVID‑19 infection	https://doi.org/10.1038/s41598-020-74492-0	15/10/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-74492-0	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract We aim to study the association of hyperlipidemia and statin use with COVID-19 severity. We analysed a retrospective cohort of 717 patients admitted to a tertiary centre in Singapore for COVID-19 infection. Clinical outcomes of interest were oxygen saturation ≤ 94% requiring supplemental oxygen, intensive-care unit (ICU) admission, invasive mechanical-ventilation and death. Patients on long term dyslipidaemia medications (statins, fibrates or ezetimibe) were considered to have dyslipidaemia. Logistic regression models were used to study the association between dyslipidaemia and clinical outcomes adjusted for age, gender and ethnicity. Statin treatment effect was determined, in a nested case–control design, through logistic treatment models with 1:3 propensity matching for age, gender and ethnicity. All statistical tests were two-sided, and statistical significance was taken as  p &lt; 0.05. One hundred fifty-six (21.8%) patients had dyslipidaemia and 97% of these were on statins. Logistic treatment models showed a lower chance of ICU admission for statin users when compared to non-statin users (ATET: Coeff (risk difference): − 0.12 (− 0.23, − 0.01);  p = 0.028). There were no other significant differences in other outcomes. Statin use was independently associated with lower ICU admission. This supports current practice to continue prescription of statins in COVID-19 patients.	['Estatina', 'Ezetimiba', 'Fibratos']	['Statin', 'Ezetimibe', 'Fibrates']
High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study	https://doi.org/10.1007/s10096-020-04078-1	20/10/2020	Artigo completo publicado em periódico científico	10.1007/s10096-020-04078-1	0934-9723	09349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Hidrocortisona', 'Prednisolona']	['Hydrocortisone', 'Prednisolone']
No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort	https://www.italjmed.org/index.php/ijm/article/view/itjm.2020.1313	18/09/2020	Artigo completo publicado em periódico científico	https://www.italjmed.org/index.php/ijm/article/view/itjm.2020.1313	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	https://doi.org/10.1016/S1473-3099(20)30831-8	15/10/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30831-8	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Vacina BBIBP-CorV']	['BBIBP-CorV vaccine']
Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)	https://doi.org/10.1016/j.nut.2020.111017	08/09/2020	Artigo completo publicado em periódico científico	10.1016/j.nut.2020.111017	0899-9007	08999007	NUTRITION	A1	0.892	150	4.65	-	['Magnésio', 'Vitamina B12', 'Vitamina D (25-hidroxivitamina D)']	['Magnesium', 'Vitamin B12', 'Vitamin D (25-hydroxyvitamin D)']
Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients	https://doi.org/10.26452/ijrps.v11iSPL1.2839	15/10/2020	Artigo completo publicado em periódico científico	10.26452/ijrps.v11iSPL1.2839	0975-7538	09757538	-	-	-	-	-	 The coronavirus disease (COVID-19) outbreak was initially reported in Wuhan, China in December 2019. Many cases of pneumonia without any apparent cause were described to be associated with seafood and wet markets in Wuhan. At present, there are no effective antiviral drugs to treat COVID-19. Umifenovir is a broad-spectrum antiviral drug used for treating several viral infections, and it reportedly inhibits SARS-CoV replication in vitro. This exploratory randomized and controlled study recruited 30 COVID-19 patients admitted to the hospital until May 18, 2020. Fifteen (15) eligible patients randomly allocated underwent umifenovir therapy (600 mg/d). Time to clinical recovery (TTCR), clinical characteristics, and tomographic results were analyzed at baseline and five days after treatment to assess the effect of umifenovir. Thirty (30) COVID-19 patients (mean age: 36.5 years [SD: 12.1, range: 19-59]), including 18 (60%) males and 12 (40%) females, were recruited for the study. There were no significant differences in age or gender, but there were significant differences in TTCR among the two categories. Body temperature (BT) and cough recuperation time [2.8 (0.6) and 2.6 (0.6) days, respectively] were highly reduced in the umifenovir category at 2.4 and 2.1 days, respectively. Moreover, many patients treated with umifenovir exhibited no side effects. In this study, pneumonia was ameliorated in 76.6% (23/30) of the patients, with moderate and potential amelioration in 36.6% and 40% of the patients, respectively. In addition, 66.6% of the patients in the umifenovir category had potential pneumonia absorption.	['Umifenovir']	['Umifenovir']
Preemptive interleukin‐6 blockade in patients with COVID‐19	https://doi.org/10.1038/s41598-020-74001-3	08/10/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-74001-3	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score &lt; 3 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes.	['Tocilizumabe']	['Tocilizumab']
Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study.	https://www.sciencedirect.com/science/article/pii/S2589537020303060	05/10/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2589537020303060	-	-	-	-	-	-	-	-	['Enoxaparina']	['Enoxaparin']
Remdesivir for the Treatment of Covid-19 — Final Report	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	08/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
Convalescent plasma for patients with severe COVID-19	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1548/5920703	10/10/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1548/5920703	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review (Review)	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub3/full	12/10/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013600.pub3/full	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
Nitazoxanide against COVID-19 in three explorative scenarios	https://jidc.org/index.php/journal/article/view/13274	09/10/2020	Artigo completo publicado em periódico científico	https://jidc.org/index.php/journal/article/view/13274	-	-	-	-	-	-	-	-	['Nitazoxanida']	['Nitazoxanide']
Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline	https://doi.org/10.3329/jbcps.v38i0.47512	12/06/2020	Artigo completo publicado em periódico científico	10.3329/jbcps.v38i0.47512	1015-0870	10150870	-	-	-	-	-	 Background: A definitive treatment of SARS CoV-2 is yet to arrive and the human death toll rises exponentially globally. In this health emergency, it might be useful to look into the old therapies which could be effective against the virus. In vitro research showed Ivermectin could decrease the concentration of coronavirus 4000 to 5000 folds in living lung tissue.&#x0D;Aim: In this prospective study a combination of Ivermectin and Doxycycline will be evaluated therapeutically to treat COVID-19 patients. Methods: 100 COVID-19 patients were enrolled in this study with a predefined inclusion and exclusion criteria. RT- PCR of the SERS-CoV-2 will be done at designated government hospitals. The clinical features and response to treatment were noted according to a dedicated protocol.&#x0D;Results: In this study male and female were 64 and 36 respectively, the age ranged between 8 to 84 years. Retesting was done between 4 and 18 days of starting medication. All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects.&#x0D;Conclusion: Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Medical societies and institutions should undertake larger multi center studies to validate and recommend this combination therapy to include in national guidelines.&#x0D;J Bangladesh Coll Phys Surg 2020; 38(0): 10-15	['Doxiciclina', 'Ivermectina']	['Doxycycline', 'Ivermectin']
Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)	https://doi.org/10.1016/j.chest.2020.10.009	02/10/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.10.009	0012-3692	00123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Ivermectina']	['Ivermectin']
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients	https://ideas.repec.org/a/adm/journl/v9y2020i9p31-35.html	30/09/2020	Artigo completo publicado em periódico científico	https://ideas.repec.org/a/adm/journl/v9y2020i9p31-35.html	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia	https://doi.org/10.1016/j.jmii.2020.09.003	05/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jmii.2020.09.003	1684-1182	16841182	JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION	A4	1.748	63	7.83	-	['Azitromicina', 'Ciclesonida', 'Hidroxicloroquina']	['Azithromycin', 'Ciclesonide', 'Hydroxychloroquine']
Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality	https://doi.org/10.1002/phar.2467	12/10/2020	Artigo completo publicado em periódico científico	10.1002/phar.2467	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2022926	08/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2022926	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men	https://doi.org/10.1111/jdv.16953	25/09/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16953	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Finasterida', 'Finasterida', 'Finasterida', 'Finasterida']	['Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Spironolactone', 'Spironolactone', 'Spironolactone', 'Spironolactone', ' Finasteride', 'Finasteride', 'Finasteride', 'Finasteride']
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	https://www.nejm.org/doi/full/10.1056/NEJMoa2027906	14/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2027906	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162']	['BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine']
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30341-6/fulltext	28/09/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30341-6/fulltext	-	-	-	-	-	-	-	-	['Vilobelimabe', 'Vilobelimabe']	['Vilobelimab', 'Vilobelimab']
Tocilizumab Therapy of COVID-19: A Comparison of Subcutaneous and Intravenous Therapies	https://doi.org/10.1016/j.ijid.2020.09.1447	22/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1447	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation	https://doi.org/10.1186/s13054-020-03306-6	29/09/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03306-6	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is extremely variable, ranging from asymptomatic patients to those who develop severe acute respiratory distress syndrome (ARDS). As for now, there are still no really effective therapies for coronavirus disease 2019 (COVID-19). Some evidences suggest that tocilizumab (TCZ) may avoid the progression of severe COVID-19. The aim of this retrospective case-control study was to analyze the efficacy and safety of TCZ in patients with COVID-19 ARDS undergoing noninvasive mechanical ventilation (NIV).  Methods Seventy-nine consecutive patients with severe COVID-19 pneumonia and worsening acute respiratory failure (ARF) were admitted to the Pulmonology Unit of Azienda USL of Reggio Emilia-IRCCS. All patients were inflamed (elevated CRP and IL-6 levels) and received NIV at admission according to the presence of a pO 2/FiO 2 ratio ≤ 200 mmHg. The possibility of being treated with TCZ depended on the drug availability. The primary outcome was the in-hospital mortality rate. A secondary composite outcome of worsening was represented by the patients who died in the pulmonology unit or were intubated.  Results Out of 79 patients, 41 were treated with TCZ. Twenty-eight patients received intravenous (IV) TCZ and 13 patients received subcutaneous (SC) TCZ. In-hospital overall mortality rate was 38% (30/79 patients). The probabilities of dying and being intubated during the follow-up using Kaplan-Meier method were significantly lower in total patients treated with TCZ compared to those of patients not treated with TCZ (log-rank  p value = 0.006 and 0.036, respectively). However, using Cox multivariate analyses adjusted for age and Charlson comorbidity index only the association with the reduced risk of being intubated or dying maintained the significance (HR 0.44, 95%CI 0.22–0.89,  p = 0.022). Two patients treated with TCZ developed cavitating lung lesions during the follow-up.  Conclusions This study shows that TCZ treatment may be effective in COVID-19 patients with severe respiratory impairment receiving NIV. More data on safety are required. Randomized controlled trials are needed to confirm these results.	['Tocilizumabe']	['Tocilizumab']
IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: na observational study	https://doi.org/10.1016/j.jaci.2020.09.018	17/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.09.018	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Tocilizumabe']	['Tocilizumab']
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size	https://doi.org/10.1016/j.biopha.2020.110825	30/09/2020	Artigo completo publicado em periódico científico	10.1016/j.biopha.2020.110825	0753-3322	07533322	BIOMEDICINE & PHARMACOTHERAPY	A2	1.194	109	7.17	-	['Favipiravir', 'Tocilizumabe']	['Favipiravir', 'Tocilizumab']
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience	https://journals.lww.com/cardiovascularpharm/Abstract/2020/10000/Fondaparinux_Use_in_Patients_With_COVID_19__A.1.aspx	01/10/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/cardiovascularpharm/Abstract/2020/10000/Fondaparinux_Use_in_Patients_With_COVID_19__A.1.aspx	-	-	-	-	-	-	-	-	['Enoxaparina', 'Fondaparinux']	['Enoxaparin', 'Fondaparinux']
Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study	https://www.mdpi.com/2079-7737/9/10/310	24/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2079-7737/9/10/310	-	-	-	-	-	-	-	-	['Enoxaparina', 'Fondaparinux', 'Heparina']	['Enoxaparin', 'Fondaparinux', 'Heparin']
Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies	https://doi.org/10.1002/rmv.2180	06/10/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2180	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Anticoagulantes']	['Anticoagulants']
Prophylactic anticoagulants for patients hospitalised with COVID-19	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013739/full?cookiesEnabled	02/10/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013739/full?cookiesEnabled	-	-	-	-	-	-	-	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes', 'Heparina', 'Pentassacarídeos']	['Vitamin K (VKA) antagonists', 'Anticoagulants', 'Heparin', 'Pentasaccharides']
Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis	https://doi.org/10.1016/j.ijid.2020.09.1443	28/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1443	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']
Convalescent plasma therapy in patients with COVID-19.	https://doi.org/10.1016/j.transci.2020.102955	19/09/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102955	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Plasma convalescente']	['Convalescent Plasma']
Is oseltamivir suitable for fighting against COVID-19: In silico assessment,in vitro and retrospective study	https://doi.org/10.1016/j.bioorg.2020.104257	02/09/2020	Artigo completo publicado em periódico científico	10.1016/j.bioorg.2020.104257	0045-2068	00452068	BIOORGANIC CHEMISTRY (PRINT)	A2	0.728	66	5.22	-	['Oseltamivir']	['Oseltamivir']
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study	https://doi.org/10.1186/s12879-020-05425-5	02/10/2020	Artigo completo publicado em periódico científico	10.1186/s12879-020-05425-5	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract  Background The global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.  Methods Patients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.  Results A total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (16 ± 9.7 vs 23 ± 10.5 days;  P = 0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 ± 8.5 days to 10 ± 2.9 days compared with delayed intervention group ( P = 0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.  Conclusions Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.	['Interferon alfa', 'Lopinavir', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ritonavir']
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	https://doi.org/10.1016/S0140-6736(20)32013-4	05/10/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32013-4	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension	https://doi.org/10.1111/jch.14038	02/10/2020	Artigo completo publicado em periódico científico	10.1111/jch.14038	1524-6175	15246175	THE JOURNAL OF CLINICAL HYPERTENSION (GREENWICH, CONN.)	A3	0.875	70	2.17	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Ii Receptor Blockers and Prognosis of Hypertensive Patients Hospitalized With Covid-19	https://onlinelibrary.wiley.com/doi/10.1111/imj.15078	06/10/2020	Artigo completo publicado em periódico científico	10.1111/imj.15078	1444-0903	14440903	INTERNAL MEDICINE JOURNAL (PRINT)	A4	0.590	74	1.53	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies	https://doi.org/10.1016/j.vph.2020.106805	28/09/2020	Artigo completo publicado em periódico científico	10.1016/j.vph.2020.106805	1537-1891	15371891	VASCULAR PHARMACOLOGY	A2	1.308	100	6.03	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study	https://doi.org/10.1016/j.jsps.2020.09.019	01/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jsps.2020.09.019	1319-0164	13190164	SAUDI PHARMACEUTICAL JOURNAL	A2	0.613	57	4.71	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A Pandemic Hospital Experience	https://www.bakirkoytip.org/jvi.aspx?un=BMJ-50469&volume=16&issue=3	30/09/2020	Artigo completo publicado em periódico científico	https://www.bakirkoytip.org/jvi.aspx?un=BMJ-50469&volume=16&issue=3	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review	https://doi.org/10.1016/j.nmni.2020.100776	05/10/2020	Artigo completo publicado em periódico científico	10.1016/j.nmni.2020.100776	2052-2975	20522975	NEW MICROBES NEW INFECT	B2	0.737	33	3.44	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19	https://doi.org/10.1016/j.cmi.2020.09.045	29/09/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.09.045	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Dexametasona', 'Hidrocortisona', 'Prednisolona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Hydrocortisone', 'Prednisolone', 'Prednisone']
Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19	https://doi.org/10.1155/2020/2854186	24/09/2020	Artigo completo publicado em periódico científico	10.1155/2020/2854186	2314-6133	23146133	BIOMED RESEARCH INTERNATIONAL	A3	0.647	147	3.5	  Objectives. To evaluate the role of short-term low-dose glucocorticoids in mild COVID-19 patients.  Methods. We conducted a retrospective, cross-sectional, single-center study in Kunming, China. A total of 33 mild COVID-19 cases were divided into two treatment groups (with and without glucocorticoids, methylprednisolone, were used in this setting), and the absolute value of peripheral blood lymphocyte count; CD3+, CD4+, and CD8+ T cell counts; and the time to achieve negative transformation of a nucleic acid pharyngeal swab were recorded. Peripheral blood lymphocyte and T cell counts were compared between the treatment group and 25 healthy individuals. At the point of time when there was a 50% accumulation conversion rate (positive to negative nucleic acid on pharyngeal swab), and the nucleic acid turned negative in half of the patients in two groups, the peripheral blood lymphocyte and T cell counts were compared between treatment groups.  Results. The mean cumulative time for the 50% negative conversion rate of the nucleic acid in the pharyngeal swab was <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mn>17.7</mml:mn><mml:mo>±</mml:mo><mml:mn>5.1</mml:mn></mml:math> days and <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mn>13.9</mml:mn><mml:mo>±</mml:mo><mml:mn>5.4</mml:mn></mml:math> days in the glucocorticoid group and the nonglucocorticoid group, respectively. The absolute peripheral blood lymphocyte count and the T cell subset count in the glucocorticoid group were lower than those in the nonglucocorticoid group. When the nucleic acid turned negative in half of the patients, the absolute value of peripheral blood lymphocyte count and CD4+ T cells of the glucocorticoid group and the nonglucocorticoid group was not significantly different; the CD3+ and CD8+ T cells in the glucocorticoid group were lower than those in the nonglucocorticoid group. The absolute peripheral blood lymphocyte count, CD3+ T cells, and CD4+ T cells in the glucocorticoid group were lower than those of the healthy group during the whole disease period, and CD8+ T cells returned to normal at 19-21 days of the disease period. There was no significant difference between the nonglucocorticoid group and the healthy group for absolute peripheral blood lymphocyte and CD8+ T cells; moreover, CD3+ T cells and CD4+ T cells were lower in the nonglucocorticoid group than those in the healthy group from the day of admission to the 18th day and returned to normal at the period of 19-21 days. The absolute peripheral lymphocyte count (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.048</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.727</mml:mn></mml:math>) and T cell subset count (CD3: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.042</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.655</mml:mn></mml:math>; CD4: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>P</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.599</mml:mn></mml:math>; and CD8: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.034</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.550</mml:mn></mml:math>) in the nonglucocorticoid group were higher than those in the glucocorticoid group, and the difference between the groups was statistically significant.  Conclusions. This study found that the use of short-term, low-dose glucocorticoids does not negatively influence the clinical outcome, without affecting the final clearance of viral nucleic acid in mild COVID-19 patients.	['Prednisona']	['Prednisone']
Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis	https://www.sciencedirect.com/science/article/pii/S1876034120306638	29/09/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1876034120306638	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo	https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1240	02/10/2020	Artigo completo publicado em periódico científico	https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1240	0002-9637	00029637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Azitromicina', 'Cloroquina']	['Azithromycin', 'Chloroquine']
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels	https://doi.org/10.1371/journal.pone.0239252	17/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0239252	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide	https://peerj.com/articles/10112/	01/10/2020	Artigo completo publicado em periódico científico	https://peerj.com/articles/10112/	-	-	-	-	-	-	-	-	['Vacina influenza']	['Influenza vaccine']
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses	https://doi.org/10.1038/s41586-020-2814-7	30/09/2020	Artigo completo publicado em periódico científico	10.1038/s41586-020-2814-7	0028-0836	00280836	NATURE (LONDON)	A1	17.897	1276	19.35	-	['Vacina BNT162']	['BNT162 vaccine']
Serum levels of Vitamin C and Vitamin D in a cohort of critically ill COVID-19 patients of a North American Community Hospital Intensive Care Unit in May 2020. A Pilot Study	https://doi.org/10.1016/j.medidd.2020.100064	18/09/2020	Artigo completo publicado em periódico científico	10.1016/j.medidd.2020.100064	2590-0986	25900986	Medicine in Drug Discovery	-	0.306	5	3.33	-	['Ácido ascórbico', 'Vitamina D (25-hidroxivitamina D)']	['Ascorbic acid', 'Vitamin D (25-hydroxyvitamin D)']
COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients	https://doi.org/10.1016/j.ijcha.2020.100637	11/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcha.2020.100637	2352-9067	23529067	INTERNATIONAL JOURNAL OF CARDIOLOGY HEART & VASCULATURE	B2	0.803	25	2.27	-	['Azitromicina', 'Cloroquina', 'Cobicistato', 'Darunavir', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Azithromycin', 'Chloroquine', 'Cobicistat', 'Darunavir', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/32958501/	21/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32958501/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina', 'Imunoglobulina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Hydroxychloroquine', 'Immunoglobulin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Umifenovir']
Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort	https://doi.org/10.1055/s-0040-1716721	26/09/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1716721	2512-9465	25129465	-	-	-	-	-	 Abstract A hypercoagulable state has been described in coronavirus disease 2019 (COVID-19) patients. Others have reported a survival advantage with prophylactic anticoagulation (pAC) and therapeutic anticoagulation (tAC), but these retrospective analyses have important limitations such as confounding by indication. We studied the impact of tAC and pAC compared with no anticoagulation (AC) on time to death in COVID-19. We performed a cross-sectional analysis of 127 deceased COVID-19 patients and compared time to death in those who received tAC (n = 67), pAC (n = 47), and no AC (n = 13). Median time to death was longer with higher doses of AC (11 days for tAC, 8 days for pAC, and 4 days for no AC, p &lt; 0.001). In multivariate analysis, AC was associated with longer time to death, both at prophylactic (hazard ratio [HR] = 0.29; 95% confidence interval [CI]: 0.15 to 0.58; p &lt; 0.001) and therapeutic doses (HR = 0.15; 95% CI: 0.07 to 0.32; p &lt; 0.001) compared with no AC. Bleeding rates were similar among tAC and remaining patients (19 vs. 18%; p = 0.877). In deceased COVID-19 patients, AC was associated with a delay in death in a dose-dependent manner. Randomized trials are required to prospectively investigate the benefit and safety of higher doses of AC in this population.	['Corticosteroides', 'Heparina']	['Corticosteroids', 'Heparin']
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines	https://pubmed.ncbi.nlm.nih.gov/32640479/	15/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32640479/	-	-	-	-	-	-	-	-	['Fondaparinux', 'Heparina']	['Fondaparinux', 'Heparin']
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy	https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14817	27/03/2020	Artigo completo publicado em periódico científico	10.1111/jth.14817	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Heparina']	['Heparin']
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	https://www.thrombosisresearch.com/article/S0049-3848(20)30530-2/fulltext	20/09/2020	Artigo completo publicado em periódico científico	https://www.thrombosisresearch.com/article/S0049-3848(20)30530-2/fulltext	-	-	-	-	-	-	-	-	['Enoxaparina']	['Enoxaparin']
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study	https://doi.org/10.2337/dc20-1521	29/09/2020	Artigo completo publicado em periódico científico	10.2337/dc20-1521	0149-5992	01495992	DIABETES CARE	A1	6.528	380	12.25	                    OBJECTIVE                   Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.                                                  RESEARCH DESIGN AND METHODS                   In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation &amp;lt;95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020.                                                  RESULTS                   Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29–0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively.                                                  CONCLUSIONS                   In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.               	['Sitagliptina']	['Sitagliptin']
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus pneumonia: results of a randomized, open-labeled prospective study	https://journals.lww.com/cmj/fulltext/2020/05050/comparative_effectiveness_and_safety_of_ribavirin.24.aspx	05/05/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/cmj/fulltext/2020/05050/comparative_effectiveness_and_safety_of_ribavirin.24.aspx	-	-	-	-	-	-	-	-	['Interferon alfa', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ribavirin', 'Ritonavir']
Ivermectin treatment may improve the prognosis of patients with COVID-19	https://doi.org/10.1016/j.arbres.2020.08.007	24/09/2020	Artigo completo publicado em periódico científico	10.1016/j.arbres.2020.08.007	0300-2896	03002896	ARCHIVOS DE BRONCONEUMOLOGÍA (ED. IMPRESA)	A4	0.262	52	0.98	-	['Ivermectina']	['Ivermectin']
Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study	10.3329/imcjms.v14i2.52826	03/09/2020	Artigo completo publicado em periódico científico	10.3329/imcjms.v14i2.52826	2519-1586	25191586	-	-	-	-	-	 Background and objectives: Various existing non-antiviral drugs are being used to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based mostly on existing data from previous coronavirus outbreaks. Ivermectin is one of such agents being widely used to treat early-stage of COVID-19. This study evaluated the outcome of ivermectin treated mild to moderate COVID-19 cases compared to usual care.&#x0D;Methods: This open-label randomised controlled study was conducted at a sub-district (Upazila) health complex from 1st May 2020 to the end of July 2020. Consecutive RT-PCR positive eligible COVID-19 patients were randomised into control and intervention arms. In the intervention arm, ivermectin 200 micrograms/kg single dose was administered orally in addition to usual care and was followed up till recovery. Repeat RT-PCR was done on day ten since the first positive result. The end point with regard to treatment outcome was time required for the resolution of symptoms from the onset of the symptoms and following enrollement in the study.&#x0D;Results: A total of 62 mild to moderate COVID-19 patients were enrolled in the study. There were 30 patients in the control arm and 32 patients in the intervention arm. Total recovery time from the onset of symptoms to complete resolution of symptoms of the patients in the intervention arm was 10.09 ± 3.236 days, compared to 11.50 ± 5.32 days in the control arm (95% CI -0.860,3.627, p&gt;. 05) and was not significantly different. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days, which also did not differ significantly from the control arm of 6.33 ± 4.23 days (95% CI – 0.766, 2.808, p&gt; 0.05). Results of negative repeat RT- PCR were not significantly different between control and intervention arms (control 90% vs intervention 95%, p&gt;.05).&#x0D;Conclusion: Ivermectin had no beneficial effect on the disease course over usual care in mild to moderate COVID-19 cases.&#x0D;Ibrahim Med. Coll. J. 2020; 14(2): 11-18	['Ivermectina']	['Ivermectin']
An open-label, randomized trial of the combination of IFN-k plus TFF2 with standard care in the treatment of patients with moderate COVID-19	https://doi.org/10.1016/j.eclinm.2020.100547	20/09/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100547	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Interferon kappa', 'TFF2']	['Interferon kappa', 'TFF2']
The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy	https://doi.org/10.1016/j.ijcard.2020.09.062	24/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.09.062	0167-5273	01675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Antagonistas do Receptor da Angiotensina II', 'Heparina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Heparin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities	https://link.springer.com/article/10.1007/s11906-020-01101-w	10/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11906-020-01101-w	1522-6417	15226417	CURRENT HYPERTENSION REPORTS (PRINT)	A3	1.413	79	5.79	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Ibuprofen use and clinical outcomes in COVID-19 patients	https://doi.org/10.1016/j.cmi.2020.06.003	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.06.003	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Ibuprofeno', 'Paracetamol']	['Ibuprofen', 'Paracetamol']
Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients	https://doi.org/10.1016/j.ijid.2020.09.1460	23/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1460	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen	https://doi.org/10.1016/j.ijcard.2020.09.038	18/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.09.038	0167-5273	01675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients	https://doi.org/10.1007/s11739-020-02505-x	30/09/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02505-x	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	 Abstract This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5–12) days. Hydroxychloroquine had been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0.44 (0.29–0.67). This association remained significant when saturation of oxygen &lt; 90% and temperature &gt; 37 °C were added to de model with OR 0.45 (0.30–0.68)  p &lt; 0.001, and also when all the other drugs, and time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess the causal effects of hydroxychloroquine in different therapeutic regimes are required.	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings	https://pubmed.ncbi.nlm.nih.gov/32971536/	24/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32971536/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients	https://doi.org/10.1093/ofid/ofaa446	23/09/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa446	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized controlled trials are needed to determine the safety and efficacy of HCQ for the treatment of hospitalized patients with COVID-19.                                                  Methods                   We conducted a multicenter, double-blind randomized clinical trial of HCQ among patients hospitalized with laboratory-confirmed COVID-19. Subjects were randomized in a 1:1 ratio to HCQ or placebo for 5 days and followed for 30 days. The primary efficacy outcome was a severe disease progression composite end point (death, intensive care unit admission, mechanical ventilation, extracorporeal membrane oxygenation, and/or vasopressor use) at day 14.                                                  Results                   A total of 128 patients were included in the intention-to-treat analysis. Baseline demographic, clinical, and laboratory characteristics were similar between the HCQ (n = 67) and placebo (n = 61) arms. At day 14, 11 (16.4%) subjects assigned to HCQ and 6 (9.8%) subjects assigned to placebo met the severe disease progression end point, but this did not achieve statistical significance (P = .350). There were no significant differences in COVID-19 clinical scores, number of oxygen-free days, SARS-CoV-2 clearance, or adverse events between HCQ and placebo. HCQ was associated with a slight increase in mean corrected QT interval, an increased D-dimer, and a trend toward an increased length of stay.                                                  Conclusions                   In hospitalized patients with COVID-19, our data suggest that HCQ does not prevent severe outcomes or improve clinical scores. However, our conclusions are limited by a relatively small sample size, and larger randomized controlled trials or pooled analyses are needed.               	['Hidroxicloroquina']	['Hydroxychloroquine']
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers A Randomized Clinical Trial	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265	30/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis	https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z	24/09/2020	Artigo completo publicado em periódico científico	https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z	1743-422X	1743422X	VIROLOGY JOURNAL	A3	1.091	88	4.9	 Abstract  Background The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that enzyme. We have conducted this systematic review and meta-analysis on efficacy and safety of the drug FVP as a treatment for COVID-19.  Methods Databases like Pubmed, Pubmed Central, Scopus, Embase, Google Scholar, preprint sites, and clinicaltirals.gov were searched. The studies with the standard of care (SOC) and FVP as a treatment drug were considered as the treatment group and the SOC with other antivirals and supportive care as the control group. Quantitative synthesis was done using RevMan 5.4. Clinical improvement, negative conversion of reverse transcription-polymerase chain reaction (RT-PCR), adverse effects, and oxygen requirements were studied.  Results We identified a total of 1798 studies after searching the electronic databases. Nine in the qualitative studies and four studies in the quantitative synthesis met the criteria. There was a significant clinical improvement in the FVP group on the 14th day compared to the control group (RR 1.29, 1.08–1.54). Clinical deterioration rates were less likely in the FVP group though statistically not significant (OR 0.59, 95% CI 0.30–1.14) at the endpoint of study (7–15 days). The meta-analysis showed no significant differences between the two groups on viral clearance (day 14: RR 1.06, 95% CI 0.84–1.33), non-invasive ventilation or oxygen requirement (OR 0.76, 95% CI 0.42–1.39), and adverse effects (OR 0.69, 0.13–3.57). There are 31 randomized controlled trials (RCTs) registered in different parts of the world focusing FVP for COVID-19 treatment.  Conclusion There is a significant clinical and radiological improvement following treatment with FVP in comparison to the standard of care with no significant differences on viral clearance, oxygen support requirement and side effect profiles.	['Favipiravir']	['Favipiravir']
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	https://doi.org/10.1053/j.gastro.2020.05.053	21/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.053	0016-5085	00165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Famotidina']	['Famotidine']
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	https://doi.org/10.1016/S2213-2600(20)30415-X	24/09/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30415-X	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Corticosteroides']	['Corticosteroids']
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study	https://doi.org/10.1016/j.cmi.2020.09.014	21/09/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.09.014	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Dexametasona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Prednisone']
Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.	https://doi.org/10.1007/s40121-020-00337-y	28/09/2020	Artigo completo publicado em periódico científico	10.1007/s40121-020-00337-y	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']
Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis	https://www.frontiersin.org/articles/10.3389/fphar.2020.571156/full	09/09/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.571156/full	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study	https://www.panafrican-med-journal.com/content/series/37/1/9/full/	15/09/2020	Artigo completo publicado em periódico científico	https://www.panafrican-med-journal.com/content/series/37/1/9/full/	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Vitamin D sufficiency, a serum 25hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection	https://doi.org/10.1371/journal.pone.0239799	25/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0239799	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	https://www.nejm.org/doi/full/10.1056/NEJMoa2028436	29/09/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2028436	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']
Could Vitamins Help in the Fight Against COVID-19?	https://www.mdpi.com/2072-6643/12/9/2550	23/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/9/2550	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Vitamina A', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina E']	['Ascorbic acid', 'Vitamin A', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin E']
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study	https://doi.org/10.1016/j.ebiom.2020.102999	16/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ebiom.2020.102999	2352-3964	23523964	EBIOMEDICINE	A1	2.663	79	7.76	-	['Tocilizumabe']	['Tocilizumab']
Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients withbilateral pulmonary lesions: a randomized, controlled, open-label, multicenter trial	https://ssrn.com/abstract=3667681	29/08/2020	Artigo completo publicado em periódico científico	https://ssrn.com/abstract=3667681	-	-	-	-	-	-	-	-	[]	[]
Decreased mortality in COVID-19 patients treated with Tocilizumab: a rapid systematic review and meta-analysis of observational studies	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1445/5910379	23/09/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1445/5910379	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review	https://www.mdpi.com/2077-0383/9/9/2935	11/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/9/2935	-	-	-	-	-	-	-	-	['Imunomoduladores']	['Immunomodulators']
Convalescent Plasma for the Treatment of Patients with Severe Coronavirus Disease 2019; a Preliminary Report	https://doi.org/10.1002/jmv.26537	23/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26537	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1443/5910353	23/09/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1443/5910353	-	-	-	-	-	-	-	-	['N-acetilcisteína']	['N-acetylcysteine']
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	https://doi.org/10.1183/13993003.02808-2020	17/09/2020	Artigo completo publicado em periódico científico	10.1183/13993003.02808-2020	0903-1936	09031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Introduction There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.  Methods We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day −1 for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.  Results 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%  versus 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9%  versus 42.9%; p&lt;0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p&lt;0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.  Conclusions Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.	['Prednisona']	['Prednisone']
Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial	https://doi.org/10.1093/cid/ciaa1417	21/09/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1417	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   We aimed to evaluate the efficacy and safety of leflunomide, an approved dihydroorotate dehydrogenase inhibitor, to treat coronavirus disease 2019 (COVID-19) patients with prolonged postsymptomatic viral shedding.                                                  Methods                   We conducted a prospective, randomized controlled, open-label trial involving hospitalized adult COVID-19 patients with prolonged polymerase chain reaction (PCR) positivity. Patients were randomly assigned to receive either leflunomide (50 mg every 12 hours, 3 consecutive times, orally; then 20 mg once daily for 8 days), in addition to nebulized interferon alpha 2a (IFN-α-2a, 3 million IU each time, twice daily for 10 days), or nebulized IFN-α-2a alone for 10 days. The primary endpoint was the duration of viral shedding.                                                  Results                   A total of 50 COVID-19 patients with prolonged PCR positivity were randomized into 2 groups: 26 were assigned to the leflunomide plus IFN-α-2a group, and 24 were assigned to the interferon-alone group. Treatment with leflunomide was not associated with a difference from the interferon-alone group in the duration of viral shedding (hazard ratio for negative reverse-transcription PCR, 0.70 [95% confidence interval, .391–1.256]; P = .186). In addition, the patients given leflunomide did not have a substantially shorter length of hospital stay than patients treated with interferon alone, with median durations of 29.0 (interquartile range [IQR], 19.3–47.3) days and 33.0 (IQR, 29.3–42.8) days, respectively (P = .170). Two leflunomide recipients were unable to complete the full 10-day course of administration due to adverse events.                                                  Conclusions                   In COVID-19 patients with prolonged PCR positivity, no benefit in terms of the duration of viral shedding was observed with the combined treatment of leflunomide and IFN-α-2a beyond IFN-α-2a alone.               	['Leflunomida']	['Leflunomide']
Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19	https://link.springer.com/article/10.1007/s40292-020-00409-7	19/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40292-020-00409-7	1120-9879	11209879	HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION	A4	0.749	24	2.45	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)	https://doi.org/10.1016/j.ijcha.2020.100638	12/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcha.2020.100638	2352-9067	23529067	INTERNATIONAL JOURNAL OF CARDIOLOGY HEART & VASCULATURE	B2	0.803	25	2.27	-	['Azitromicina', 'Esteroides', 'Hidroxicloroquina']	['Azithromycin', 'Ssteroids', 'Hydroxychloroquine']
Hydroxychloroquine and Interferons for the Prophylaxis and Early Treatment of Covid-19-Current Clinical Advances	https://www.longdom.org/open-access/hydroxychloroquine-and-interferons-for-the-prophylaxis-and-early-treatment-of-covid19current-clinical-advances.pdf	04/09/2020	Artigo completo publicado em periódico científico	https://www.longdom.org/open-access/hydroxychloroquine-and-interferons-for-the-prophylaxis-and-early-treatment-of-covid19current-clinical-advances.pdf	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Interferon']	['Hydroxychloroquine', 'Interferon']
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study	https://doi.org/10.1016/S2665-9913(20)30305-2	21/09/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30305-2	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.	https://doi.org/10.1186/s13054-020-03287-6	21/09/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03287-6	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Corticosteroides']	['Corticosteroids']
A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19	https://aac.asm.org/content/early/2020/09/16/AAC.01897-20	21/09/2020	Artigo completo publicado em periódico científico	https://aac.asm.org/content/early/2020/09/16/AAC.01897-20	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them (Review)	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013627.pub2/full	16/09/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013627.pub2/full	-	-	-	-	-	-	-	-	['Enxaguantes bucais', 'Spray nasal']	['Mouthwashes', 'Nose spray']
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013626.pub2/full	16/09/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013626.pub2/full	-	-	-	-	-	-	-	-	['Enxaguantes bucais', 'Spray nasal']	['Mouthwashes', 'Nose spray']
Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)	https://doi.org/10.1186/s13643-020-01371-0	09/05/2020	Artigo completo publicado em periódico científico	10.1186/s13643-020-01371-0	2046-4053	20464053	SYSTEMATIC REVIEWS	A2	0.947	68	3.24	 Abstract                  Background                 COVID-19 is a rapidly spreading virus infection that has quickly caused extensive burden to individual, families, countries, and the globe. No intervention has yet been proven effective for the treatment of COVID-19. Some randomized clinical trials assessing the effects of different drugs have been published, and more are currently underway. There is an urgent need for a living, dynamic systematic review that continuously evaluates the beneficial and harmful effects of all available interventions for COVID-19.                                Methods/design                 We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and perform risk of bias assessment. We will include randomized clinical trials comparing any intervention for the treatment of COVID-19 (e.g., pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions) with any comparator (e.g., an “active” comparator, standard care, placebo, no intervention, or “active placebo”) for participants in all age groups with a diagnosis of COVID-19. Primary outcomes will be all-cause mortality and serious adverse events. Secondary outcomes will be admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, Trial Sequential Analyses, network meta-analysis, and individual patient data meta-analyses. Risk of bias will be assessed with domains, an eight-step procedure will be used to assess if the thresholds for clinical significance are crossed, and the certainty of the evidence will be assessed by Grading of Recommendations, Assessment, Development and Evaluations (GRADE).                                Discussion                 COVID-19 has become a pandemic with substantial mortality. A living systematic review evaluating the beneficial and harmful effects of pharmacological and other interventions is urgently needed. This review will continuously inform best practice in treatment and clinical research of this highly prevalent disease.                                Systematic review registration                 PROSPERO CRD42020178787              	['Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', ' Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir' ]
Palliative Care Utilization Among Patients With COVID-19 in an Underserved Population: A Single-Center Retrospective Study	https://doi.org/10.1016/j.jpainsymman.2020.05.022	23/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jpainsymman.2020.05.022	0885-3924	08853924	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT	A1	1.527	147	4.2	-	['Cuidados paliativos']	['Palliative care']
Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a singlecenter descriptive study	https://doi.org/10.1186/s12879-020-05252-8	29/07/2020	Artigo completo publicado em periódico científico	10.1186/s12879-020-05252-8	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract  Background We aimed to report the epidemiological and clinical characteristics of hospitalized patients with coronavirus disease-19 (COVID-19) in Zengdu District, Hubei Province, China.  Methods Clinical data on COVID-19 inpatients in Zengdu Hospital from January 27 to March 11, 2020 were collected; this is a community hospital in an area surrounding Wuhan and supported by volunteer doctors. All hospitalized patients with COVID-19 were included in this study. The epidemiological findings, clinical features, laboratory findings, radiologic manifestations, and clinical outcomes of these patients were analyzed. The patients were followed up for clinical outcomes until March 22, 2020. Severe COVID-19 cases include severe and critical cases diagnosed according to the seventh edition of China’s COVID-19 diagnostic guidelines. Severe and critical COVID-19 cases were diagnosed according to the seventh edition of China’s COVID-19 diagnostic guidelines.  Results All hospitalized COVID-19 patients, 276 (median age: 51.0 years), were enrolled, including 262 non-severe and 14 severe patients. The proportion of patients aged over 60 years was higher in the severe group (78.6%) than in the non-severe group (18.7%,  p &lt; 0.01). Approximately a quarter of the patients (24.6%) had at least one comorbidity, such as hypertension, diabetes, or cancer, and the proportion of patients with comorbidities was higher in the severe group (85.7%) than in the non-severe group (21.4%,  p &lt; 0.01). Common symptoms included fever (82.2% [227/276]) and cough (78.0% [218/276]). 38.4% (106/276) of the patients had a fever at the time of admission. Most patients (94.9% [204/276]) were cured and discharged; 3.6% (10/276) deteriorated to a critical condition and were transferred to another hospital. The median COVID-19 treatment duration and hospital stay were 14.0 and 18.0 days, respectively.  Conclusions Most of the COVID-19 patients in Zengdu had mild disease. Older patients with underlying diseases were at a higher risk of progression to severe disease. The length of hospital-stay and antiviral treatment duration for COVID-19 were slightly longer than those in Wuhan. This work will contribute toward an understanding of COVID-19 characteristics in the areas around the core COVID-19 outbreak region and serve as a reference for decision-making for epidemic prevention and control in similar areas.	['Antivirais', 'Corticosteroides']	['Antivirals', 'Corticosteroids']
Analysis of the predictive factors for critical illness of COVID-19 during treatment - Relationship between serum zinc level and critical illness of COVID-19	https://pubmed.ncbi.nlm.nih.gov/32911042/	07/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32911042/	-	-	-	-	-	-	-	-	['Zinco']	['Zinc']
Impact of Vitamin D Deﬁciency on COVID-19—A Prospective Analysis from the CovILD Registry	https://pubmed.ncbi.nlm.nih.gov/32932831/	11/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32932831/	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Vitamin D Deficiency and Outcome of COVID-19 Patients	https://www.mdpi.com/2072-6643/12/9/2757	10/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/9/2757	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial	https://www.sciencedirect.com/science/article/pii/S2095809920302411	08/09/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2095809920302411	-	-	-	-	-	-	-	-	['Triazavirina']	['Triazavirin']
Observational study on off-label use of tocilizumab in patients with severe COVID-19	https://pubmed.ncbi.nlm.nih.gov/32912961/	10/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32912961/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Efficacy of Tocilizumab in COVID-19: A Systematic review and Meta-Analysis	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26509	12/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26509	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients	https://doi.org/10.1016/j.jcrc.2020.08.025	02/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.08.025	0883-9441	08839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Solução salina heparinizada']	['Heparinized saline']
Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680	10/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680	-	-	-	-	-	-	-	-	['Fator estimulante de colônia para granulócitos humano recombinante (rhG-CSF)']	['Recombinant human granulocyte colony stimulating factor (rhG-CSF)']
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	https://doi.org/10.1038/s41591-020-1088-9	15/09/2020	Artigo completo publicado em periódico científico	10.1038/s41591-020-1088-9	1078-8956	10788956	NATURE MEDICINE (PRINT)	A1	24.161	576	34.05	-	['Plasma convalescente']	['Convalescent Plasma']
Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma	https://doi.org/10.1016/j.eclinm.2020.100525	09/09/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100525	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Plasma convalescente']	['Convalescent Plasma']
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran	https://doi.org/10.1620/tjem.252.73	09/09/2020	Artigo completo publicado em periódico científico	10.1620/tjem.252.73	0040-8727	00408727	Tohoku Journal of Experimental Medicine	-	0.558	62	2.5	-	['Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Ribavirina', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Ribavirin', 'Ritonavir']
Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region	https://doi.org/10.1371/journal.pone.0238827	09/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0238827	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Dexametasona', 'Hidrocortisona', 'Prednisona']	['Dexamethasone', 'Hydrocortisone', 'Prednisone']
The effect of antivirals on COVID-19: a systematic review	https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1823832	12/09/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2021.1823832	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida.	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232020000903517&lng=en	28/08/2020	Artigo completo publicado em periódico científico	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232020000903517&lng=en	-	-	-	-	-	-	-	-	['Heparina', 'Hidroxicloroquina', 'Interferon alfa', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Heparin', 'Hydroxychloroquine', 'Interferon alfa', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis	https://doi.org/10.1016/j.jksus.2020.09.002	06/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jksus.2020.09.002	1018-3647	10183647	JOURNAL OF KING SAUD UNIVERSITY - SCIENCE	A1	0.513	45	4.07	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir', 'Remdesivir']
Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients	https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001250	15/09/2020	Artigo completo publicado em periódico científico	https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001250	0022-2615	00222615	JOURNAL OF MEDICAL MICROBIOLOGY	B2	0.680	122	2.89	                    Introduction. COVID-19 has rapidly emerged as a pandemic infection that has caused significant mortality and economic losses. Potential therapies and prophylaxis against COVID-19 are urgently needed to combat this novel infection. As a result of  in vitro evidence suggesting zinc sulphate may be efficacious against COVID-19, our hospitals began using zinc sulphate as add-on therapy to hydroxychloroquine and azithromycin.                                   Aim. To compare outcomes among hospitalized COVID-19 patients ordered to receive hydroxychloroquine and azithromycin plus zinc sulphate versus hydroxychloroquine and azithromycin alone.                                   Methodology. This was a retrospective observational study. Data was collected from medical records for all patients with admission dates ranging from 2 March 2020 through to 11 April 2020. Initial clinical characteristics on presentation, medications given during the hospitalization, and hospital outcomes were recorded. The study included patients admitted to any of four acute care NYU Langone Health Hospitals in New York City. Patients included were admitted to the hospital with at least one positive COVID-19 test and had completed their hospitalization. Patients were excluded from the study if they were never admitted to the hospital or if there was an order for other investigational therapies for COVID-19.                                   Results. Patients taking zinc sulphate in addition to hydroxychloroquine and azithromycin ( n=411) and patients taking hydroxychloroquine and azithromycin alone ( n=521) did not differ in age, race, sex, tobacco use or relevant comorbidities. The addition of zinc sulphate did not impact the length of hospitalization, duration of ventilation or intensive care unit (ICU) duration. In univariate analyses, zinc sulphate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU and mortality or transfer to hospice for patients who were never admitted to the ICU. After adjusting for the time at which zinc sulphate was added to our protocol, an increased frequency of being discharged home (OR 1.53, 95 % CI 1.12–2.09) and reduction in mortality or transfer to hospice among patients who did not require ICU level of care remained significant (OR 0.449, 95 % CI 0.271–0.744).                                   Conclusion. This study provides the first  in vivo evidence that zinc sulphate may play a role in therapeutic management for COVID-19.	['Azitromicina', 'Hidroxicloroquina', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Zinc']
Utilidad y seguridad de la automonitorizacion electrocardiográfica durante el tratamiento con hidroxicloroquina y azitromicina en pacientes con COVID-19	https://doi.org/10.1016/j.recesp.2020.08.012	04/09/2020	Artigo completo publicado em periódico científico	10.1016/j.recesp.2020.08.012	0300-8932	03008932	Revista Espanola de Cardiologia	-	0.407	70	1.33	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability	https://doi.org/10.37616/2212-5043.1088	20/08/2020	Artigo completo publicado em periódico científico	10.37616/2212-5043.1088	2212-5043	22125043	Journal of the Saudi Heart Association	-	0.194	18	0.59	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients	https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12860	14/09/2020	Artigo completo publicado em periódico científico	10.1111/cts.12860	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety	https://doi.org/10.2147/CPAA.S269156	17/08/2020	Artigo completo publicado em periódico científico	10.2147/CPAA.S269156	1179-1438	11791438	Clinical Pharmacology: Advances and Applications	-	0.510	29	2.18	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System	https://doi.org/10.3389/fimmu.2020.02072	14/08/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.02072	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Conestate alfa']	['Conestate alpha']
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19	https://www.mdpi.com/2077-0383/9/9/2961/htm	14/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/9/2961/htm	-	-	-	-	-	-	-	-	['Colchicina']	['Colchicine']
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients	https://www.mdpi.com/2077-0383/9/9/2943	11/09/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/9/2943	-	-	-	-	-	-	-	-	['Anakinra', 'Canrenona', 'Hidroxicloroquina', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)', 'Lopinavir', 'Prednisona', 'Ritonavir']	['Anakinra', 'Canrenone', 'Hydroxychloroquine', 'Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)', 'Lopinavir', 'Prednisone', 'Ritonavir']
Clinical characteristics of 132 healthcare workers cases with COVID-19: a retrospective study from a single center in Wuhan, China	https://doi.org/10.1002/jmv.26511	14/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26511	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Antibióticos', 'Antivirais', 'Corticosteroides', 'Gamaglobulina', 'Interferon alfa']	['Antibiotics', 'Antivirals', 'Corticosteroids', 'Gammaglobulin', 'Interferon alpha']
Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19	https://advances.sciencemag.org/content/6/32/eabc1463	05/08/2020	Artigo completo publicado em periódico científico	https://advances.sciencemag.org/content/6/32/eabc1463	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Correlation between immunity from BCG and the morbidity and mortality of COVID-19	https://doi.org/10.1186/s40794-020-00117-z	28/08/2020	Artigo completo publicado em periódico científico	10.1186/s40794-020-00117-z	2055-0936	20550936	Tropical Diseases, Travel Medicine and Vaccines	-	0.734	16	3.1	 Abstract  Background To investigate the association between parameters indicating immunity from BCG at country level (presence of BCG vaccination policy, BCG coverage, age-specific incidence of tuberculosis (TB)) and the morbidity and mortality of COVID-19.  Methods Country-specific data for COVID-19 cases and deaths, demographic details, BCG coverage and policy, age-specific TB incidence and income level were obtained. The crude COVID-19 cases and deaths per 100,000 population were calculated and assessed against the parameters indicating immunity from BCG using linear regression analysis.  Results Univariate analysis identified higher income level of a country to be significantly associated with COVID-19 cases ( p &lt; 0.0001) and deaths ( p &lt; 0.0001) but not with its case fatality rate. The association between COVID-19 and TB was strongest for TB incidence in patients &gt; 65-years (Cases (r s = − 0.785, p = 0.0001)) and deaths (r s = − 0.647, p = 0.0001). Multivariate analysis identified the higher income level of a country and not having a universal BCG vaccination policy to affect the COVID-19 cases. The deaths were inversely affected by the presence of BCG vaccination policy and coverage; and positively by the TB incidence in patients &gt; 65-years.  Conclusion Significant inverse correlations observed between cases and deaths of COVID-19 and BCG related parameters highlights immunity from BCG as a likely explanation for the variation in COVID-19 across countries.	['Vacina BCG']	['BCG vaccine']
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes - Interim Analysis of 2 Randomized Clinical Trials	https://jamanetwork.com/journals/jama/fullarticle/2769612	13/08/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2769612	-	-	-	-	-	-	-	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Systematic review of the antiviral properties of TRIM56: a potential therapeutic intervention for COVID-19	https://www.tandfonline.com/doi/abs/10.1080/1744666X.2020.1822168?tab=permissions&scroll=top&	09/09/2020	Artigo completo publicado em periódico científico	10.1080/1744666X.2020.1822168?tab=permissions&scroll=top&	-	-	-	-	-	-	-	-	['TRIM56']	['TRIM56']
Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up	https://doi.org/10.1016/j.eclinm.2020.100459	17/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100459	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']
Outcome of COVID-19 patients with use of Tocilizumab: A single center experience	https://www.sciencedirect.com/science/article/pii/S1567576920319238	28/08/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1567576920319238	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial	https://doi.org/10.1016/j.intimp.2020.106869	04/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106869	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Tocilizumabe']	['Tocilizumab']
Analysis of the prophylactic effect of thymosin drugs on COVID‐19 for 435 medical staff: A hospital‐based retrospective study	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26492	08/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26492	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Timosina']	['Thymosin']
Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature	https://www.cureus.com/articles/37482-convalescent-plasma-therapy-and-its-effects-on-covid-19-patient-outcomes-a-systematic-review-of-current-literature	03/08/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/37482-convalescent-plasma-therapy-and-its-effects-on-covid-19-patient-outcomes-a-systematic-review-of-current-literature	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review	https://pubmed.ncbi.nlm.nih.gov/32894567/	24/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32894567/	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study	https://journals.sagepub.com/doi/full/10.1177/0036933020951926	01/09/2020	Artigo completo publicado em periódico científico	10.1177/0036933020951926	0036-9330	00369330	Scottish Medical Journal	-	0.293	27	1.26	  Background and aims  Hypertension is associated with an increased risk of severe outcomes with COVID-19 disease. Angiotensin Converting Enzyme (ACE) inhibitors are widely used as a first line medication for the treatment of hypertension in the UK, although their use was suggested in early reports to increase the risk associated with SARS-CoV-2 infection.   Methods  A prospective cohort study of hospitalised patients with laboratory confirmed COVID-19 was conducted across three hospital sites with patients identified on the 9th April 2020. Demographic and other baseline data were extracted from electronic case records, and patients grouped depending on ACE inhibitor usage or not. The 60-day all-cause mortality and need for intubation compared.   Results  Of the 173 patients identified, 88 (50.8%) had hypertension. Of these 27 (30.7%) used ACE inhibitors. We did not find significant differences in 60-day all-cause mortality, the requirement for invasive ventilation or length of stay between our patient cohorts after adjusting for covariates.   Conclusion  This study contributes to the growing evidence supporting the continued use of ACE inhibitors in COVID-19 disease, although adequately powered randomised controlled trials will be needed to confirm effects. 	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study	https://doi.org/10.1186/s12979-020-00194-w	14/08/2020	Artigo completo publicado em periódico científico	10.1186/s12979-020-00194-w	1742-4933	17424933	IMMUNITY & AGEING	A2	1.697	50	7.3	 Abstract  Background The SARS-CoV-2 infection has widely spread to become the greatest public health challenge to date, the COVID-19 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. The Spanish case-fatality rate is 11.22%, far higher than those reported in Asia or by other European countries. A multicentre retrospective study of demographic, clinical, laboratory and immunological features of 584 Spanish COVID-19 hospitalized patients and their outcomes was performed. The use of renin-angiotensin system blockers was also analysed as a risk factor.  Results In this study, 27.4% of cases presented a mild course, 42.1% a moderate one and for 30.5% of cases, the course was severe. Ages ranged from 18 to 98 (average 63). Almost 60 % (59.8%) of patients were male. Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19, and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of angiotensin-converting enzyme inhibitors was associated with a better prognosis. The angiotensin II receptor blocker use was associated with a more severe course.  Conclusions Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
The Association of Renin-AngiotensinAldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience	https://assets.cureus.com/uploads/original_article/pdf/39950/1599623043-20200909-16970-298t76.pdf	03/09/2020	Artigo completo publicado em periódico científico	https://assets.cureus.com/uploads/original_article/pdf/39950/1599623043-20200909-16970-298t76.pdf	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials	https://doi.org/10.1016/j.dsx.2020.08.033	01/09/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.08.033	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis	https://doi.org/10.1007/s00210-020-01964-5	06/09/2020	Artigo completo publicado em periódico científico	10.1007/s00210-020-01964-5	0028-1298	00281298	NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY	A4	0.566	93	2.99	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19	https://www.cureus.com/articles/38513-a-meta-analysis-on-the-effects-of-hydroxychloroquine-on-covid-19/metrics	24/08/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/38513-a-meta-analysis-on-the-effects-of-hydroxychloroquine-on-covid-19/metrics	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda	https://bmjopenrespres.bmj.com/content/7/1/e000646	25/08/2020	Artigo completo publicado em periódico científico	https://bmjopenrespres.bmj.com/content/7/1/e000646	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?	https://openheart.bmj.com/content/7/2/e001362	10/08/2020	Artigo completo publicado em periódico científico	https://openheart.bmj.com/content/7/2/e001362	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review	https://doi.org/10.1016/j.intimp.2020.106942	29/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106942	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Agentes anti-interleucinas', 'Esteroides', 'Hidroxicloroquina', 'Imunoglobulina', 'Plasma convalescente', 'Terapia celular', 'Terapia de purificação do sangue']	['Anti-Interleukin Agents', 'Steroidal', 'Hydroxychloroquine', 'Immunoglobulin', 'Convalescent Plasma', 'Cell Therapy', 'Blood Purification Therapy']
Are the steroids a blanket solution for COVID‐19? a systematic review and meta‐analysis	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26483	03/09/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26483	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Esteroides']	['Steroidal']
Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China	https://doi.org/10.1210/clinem/dgaa627	03/09/2020	Artigo completo publicado em periódico científico	10.1210/clinem/dgaa627	0021-972X	0021972X	THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM	A1	1.746	363	5.01	 Abstract                                   Background                   Systemic corticosteroids are now recommended in many treatment guidelines, although supporting evidence is limited to 1 randomized controlled clinical trial (RECOVERY).                                                  Objective                   To identify whether corticosteroids were beneficial to COVID-19 patients.                                                  Methods                   A total of 1514 severe and 249 critical hospitalized COVID-19 patients from 2 medical centers in Wuhan, China. Multivariable Cox models, Cox model with time-varying exposure and propensity score analysis (inverse-probability-of-treatment-weighting [IPTW] and propensity score matching [PSM]) were used to estimate the association of corticosteroid use with risk of in-hospital mortality in severe and critical cases.                                                  Results                   Corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to the non-corticosteroid group, systemic corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality in either severe cases (HR = 1.77; 95% CI, 1.08-2.89; P = 0.023), or critical cases (HR = 2.07; 95% CI, 1.08–3.98; P = 0.028). Findings were similar in time-varying Cox analysis. For patients with severe COVID-19 at admission, corticosteroid use was not associated with improved or harmful outcome in either PSM or IPTW analysis. For critical COVID-19 patients at admission, results were consistent with multivariable Cox model analysis.                                                  Conclusion                   Corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality for severe or critical cases in Wuhan. Absence of the beneficial effect in our study in contrast to that observed in the RECOVERY clinical trial may be due to biases in observational data, in particular prescription by indication bias, differences in clinical characteristics of patients, choice of corticosteroid used, timing of initiation of treatment, and duration of treatment.               	['Corticosteroides']	['Corticosteroids']
Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study	https://link.springer.com/article/10.1007/s40121-020-00332-3	02/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00332-3	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']
Agentes potencialmente terapéuticos contra el SARS-COV-2: revisión rápida de la evidencia	https://doi.org/10.17843/rpmesp.2020.372.5409	09/09/2020	Artigo completo publicado em periódico científico	10.17843/rpmesp.2020.372.5409	1726-4642	17264642	REVISTA PERUANA DE MEDICINA EXPERIMENTAL Y SALUD PUBLICA	B3	0.258	23	1.01	 El Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) del Seguro Social de Salud (EsSalud) ha desarrollado siete informes breves mediante revisiones rápidas de evidencia sobre los agentes potencialmente terapéuticos contra el SARS-CoV-2 con la finalidad de brindar información actual y relevante para los decisores, clínicos, investigadores y la comunidad académica en el Perú. Los agentes terapéuticos evaluados incluyeron cloroquina/hidroxicloroquina, lopinavir/ritonavir, tocilizumab, oseltamivir, interferón, atazanavir y plasma anti-SARS-CoV-2. La identificación de evidencia incluyó la revisión de las bases electrónicas PubMed y Cochrane Library. Adicionalmente, se realizó una búsqueda manual en las páginas web de grupos dedicados a la investigación y educación en salud, así como, en las principales sociedades o instituciones especializadas, como la Organización Mundial de la Salud (OMS) y los Centros para el Control y la Prevención de Enfermedades (CDC, por sus siglas en inglés). Asimismo, para disminuir el sesgo de publicación, se buscó en las páginas web www.clinicaltrials.gov y http://apps.who.int/trialsearch, para identificar ensayos clínicos en desarrollo o que no hayan sido publicados aún. Finalmente, se consideró extraer información con una estrategia de «bola de nieve» mediante la revisión de las listas de referencias de las revisiones sistemáticas, estudios primarios y revisiones narrativas que sean de relevancia. A la fecha de la última revisión (27 de marzo de 2020), no se dispone de evidencia para recomendar un medicamento específico para el tratamiento de pacientes con COVID-19. Se necesita de mayor evidencia, preferentemente ensayos clínicos de buena calidad, para la toma de decisiones terapéuticas contra el SARS-CoV-2.	['Atazanavir', 'Cloroquina', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumabe']	['Atazanavir', 'Chloroquine', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumab']
Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis	https://link.springer.com/article/10.1007/s11606-020-06146-w	03/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11606-020-06146-w	0884-8734	08848734	Journal of General Internal Medicine	-	1.537	192	3.25	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Chloroquine and Hydroxychloroquine in treatment of COVID-19 Disease	https://doi.org/10.37678/dcybd.2020.2387	22/08/2020	Artigo completo publicado em periódico científico	10.37678/dcybd.2020.2387	2717-6428	27176428	Journal of Critical and Intensive Care	-	0.131	5	0.41	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial	https://bi.tbzmed.ac.ir/Files/Inpress/bi-23240.pdf	19/07/2020	Artigo completo publicado em periódico científico	https://bi.tbzmed.ac.ir/Files/Inpress/bi-23240.pdf	-	-	-	-	-	-	-	-	['Bromexina']	['Bromhexine']
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-label Randomized Controlled Pilot Study	https://doi.org/10.1111/cts.12881	03/09/2020	Artigo completo publicado em periódico científico	10.1111/cts.12881	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Bromexina']	['Bromhexine']
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial	https://doi.org/10.1016/S0140-6736(20)31862-6	04/09/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31862-6	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Azitromicina']	['Azithromycin']
Observational study of azithromycin in hospitalized patients with COVID-19	https://doi.org/10.1371/journal.pone.0238681	03/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0238681	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Azitromicina']	['Azithromycin']
The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.12880	03/09/2020	Artigo completo publicado em periódico científico	10.1111/cts.12880	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Heparina']	['Heparin']
The Impact of the “Low Molecular Weight Heparin” Administration on the Clinical Course of the COVID-19 Disease	https://pubmed.ncbi.nlm.nih.gov/32892540/	06/09/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32892540/	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study	https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1749	03/09/2020	Artigo completo publicado em periódico científico	10.1002/jcph.1749	0091-2700	00912700	JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.687	121	2.9	-	['Heparina']	['Heparin']
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	https://doi.org/10.1016/S0140-6736(20)31866-3	04/09/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31866-3	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina (rAd26 and rAd5)']	['Vaccine (rAd26 and rAd5)']
Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems	https://doi.org/10.1002/jmv.26473	29/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26473	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Anakinra']	['Anakinra']
Prolongation of QT interval due tohydroxychloroquine overdose used inCOVID-19 treatment	https://pubmed.ncbi.nlm.nih.gov/32832735/	18/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32832735/	-	-	-	-	-	-	-	-	[]	[]
Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China	https://www.frontiersin.org/articles/10.3389/fphar.2020.01198/full	12/08/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.01198/full	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection	https://academic.oup.com/ndt/article/35/8/1346/5897181	26/08/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/ndt/article/35/8/1346/5897181	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Effect of oral L-Glutamine supplementation on Covid-19 treatment	https://doi.org/10.1016/j.yclnex.2020.07.003	13/08/2020	Artigo completo publicado em periódico científico	10.1016/j.yclnex.2020.07.003	2352-9393	23529393	CLINICAL NUTRITION EXPERIMENTAL	B1	0.409	14	2.42	-	['L-glutamina']	['L-glutamine']
Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19	https://www.mdpi.com/2077-0383/9/9/2800	30/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/9/2800	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Dual-Histamine Receptor Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients	https://www.sciencedirect.com/science/article/pii/S1094553920301462?via%3Dihub	29/08/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1094553920301462?via%3Dihub	-	-	-	-	-	-	-	-	['Cetirizina', 'Famotidina']	['Cetirizine', 'Famotidine']
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes	https://doi.org/10.1016/j.cmet.2020.08.013	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmet.2020.08.013	1550-4131	15504131	CELL METABOLISM	A1	9.297	292	22.01	-	['Metformina']	['Metformin']
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir	https://doi.org/10.1007/s40199-020-00369-2	28/08/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00369-2	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Atazanavir', 'Hidroxicloroquina', 'Ritonavir']	['Atazanavir', 'Hydroxychloroquine', 'Ritonavir']
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study	https://doi.org/10.1007/s12250-020-00281-8	31/08/2020	Artigo completo publicado em periódico científico	10.1007/s12250-020-00281-8	1674-0769	16740769	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Tocilizumab use in COVID -19 associated pneumonia	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26471	29/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26471	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak	https://doi.org/10.1016/j.jaad.2020.07.089	23/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaad.2020.07.089	0190-9622	01909622	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	A1	1.948	217	4.29	-	['Imunossupressores']	['Immunosuppressants']
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19	https://doi.org/10.1016/j.ijantimicag.2020.106142	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106142	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)	https://doi.org/10.1016/j.cmi.2020.08.010	26/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.08.010	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients	https://doi.org/10.1007/s40264-020-00994-5	27/08/2020	Artigo completo publicado em periódico científico	10.1007/s40264-020-00994-5	0114-5916	01145916	Drug Safety	-	1.268	131	4.42	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients	https://doi.org/10.1016/j.jaut.2020.102537	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102537	0896-8411	08968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Anakinra']	['Anakinra']
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol	https://www.frontiersin.org/article/10.3389/fmed.2020.00466	04/08/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fmed.2020.00466	2296-858X	2296858X	FRONTIERS IN MEDICINE	C	1.179	54	5.1	-	['Ruxolitinibe']	['Ruxolitinib']
Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19	https://pubmed.ncbi.nlm.nih.gov/32849949	15/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32849949	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Moxifloxacina']	['Hydroxychloroquine', 'Moxifloxacin']
A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-k plus TFF2 in patients with moderate COVID-19	https://doi.org/10.1016/j.eclinm.2020.100478	29/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100478	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Interferon kappa', 'TFF2']	['Interferon kappa', 'TFF2']
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 - The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial,	https://jamanetwork.com/journals/jama/fullarticle/2770278	02/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2770278	-	-	-	-	-	-	-	-	['Hidrocortisona']	['Hydrocortisone']
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial	https://jamanetwork.com/journals/jama/fullarticle/2770276	02/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2770276	-	-	-	-	-	-	-	-	['Hidrocortisona']	['Hydrocortisone']
Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study	https://doi.org/10.1016/j.jsbmb.2020.105751	29/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jsbmb.2020.105751	0960-0760	09600760	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY	A2	1.072	133	4.92	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial	https://jamanetwork.com/journals/jama/fullarticle/2770277	02/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2770277	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	18/08/2020	Artigo completo publicado em periódico científico	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract  Background COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19.  Objectives To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19.  Methods Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups.  Measurements and main results The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group.  Conclusions Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.  Trial registration Chinese Clinical Trial Registration; ChiCTR2000031494; Registered on 2 April 2020; http://<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.medresman.org/">www.medresman.org</jats:ext-link>	['Terapia celular']	['Cell Therapy']
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial	https://doi.org/10.1016/j.intimp.2020.106903	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106903	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon beta']	['Interferon beta']
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial	https://www.nature.com/articles/s41392-020-00286-5	27/08/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41392-020-00286-5	-	-	-	-	-	-	-	-	['Terapia celular']	['Cell Therapy']
Safety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial	https://pubmed.ncbi.nlm.nih.gov/32853672/	24/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32853672/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis	https://jamanetwork.com/journals/jama/fullarticle/2770279	02/09/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2770279	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids']
Zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infections: a rapid review	https://doi.org/10.1016/j.aimed.2020.07.009	01/08/2020	Artigo completo publicado em periódico científico	10.1016/j.aimed.2020.07.009	2212-9588	22129588	Advances in Integrative Medicine	-	0.331	12	1.57	-	['Zinco']	['Zinc']
Directly Acting Antivirals for COVID-19: Where Do We Stand?	https://www.frontiersin.org/articles/10.3389/fmicb.2020.01857/full	05/08/2020	Artigo completo publicado em periódico científico	10.3389/fmicb.2020.01857/full	-	-	-	-	-	-	-	-	['Azivudina', 'Baloxavir marboxil', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Triazavirina', 'Umifenovir']	['Azivudine', 'Baloxavir marboxil', 'Danoprevir', 'Darunavir', 'Favipiravir', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Triazavirin', 'Umifenovir']
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis	https://doi.org/10.1016/j.cmi.2020.08.02	26/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.08.02	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis	https://doi.org/10.14740/jocmr4233	12/07/2020	Artigo completo publicado em periódico científico	10.14740/jocmr4233	1918-3003	19183003	JOURNAL OF CLINICAL MEDICINE RESEARCH	B1		3	-	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review	https://doi.org/10.1016/j.aimed.2020.07.007	30/07/2020	Artigo completo publicado em periódico científico	10.1016/j.aimed.2020.07.007	2212-9588	22129588	Advances in Integrative Medicine	-	0.331	12	1.57	-	['Quercetina', 'Quercetina', 'Quercetina', 'Quercetina']	['Quercetin', 'Quercetin', 'Quercetin', 'Quercetin']
Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials	https://pubmed.ncbi.nlm.nih.gov/32827627/	19/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32827627/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey	https://www.mdpi.com/2076-393X/8/3/471	23/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-393X/8/3/471	-	-	-	-	-	-	-	-	['Vacina influenza', 'Vacina pneumocócica']	['Influenza vaccine', 'Pneumococcal vaccine']
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	https://www.nejm.org/doi/full/10.1056/NEJMoa2026920	02/09/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2026920	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Vaccine NVX-CoV2373', 'Vaccine NVX-CoV2373']
Azithromycin: The First Broad-spectrum Therapeutic	https://doi.org/10.1016/j.jtauto.2020.100062	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jtauto.2020.100062	2589-9090	25899090	Journal of Translational Autoimmunity	-	0.796	9	3.77	-	['Azitromicina']	['Azithromycin']
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review	https://doi.org/10.1016/j.jiph.2020.07.013	03/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.07.013	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Favipiravir', 'Lopinavir', 'Ostalmovir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Ostalmovir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits	https://aacnjournals.org/ajcconline/article/doi/10.4037/ajcc2020694/31146/COVID-19-and-Antimalarial-Drugs-Harms-Outweigh	25/08/2020	Artigo completo publicado em periódico científico	10.4037/ajcc2020694/31146/COVID-19-and-Antimalarial-Drugs-Harms-Outweigh	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels	https://pubmed.ncbi.nlm.nih.gov/32760206/	27/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32760206/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study	https://doi.org/10.1038/s41440-020-00535-8	21/08/2020	Artigo completo publicado em periódico científico	10.1038/s41440-020-00535-8	0916-9636	09169636	HYPERTENSION RESEARCH	A2	1.119	95	3.97	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19	http://www.sciencedirect.com/science/article/pii/S0002914920306755	12/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0002914920306755	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. view and Meta-Analysis	https://www.frontiersin.org/articles/10.3389/fmed.2020.00482/full	29/07/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.00482/full	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019	https://doi.org/10.1016/j.hroo.2020.06.002	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.hroo.2020.06.002	2666-5018	26665018	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study	https://www.nature.com/articles/s41371-020-00405-3	24/08/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41371-020-00405-3	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	https://doi.org/10.1038/s41375-020-01018-y	19/08/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-01018-y	0887-6924	08876924	LEUKEMIA	A1	4.030	202	9.5	 Abstract Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71–93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 &lt; 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.	['Ruxolitinibe']	['Ruxolitinib']
Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study	https://doi.org/10.1016/j.ijid.2020.08.045	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.045	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Efavirenz', 'Fumarato de tenofovir desoproxila', 'Lamivudina', 'Lopinavir', 'Ritonavir', 'Zidovudina']	['Efavirenz', 'Tenofovir disoproxil fumarate', 'Lamivudine', 'Lopinavir', 'Ritonavir', 'Zidovudine']
Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19	https://www.frontiersin.org/articles/10.3389/fmed.2020.00389/full	07/07/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.00389/full	-	-	-	-	-	-	-	-	['Antibióticos']	['Antibiotics']
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study	https://doi.org/10.1016/j.ejim.2020.08.019	25/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.08.019	0953-6205	09536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19	https://www.mdpi.com/2077-0383/9/8/2586	10/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/8/2586	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Is there any potential management against COVID-19? A systematic review and meta-analysis	https://doi.org/10.1007/s40199-020-00367-4	18/08/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00367-4	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Anakinra', 'Azitromicina', 'Baloxavir marboxil', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Meplazumabe', 'Plasma convalescente', 'Prednisona', 'Remdesivir', 'Ritonavir', 'Ruxolitinibe', 'Tocilizumabe', 'Umifenovir']	['Anakinra', 'Azithromycin', 'Baloxavir marboxil', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Meplazumab', 'Convalescent plasma', 'Prednisone', 'Remdesivir', 'Ritonavir' , 'Ruxolitinib', 'Tocilizumab', 'Umifenovir']
Hydroxychloroquine is protective to the heart, not Harmful: A systematic review.	https://doi.org/10.1016/j.nmni.2020.100747	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.nmni.2020.100747	2052-2975	20522975	NEW MICROBES NEW INFECT	B2	0.737	33	3.44	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review	https://www.mdpi.com/2218-0532/88/3/36	17/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2218-0532/88/3/36	-	-	-	-	-	-	-	-	['Ivermectina', 'Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin', 'Ivermectin']
Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinicaltrial	https://doi.org/10.1016/j.ejphar.2020.173494	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ejphar.2020.173494	0014-2999	00142999	EUROPEAN JOURNAL OF PHARMACOLOGY	A2	0.930	189	4.95	-	[]	[]
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition	https://doi.org/10.1016/j.ijid.2020.08.047	25/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.047	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Corticosteroides', 'Favipiravir', 'Nafamostato']	['Corticosteroids', 'Favipiravir', 'Nafamostat']
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa321/5896161	23/08/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa321/5896161	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661959/	20/08/2020	Artigo completo publicado em periódico científico	PMC:PMC7661959/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants	https://doi.org/10.1016/j.ijantimicag.2020.106144	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106144	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study	http://www.ajtmh.org/docserver/fulltext/10.4269/ajtmh.20-0873/tpmd200873.pdf?expires=1598521504&id=id&accname=guest&checksum=04453E4613C460BB3D79520B2EB76784	14/08/2020	Artigo completo publicado em periódico científico	http://www.ajtmh.org/docserver/fulltext/10.4269/ajtmh.20-0873/tpmd200873.pdf?expires=1598521504&id=id&accname=guest&checksum=04453E4613C460BB3D79520B2EB76784	-	-	-	-	-	-	-	-	['Cefalosporina', 'Hidroxicloroquina', 'Oseltamivir', 'Paracetamol']	['Cephalosporin', 'Hydroxychloroquine', 'Oseltamivir', 'Paracetamol']
Remdesivir is Effective for Moderately Severe Patients: A Re-Analysis of the First Double-Blind, Placebo-Controlled, Randomized Trial on Remdesivir for Treatment of Severe COVID-19 Patients Conducted in Wuhan City	https://doi.org/10.2147/OAJCT.S262606	30/07/2020	Artigo completo publicado em periódico científico	10.2147/OAJCT.S262606	1179-1519	11791519	Open Access Journal of Clinical Trials	-	0.785	12	0.94	-	['Remdesivir']	['Remdesivir']
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients	https://doi.org/10.1007/s11883-020-00880-6	24/08/2020	Artigo completo publicado em periódico científico	10.1007/s11883-020-00880-6	1523-3804	15233804	CURRENT ATHEROSCLEROSIS REPORTS	A4	1.284	79	5.21	 Abstract  Purpose of Review The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated. With an increasing number of COVID-19 cases worldwide, it is imperative to better understand the impact of RAAS inhibitors in hypertensive COVID patients. PubMed, Embase and the pre-print database Medrxiv were searched, and studies with data on patients on ACEi/ARB with COVID-19 were included. Random effects models were used to estimate the pooled mean difference with 95% confidence interval using Open Meta[Analyst] software.  Recent Findings A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034,  p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964,  p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908,  p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235,  p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218,  p = 0.668).  Summary This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Steroids in COVID-19: An overview	https://www.ccjm.org/content/early/2020/08/18/ccjm.87a.ccc059	20/08/2020	Artigo completo publicado em periódico científico	https://www.ccjm.org/content/early/2020/08/18/ccjm.87a.ccc059	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19	http://doi.org/10.2147/DDDT.S261154	06/08/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S261154	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Remdesivir']	['Remdesivir']
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia	https://doi.org/10.1186/s13287-020-01866-6	14/08/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01866-6	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract  Background The outbreak of a new virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the main health concern all over the world. Since effective antiviral treatments have not been developed until now, SARS-CoV-2 is severely affecting countries and territories around the world.  Methods At the present review, articles in PubMed were searched with the following terms: mesenchymal stem cells, exosomes, coronavirus, and SARS-CoV-2, either alone or in a combination form. The most relevant selected functions were mesenchymal stem cell-derived exosomes and SARS-CoV-2 virus infection.  Results SARS-CoV-2 could damage pulmonary cells and induce secretion of different types of inflammatory cytokines. In the following, these cytokines trigger inflammation that damages the lungs and results in lethal acute respiratory distress syndrome (ARDS). The main characteristic of ARDS is the onset of inflammation in pulmonary, hyaline formation, pulmonary fibrosis, and edema. Mesenchymal stem cell-derived exosomes (MSC-Exo) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment. Besides, exosomes may serve as a biomarker, drug delivery system, and vaccine for the management of the patient with SARS-CoV-2.  Conclusion MSC-Exo may serve as a promising tool in the treatment of SARS-CoV-2 pneumonia. However, further work needs to be carried out to confirm the efficacy of exosomes in the treatment of SARS-CoV-2 pneumonia.	['Exossomos derivados de células-tronco mesenquimais']	['Mesenchymal stem cell-derived exosomes']
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa331/5889946?searchresult=1	19/08/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa331/5889946?searchresult=1	-	-	-	-	-	-	-	-	['Daclatasvir', 'Hidroxicloroquina', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Sofosbuvir']	['Daclatasvir', 'Hydroxychloroquine', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Sofosbuvir']
The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients	https://www.sciencedirect.com/science/article/pii/S0022073620305288?via%3Dihub	11/08/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0022073620305288?via%3Dihub	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study	https://doi.org/10.1093/cid/ciaa1239	21/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1239	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Antibacterials may be initiated out of concern for bacterial coinfection in coronavirus disease 2019 (COVID-19). We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial coinfections in hospitalized patients with COVID-19.                                                  Methods                   A randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020 and 6/18/2020. Data were collected on early (within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial coinfections (positive microbiologic test ≤3 days). Poisson generalized estimating equation models were used to assess predictors.                                                  Results                   Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27% to 84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00–1.08] per 10 years); had a lower body mass index (ARR: 0.99 [0.99–1.00] per kg/m2), more severe illness (eg, severe sepsis; ARR: 1.16 [1.07–1.27]), a lobar infiltrate (ARR: 1.21 [1.04–1.42]); or were admitted to a for-profit hospital (ARR: 1.30 [1.15–1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs April [85.2%, 628/737], P &amp;lt; .001) and empiric antibacterial use (ARR: 0.71 [0.63–0.81] April vs March) decreased.                                                  Conclusions                   The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.               	['Ampicilina', 'Antibióticos', 'Cefotaxima', 'Ceftarolina', 'Ceftriaxona', 'Levofloxacina', 'Moxifloxacina', 'Sulbactam']	['Ampicillin', 'Antibiotics', 'Cefotaxime', 'Ceftaroline', 'Ceftriaxone', 'Levofloxacin', 'Moxifloxacin', 'Sulbactam']
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia	https://doi.org/10.1371/journal.pone.0237831	20/08/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0237831	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Prednisona', 'Tocilizumabe']	['Prednisone', 'Tocilizumab']
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial	https://pubmed.ncbi.nlm.nih.gov/32821939/	21/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32821939/	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
Remdesivir and its antiviral activity against COVID-19: A systematic review	http://www.sciencedirect.com/science/article/pii/S2213398420301810	07/08/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S2213398420301810	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir']
Fatal COVID-19 in an MS patient on natalizumab: A case report	https://journals.sagepub.com/doi/full/10.1177/2055217320942931	10/08/2020	Artigo completo publicado em periódico científico	10.1177/2055217320942931	2055-2173	20552173	MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL	C	0.849	20	2.59	  We report a fatal case of COVID-19 in a 51-year-old African American woman with multiple sclerosis on natalizumab. She had multiple risk factors for severe COVID-19 disease including race, obesity, hypertension, and elevated inflammatory markers, but the contribution of natalizumab to her poor outcome remains unknown. We consider whether altered dynamics of peripheral immune cells in the context of natalizumab treatment could worsen the cytokine storm syndrome associated with severe COVID-19. We discuss extended interval dosing as a risk-reduction strategy for multiple sclerosis patients on natalizumab, and the use of interleukin-6 inhibitors in such patients who contract COVID-19. 	['Natalizumabe']	['Natalizumab']
Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)	https://www.mdpi.com/2218-273X/10/8/1171	11/08/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2218-273X/10/8/1171	-	-	-	-	-	-	-	-	['Adrecizumabe']	['Adrecizumab']
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China	https://doi.org/10.1177/1559325820949740	14/08/2020	Artigo completo publicado em periódico científico	10.1177/1559325820949740	1559-3258	15593258	DOSE-RESPONSE	A2	0.453	41	2.52	  Objective:  To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19).   Methods:  We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.   Results:  The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P &lt; 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P &lt; 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P &lt; 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P &lt; 0.05).   Conclusion:  The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge. 	['Interferon alfa', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit	https://doi.org/10.1016/j.thromres.2020.07.035	21/07/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.07.035	0049-3848	00493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Nadroparina']	['Nadroparin']
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa332/5889947	19/08/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa332/5889947	-	-	-	-	-	-	-	-	['Daclatasvir', 'Daclatasvir', 'Ribavirina', 'Ribavirina', 'Sofosbuvir', 'Sofosbuvir']	['Daclatasvir', 'Daclatasvir', 'Ribavirin', 'Ribavirin', 'Sofosbuvir', 'Sofosbuvir']
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa334/5889948	19/08/2020	Artigo completo publicado em periódico científico	10.1093/jac/dkaa334/5889948	-	-	-	-	-	-	-	-	['Daclatasvir', 'Sofosbuvir']	['Daclatasvir', 'Sofosbuvir']
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. Scientific brief	https://www.researchgate.net/publication/342938782_The_use_of_non-steroidal_anti-inflammatory_drugs_NSAIDs_in_patients_with_COVID-19_Scientific_Brie	23/08/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/342938782_The_use_of_non-steroidal_anti-inflammatory_drugs_NSAIDs_in_patients_with_COVID-19_Scientific_Brie	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
COVID-19 and multisystem inflammatory syndrome in children and adolescents	https://doi.org/10.1016/S1473-3099(20)30651-4	17/08/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30651-4	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Epinephrine', 'Epinephrine', 'Epinephrine', 'Epinephrine ', 'Epinephrine', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone ', 'Prednisone', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Tocilizumab for severe COVID‐19 pneumonia: case series of 5 Australian patients	https://doi.org/10.1111/1756-185X.13913	13/08/2020	Artigo completo publicado em periódico científico	10.1111/1756-185X.13913	1756-1841	17561841	INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (PRINT)	B1	0.625	46	2.35	-	['Hidroxicloroquina', 'Lopinavir', 'Piperacilina-tazobactam', 'Prednisona', 'Ritonavir', 'Tocilizumabe', 'Vancomicina']	['Hydroxychloroquine', 'Lopinavir', 'Piperacillin-tazobactam', 'Prednisone', 'Ritonavir', 'Tocilizumab', 'Vancomycin']
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients	https://link.springer.com/article/10.1007/s11239-020-02243-z	13/08/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11239-020-02243-z	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Enoxaparina']	['Enoxaparin']
Impact of Famotidine Use on Clinical Outcomes of Hospitalized COVID-19 Patients	https://journals.lww.com/ajg/Documents/AJG-20-2074_R1.pdf	20/08/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/ajg/Documents/AJG-20-2074_R1.pdf	-	-	-	-	-	-	-	-	['Famotidina']	['Famotidine']
Baricitinib restrains the immune dysregulation in severe COVID-19 patients	https://doi.org/10.1172/JCI141772	18/08/2020	Artigo completo publicado em periódico científico	10.1172/JCI141772	0021-9738	00219738	THE JOURNAL OF CLINICAL INVESTIGATION	A1	5.527	505	14.12	-	['Baricitinibe', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Baricitinib', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis	https://onlinelibrary.wiley.com/doi/10.1111/eci.13383	18/08/2020	Artigo completo publicado em periódico científico	10.1111/eci.13383	0014-2972	00142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Anticorpo (47D11)', 'Anticorpos n3086/n3113', 'Auranofina', 'Azitromicina', 'Beta-d-N4-hydroxycytidine', 'Cloroquina', 'Corticosteroides', 'Darunavir', 'Emetine', 'Hidroxicloroquina', 'Homoharringtonina (HHT)', 'Interferon alfa', 'Interferon beta', 'Ivermectina', 'Lianhua Qingwen (Medicina Tradicional Chinesa)', 'Lopinavir', 'Pudilan Xiaoyan', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Antibody (47D11)', 'N3086/n3113 antibodies', 'Auranofin', 'Azithromycin', 'Beta-d-N4-hydroxycytidine', 'Chloroquine', 'Corticosteroids', 'Darunavir', 'Emetine', ' Hydroxychloroquine', 'Homoharringtonine (HHT)', 'Interferon alpha', 'Interferon beta', 'Ivermectin', 'Lianhua Qingwen (Traditional Chinese Medicine)', 'Lopinavir', 'Pudilan Xiaoyan', 'Remdesivir', 'Ritonavir' , 'Tocilizumab', 'Umifenovir']
Recent Updates Published About Favipiravir in COVID-19	https://pharmascope.org/ijrps/article/view/2373	06/07/2020	Artigo completo publicado em periódico científico	https://pharmascope.org/ijrps/article/view/2373	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient	https://clinowl.com/oral-corticosteroid-relieves-post-covid-19-anosmia-in-a-35-year-old-patient/	18/08/2020	Artigo completo publicado em periódico científico	https://clinowl.com/oral-corticosteroid-relieves-post-covid-19-anosmia-in-a-35-year-old-patient/	-	-	-	-	-	-	-	-	['Prednisolona']	['Prednisolone']
Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia	https://doi.org/10.1016/j.transci.2020.102904	03/08/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102904	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Favipiravir', 'Hidroxicloroquina', 'Imunoglobulina', 'Meropenem', 'Moxifloxacina', 'Oseltamivir', 'Prednisona']	['Favipiravir', 'Hydroxychloroquine', 'Immunoglobulin', 'Meropenem', 'Moxifloxacin', 'Oseltamivir', 'Prednisone']
Neumonía por COVID-19 y uso de tocilizumab	https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17893	03/07/2020	Artigo completo publicado em periódico científico	https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17893	-	-	-	-	-	-	-	-	['Azitromicina', 'Enoxaparina', 'Hidroxicloroquina', 'Linezolida', 'Meropenem', 'Piperacilina-tazobactam', 'Prednisona', 'Tocilizumabe']	['Azithromycin', 'Enoxaparin', 'Hydroxychloroquine', 'Linezolid', 'Meropenem', 'Piperacillin-tazobactam', 'Prednisone', 'Tocilizumab']
Heparin-induced thrombocytopenia in COVID-19 patients with severe acute respiratory distress syndrome requiring extracorporeal membrane oxygenation: two case reports	https://doi.org/10.1007/s10047-020-01203-x	12/08/2020	Artigo completo publicado em periódico científico	10.1007/s10047-020-01203-x	1434-7229	14347229	Journal of Artificial Organs	-	0.331	40	1.49	-	['Argatrobana', 'Heparina']	['Argatroban', 'Heparin']
A case report of a pregnant woman infected with coronavirus disease 2019 pneumonia	https://pubmed.ncbi.nlm.nih.gov/32791731/	24/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32791731/	-	-	-	-	-	-	-	-	['Cefalosporina']	['Cephalosporin']
Steroids: A Therapeutic Option for COVID-19 Pneumonia Patients With ESRD?	https://pubmed.ncbi.nlm.nih.gov/32775845/	17/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32775845/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Severe arterial thromboembolism in patients with Covid- 19	https://doi.org/10.1016/j.jcrc.2020.08.002	08/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.08.002	0883-9441	08839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York	https://pubmed.ncbi.nlm.nih.gov/32802622	11/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32802622	-	-	-	-	-	-	-	-	['Doxiciclina']	['Doxycycline']
Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan	https://doi.org/10.1016/j.jfma.2020.07.033	29/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jfma.2020.07.033	0929-6646	09296646	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (PRINT)	A1	0.779	59	2.92	-	['Azitromicina', 'Ceftriaxona', 'Hidroxicloroquina', 'Teicoplanina']	['Azithromycin', 'Ceftriaxone', 'Hydroxychloroquine', 'Teicoplanin']
Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia	https://www.ahajournals.org/doi/10.1161/CIRCEP.120.008798	09/07/2020	Artigo completo publicado em periódico científico	10.1161/CIRCEP.120.008798	1941-3149	19413149	CIRCULATION. ARRHYTHMIA AND ELECTROPHYSIOLOGY	A1	2.471	113	5.0	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Corticosteroid prevents COVID-19 progressionwithin its therapeutic window: a multicenter, proof-of-concept, observational study	https://doi.org/10.1080/22221751.2020.1807885	14/08/2020	Artigo completo publicado em periódico científico	10.1080/22221751.2020.1807885	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	[]	[]
Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients	https://doi.org/10.1161/JAHA.120.017736	18/08/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.017736	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">There has been significant controversy about the effects of pre‐hospitalization use of renin‐angiotensin system (RAS) inhibitors on the prognosis of patients with hypertension and coronavirus disease 2019.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              We retrospectively assessed 2297 hospitalized patients with coronavirus disease 2019 at Tongji Hospital in Wuhan, China, from January 10 to March 30, 2020; and identified 1182 patients with known hypertension on pre‐hospitalization therapy. We compared the baseline characteristics and in‐hospital mortality between patients with hypertension taking RAS inhibitors (n=355) versus non‐RAS inhibitors (n=827). Of the 1182 patients with hypertension (median age 68 years, 49.1% male), 12/355 (3.4%) patients died in the RAS inhibitors group versus 95/827 (11.5%) patients in the non‐RAS inhibitors group (               P              &lt;0.0001). Adjusted hazard ratio for mortality was 0.28 (95% CI 0.15–0.52,               P              &lt;0.0001) at 45 days in the RAS inhibitors group compared with non‐RAS inhibitors group. Similar findings were observed when patients taking angiotensin receptor blockers (n=289) or angiotensin‐converting enzyme inhibitors (n=66) were separately compared with non‐RAS inhibitors group. The RAS inhibitors group compared with non‐RAS inhibitors group had lower levels of C‐reactive protein (median 13.5 versus 24.4 pg/mL;               P              =0.007) and interleukin‐6 (median 6.0 versus 8.5 pg/mL;               P              =0.026) on admission. The protective effect of RAS inhibitors on mortality was confirmed in a meta‐analysis of published data when our data were added to previous studies (odd ratio 0.44, 95% CI 0.29–0.65,               P              &lt;0.0001).                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">In a large single center retrospective analysis, we observed a protective effect of pre‐hospitalization use of RAS inhibitors on mortality in patients with hypertension and coronavirus disease 2019, which might be associated with reduced inflammatory response.          	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26442	18/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26442	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: a new challenge overcome?	https://doi.org/10.1016/j.ijcard.2020.07.041	29/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.07.041	0167-5273	01675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
The application of corticosteroids in COVID-19: A two-edged sword	https://content.sciendo.com/view/journals/jtim/8/2/article-p66.xml?language=en	25/06/2020	Artigo completo publicado em periódico científico	https://content.sciendo.com/view/journals/jtim/8/2/article-p66.xml?language=en	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Uncontrolled mass use of hydroxychloroquine	https://doi.org/10.26452/ijrps.v11iSPL1.2734	06/08/2020	Artigo completo publicado em periódico científico	10.26452/ijrps.v11iSPL1.2734	0975-7538	09757538	-	-	-	-	-	 Hydroxychloroquine (HCQ) has previously been shown to inhibit coronavirus replication in vitro. But antiviral properties mechanisms are not well known, HCQ is a weak base that accumulates in lysosomes, modifies their pH, and interferes with some enzymes. In the lack of confirmed efficacy, the initial potential risk is not to expose patients to adverse effects. However, results from preliminary clinical studies have drawn inconclusive results regarding the efficacy of HCQ in coronavirus disease 2019 (COVID-19), due to several important weaknesses in research methodologies. Hypokalemia often occurs in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), possibly due to the particular tropism of SARS-CoV-2 with regard to Angiotensin-converting enzyme 2 (ACE2). The wide use of HCQ, even against medical advice, will show an impact on ongoing clinical trials. It is important that we can recruite COVID-19 patients in these research studies to generate appropriate data regarding drugs that show promising efficacy against COVID-19. Currently, only doctors should be allowed to prescribe HCQ, and treatment should be confined to hospital settings, with proper cardiac and therapeutic drug monitoring.	['Hidroxicloroquina']	['Hydroxychloroquine']
Short-term corticosteroid therapy for early exacerbation of COVID-19 pneumonia: a case report	https://pubmed.ncbi.nlm.nih.gov/32796809/	14/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32796809/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients	https://doi.org/10.1016/j.ijid.2020.08.024	12/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.024	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']
Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study	https://doi.org/10.1016/j.intimp.2020.106873	06/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106873	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Timosina']	['Thymosin']
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study	https://doi.org/10.1016/S2665-9913(20)30277-0	14/08/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30277-0	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Tocilizumabe']	['Tocilizumab']
Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients	https://doi.org/10.3329/jbcps.v38i0.47514	12/06/2020	Artigo completo publicado em periódico científico	10.3329/jbcps.v38i0.47514	1015-0870	10150870	-	-	-	-	-	 Introduction: The whole world is on the brink of collapse due to the outbreak of COVID-19 with no solution to treat these cases with any specific drug. Extensive search for the Vaccine or effective treatment is going on while alarming infection and death toll is rising every day.&#x0D;Aim: The study will compare the effect of Ivermectin with Doxycycline and Hydoxychloroquine with Azythromicin on a selective group of COVID -19 positive patients.&#x0D;Method: This is a comparative study that included 400 patients of COVID 19 positive patient who were divided in to two groups. Group- A Received Ivermectin with Doxycycline and the other group- B received hydroxichloroquine(HCQ) with azithromycin.&#x0D;Result: Viral clearance is 132 ( 66%) on day 5 and 167( 83.5% ) on day 6. Among them 33(16.5%) remain PCR positive after 6th day of Ivermectin ingestion in Group A. Whereas there is154 ( 77.0%) viral clearance at 11th day and 163(81.5%) viral clearance at 12th day of Hydroxychloroquine ingestion in Group B. Among them 37 (18.5%) remain PCR positive after 12 day in group B. The P value is 0.000427 which is significant considering 5th day viral clearance of Ivermectin ingestion and 11th day of Hydroxychloroquine ingestion. But considering 6th day and 12th day the P-value is 0.59 which is not significant.&#x0D;Conclusion: It appears Ivermectin and Doxycycline is safeand effective combination drug therapy in COVID- 19infected patients but need further extensive study to find out the scope of application on other groups of patients.&#x0D;J Bangladesh Coll Phys Surg 2020; 38(0): 5-9	['Azitromicina', 'Doxiciclina', 'Hidroxicloroquina', 'Ivermectina']	['Azithromycin', 'Doxycycline', 'Hydroxychloroquine', 'Ivermectin']
Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial	https://www.springermedizin.de/auxora-versus-standard-of-care-for-the-treatment-of-severe-or-cr/18284134	01/08/2020	Artigo completo publicado em periódico científico	https://www.springermedizin.de/auxora-versus-standard-of-care-for-the-treatment-of-severe-or-cr/18284134	-	-	-	-	-	-	-	-	['Auxora']	['Auxora']
Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure	https://pubmed.ncbi.nlm.nih.gov/32792041/	31/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32792041/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy	https://doi.org/10.1136/jitc-2020-001089	11/08/2020	Artigo completo publicado em periódico científico	10.1136/jitc-2020-001089	2051-1426	20511426	JOURNAL FOR IMMUNOTHERAPY OF CANCER	A1	3.450	80	12.01	  Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.  Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.  Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.	['Sarilumabe']	['Sarilumab']
Tocilizumab exerts anti-inflammatory activity in six critically ill COVID-19 patients: a retrospective analysis	http://dx.doi.org/10.21037/atm-20-5080	13/07/2020	Artigo completo publicado em periódico científico	10.21037/atm-20-5080	2305-5839	23055839	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2	https://pubmed.ncbi.nlm.nih.gov/32790652/	13/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32790652/	-	-	-	-	-	-	-	-	['Ácido acetilsalicílico', 'Imunoglobulina']	['Acetylsalicylic acid', 'Immunoglobulin']
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study	https://doi.org/10.1371/journal.pone.0237693	13/08/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0237693	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad	http://www.sciencedirect.com/science/article/pii/S0025775320304486	09/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0025775320304486	-	-	-	-	-	-	-	-	['Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816	12/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1177/5891816	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults	https://www.nature.com/articles/s41586-020-2639-4	12/08/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41586-020-2639-4	-	-	-	-	-	-	-	-	['Vacina de RNA']	['RNA vaccine']
Risk of QTc prolongation with Chloroquine/Hyroxychloroquine and Azithromycin treatment for COVID-19: Quantification and precautions for a busy clinician	https://onlinelibrary.wiley.com/doi/full/10.1002/joa3.12393	03/07/2020	Artigo completo publicado em periódico científico	10.1002/joa3.12393	1880-4276	18804276	JOURNAL OF ARRHYTMIA	B1	0.489	25	1.36	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review	https://doi.org/10.1177/2049936120947517	04/08/2020	Artigo completo publicado em periódico científico	10.1177/2049936120947517	2049-9361	20499361	Therapeutic Advances in Infectious Disease	-	0.633	14	2.79	  The predicament arising from the coronavirus disease 2019 (COVID-19) pandemic has become one of the most significant modern public health challenges. Despite uncertainties in the viral determinants and pathogenesis, it is crucial to accurately inspect all available evidence to construct accurate clinical guidelines for optimised patient care. This study aims to discuss the available evidence for the use of chloroquine (CQ) and hydroxychloroquine (HCQ) against COVID-19. Early in vitro studies of CQ/HCQ against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are convincing. But contradictory evidence exists on the clinical use of CQ/HCQ, either alone or in combination with azithromycin. As of now, there is no compelling clinical evidence on CQ, HCQ, and azithromycin in COVID-19 and the available evidence is limited to methodologically inferior non-randomised studies. Studies have also shown detrimental drug reactions to CQ and ‘HCQ plus azithromycin’, mainly cardiac side effects in hospitalised patients with coexisting cardiovascular comorbidities. Therefore, we recommend that physicians avoid high doses and exercise extreme caution in the compassionate use of CQ/HCQ, either alone or in combination with other antiviral drugs. 	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Prolonged QT Interval in a PatientWith Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin	https://doi.org/10.1177/2324709620948407	12/08/2020	Artigo completo publicado em periódico científico	10.1177/2324709620948407	2324-7096	23247096	JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS (ONLINE)	A4	0.296	15	1.13	  Recent reports have suggested an increased risk of QT prolongation and subsequent life-threatening ventricular arrhythmias, particularly torsade de pointes, in patients with coronavirus disease-2019 (COVID-19) treated with hydroxychloroquine and azithromycin. In this article, we report the case of a 75-year-old female with a baseline prolonged QT interval in whom the COVID-19 illness resulted in further remarkable QT prolongation (&gt;700 ms), precipitating recurrent self-terminating episodes of torsade de pointes that necessitated temporary cardiac pacing. Despite the correction of hypoxemia and the absence of reversible factors, such as adverse medication effects, electrolyte derangements, and usage of hydroxychloroquine/azithromycin, the QT interval remained persistently prolonged compared with the baseline with subsequent degeneration into ventricular tachycardia and death. Thus, we highlight that COVID-19 illness itself can potentially lead to further prolongation of QT interval and unmask fatal ventricular arrhythmias in patients who have a prolonged QT and low repolarization reserve at baseline. 	[]	[]
Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review	https://www.cureus.com/articles/33660-cardiovascular-considerations-of-experimental-hydroxychloroquine-therapy-on-patients-diagnosed-with-covid-19-a-case-series-review/metrics	17/07/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/33660-cardiovascular-considerations-of-experimental-hydroxychloroquine-therapy-on-patients-diagnosed-with-covid-19-a-case-series-review/metrics	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769237	13/08/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769237	-	-	-	-	-	-	-	-	['Acetato de icatibanto']	['Icatibant acetate']
Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19	https://doi.org/10.1016/j.medcli.2020.07.004	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.07.004	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Late Onset Infectious Complications and Safety of Tocilizumab in the Management of COVID-19	https://doi.org/10.1002/jmv.26429	13/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26429	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review	https://doi.org/10.2196/preprints.21758	13/08/2020	Artigo completo publicado em periódico científico	10.2196/preprints.21758	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical	https://jamanetwork.com/journals/jama/fullarticle/2769612	13/08/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2769612	-	-	-	-	-	-	-	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary	https://emj.bmj.com/content/emermed/37/7/450.2.full.pdf	02/07/2020	Artigo completo publicado em periódico científico	https://emj.bmj.com/content/emermed/37/7/450.2.full.pdf	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?	https://doi.org/10.1097/CRD.0000000000000329	13/08/2020	Artigo completo publicado em periódico científico	10.1097/CRD.0000000000000329	1061-5377	10615377	CARDIOLOGY IN REVIEW (PRINT)	A4	0.622	59	2.39	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019	https://doi.org/10.1007/s11239-020-02248-8	11/08/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02248-8	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Argatrobana']	['Argatroban']
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19	https://doi.org/10.1093/ajhp/zxaa287	11/08/2020	Artigo completo publicado em periódico científico	10.1093/ajhp/zxaa287	1079-2082	10792082	American Journal of Health-System Pharmacy	-	0.483	99	1.59	 Abstract                                   Purpose                   Successful use of alteplase and argatroban to treat a patient with coronavirus disease 2019 (COVID-19)–associated massive pulmonary embolism with cardiac arrest is reported.                                                  Summary                   This case report describes a 42-year-old male with COVID-19 who developed a massive pulmonary embolism resulting in cardiac arrest after suspected failure of low-molecular-weight heparin therapy for a deep venous thrombosis. Administration of two 50-mg doses of intravenous alteplase resulted in return of spontaneous circulation, and low-dose argatroban was used as follow-up anticoagulation therapy without complications. This is the first case report of use of argatroban in a patient with COVID-19 with cardiac arrest–associated massive pulmonary embolism after failure of previous anticoagulation efforts.                                                  Conclusion                   Argatroban may be used as an alternate anticoagulation strategy in COVID-19 patients who fail low-molecular weight therapy. A risk versus benefit discussion should be had regarding appropriateness of therapy as well as dosing. More data is needed to understand the unique hypercoagulable condition in COVID-19 patients as well as research that further highlights the role of argatroban and bivalirudin therapy in this patient population.               	['Argatrobana']	['Argatroban']
Plasma exchange in critically ill COVID-19 patients	https://doi.org/10.1186/s13054-020-03171-3	04/08/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03171-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Plasmaferese']	['Plasmapheresis']
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab	https://www.sciencedirect.com/science/article/pii/S2211034820305174	04/08/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2211034820305174	-	-	-	-	-	-	-	-	['Ocrelizumabe']	['Ocrelizumab']
QTc prolongation during antiviral therapy in two COVID-19 patients	https://onlinelibrary.wiley.com/doi/full/10.1111/jcpt.13183	21/07/2020	Artigo completo publicado em periódico científico	10.1111/jcpt.13183	0269-4727	02694727	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (PRINT)	B1	0.517	76	2.22	-	['Cloreto de potássio', 'Cloroquina', 'Lopinavir', 'Pantoprazol', 'Prednisona', 'Ritonavir', 'Umifenovir']	['Potassium chloride', 'Chloroquine', 'Lopinavir', 'Pantoprazole', 'Prednisone', 'Ritonavir', 'Umifenovir']
Evaluation of retinotoxicity of COVID-19 treatment: hydroxychloroquine and lopinavir/ritonavir	https://doi.org/10.1002/jmv.26420	12/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26420	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Impact of implementation of an individualised thromboprophylaxis protocol T in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study	https://doi.org/10.1016/j.thromres.2020.07.038	22/07/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.07.038	0049-3848	00493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Nadroparina']	['Nadroparin']
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results	https://doi.org/10.1016/j.ijantimicag.2020.106136	08/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106136	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']
SARS-CoV-2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in COVID-19 Patients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa505/5890960	11/08/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa505/5890960	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Vitamin D deficiency as a predictor of poor prognosis in patients with acute  respiratory failure due to COVID-19	https://link.springer.com/article/10.1007/s40618-020-01370-x	09/08/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40618-020-01370-x	1720-8386	17208386	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (ONLINE)	A3	0.936	87	4.35	 Abstract                  Purpose                 Hypovitaminosis D is a highly spread condition correlated with increased risk of respiratory tract infections. Nowadays, the world is in the grip of the Coronavirus disease 19 (COVID 19) pandemic. In these patients, cytokine storm is associated with disease severity. In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis.                                Methods                 In this retrospective, observational study, we analysed demographic, clinical and laboratory data of 42 patients with acute respiratory failure due to COVID-19, treated in Respiratory Intermediate Care Unit (RICU) of the Policlinic of Bari from March, 11 to April 30, 2020.                                Results                 Eighty one percent of patients had hypovitaminosis D. Based on vitamin D levels, the population was stratified into four groups: no hypovitaminosis D, insufficiency, moderate deficiency, and severe deficiency. No differences regarding demographic and clinical characteristics were found. A survival analysis highlighted that, after 10 days of hospitalization, severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk ( p = 0.019).                                Conclusions                 High prevalence of hypovitaminosis D was found in COVID-19 patients with acute respiratory failure, treated in a RICU. Patients with severe vitamin D deficiency had a significantly higher mortality risk. Severe vitamin D deficiency may be a marker of poor prognosis in these patients, suggesting that adjunctive treatment might improve disease outcomes.              	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Convalescent Plasma Therapy on Patients with Severe or Life-Threatening COVID-19: A Metadata Analysis	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa509/5890481	10/08/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa509/5890481	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente']	['Convalescent Plasma', 'Convalescent Plasma']
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials	https://doi.org/10.1007/s00228-020-02962-5	11/08/2020	Artigo completo publicado em periódico científico	10.1007/s00228-020-02962-5	0031-6970	00316970	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.732	114	2.61	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis	https://doi.org/10.1101/2020.05.14.20101774	12/08/2020	Artigo completo publicado em periódico científico	10.1101/2020.05.14.20101774	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSCoV-2 infection: a retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26407	10/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26407	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality	https://doi.org/10.1016/j.ajpath.2020.08.001	10/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ajpath.2020.08.001	0002-9440	00029440	THE AMERICAN JOURNAL OF PATHOLOGY (PRINT)	A1	1.619	289	4.82	-	['Plasma convalescente']	['Convalescent Plasma']
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients - Results from a real-life patient cohort	https://doi.org/10.1007/s00508-020-01720-y	10/08/2020	Artigo completo publicado em periódico científico	10.1007/s00508-020-01720-y	0043-5325	00435325	Wiener Klinische Wochenschrift	-	0.497	54	1.65	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
TREATMENT WITH HYDROXYCHLOROQUINE IN PATIENTS WITH COVID-19. EXPERIENCE OF A NEUROLOGY DEPARTMENT	https://doi.org/10.31925/farmacia.2020.4.3	30/04/2020	Artigo completo publicado em periódico científico	10.31925/farmacia.2020.4.3	0014-8237	00148237	Farmacia	-	0.265	27	1.27	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Favipiravir y/o umifenovir en infección por COVID-19	www.iecs.org.arr	14/07/2020	Artigo completo publicado em periódico científico	www.iecs.org.arr	-	-	-	-	-	-	-	-	['Favipiravir', 'Umifenovir']	['Favipiravir', 'Umifenovir']
Documento de Evaluación de Tecnologías Sanitarias – Informe de Respuesta Rápida: Ivermectina para COVID-19	www.iecs.org.ar	12/08/2020	Artigo completo publicado em periódico científico	www.iecs.org.ar	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis	https://doi.org/10.1002/jmv.26408	10/08/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26408	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?	https://doi.org/10.1007/s11739-020-02383-3	26/05/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02383-3	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Bromexina', 'Bromexina', 'Bromexina', 'Bromexina', 'Bromexina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Bromhexine', 'Bromhexine', 'Bromhexine', 'Bromhexine', 'Bromhexine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']
Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?	https://pubmed.ncbi.nlm.nih.gov/32725286/	28/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32725286/	-	-	-	-	-	-	-	-	['Nitazoxanida', 'Nitazoxanida']	['Nitazoxanide', 'Nitazoxanide']
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects	https://doi.org/10.1080/14712598.2020.1796963	03/08/2020	Artigo completo publicado em periódico científico	10.1080/14712598.2020.1796963	1471-2598	14712598	EXPERT OPINION ON BIOLOGICAL THERAPY	A2	1.001	91	4.61	-	['Anticorpos', 'Imunoglobulina', 'Plasma convalescente']	['Antibodies', 'Immunoglobulin', 'Convalescent Plasma']
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19	https://doi.org/10.1016/j.intimp.2020.106749	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106749	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Baricitinibe']	['Baricitinib']
Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients	http://doi.org/10.2147/DDDT.S259058	28/07/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S259058	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Interferon alfa', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interferon alfa', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32725351	28/07/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32725351	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Micofenolato de mofetila', 'Prednisona', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Mycophenolate mofetil', 'Prednisone', 'Ritonavir']
COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature	https://www.dovepress.com/covid-19-in-liver-transplant-patients-report-of-2-cases-and-review-of--peer-reviewed-article-IMCRJ	31/07/2020	Artigo completo publicado em periódico científico	https://www.dovepress.com/covid-19-in-liver-transplant-patients-report-of-2-cases-and-review-of--peer-reviewed-article-IMCRJ	-	-	-	-	-	-	-	-	['Ácido fólico', 'Ácido ursodesoxicólico', 'Cotrimoxazol', 'Hidroxicloroquina', 'Meropenem', 'Micofenolato de mofetila', 'Prednisolona', 'Tacrolimus']	['Folic acid', 'Ursodeoxycholic acid', 'Cotrimoxazole', 'Hydroxychloroquine', 'Meropenem', 'Mycophenolate mofetil', 'Prednisolone', 'Tacrolimus']
Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19	https://doi.org/10.1007/s11684-020-0810-9	06/08/2020	Artigo completo publicado em periódico científico	10.1007/s11684-020-0810-9	2095-0217	20950217	Frontiers of Medicine	-	1.905	48	9.52	-	['Terapia celular']	['Cell Therapy']
Corticoides sistémicos en COVID-19	www.iecs.org.ar	11/08/2020	Artigo completo publicado em periódico científico	www.iecs.org.ar	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Stem cell therapy for Covid‐19: possibilities and challenges	https://doi.org/10.1002/cbin.11440	07/08/2020	Artigo completo publicado em periódico científico	10.1002/cbin.11440	1065-6995	10656995	CELL BIOLOGY INTERNATIONAL (PRINT)	A4	0.762	81	4.0	-	['Terapia celular']	['Cell Therapy']
Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results	https://doi.org/10.1007/s42399-020-00374-1	03/08/2020	Artigo completo publicado em periódico científico	10.1007/s42399-020-00374-1	2523-8973	25238973	-	-	-	-	-	-	['Ozonioterapia']	['Ozone Therapy']
Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells	https://doi.org/10.1097/MD.0000000000021429	31/07/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000021429	0025-7974	00257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Terapia celular']	['Cell Therapy']
Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series	https://pubmed.ncbi.nlm.nih.gov/32757500/	23/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32757500/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19	https://doi.org/10.1111/trf.15975	08/08/2020	Artigo completo publicado em periódico científico	10.1111/trf.15975	0041-1132	00411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente', 'Plasma convalescente']	['Convalescent Plasma', 'Convalescent Plasma']
Morning vs. evening administration of antiviral therapy in COVID-19 patients. A preliminary retrospective study in Ferrara, Italy	https://pubmed.ncbi.nlm.nih.gov/32767353/	10/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32767353/	-	-	-	-	-	-	-	-	['Darunavir', 'Ritonavir']	['Darunavir', 'Ritonavir']
Corticosteroid therapy for patients with severe novel Coronavirus disease 2019	https://www.docwirenews.com/abstracts/corticosteroid-therapy-for-patients-with-severe-novel-coronavirus-disease-2019/	08/08/2020	Artigo completo publicado em periódico científico	https://www.docwirenews.com/abstracts/corticosteroid-therapy-for-patients-with-severe-novel-coronavirus-disease-2019/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?	https://doi.org/10.1038/s41419-020-2720-9	08/07/2020	Artigo completo publicado em periódico científico	10.1038/s41419-020-2720-9	2041-4889	20414889	CELL DEATH & DISEASE	A2	2.099	128	9.13	 Abstract Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic. Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been proposed. Here we discuss the plausibility of two of them: the universal vaccination with  Bacillus Calmette–Guerin (BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic; we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no longer recommend it officially for the fight against malaria, due to the development of resistance to  Plasmodium, but its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.	['Cloroquina', 'Cloroquina', 'Vacina BCG', 'Vacina BCG']	['Chloroquine', 'Chloroquine', 'BCG Vaccine', 'BCG Vaccine']
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication	https://pubmed.ncbi.nlm.nih.gov/32757497/	16/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32757497/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study	https://doi.org/10.1016/j.eclinm.2020.100418	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100418	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']
Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation	https://www.ijidonline.com/article/S1201-9712(20)30616-0/fulltext	05/08/2020	Artigo completo publicado em periódico científico	https://www.ijidonline.com/article/S1201-9712(20)30616-0/fulltext	-	-	-	-	-	-	-	-	['Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab']
Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab	https://doi.org/10.1016/j.ijid.2020.07.081	05/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.081	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Tocilizumabe']	['Anakinra', 'Tocilizumab']
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial	https://doi.org/10.1093/cid/ciaa1176	09/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1176	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.                Clinical Trials Registration. NCT04434248.	['Favipiravir']	['Favipiravir']
SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial	https://doi.org/10.1016/j.ijid.2020.07.053	02/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.053	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Lopinavir', 'Novaferon', 'Ritonavir']	['Lopinavir', 'Novaferon', 'Ritonavir']
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis	https://doi.org/10.1002/clc.23421	05/08/2020	Artigo completo publicado em periódico científico	10.1002/clc.23421	0160-9289	01609289	CLINICAL CARDIOLOGY (MAHWAH, N.J.)	A2	0.983	77	2.8	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Searching for COVID-19 treatments: First, do no harm	https://doi.org/10.1093/ajhp/zxaa257	03/08/2020	Artigo completo publicado em periódico científico	10.1093/ajhp/zxaa257	1079-2082	10792082	American Journal of Health-System Pharmacy	-	0.483	99	1.59	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
The role of remdesivir in COVID -19 infection	https://emj.bmj.com/content/37/8/522.1	24/07/2020	Artigo completo publicado em periódico científico	https://emj.bmj.com/content/37/8/522.1	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Therapeutic response to corticosteroids in a critically ill patient with COVID-19	https://doi.org/10.1097/MD.0000000000021597	31/07/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000021597	0025-7974	00257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Corticosteroides']	['Corticosteroids']
A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362790/	15/07/2020	Artigo completo publicado em periódico científico	PMC:PMC7362790/	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al	https://ard.bmj.com/content/early/2020/08/04/annrheumdis-2020-218590	04/08/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/08/04/annrheumdis-2020-218590	-	-	-	-	-	-	-	-	['Rituximabe']	['Rituximab']
The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective,single-center trial	https://doi.org/10.1016/j.medcli.2020.06.007	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.007	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review	https://doi.org/10.1007/s11239-020-02235-z	03/08/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02235-z	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	 Abstract Many aspects of care such as management of hypercoagulable state in COVID-19 patients, especially those admitted to intensive care units is challenging in the rapidly evolving pandemic of novel coronavirus disease 2019 (COVID-19). We seek to systematically review the available evidence regarding the anticoagulation approach to prevent venous thromboembolism (VTE) among COVID-19 patients admitted to intensive care units. Electronic databases were searched for studies reporting venous thromboembolic events in patients admitted to the intensive care unit receiving any type of anticoagulation (prophylactic or therapeutic). The pooled prevalence (and 95% confidence interval [CI]) of VTE among patients receiving anticoagulant were calculated using the random-effects model. Subgroup pooled analyses were performed with studies reported prophylactic anticoagulation alone and with studies reported mixed prophylactic and therapeutic anticoagulation. We included twelve studies (8 Europe; 2 UK; 1 each from the US and China) in our systematic review and meta-analysis. All studies utilized LMWH or unfractionated heparin as their pharmacologic thromboprophylaxis, either prophylactic doses or therapeutic doses. Seven studies reported on the proportion of patients with the previous history of VTE (range 0–10%). The pooled prevalence of VTE among ICU patients receiving prophylactic or therapeutic anticoagulation across all studies was 31% (95% CI 20–43%). Subgroup pooled analysis limited to studies reported prophylactic anticoagulation alone and mixed (therapeutic and prophylactic anticoagulation) reported pooled prevalences of VTE of 38% (95% CI 10–70%) and 27% (95% CI 17–40%) respectively. With a high prevalence of thromboprophylaxis failure among COVID-19 patients admitted to intensive care units, individualised rather than protocolised VTE thromboprophylaxis would appear prudent at interim.	['Heparina', 'Heparina']	['Heparin', 'Heparin']
The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts	https://www.cureus.com/articles/34785-the-potential-vaccine-component-for-covid-19-a-comprehensive-review-of-global-vaccine-development-efforts	27/06/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/34785-the-potential-vaccine-component-for-covid-19-a-comprehensive-review-of-global-vaccine-development-efforts	-	-	-	-	-	-	-	-	['Ad5-nCoV', 'Vacina ChAdOx1 nCoV-19', 'Vacina mRNA-1273']	['Ad5-nCoV', 'Vaccine ChAdOx1 nCoV-19', 'Vaccine mRNA-1273']
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01708/full	10/07/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01708/full	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Imunoglobulina', 'Tocilizumabe']	['Corticosteroids', 'Hydroxychloroquine', 'Immunoglobulin', 'Tocilizumab']
COVID-19, asthma, and biologic therapies: What we need to know	https://doi.org/10.1016/j.waojou.2020.100126	16/05/2020	Artigo completo publicado em periódico científico	10.1016/j.waojou.2020.100126	1939-4551	19394551	THE WORLD ALLERGY ORGANIZATION JOURNAL	A1	1.140	44	4.79	-	['Benralizumabe', 'Corticosteroides', 'Dupilumabe', 'Mepolizumabe', 'Omalizumabe', 'Reslizumabe']	['Benralizumab', 'Corticosteroids', 'Dupilumab', 'Mepolizumab', 'Omalizumab', 'Reslizumab']
Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España	https://doi.org/10.1016/j.medcli.2020.06.018	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.018	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Terapia celular']	['Cell Therapy']
Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID‑19	https://doi.org/10.1007/s12272-020-01258-7	01/08/2020	Artigo completo publicado em periódico científico	10.1007/s12272-020-01258-7	0253-6269	02536269	Archives of Pharmacal Research	-	0.930	93	5.08	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
COVID-19 in pediatric patients: A case series	https://journals.sbmu.ac.ir/jcma/article/view/29690	09/04/2020	Artigo completo publicado em periódico científico	https://journals.sbmu.ac.ir/jcma/article/view/29690	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Oseltamivir']	['Azithromycin', 'Hydroxychloroquine', 'Oseltamivir']
Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report	https://www.frontiersin.org/article/10.3389/fmed.2020.00388	16/07/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fmed.2020.00388	2296-858X	2296858X	FRONTIERS IN MEDICINE	C	1.179	54	5.1	-	['Imunoglobulina']	['Immunoglobulin']
Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study	https://doi.org/10.1186/s13613-020-00706-3	31/07/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00706-3	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	 Abstract  Background Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration and poor prognosis in COVID-19 patients with severe disease have not been well identified.  Methods In this retrospective, single-center cohort study, 1190 adult inpatients (≥ 18 years old) with laboratory-confirmed COVID-19 and determined outcomes (discharged or died) were included from Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020. The final follow-up date was March 2, 2020. Clinical data including characteristics, laboratory and imaging information as well as treatments were extracted from electronic medical records and compared. A multivariable logistic regression model was used to explore the potential predictors associated with in-hospital deterioration and death.  Results 1190 patients with confirmed COVID-19 were included. Their median age was 57 years (interquartile range 47–67 years). Two hundred and sixty-one patients (22%) developed a severe illness after admission. Multivariable logistic regression demonstrated that higher SOFA score (OR 1.32, 95% CI 1.22–1.43, per score increase,  p &lt; 0.001 for deterioration and OR 1.30, 95% CI 1.11–1.53, per score increase,  p = 0.001 for death), lymphocytopenia (OR 1.81, 95% CI 1.13–2.89  p = 0.013 for deterioration; OR 4.44, 95% CI 1.26–15.87,  p = 0.021 for death) on admission were independent risk factors for in-hospital deterioration from not severe to severe disease and for death in severe patients. On admission D-dimer greater than 1 μg/L (OR 3.28, 95% CI 1.19–9.04,  p = 0.021), leukocytopenia (OR 5.10, 95% CI 1.25–20.78), thrombocytopenia (OR 8.37, 95% CI 2.04–34.44) and history of diabetes (OR 11.16, 95% CI 1.87–66.57,  p = 0.008) were also associated with higher risks of in-hospital death in severe COVID-19 patients. Shorter time interval from illness onset to non-invasive mechanical ventilation in the survivors with severe disease was observed compared with non-survivors (10.5 days, IQR 9.25–11.0 vs. 16.0 days, IQR 11.0–19.0 days,  p = 0.030). Treatment with glucocorticoids increased the risk of progression from not severe to severe disease (OR 3.79, 95% CI 2.39–6.01,  p &lt; 0.001). Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05–0.64,  p &lt; 0.001).  Conclusions High SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. On admission elevated D-dimer, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.	['Corticosteroides', 'Ganciclovir', 'Oseltamivir']	['Corticosteroids', 'Ganciclovir', 'Oseltamivir']
The characteristics and outcomes of 681 severe cases with COVID-19 in China.	https://doi.org/10.1016/j.jcrc.2020.07.003	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.07.003	0883-9441	08839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Ácido ascórbico', 'Antibióticos', 'Antifúngicos', 'Antivirais', 'Corticosteroides', 'Ganciclovir', 'Imunoglobulina', 'Interferon alfa', 'Oseltamivir', 'Ribavirina', 'Umifenovir']	['Ascorbic acid', 'Antibiotics', 'Antifungals', 'Antivirals', 'Corticosteroids', 'Ganciclovir', 'Immunoglobulin', 'Interferon alpha', 'Oseltamivir', 'Ribavirin', 'Umifenovir']
Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh	https://pubmed.ncbi.nlm.nih.gov/32742969	06/08/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32742969	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study	https://www.frontiersin.org/articles/10.3389/fphar.2020.01071/full	14/07/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.01071/full	-	-	-	-	-	-	-	-	['Interferon alfa', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ribavirin', 'Ritonavir']
A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization	https://www.sciencedirect.com/science/article/pii/S1359610120301167	01/07/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1359610120301167	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects	https://doi.org/10.3389/fimmu.2020.01660	14/07/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01660	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Imunoglobulina']	['Immunoglobulin']
Multisystem Inflammatory Syndrome With Complete Kawasaki Disease Features Associated With SARS-CoV-2 Infection in a Young Adult. A Case Report	https://doi.org/10.3389/fmed.2020.00428	14/07/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.00428	2296-858X	2296858X	FRONTIERS IN MEDICINE	C	1.179	54	5.1	-	['Colchicina', 'Corticosteroides', 'Imunoglobulina', 'Tocilizumabe']	['Colchicine', 'Corticosteroids', 'Immunoglobulin', 'Tocilizumab']
Prolonged asymptomatic SARS-CoV-2 infection in a child receiving immunosuppressive therapy	https://doi.org/10.1002/ppul.24983	31/07/2020	Artigo completo publicado em periódico científico	10.1002/ppul.24983	8755-6863	87556863	PEDIATRIC PULMONOLOGY	A1	0.927	111	3.21	-	['Metotrexato', 'Prednisona']	['Methotrexate', 'Prednisone']
Interferon-α2b spray inhalation did not shorten vírus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study	https://www.docwirenews.com/abstracts/interferon-%CE%B12b-spray-inhalation-did-not-shorten-virus-shedding-time-of-sars-cov-2-in-hospitalized-patients-a-preliminary-matched-case-control-study/	04/08/2020	Artigo completo publicado em periódico científico	https://www.docwirenews.com/abstracts/interferon-%CE%B12b-spray-inhalation-did-not-shorten-virus-shedding-time-of-sars-cov-2-in-hospitalized-patients-a-preliminary-matched-case-control-study/	-	-	-	-	-	-	-	-	['Interferon alfa']	['Interferon alpha']
Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019	https://doi.org/10.1111/crj.13243	04/08/2020	Artigo completo publicado em periódico científico	10.1111/crj.13243	1752-6981	17526981	THE CLINICAL RESPIRATORY JOURNAL (PRINT)	B1	0.560	36	2.11	-	['Corticosteroides', 'Oseltamivir', 'Umifenovir']	['Corticosteroids', 'Oseltamivir', 'Umifenovir']
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time	https://c19study.com/davido.html	02/08/2020	Artigo completo publicado em periódico científico	https://c19study.com/davido.html	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin usage in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis	https://www.mp.pl/paim/issue/article/15543	04/08/2020	Artigo completo publicado em periódico científico	https://www.mp.pl/paim/issue/article/15543	-	-	-	-	-	-	-	-	['Antibióticos', 'Corticosteroides', 'Ganciclovir', 'Imunoglobulina', 'Lopinavir', 'Oseltamivir', 'Prednisona', 'Ritonavir']	['Antibiotics', 'Corticosteroids', 'Ganciclovir', 'Immunoglobulin', 'Lopinavir', 'Oseltamivir', 'Prednisone', 'Ritonavir']
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19	https://doi.org/10.1016/j.lfs.2020.118185	01/08/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.118185	0024-3205	00243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Anticorpos', 'Imunoglobulina', 'Interferon', 'Plasma convalescente', 'Terapia celular']	['Antibodies', 'Immunoglobulin', 'Interferon', 'Convalescent Plasma', 'Cell Therapy']
Tocilizumab for COVID-19: a real ‘miracle drug’?	https://doi.org/10.1080/23744235.2020.1780307	17/06/2020	Artigo completo publicado em periódico científico	10.1080/23744235.2020.1780307	2374-4235	23744235	INFECTIOUS DISEASES (PRINT)	B1	0.799	75	2.39	-	['Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab']
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection	https://doi.org/10.1016/j.mayocp.2020.05.005	19/05/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.05.005	0025-6196	00256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019: A Case Report	https://pubmed.ncbi.nlm.nih.gov/32727996/	28/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32727996/	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients	https://onlinelibrary.wiley.com/doi/10.1111/joim.13163	03/08/2020	Artigo completo publicado em periódico científico	10.1111/joim.13163	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Tocilizumabe']	['Tocilizumab']
Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease  2019	https://onlinelibrary.wiley.com/doi/10.1002/cti2.1159	26/07/2020	Artigo completo publicado em periódico científico	10.1002/cti2.1159	2050-0068	20500068	Clinical and Translational Immunology	-	1.771	39	5.9	-	['Inibidores da Ciclooxigenase-2 (COX-2)']	['Cyclooxygenase-2 (COX-2) Inhibitors']
A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients	https://journals.lww.com/jaids/Abstract/9000/A_retrospective_evaluation_on_the_efficacy_of.96114.aspx	22/07/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/jaids/Abstract/9000/A_retrospective_evaluation_on_the_efficacy_of.96114.aspx	-	-	-	-	-	-	-	-	['Cloroquina', 'Lopinavir', 'Ritonavir']	['Chloroquine', 'Lopinavir', 'Ritonavir']
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13162	03/08/2020	Artigo completo publicado em periódico científico	10.1111/joim.13162	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Tocilizumabe']	['Tocilizumab']
Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐analysis	https://onlinelibrary.wiley.com/doi/10.1002/art.41469	02/08/2020	Artigo completo publicado em periódico científico	10.1002/art.41469	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Anakinra', 'Anakinra', 'Baricitinibe', 'Baricitinibe', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Imunoglobulina', 'Imunoglobulina', 'Siltuximabe', 'Siltuximabe', 'Tocilizumabe', 'Tocilizumabe']	['Anakinra', 'Anakinra', 'Baricitinib', 'Baricitinib', 'Chloroquine', 'Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Immunoglobulin', 'Immunoglobulin', ' Siltuximab', 'Siltuximab', 'Tocilizumab', 'Tocilizumab']
Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19	https://www.sciencedirect.com/science/article/pii/S1138359320302240	11/07/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1138359320302240	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis	https://www.mdpi.com/2077-0383/9/8/2392	27/07/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/8/2392	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31346	30/07/2020	Artigo completo publicado em periódico científico	https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31346	-	-	-	-	-	-	-	-	['Anakinra', 'Azitromicina', 'Baricitinibe', 'Canaquinumabe', 'Cloroquina', 'Colchicina', 'Darunavir', 'Dexametasona', 'Favipiravir', 'Fedratinibe', 'Hidroxicloroquina', 'Interferon alfa', 'Interferon beta', 'Lopinavir', 'Prednisona', 'Remdesivir', 'Ritonavir', 'Ruxolitinibe', 'Sarilumabe', 'Siltuximabe', 'Tocilizumabe', 'Umifenovir']	['Anakinra', 'Azithromycin', 'Baricitinib', 'Canakinumab', 'Chloroquine', 'Colchicine', 'Darunavir', 'Dexamethasone', 'Favipiravir', 'Fedratinib', 'Hydroxychloroquine', 'Interferon alfa', 'Interferon beta', 'Lopinavir', 'Prednisone', 'Remdesivir', 'Ritonavir', 'Ruxolitinib', 'Sarilumab', 'Siltuximab', 'Tocilizumab', 'Umifenovir']
Ascorbate as Prophylaxis and Therapy for COVID-19—Update From Shanghai and U.S. Medical Institutions	https://doi.org/10.1177/2164956120934768	20/07/2020	Artigo completo publicado em periódico científico	10.1177/2164956120934768	2164-9561	21649561	Global Advances In Health and Medicine	-	0.448	21	1.9	  Background  No validated treatments have been identified for the COVID-19 pandemic virus; several are currently in randomized clinical trials. Diagnostic instruments are rapidly evolving. Symptoms range from those of a common cold to acute respiratory distress syndrome (ARDS), to sepsis arising from the flood of inflammatory bacterial and viral pathogens in the blood. Mortality generally arises from cytokine storms of uncontrolled inflammation, oxidative injury, and damage to the alveolar-capillary barrier, with secondary bacterial infection. To address the indisputably urgent need for therapeutics for COVID-19, a specialized interdisciplinary medical panel convened in Shanghai in March 2020 to consider all relevant clinical and experimental evidence on the possible utility of intravenous (IV) ascorbate in the treatment of COVID-19-related ARDS.   Methods  The panel convened multidisciplinary medical experts and reviewed all relevant in vitro, in vivo, clinical studies and randomized controlled trials on IV ascorbate and issued a consensus report on 23 March 2020 noting that substantial differences in serum concentrations of ascorbate are achieved through IV administration in contrast with the oral route.   Findings  The Shanghai panel, and a parallel medical group in Guangzhou, are advising the use of high-dose IV ascorbate for the treatment of ARDS, along with other supportive therapies, including Vitamin D and zinc. We report preliminary progress in using this treatment for 50 consecutive cases treated in Shanghai hospitals, consistent with earlier reports from a meta-analysis of the use of IV ascorbate to treat sepsis. We provide an instructive clinical anecdote regarding a single family where one elderly member with cardiac and other major comorbidities developed and survived ARDS-related sepsis following daily treatments that included 15 g of IV ascorbate. None of her adult caregivers who had ingested between 2 and 10 g of ascorbate daily developed COVID-19. 	['Ácido ascórbico']	['Ascorbic acid']
Effect of favipiravir and an anti- inflammatory strategy for COVID-19	https://doi.org/10.1186/s13054-020-03137-5	09/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03137-5	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir']	['Favipiravir']
Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report	https://link.springer.com/article/10.1007/s10557-020-07044-3	30/07/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10557-020-07044-3	0920-3206	09203206	CARDIOVASCULAR DRUGS AND THERAPY	A2	0.860	71	3.51	-	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']
COVID-19 in a Patient With Rheumatoid Arthritis During Tocilizumab Treatment	https://journals.lww.com/jclinrheum/Citation/9000/COVID_19_in_a_Patient_With_Rheumatoid_Arthritis.98581.aspx	23/07/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/jclinrheum/Citation/9000/COVID_19_in_a_Patient_With_Rheumatoid_Arthritis.98581.aspx	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab  and NIV in a Patient with COVID-19 Pneumonia/ARDS	https://pubmed.ncbi.nlm.nih.gov/32727107/	27/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32727107/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience	http://thecovidnewsusa.com/2020/08/01/clinical-efficacy-of-glucocorticoid-on-the-treatment-of-patients-with-covid-19-pneumonia-a-single-center-experience-2/	28/07/2020	Artigo completo publicado em periódico científico	http://thecovidnewsusa.com/2020/08/01/clinical-efficacy-of-glucocorticoid-on-the-treatment-of-patients-with-covid-19-pneumonia-a-single-center-experience-2/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome	https://pubmed.ncbi.nlm.nih.gov/32732245/	30/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32732245/	-	-	-	-	-	-	-	-	['Colchicina']	['Colchicine']
COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes	https://onlinelibrary.wiley.com/doi/10.1002/art.41456	28/07/2020	Artigo completo publicado em periódico científico	10.1002/art.41456	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Agentes anti-interleucinas', 'Antagonistas de TNF', 'Anticorpos neutralizantes direcionados a IL-17', 'Corticosteroides', 'Hidroxicloroquina', 'Inibidores de Janus Kinase (JAK)', 'Metotrexato']	['Anti-Interleukin Agents', 'TNF Antagonists', 'IL-17 Targeted Neutralizing Antibodies', 'Corticosteroids', 'Hydroxychloroquine', 'Janus Kinase (JAK) Inhibitors', 'Methotrexate']
The Association of Interleukin-6 value, Interleukin inhibitors and Outcomes of Patients with COVID-19 in New York City	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26365	28/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26365	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people	https://heart.bmj.com/content/heartjnl/early/2020/07/31/heartjnl-2020-317393.full.pdf	13/07/2020	Artigo completo publicado em periódico científico	https://heart.bmj.com/content/heartjnl/early/2020/07/31/heartjnl-2020-317393.full.pdf	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Drug treatments for covid-19: living systematic review and network meta-analysis.	https://www.bmj.com/content/370/bmj.m2980	30/07/2020	Artigo completo publicado em periódico científico	https://www.bmj.com/content/370/bmj.m2980	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']
Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis	https://www.tandfonline.com/doi/full/10.1080/17476348.2020.1804365	31/07/2020	Artigo completo publicado em periódico científico	10.1080/17476348.2020.1804365	1747-6348	17476348	EXPERT REVIEW OF RESPIRATORY MEDICINE	A3	0.939	47	3.79	-	['Corticosteroides']	['Corticosteroids']
BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data	https://doi.org/10.1111/lam.13365	30/07/2020	Artigo completo publicado em periódico científico	10.1111/lam.13365	0266-8254	02668254	LETTERS IN APPLIED MICROBIOLOGY	A4	0.593	116	3.35	-	['Vacina BCG', 'Vacina BCG']	['BCG vaccine', 'BCG vaccine']
Tratamento precoce para COVID-19 baseado em evidência científica.	https://periodicos.unifor.br/RBPS/article/view/10993	02/08/2020	Artigo completo publicado em periódico científico	https://periodicos.unifor.br/RBPS/article/view/10993	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Remdesivir: A beacon of hope from Ebola virus disease to COVID-19	https://doi.org/10.1002/rmv.2133	30/07/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2133	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir']
Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management	https://pubmed.ncbi.nlm.nih.gov/32726238/	03/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32726238/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Liver injury in remdesivir-treated COVID-19 patients	https://doi.org/10.1007/s12072-020-10077-3	28/07/2020	Artigo completo publicado em periódico científico	10.1007/s12072-020-10077-3	1936-0533	19360533	HEPATOLOGY INTERNATIONAL	A3	1.555	52	6.63	-	['Remdesivir']	['Remdesivir']
Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)	https://doi.org/10.1016/j.cgh.2020.07.050	02/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cgh.2020.07.050	1542-3565	15423565	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	A1	2.691	183	5.19	-	['Remdesivir']	['Remdesivir']
Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge	https://doi.org/10.1016/j.ijid.2020.07.023	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.023	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Sarilumabe', 'Tocilizumabe']	['Sarilumab', 'Tocilizumab']
Appropriate use of Tocilizumab in COVID-19 Infection	https://doi.org/10.1016/j.ijid.2020.07.036	26/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.036	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']
Vitamin D high doses supplementation could represent a promising alternative to prevent or treat COVID-19 infection	https://clinowl.com/vitamin-d-high-doses-supplementation-could-represent-a-promising-alternative-to-prevent-or-treat-covid-19-infection/	29/05/2020	Artigo completo publicado em periódico científico	https://clinowl.com/vitamin-d-high-doses-supplementation-could-represent-a-promising-alternative-to-prevent-or-treat-covid-19-infection/	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia	https://doi.org/10.1177/1074248420935740	23/07/2020	Artigo completo publicado em periódico científico	10.1177/1074248420935740	1074-2484	10742484	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS	A2	0.685	52	2.63	  In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection. The search for a useful vaccination is ongoing and it will probably not be available before the end of 2020. In this review, we highlight hydroxychloroquine (HCQ) as a potential agent to prevent coronavirus disease 2019 (COVID-19) and reduce as well as shorten clinical symptoms. Moreover, it might serve as a potential post-exposition prophylaxis. Although it has been used in the treatment of rheumatoid arthritis, discoid or systemic lupus erythematosus, and malaria prophylaxis and therapy for decades, knowledge on HCQ as a potential treatment for COVID-19 is limited and multiple clinical trials have just emerged. Especially, rare HCQ side effects which were of minor importance for use in selected indications might gain major relevance with population-wide application. These rare side effects include retinopathy and—even more important—QT prolongation leading to sudden cardiac death by malignant arrhythmias. 	['Hidroxicloroquina']	['Hydroxychloroquine']
Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367013/	17/07/2020	Artigo completo publicado em periódico científico	PMC:PMC7367013/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Heparin-Induced Thrombocytopenia in COVID-19	https://www.unboundmedicine.com/medline/citation/32720827/Heparin-Induced_Thrombocytopenia_in_COVID-19.	30/07/2020	Artigo completo publicado em periódico científico	https://www.unboundmedicine.com/medline/citation/32720827/Heparin-Induced_Thrombocytopenia_in_COVID-19.	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir	https://doi.org/10.1016/j.medcli.2020.06.026	09/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.026	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study	https://ard.bmj.com/content/early/2020/07/20/annrheumdis-2020-218479.citation-tools	20/07/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/07/20/annrheumdis-2020-218479.citation-tools	-	-	-	-	-	-	-	-	['Prednisona', 'Tocilizumabe']	['Prednisone', 'Tocilizumab']
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients	https://doi.org/10.1016/j.jaut.2020.102511	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102511	0896-8411	08968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']
Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study	http://www.ijmm.org/text.asp?2020/38/1/117/290693	25/07/2020	Artigo completo publicado em periódico científico	http://www.ijmm.org/text.asp?2020/38/1/117/290693	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU.	https://clinowl.com/outcome-of-non-critical-covid-19-patients-with-early-hospitalization-and-early-antiviral-treatment-outside-the-icu/	29/07/2020	Artigo completo publicado em periódico científico	https://clinowl.com/outcome-of-non-critical-covid-19-patients-with-early-hospitalization-and-early-antiviral-treatment-outside-the-icu/	-	-	-	-	-	-	-	-	['Azitromicina', 'Favipiravir', 'Hidroxicloroquina']	['Azithromycin', 'Favipiravir', 'Hydroxychloroquine']
Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression	https://www.frontiersin.org/articles/10.3389/fpubh.2020.00355/full	03/07/2020	Artigo completo publicado em periódico científico	10.3389/fpubh.2020.00355/full	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience	https://pubmed.ncbi.nlm.nih.gov/32718713	09/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32718713	-	-	-	-	-	-	-	-	['Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab']
COVID-19: Mechanisms of Vaccination and Immunity	https://www.mdpi.com/2076-393X/8/3/404	22/07/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-393X/8/3/404	-	-	-	-	-	-	-	-	['Ad5-nCoV', 'Ad5-nCoV', 'AG0301-Covid19', 'AG0301-Covid19', 'CoronaVac', 'CoronaVac', 'COVAC1 (LNP-nCoVsaRNA)', 'COVAC1 (LNP-nCoVsaRNA)', 'Gam-COVID-Vac', 'Gam-COVID-Vac', 'Vacina BBIBP-CorV', 'Vacina BBIBP-CorV', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina Curevac', 'Vacina Curevac', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Ad5-nCoV', 'Ad5-nCoV', 'AG0301-Covid19', 'AG0301-Covid19', 'CoronaVac', 'CoronaVac', 'COVAC1 (LNP-nCoVsaRNA)', 'COVAC1 (LNP-nCoVsaRNA)' , 'Gam-COVID-Vac', 'Gam-COVID-Vac', 'BBIBP-CorV Vaccine', 'BBIBP-CorV Vaccine', 'ChAdOx1 Vaccine nCoV-19', 'ChAdOx1 Vaccine nCoV-19', 'Curevac Vaccine' ', 'Curevac vaccine', 'INO-4800 vaccine', 'INO-4800 vaccine', 'NVX-CoV2373 vaccine', 'NVX-CoV2373 vaccine']
Hydroxychloroquine and azithromycin combination could be lethal to covid-19 patients	https://doi.org/10.31925/farmacia.2020.3.2	31/05/2020	Artigo completo publicado em periódico científico	10.31925/farmacia.2020.3.2	0014-8237	00148237	Farmacia	-	0.265	27	1.27	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Neurological Disorders Identified during Treatment of a SARS-CoV-2 Infection	https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_5447-20/_article/-char/ja/	29/07/2020	Artigo completo publicado em periódico científico	https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_5447-20/_article/-char/ja/	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids	https://www.tandfonline.com/doi/abs/10.1080/14767058.2020.1797669?journalCode=ijmf20	26/07/2020	Artigo completo publicado em periódico científico	10.1080/14767058.2020.1797669?journalCode=ijmf20	-	-	-	-	-	-	-	-	['Azitromicina', 'Lopinavir', 'Plasma convalescente', 'Prednisona', 'Ritonavir']	['Azithromycin', 'Lopinavir', 'Convalescent Plasma', 'Prednisone', 'Ritonavir']
Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia	https://doi.org/10.1016/j.eclinm.2020.100467	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100467	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']
Medication utilization in patients in New York hospitals during the COVID-19 pandemic	https://doi.org/10.1093/ajhp/zxaa251	24/07/2020	Artigo completo publicado em periódico científico	10.1093/ajhp/zxaa251	1079-2082	10792082	American Journal of Health-System Pharmacy	-	0.483	99	1.59	 Abstract                                   Purpose                   Utilization of hydroxychloroquine, chloroquine, and supportive therapy drugs in hospitals in New York during the early weeks of the coronavirus disease 2019 (COVID-19) pandemic was analyzed.                                                  Summary                   Drug utilization trends for 7 medications used to treat patients with suspected or confirmed COVID-19 at 47 New York hospitals were identified. The data demonstrated sharp increases in aggregate utilization of hydroxychloroquine and chloroquine and the number of patients receiving either drug beginning on March 15, with a notable 20% median increase per day through March 31. The net quantity of drug charge units per day for midazolam, propofol, ketamine, cisatracurium, and fentanyl also increased during the study period. Following peak utilization, use of all study drugs decreased at different times throughout April 2020. The data were used to provide information to various stakeholders in the drug supply chain during the initial surge of the pandemic.                                                  Conclusion                   This analysis describes the increased use, beginning in mid-March 2020, of hydroxychloroquine, chloroquine, midazolam, propofol, ketamine, cisatracurium, and fentanyl in 47 hospitals in New York State. The increased utilization of supportive therapy drugs was consistent with the surge in patients with presumed or confirmed COVID-19 during the study period. These data and observations can help clinicians, health-system leaders, manufacturers, wholesalers, and policymakers understand the impact of current and future pandemics on the drug supply chain.               	['Cetamina', 'Cisatracúrio', 'Cloroquina', 'Fentanil', 'Hidroxicloroquina', 'Midazolam', 'Propofol']	['Ketamine', 'Cisatracurium', 'Chloroquine', 'Fentanyl', 'Hydroxychloroquine', 'Midazolam', 'Propofol']
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients	https://doi.org/10.1016/j.chom.2020.07.005	18/07/2020	Artigo completo publicado em periódico científico	10.1016/j.chom.2020.07.005	1931-3128	19313128	CELL HOST & MICROBE	A1	9.373	201	19.72	-	['Interferon alfa']	['Interferon alpha']
Tocilizumab for severe COVID-19: a systematic review and meta-analysis	http://www.sciencedirect.com/science/article/pii/S0924857920302867	23/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0924857920302867	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Vacunas para SARS-CoV-2, diferentes estrategias de los desarrollos en curso	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1102739	30/06/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1102739	-	-	-	-	-	-	-	-	['AG0301-Covid19', 'CoronaVac', 'MVC-COV1901', 'Vacina BBIBP-CorV', 'Vacina ChAdOx1 nCoV-19', 'Vacina INO-4800']	['AG0301-Covid19', 'CoronaVac', 'MVC-COV1901', 'BBIBP-CorV Vaccine', 'ChAdOx1 nCoV-19 Vaccine', 'INO-4800 Vaccine']
Remdesivir—Bringing Hope for COVID-19 Treatment	https://www.mdpi.com/2218-0532/88/2/29	12/06/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2218-0532/88/2/29	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine	https://doi.org/10.1016/j.clim.2020.108544	22/07/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108544	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['N-acetilcisteína']	['N-acetylcysteine']
Successful treatment of two Japanese ESRD cases with severe COVID‐19 pneumonia	https://doi.org/10.1007/s13730-020-00512-7	26/07/2020	Artigo completo publicado em periódico científico	10.1007/s13730-020-00512-7	2192-4449	21924449	-	-	-	-	-	-	['Imunoglobulina', 'Tocilizumabe']	['Immunoglobulin', 'Tocilizumab']
COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab	https://doi.org/10.1016/j.msard.2020.102402	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102402	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Alemtuzumabe']	['Alemtuzumab']
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure – a cautionary case series	https://doi.org/10.1186/s13054-020-03158-0	17/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03158-0	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Infliximabe']	['Infliximab']
High‐dose, short‐term corticosteroids for ARDS caused by COVID ‐19: a case series	https://doi.org/10.1002/rcr2.596	04/06/2020	Artigo completo publicado em periódico científico	10.1002/rcr2.596	2051-3380	20513380	Respirology Case Reports	-	0.261	12	0.84	-	['Corticosteroides']	['Corticosteroids']
Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C	https://pubmed.ncbi.nlm.nih.gov/32709838/	25/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32709838/	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Azitromicina', 'Colchicina', 'Hidroxicloroquina']	['Ascorbic acid', 'Azithromycin', 'Colchicine', 'Hydroxychloroquine']
An infant with coronavirus disease 2019 in China: A case report	https://pubmed.ncbi.nlm.nih.gov/32702935/	17/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32702935/	-	-	-	-	-	-	-	-	['Interferon alfa']	['Interferon alpha']
High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection	https://onlinelibrary.wiley.com/doi/10.1111/eci.13358	23/07/2020	Artigo completo publicado em periódico científico	10.1111/eci.13358	0014-2972	00142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study	https://cancerdiscovery.aacrjournals.org/content/early/2020/07/21/2159-8290.CD-20-0941	22/07/2020	Artigo completo publicado em periódico científico	https://cancerdiscovery.aacrjournals.org/content/early/2020/07/21/2159-8290.CD-20-0941	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Remdesivir', 'Tocilizumabe']	['Corticosteroids', 'Hydroxychloroquine', 'Remdesivir', 'Tocilizumab']
Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study	https://doi.org/10.1016/j.ijantimicag.2020.106114	23/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106114	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Ribavirina']	['Ribavirin']
Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1041/5876045	24/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1041/5876045	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents	https://pubmed.ncbi.nlm.nih.gov/32674818	15/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32674818	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Estatina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Statin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients	https://www.europeanreview.org/article/21916	28/07/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/21916	-	-	-	-	-	-	-	-	['Sarilumabe', 'Siltuximabe', 'Tocilizumabe']	['Sarilumab', 'Siltuximab', 'Tocilizumab']
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review	http://www.sciencedirect.com/science/article/pii/S2531043720301537	20/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S2531043720301537	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
BCG vaccination and COVID-19: Much ado about nothing?	https://doi.org/10.1016/j.mehy.2020.110109	15/07/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110109	0306-9877	03069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Vacina BCG']	['BCG vaccine']
Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide	https://doi.org/10.1111/tid.13425	23/07/2020	Artigo completo publicado em periódico científico	10.1111/tid.13425	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Imunossupressores']	['Immunosuppressants']
Therapeutic Plasma Exchange: a potential management strategy for critically III COVID-19 patients. 2020	https://doi.org/10.1177/0885066620940259	15/07/2020	Artigo completo publicado em periódico científico	10.1177/0885066620940259	0885-0666	08850666	JOURNAL OF INTENSIVE CARE MEDICINE (PRINT)	A4	0.807	62	3.05	 In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited autopsies, clinical observations, and laboratory data suggest that high cytokine levels and a procoagulant state can precipitate acute respiratory distress syndrome and multi-organ dysfunction syndrome in critically ill patients. To complicate matters, comorbidities may affect the response to medical treatments currently in use, all of which are still in trial phase. Therapeutic plasma exchange (TPE) merits consideration in the treatment of critically ill COVID-19 patients and is an avenue for clinical trials to pursue. If efficacious, faster recovery of patients may lead to shorter intensive care unit stays and less time on mechanical ventilation. Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients.	['Plasmaferese']	['Plasmapheresis']
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma	https://doi.org/10.1016/j.transci.2020.102871	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102871	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Plasma convalescente']	['Convalescent Plasma']
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy	https://doi.org/10.1093/infdis/jiaa446	23/07/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa446	0022-1899	00221899	THE JOURNAL OF INFECTIOUS DISEASES	A1	2.509	261	5.29	 Abstract                The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.	['Remdesivir']	['Remdesivir']
As the COVID-19 pandemic drags on, where have all the STEMIs gone?	https://doi.org/10.1016/j.ijcha.2020.100550	31/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcha.2020.100550	2352-9067	23529067	INTERNATIONAL JOURNAL OF CARDIOLOGY HEART & VASCULATURE	B2	0.803	25	2.27	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236778	23/07/2020	Artigo completo publicado em periódico científico	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236778	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study	https://doi.org/10.1016/j.jaut.2020.102523	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102523	0896-8411	08968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']
Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study	https://doi.org/10.1186/s13054-020-03164-2	19/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03164-2	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Agentes bloqueadores neuromusculares']	['Neuromuscular blocking agents']
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19	http://www.pnas.org/content/early/2020/07/21/2009017117.abstract	22/07/2020	Artigo completo publicado em periódico científico	http://www.pnas.org/content/early/2020/07/21/2009017117.abstract	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study	https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15495	23/07/2020	Artigo completo publicado em periódico científico	10.1111/febs.15495	1742-464X	1742464X	THE FEBS JOURNAL (PRINT)	A2	1.611	212	5.67	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial	https://doi.org/10.1007/s12250-020-00258-7	21/07/2020	Artigo completo publicado em periódico científico	10.1007/s12250-020-00258-7	1674-0769	16740769	-	-	-	-	-	-	['Leflunomida']	['Leflunomide']
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology	https://doi.org/10.1016/j.rec.2020.04.025	19/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rec.2020.04.025	1885-5857	18855857	REVISTA ESPAÑOLA DE CARDIOLOGÍA (INTERNET. ENGLISH ED.)	A4	0.385	7	0.98	-	['Clopidogrel', 'Heparina', 'Ticagrelor']	['Clopidogrel', 'Heparin', 'Ticagrelor']
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini- Review	https://www.sciencedirect.com/science/article/pii/S0188440920305907?via%3Dihub	19/07/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0188440920305907?via%3Dihub	-	-	-	-	-	-	-	-	['Adalimumabe', 'Anakinra', 'Infliximabe', 'Tocilizumabe']	['Adalimumab', 'Anakinra', 'Infliximab', 'Tocilizumab']
Azithromycin in COVID‑19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines	https://doi.org/10.1007/s40264-020-00976-7	21/07/2020	Artigo completo publicado em periódico científico	10.1007/s40264-020-00976-7	0114-5916	01145916	Drug Safety	-	1.268	131	4.42	-	['Azitromicina']	['Azithromycin']
Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state	https://onlinelibrary.wiley.com/doi/full/10.1111/resp.13912	21/07/2020	Artigo completo publicado em periódico científico	10.1111/resp.13912	1323-7799	13237799	RESPIROLOGY (CARLTON SOUTH. PRINT)	A2	1.265	94	3.08	-	['Tocilizumabe']	['Tocilizumab']
A Case of COVID-19 in a Patient with Asymptomatic Hemoglobin D Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency	https://pubmed.ncbi.nlm.nih.gov/32697769/	22/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32697769/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16962	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16962	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Gilteritinibe']	['Gilteritinib']
The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report	https://www.karger.com/Article/FullText/509738	21/07/2020	Artigo completo publicado em periódico científico	https://www.karger.com/Article/FullText/509738	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
High-dose chemotherapy in a patient with coronavirus disease (COVID-19)	https://doi.org/10.1016/j.ejca.2020.06.026	04/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ejca.2020.06.026	0959-8049	09598049	EUROPEAN JOURNAL OF CANCER	A1	2.865	224	7.68	-	['Darunavir', 'Hidroxicloroquina', 'Ritonavir']	['Darunavir', 'Hydroxychloroquine', 'Ritonavir']
Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy	https://doi.org/10.2450/2020.0164-20	13/07/2020	Artigo completo publicado em periódico científico	10.2450/2020.0164-20	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia	https://doi.org/10.1186/s13054-020-03142-8	11/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03142-8	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Terapia celular']	['Cell Therapy']
Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study	https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1800453	01/08/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2020.1800453	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Tocilizumabe']	['Tocilizumab']
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19.	https://doi.org/10.1056/NEJMoa2019014	23/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2019014	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Use of remdesivir for patients with Covid-19: a review article	http://dx.doi.org/10.1590/1806-9282.66.6.838	20/07/2020	Artigo completo publicado em periódico científico	10.1590/1806-9282.66.6.838	1806-9282	18069282	-	-	-	-	-	 SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.	['Remdesivir']	['Remdesivir']
Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic	https://doi.org/10.1007/s12291-020-00907-4	10/07/2020	Artigo completo publicado em periódico científico	10.1007/s12291-020-00907-4	0970-1915	09701915	Indian Journal of Clinical Biochemistry	-	0.380	45	2.07	-	['Vacina de DNA', 'Vacina de RNA']	['DNA vaccine', 'RNA vaccine']
Hydroxychloroquine for COVID-19: What is Our Current State of Knowledge?	https://www.japi.org/v2c4d434/hydroxychloroquine-for-covid-19-what-is-our-current-state-of-knowledge-	24/05/2020	Artigo completo publicado em periódico científico	https://www.japi.org/v2c4d434/hydroxychloroquine-for-covid-19-what-is-our-current-state-of-knowledge-	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Anticoagulation, immortality, and observations of COVID-19	https://doi.org/10.1002/rth2.12398	29/05/2020	Artigo completo publicado em periódico científico	10.1002/rth2.12398	2475-0379	24750379	RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS	C	1.817	24	4.32	-	['Azitromicina', 'Hidroxicloroquina', 'Inibidores de Interleucina-1', 'Remdesivir']	['Azithromycin', 'Hydroxychloroquine', 'Interleukin-1 Inhibitors', 'Remdesivir']
Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)	https://doi.org/10.1016/j.dsx.2020.07.011	11/07/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.07.011	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Estatina']	['Statin']
Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03058-3	10/06/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03058-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Heparina']	['Heparin']
Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic	https://www.ejcancer.com/article/S0959-8049(20)30336-1/pdf	17/06/2020	Artigo completo publicado em periódico científico	https://www.ejcancer.com/article/S0959-8049(20)30336-1/pdf	-	-	-	-	-	-	-	-	['Ipilimumabe', 'Nivolumabe', 'Prednisona']	['Ipilimumab', 'Nivolumab', 'Prednisone']
Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria	https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1795062	16/07/2020	Artigo completo publicado em periódico científico	10.1080/09546634.2020.1795062	0954-6634	09546634	JOURNAL OF DERMATOLOGICAL TREATMENT (PRINT)	A3	0.737	56	2.62	-	['Anti-histamínicos', 'Esteroides']	['Antihistamines', 'Ssteroids']
Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer	https://doi.org/10.1111/bjh.16966	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16966	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Ruxolitinibe', 'Tocilizumabe']	['Ruxolitinib', 'Tocilizumab']
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection	https://doi.org/10.1111/bjh.17014	11/07/2020	Artigo completo publicado em periódico científico	10.1111/bjh.17014	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Remdesivir']	['Remdesivir']
Acute cor pulmonale in COVID-19-related ARDS: improvement with almitrine infusion	https://doi.org/10.1016/j.jaccas.2020.06.011	16/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jaccas.2020.06.011	2666-0849	26660849	JACC: Case Reports	-	0.196	5	0.48	-	['Almitrina']	['Almitrine']
Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab	https://doi.org/10.1016/j.cllc.2020.05.027	02/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cllc.2020.05.027	1525-7304	15257304	Clinical Lung Cancer	-	1.202	63	4.46	-	['Durvalumabe']	['Durvalumab']
Effectiveness of Tocilizumab in a COVID-19 Patientwith Cytokine Release Syndrome	https://www.ejcrim.com/index.php/EJCRIM/article/view/1731	22/05/2020	Artigo completo publicado em periódico científico	https://www.ejcrim.com/index.php/EJCRIM/article/view/1731	-	-	-	-	-	-	-	-	[]	[]
SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor	https://doi.org/10.1016/j.mehy.2020.110040	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110040	0306-9877	03069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Secuquinumabe']	['Secukinumab']
Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation	https://doi.org/10.1016/j.idcr.2020.e008888	26/06/2020	Artigo completo publicado em periódico científico	10.1016/j.idcr.2020.e008888	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports	https://clinowl.com/tailoring-steroids-in-the-treatment-of-covid-19-pneumonia-assisted-by-ct-scans-three-case-reports/	14/07/2020	Artigo completo publicado em periódico científico	https://clinowl.com/tailoring-steroids-in-the-treatment-of-covid-19-pneumonia-assisted-by-ct-scans-three-case-reports/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome.	https://onlinelibrary.wiley.com/doi/10.1002/rth2.12390	20/05/2020	Artigo completo publicado em periódico científico	10.1002/rth2.12390	2475-0379	24750379	RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS	C	1.817	24	4.32	-	['Heparina']	['Heparin']
A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy	https://pubmed.ncbi.nlm.nih.gov/32628001/	06/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32628001/	-	-	-	-	-	-	-	-	['Anti-inflamatórios', 'Anticorpos', 'Cloroquina', 'Enoxaparina', 'Fondaparinux', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Oxigenoterapia', 'Ritonavir', 'Tocilizumabe', 'Varfarina']	['Anti-inflammatory', 'Antibodies', 'Chloroquine', 'Enoxaparin', 'Fondaparinux', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Oxygen Therapy', 'Ritonavir', 'Tocilizumab', 'Warfarin' ]
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection	https://doi.org/10.1007/s00380-020-01671-4	16/07/2020	Artigo completo publicado em periódico científico	10.1007/s00380-020-01671-4	0910-8327	09108327	HEART AND VESSELS	A3	0.551	49	1.82	-	['Azitromicina', 'Darunavir', 'Hidroxicloroquina', 'Ritonavir']	['Azithromycin', 'Darunavir', 'Hydroxychloroquine', 'Ritonavir']
The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: the Padua province experience	https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.15022	21/07/2020	Artigo completo publicado em periódico científico	10.1111/jth.15022	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Enoxaparina', 'Fondaparinux', 'Heparina']	['Enoxaparin', 'Fondaparinux', 'Heparin']
Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)	https://doi.org/10.1016/j.mayocp.2020.04.027	29/04/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.04.027	0025-6196	00256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Anticorpos', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Inibidores de interleucina-6', 'Lenzilumabe', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Sarilumabe', 'Tocilizumabe']	['Antibodies', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interleukin-6 inhibitors', 'Lenzilumab', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Sarilumab', 'Tocilizumab']
Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns	https://pubmed.ncbi.nlm.nih.gov/32687267/	14/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32687267/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
The potential role of IL-6 in monitoring severe case of coronavirus disease 2019	https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2	10/03/2020	Artigo completo publicado em periódico científico	10.1101/2020.03.01.20029769v2	-	-	-	-	-	-	-	-	['Corticosteroides', 'Imunoglobulina', 'Interleucina-6 basal (IL-6)', 'Lopinavir', 'Oseltamivir', 'Oxigenoterapia', 'Ritonavir', 'Umifenovir']	['Corticosteroids', 'Immunoglobulin', 'Baseline Interleukin-6 (IL-6)', 'Lopinavir', 'Oseltamivir', 'Oxygen Therapy', 'Ritonavir', 'Umifenovir']
Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib	https://doi.org/10.1111/tid.13401	06/07/2020	Artigo completo publicado em periódico científico	10.1111/tid.13401	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Ruxolitinibe']	['Ruxolitinib']
Safety and Efficacy of Amiodarone in a Patient With COVID-19	https://doi.org/10.1016/j.jaccas.2020.04.053	15/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaccas.2020.04.053	2666-0849	26660849	JACC: Case Reports	-	0.196	5	0.48	-	['Amiodarona']	['Amiodarone']
Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0583	19/06/2020	Artigo completo publicado em periódico científico	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0583	0002-9637	00029637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Azitromicina', 'Favipiravir', 'Hidroxicloroquina', 'Oseltamivir']	['Azithromycin', 'Favipiravir', 'Hydroxychloroquine', 'Oseltamivir']
Heparin‐induced Thrombocytopenia with Thrombosis in COVID‐19 Adult Respiratory Distress Syndrome	https://doi.org/10.1002/rth2.12390	20/05/2020	Artigo completo publicado em periódico científico	10.1002/rth2.12390	2475-0379	24750379	RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS	C	1.817	24	4.32	-	['Heparina']	['Heparin']
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16798	07/05/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16798	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Pembrolizumabe']	['Pembrolizumab']
The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series	https://www.cureus.com/articles/32936-the-role-of-interleukin-6-inhibitors-in-the-treatment-of-covid-19-infections-a-case-series	15/06/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/32936-the-role-of-interleukin-6-inhibitors-in-the-treatment-of-covid-19-infections-a-case-series	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14489	21/07/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14489	0306-5251	03065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei	https://pubmed.ncbi.nlm.nih.gov/32692230/	20/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32692230/	-	-	-	-	-	-	-	-	['Antibióticos', 'Corticosteroides', 'Interferon', 'Lopinavir', 'Medicina Tradicional Chinesa', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	['Antibiotics', 'Corticosteroids', 'Interferon', 'Lopinavir', 'Traditional Chinese Medicine', 'Oseltamivir', 'Ritonavir', 'Umifenovir']
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience	https://doi.org/10.1080/09546634.2020.1789041	09/07/2020	Artigo completo publicado em periódico científico	10.1080/09546634.2020.1789041	0954-6634	09546634	JOURNAL OF DERMATOLOGICAL TREATMENT (PRINT)	A3	0.737	56	2.62	-	['Rituximabe']	['Rituximab']
Use of tocilizumab in kidney transplant recipients with COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16192	12/07/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16192	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']
Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with pcr positive SARS-Cov-2 infection including drug induced changes in the corrected qt interval (QTc) (2020)	https://doi.org/10.1016/j.hrthm.2020.06.033	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.06.033	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID-19 patients with hypertension in Wuhan: A hospital-based retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26315	20/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26315	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Remdesivir for the Treatment of Covid-19 - Preliminary Report	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	22/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir']	['Remdesivir']
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab	https://www.sciencedirect.com/science/article/pii/S221103482030417X	26/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S221103482030417X	-	-	-	-	-	-	-	-	['Ocrelizumabe']	['Ocrelizumab']
Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study	https://www.bmj.com/content/369/bmj.m2094	03/06/2020	Artigo completo publicado em periódico científico	https://www.bmj.com/content/369/bmj.m2094	-	-	-	-	-	-	-	-	['Ácido acetilsalicílico', 'Antibióticos', 'Corticosteroides', 'Imunoglobulina']	['Acetylsalicylic acid', 'Antibiotics', 'Corticosteroids', 'Immunoglobulin']
Gastrointestinal Perforation After Treatment With Tocilizumab: An Unexpected Consequence of COVID-19 Pandemic	https://doi.org/10.1177/0003134820926481	15/07/2020	Artigo completo publicado em periódico científico	10.1177/0003134820926481	0003-1348	00031348	THE AMERICAN SURGEON	B2	0.293	95	0.76	-	['Tocilizumabe']	['Tocilizumab']
Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report	https://www.sciencedirect.com/science/article/pii/S0041134520325756	07/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0041134520325756	-	-	-	-	-	-	-	-	['Clazakizumab']	['Clazakizumab']
Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province	https://doi.org/10.3389/fmed.2020.00249	28/06/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.00249	2296-858X	2296858X	FRONTIERS IN MEDICINE	C	1.179	54	5.1	-	['Antibióticos', 'Interferon', 'Ribavirina', 'Umifenovir']	['Antibiotics', 'Interferon', 'Ribavirin', 'Umifenovir']
QT Interval Evaluation Associated With Use of Hydroxychloroquine with Combined Use of Azithromycin Among Hospitalized Children Positive for COVID-19	https://www.cambridge.org/core/journals/cardiology-in-the-young/article/qt-interval-evaluation-associated-with-use-of-hydroxychloroquine-with-combined-use-of-azithromycin-among-hospitalized-children-positive-for-covid19/2A096D3D1076335059490A691EC076A9	20/07/2020	Artigo completo publicado em periódico científico	https://www.cambridge.org/core/journals/cardiology-in-the-young/article/qt-interval-evaluation-associated-with-use-of-hydroxychloroquine-with-combined-use-of-azithromycin-among-hospitalized-children-positive-for-covid19/2A096D3D1076335059490A691EC076A9	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14482	20/07/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14482	0306-5251	03065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19	https://doi.org/10.1016/j.jcrc.2020.06.019	11/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.06.019	0883-9441	08839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(20)31605-6	20/07/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31605-6	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Ad5-nCoV']	['Ad5-nCoV']
A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01802-8	16/07/2020	Artigo completo publicado em periódico científico	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01802-8	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.	['Plasma convalescente', 'Terapia celular']	['Convalescent Plasma', 'Cell Therapy']
Vitamin D Sufficiency Reduced Risk for Morbidity and Mortality in COVID-19 Patients	http://dx.doi.org/10.2139/ssrn.3616008	14/07/2020	Artigo completo publicado em periódico científico	10.2139/ssrn.3616008	1556-5068	15565068	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
COVID-19 in two infants in China	https://onlinelibrary.wiley.com/doi/full/10.1002/iid3.319	02/07/2020	Artigo completo publicado em periódico científico	10.1002/iid3.319	2050-4527	20504527	IMMUNITY, INFLAMMATION AND DISEASE	B3	0.562	22	2.33	-	['Amoxicilina', 'Clavulanato de potássio', 'Imunoglobulina', 'Interferon', 'Oseltamivir', 'Ribavirina', 'Roxitromicina', 'Umifenovir']	['Amoxicillin', 'Potassium Clavulanate', 'Immunoglobulin', 'Interferon', 'Oseltamivir', 'Ribavirin', 'Roxithromycin', 'Umifenovir']
The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data	https://pubmed.ncbi.nlm.nih.gov/32682360/	19/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32682360/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
A critical evaluation of glucocorticoids in the management of severe COVID19	https://doi.org/10.1016/j.cytogfr.2020.06.012	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cytogfr.2020.06.012	1359-6101	13596101	CYTOKINE & GROWTH FACTOR REVIEWS	A1	2.756	168	14.32	-	['Dexametasona', 'Prednisona']	['Dexamethasone', 'Prednisone']
The cardiovascular effects of treatment with hydroxychloroquine and azithromycin	https://doi.org/10.1002/phar.2445	16/07/2020	Artigo completo publicado em periódico científico	10.1002/phar.2445	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study	https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13318	18/07/2020	Artigo completo publicado em periódico científico	10.1002/ijgo.13318	0020-7292	00207292	INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS	A3	0.956	103	3.59	-	['Azitromicina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	https://www.nejm.org/doi/10.1056/NEJMoa2021436	17/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021436	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Dexametasona']	['Dexamethasone']
Effet bénéfique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19: résultats d'une étude observationnelle	https://doi.org/10.1016/j.phclin.2020.06.001	09/06/2020	Artigo completo publicado em periódico científico	10.1016/j.phclin.2020.06.001	2211-1042	22111042	Pharmacien Hospitalier et Clinicien	-	0.218	8	0.4	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Mild COVID‐19 infection in an NMO patient treated with tocilizumab: a confrmation of anti‐IL‐6 protective role?	https://doi.org/10.1007/s00415-020-10039-7	07/07/2020	Artigo completo publicado em periódico científico	10.1007/s00415-020-10039-7	0340-5354	03405354	JOURNAL OF NEUROLOGY (PRINT)	A2	1.359	144	4.75	-	['Tocilizumabe']	['Tocilizumab']
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218244	25/06/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218244	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?	https://doi.org/10.1016/j.ijantimicag.2020.106056	13/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106056	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors	https://doi.org/10.1016/j.medcli.2020.06.013	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.013	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext	20/07/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext	-	-	-	-	-	-	-	-	['Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 vaccine']
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies	https://ard.bmj.com/content/79/5/667	15/04/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/79/5/667	-	-	-	-	-	-	-	-	['Abatacept', 'Adalimumabe', 'Baricitinibe', 'Etanercepte', 'Hidroxicloroquina', 'Tocilizumabe', 'Tofacitinibe']	['Abatacept', 'Adalimumab', 'Baricitinib', 'Etanercept', 'Hydroxychloroquine', 'Tocilizumab', 'Tofacitinib']
Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis	https://doi.org/10.1016/j.rmcr.2020.101115	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rmcr.2020.101115	2213-0071	22130071	RESPIRATORY MEDICINE CASE REPORTS	B2	0.354	19	1.23	-	['Remdesivir', 'Tocilizumabe']	['Remdesivir', 'Tocilizumab']
Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock	https://www.nejm.org/doi/full/10.1056/NEJMcpc2004975	15/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMcpc2004975	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonista de β-adrenérgico', 'Cefepima', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Vancomicina']	['β-Adrenergic Antagonist', 'Cefepime', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Vancomycin']
Cardiac Dysfunction and Shock in Pediatric Patients With COVID-19	https://doi.org/10.1016/j.jaccas.2020.05.082	18/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jaccas.2020.05.082	2666-0849	26660849	JACC: Case Reports	-	0.196	5	0.48	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
COVID-19 in a patient with active tuberculosis: A rare case-report	https://doi.org/10.1016/j.rmcr.2020.101146	04/07/2020	Artigo completo publicado em periódico científico	10.1016/j.rmcr.2020.101146	2213-0071	22130071	RESPIRATORY MEDICINE CASE REPORTS	B2	0.354	19	1.23	-	['Dexametasona', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Dexamethasone', 'Lopinavir', 'Ribavirin', 'Ritonavir']
Multiple Acute Ischemic Strokes in a COVID-19 Patient: a Case Report	http://link.springer.com/10.1007/s42399-020-00388-9	04/07/2020	Artigo completo publicado em periódico científico	http://link.springer.com/10.1007/s42399-020-00388-9	2523-8973	25238973	-	-	-	-	-	-	['Ganciclovir', 'Linezolida', 'Meropenem', 'Oseltamivir', 'Rezolsta']	['Ganciclovir', 'Linezolid', 'Meropenem', 'Oseltamivir', 'Rezolsta']
Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study	https://doi.org/10.1002/jmv.26308	16/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26308	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial	https://doi.org/10.7326/M20-4207	16/07/2020	Artigo completo publicado em periódico científico	10.7326/M20-4207	0003-4819	00034819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1009/5872589	16/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1009/5872589	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial	https://doi.org/10.1128/AAC.01061-20	13/07/2020	Artigo completo publicado em periódico científico	10.1128/AAC.01061-20	0066-4804	00664804	Antimicrobial Agents and Chemotherapy	-	1.546	269	5.16	 To the best of our knowledge, there is no published study on the use of interferon β-1a (IFN β-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN β-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group received IFN β-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-μg/ml (12 million IU/ml) dose of interferon β-1a was subcutaneously injected three times weekly for two consecutive weeks.	['Interferon beta']	['Interferon beta']
Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19	https://doi.org/10.1093/ofid/ofaa241	21/06/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa241	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients.                                                  Methods                   In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)–confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary end point was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population (clinicaltrials.gov: NCT04252274).                                                  Results                   From January 30, 2020, to February 6, 2020, a total of 30 patients were enrolled, of whom 18 (60%) were male, aged 47.2 ± 2.8 years; 63.3% (19/30) of the participants had fever, and 46.7% (14/30) had cough at enrollment. The participants were randomized (range) at 4 (2–5) days after onset of symptoms. The proportion of negative PCR results at day 7 was 46.7% (7/15) and 60.0% (9/15) in the DRV/c and control groups (P = .72), respectively. The viral clearance rate at day 3 was 20% (3/15) in both study groups, while the number increased to 26.7% (4/15) in the DRV/c group and remained 20% (3/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV/c group progressed to critical illness and discontinued DRV/c, while all the patients in the control group were stable (P = 1.0). The frequencies of adverse events in the 2 groups were comparable.                                                  Conclusions                   Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated.               	['Cobicistato', 'Darunavir']	['Cobicistat', 'Darunavir']
Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection	http://www.ncbi.nlm.nih.gov/pubmed/32667699	15/07/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32667699	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Baloxavir marboxil', 'Baloxavir marboxil', 'Corticosteroides', 'Corticosteroides', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe']	['Azithromycin', 'Azithromycin', 'Baloxavir marboxil', 'Baloxavir marboxil', 'Corticosteroids', 'Corticosteroids', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir' , 'Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab']
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!	https://doi.org/10.1016/j.jceh.2020.06.003	07/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jceh.2020.06.003	0973-6883	09736883	Journal of Clinical and Experimental Hepatology	-	0.718	39	3.22	-	['Ad5-nCoV', 'CoronaVac', 'Vacina BNT162', 'Vacina ChAdOx1 nCoV-19', 'Vacina INO-4800', 'Vacina mRNA-1273']	['Ad5-nCoV', 'CoronaVac', 'BNT162 Vaccine', 'ChAdOx1 Vaccine nCoV-19', 'INO-4800 Vaccine', 'mRNA-1273 Vaccine']
A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic	https://www.frontiersin.org/articles/10.3389/fphar.2020.00937/full	19/06/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.00937/full	-	-	-	-	-	-	-	-	['Vacina de DNA', 'Vacina de RNA']	['DNA vaccine', 'RNA vaccine']
Corticosteroid administration for viral pneumonia: COVID-19 and beyond	https://doi.org/10.1016/j.cmi.2020.06.020	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.06.020	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides']	['Corticosteroids']
Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy	https://doi.org/10.1016/j.retram.2020.04.003	01/05/2020	Artigo completo publicado em periódico científico	10.1016/j.retram.2020.04.003	2452-3186	24523186	Current Research in Translational Medicine	-	0.749	61	3.54	-	['Terapia celular']	['Cell Therapy']
Rethinking interleukin-6 blockade for treatment of COVID-19	https://doi.org/10.1016/j.mehy.2020.110053	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110053	0306-9877	03069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Inibidores de interleucina-6']	['Interleukin-6 inhibitors']
Severe coronavirus infection in pregnancy: challenging cases report	https://doi.org/10.1590/s1678-9946202062049	13/07/2020	Artigo completo publicado em periódico científico	10.1590/s1678-9946202062049	1678-9946	16789946	REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SÃO PAULO	B1	0.538	52	2.01	-	['Azitromicina', 'Ceftriaxona', 'Corticosteroides', 'Enoxaparina', 'Hidroxicloroquina', 'Meropenem', 'Oseltamivir', 'Vancomicina']	['Azithromycin', 'Ceftriaxone', 'Corticosteroids', 'Enoxaparin', 'Hydroxychloroquine', 'Meropenem', 'Oseltamivir', 'Vancomycin']
Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy	https://doi.org/10.1161/JAHA.120.016948	07/07/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.016948	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             BACKGROUND            <jats:p xml:lang="en">Coronavirus disease 2019 (COVID‐19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. Thus, patients with hypertension with COVID‐19 could have worse prognosis. Indeed, angiotensin‐converting enzyme inhibitors and/or angiotensin receptor blockers may interfere with angiotensin‐converting enzyme 2 expression/activity. Thus, patients with hypertension undergoing angiotensin‐converting enzyme inhibitor and/or angiotensin receptor blockers drug therapy may be at a higher risk of contracting a serious COVID‐19 infection and should be monitored. Moreover, in the present study we investigated the effects of angiotensin‐converting enzyme inhibitor versus angiotensin receptor blockers versus calcium channel blockers on clinical outcomes as mechanical ventilation, intensive care unit admissions, heart injury, and death in 62 patients with hypertension hospitalized for COVID‐19 infection.                    <jats:sec xml:lang="en">             METHODS AND RESULTS            <jats:p xml:lang="en">              The multicenter study was prospectively conducted at Department of Infectious Diseases of Sant'Anna Hospital of Caserta, and of University of Campania "Luigi Vanvitelli" of Naples, at Department of Advanced Surgical and Medical Sciences of University of Campania "Luigi Vanvitelli," Naples, and at General Medical Assistance Unit "FIMG," Naples, Italy. Lowest values of left ventricle ejection fraction predicted deaths (1.142, 1.008–1.294,               P              &lt;0.05), while highest values of interleukin‐6 predicted the admission to intensive care unit (1.617, 1.094–2.389), mechanical ventilation (1.149, 1.082–1.219), heart injuries (1.367, 1.054–1.772), and deaths (4.742, 1.788–8.524).                                <jats:sec xml:lang="en">             CONCLUSIONS            <jats:p xml:lang="en">Anti‐hypertensive drugs didn't affect the prognosis in patients with COVID‐19. Consequently, tailored anti‐inflammatory and immune therapies in addition to chronic antihypertensive therapy, could prevent a worse prognosis, as well as improve the clinical outcomes in patients with hypertension with COVID‐19 infection.          	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study	https://ard.bmj.com/content/early/2020/07/08/annrheumdis-2020-218243.citation-tools	09/07/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/07/08/annrheumdis-2020-218243.citation-tools	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
A retrospective review of memantine use and COVID-19-associated mortality from a national database	https://doi.org/10.1002/jmv.26266	07/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26266	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Memantina']	['Memantine']
Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study	https://doi.org/10.1186/s13054-020-03154-4	14/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03154-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Atorvastatina']	['Atorvastatin']
The Use of IV vitamin C for patients with COVID-19: a single center observational study	https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1794819	14/07/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2020.1794819	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Ácido ascórbico']	['Ascorbic acid']
Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis	https://doi.org/10.4414/smw.2020.20316	15/07/2020	Artigo completo publicado em periódico científico	10.4414/smw.2020.20316	1424-3997	14243997	Swiss Medical Weekly	-	0.694	74	2.35	-	['Antibióticos', 'Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Antibiotics', 'Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']
The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305763/	20/06/2020	Artigo completo publicado em periódico científico	PMC:PMC7305763/	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Fibrinolíticos']	['Anticoagulants', 'Fibrinolytics']
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies	https://www.msard-journal.com/article/S2211-0348(20)30382-5/abstract	15/06/2020	Artigo completo publicado em periódico científico	https://www.msard-journal.com/article/S2211-0348(20)30382-5/abstract	-	-	-	-	-	-	-	-	['Ocrelizumabe', 'Rituximabe']	['Ocrelizumab', 'Rituximab']
Covid-19: A systemic disease treated with a wide-ranging approach: A case report	https://pubmed.ncbi.nlm.nih.gov/32650356/	03/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32650356/	-	-	-	-	-	-	-	-	['Darunavir', 'Dexametasona', 'Enoxaparina', 'Hidroxicloroquina', 'Ritonavir', 'Tocilizumabe']	['Darunavir', 'Dexamethasone', 'Enoxaparin', 'Hydroxychloroquine', 'Ritonavir', 'Tocilizumab']
A Case of COVID-19 with Acute Myocardial Infarction and Cardiogenic Shock	https://doi.org/10.3346/jkms.2020.35.e258	13/07/2020	Artigo completo publicado em periódico científico	10.3346/jkms.2020.35.e258	1011-8934	10118934	Journal of Korean Medical Science	-	1.037	73	3.46	-	['Lopinavir', 'Oxigenação por membrana extracorpórea (ECMO)', 'Ritonavir']	['Lopinavir', 'Extracorporeal membrane oxygenation (ECMO)', 'Ritonavir']
First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test	https://doi.org/10.1111/cod.13657	12/07/2020	Artigo completo publicado em periódico científico	10.1111/cod.13657	0105-1873	01051873	CONTACT DERMATITIS	A1	0.810	100	1.97	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study	https://doi.org/10.1016/j.eclinm.2020.100410	15/07/2020	Artigo completo publicado em periódico científico	10.1016/j.eclinm.2020.100410	2589-5370	25895370	EClinicalMedicine	-	4.657	44	9.79	-	['Tocilizumabe']	['Tocilizumab']
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19	https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15464	13/07/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15464	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             The severe acute respiratory syndrome coronavirus 2 is known to infect host cells by interacting with ACE2 (angiotensin-converting enzyme 2) expressed in the respiratory epithelium. There have been concerns on whether alterations of ACE2 expression by renin-angiotensin-aldosterone system (RAAS) inhibitors would contribute to the infectivity and severity of coronavirus disease 2019 (COVID-19). We performed a case-control study to investigate the association between RAAS inhibitors and risk and severity of COVID-19 infection in South Korea using the population-based data provided by the Korean National Health Insurance System. Of 16 281 subjects with hypertension, there were 950 (5.8%) confirmed COVID-19 cases. After case-control matching, multivariable-adjusted conditional logistic regression analysis was performed. The adjusted odds ratio and 95% CIs for COVID-19 infection and long-term hospitalization comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors was 1.161 (0.958–1.407) and 0.863 (0.533–1.397), respectively. When comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors for intensive care unit admission, high-flow oxygen therapy, and death, the adjusted odds ratios (95% CIs) were 1.515 (0.402–5.701), 0.663 (0.272–1.619), and 1.363 (0.513–3.662), respectively. In all analyses,             P            values were not significant (             P            &gt;0.05). The present study demonstrates the absence of an identifiable association between the exposure to RAAS inhibitors and risk and severity of COVID-19 infection, supporting the current medical guidelines and recommendations that patients should not discontinue RAAS inhibitors out of a concern that they are at increased risk for infection or severe illness of COVID-19.          	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients	https://doi.org/10.1161/HYPERTENSIONAHA.120.15289	13/07/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15289	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8             +            cells on admission. Patients with hypertension were more likely to have comorbidities and complications and were more likely to be classified as critically ill than those without hypertension. Cox regression analysis revealed that hypertension (hazard ratio, 95% CI, unmatched cohort [1.80, 1.20–2.70]; matched cohort [2.24, 1.36–3.70]) was independently associated with all-cause mortality in patients with COVID-19. In addition, hypertensive patients with a history of RAAS inhibitor treatment had lower levels of C-reactive protein and higher levels of CD4             +            cells. The mortality of patients in the RAAS inhibitor group (9.8% versus 26.1%) was significantly lower than that of patients in the non-RAAS inhibitor group. In conclusion, hypertension may be an independent risk factor for all-cause mortality in patients with COVID-19. Patients who previously used RAAS inhibitors may have a better prognosis.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?	https://doi.org/10.1111/joim.13121	01/07/2020	Artigo completo publicado em periódico científico	10.1111/joim.13121	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Esomeprazol', 'Omeprazol', 'Pantoprazol']	['Esomeprazole', 'Omeprazole', 'Pantoprazole']
A Randomized, Open‐label, Controlled Clinical Trial of Azivudine Tablets in the Treatment of Mild and Common COVID‐19, A Pilot Study	https://doi.org/10.1002/advs.202001435	14/07/2020	Artigo completo publicado em periódico científico	10.1002/advs.202001435	2198-3844	21983844	Advanced Science	-	3.984	128	16.41	-	['Azivudina']	['Azivudine']
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?	https://doi.org/10.1016/j.ejca.2020.06.017	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejca.2020.06.017	0959-8049	09598049	EUROPEAN JOURNAL OF CANCER	A1	2.865	224	7.68	-	['Obinutuzumabe', 'Obinutuzumabe', 'Ocrelizumabe', 'Ocrelizumabe', 'Ofatumumabe', 'Ofatumumabe', 'Rituximabe', 'Rituximabe']	['Obinutuzumab', 'Obinutuzumab', 'Ocrelizumab', 'Ocrelizumab', 'Ofatumumab', 'Ofatumumab', 'Rituximab', 'Rituximab']
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	https://doi.org/10.1056/NEJMoa2022483	14/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2022483	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']
Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents	https://doi.org/10.1177/2045125320935306	22/06/2020	Artigo completo publicado em periódico científico	10.1177/2045125320935306	2045-1253	20451253	-	-	-	-	-	  As yet, no agents have been approved for the treatment of COVID-19, although several experimental drugs are being used off licence. These may have serious adverse effects and potential drug interactions with psychotropic agents. We reviewed the common agents being used across the world for the treatment of COVID-19 and investigated their drug interaction potential with psychotropic agents using several drug interaction databases and resources. A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab. Many serious adverse effects and potential drug interactions with psychotropic agents were identified. The most problematic agents were found to be ATV, AZI, CLQ, HCLQ, FAM and LPV/r in terms of both pharmacokinetic as well as serious pharmacodynamic drug interactions, including QTc prolongation and neutropenia. Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clinical trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents. 	['Atazanavir', 'Azitromicina', 'Cloroquina', 'Dipiridamol', 'Famotidina', 'Favipiravir', 'Hidroxicloroquina', 'Lopinavir', 'Nitazoxanida', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe']	['Atazanavir', 'Azithromycin', 'Chloroquine', 'Dipyridamole', 'Famotidine', 'Favipiravir', 'Hydroxychloroquine', 'Lopinavir', 'Nitazoxanide', 'Remdesivir', 'Ribavirin', 'Ritonavir', ' Tocilizumab']
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic	https://doi.org/10.1007/s11845-020-02291-7	06/07/2020	Artigo completo publicado em periódico científico	10.1007/s11845-020-02291-7	0021-1265	00211265	IRISH JOURNAL OF MEDICAL SCIENCE	A4	0.410	36	1.68	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Pros and cons of corticosteroid therapy for COVID-19 patients	https://doi.org/10.1016/j.resp.2020.103492	10/07/2020	Artigo completo publicado em periódico científico	10.1016/j.resp.2020.103492	1569-9048	15699048	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY	A4	0.635	102	2.53	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Coronavirus disease 2019 rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?	https://doi.org/10.1111/dth.14011	12/07/2020	Artigo completo publicado em periódico científico	10.1111/dth.14011	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Secuquinumabe']	['Secukinumab']
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection	https://doi.org/10.1016/j.clinre.2020.05.014	10/06/2020	Artigo completo publicado em periódico científico	10.1016/j.clinre.2020.05.014	2210-7401	22107401	CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY	A4	0.585	59	2.14	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases	https://www.cureus.com/articles/34773-pulse-therapy-with-corticosteroids-and-intravenous-immunoglobulin-in-the-management-of-severe-tocilizumab-resistant-covid-19-a-report-of-three-clinical-cases	07/07/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/34773-pulse-therapy-with-corticosteroids-and-intravenous-immunoglobulin-in-the-management-of-severe-tocilizumab-resistant-covid-19-a-report-of-three-clinical-cases	-	-	-	-	-	-	-	-	['Corticosteroides', 'Imunoglobulina']	['Corticosteroids', 'Immunoglobulin']
Management of the first severe case of COVID-19 in the small islands of Maldives	https://www.sciencedirect.com/science/article/pii/S2213007120302082	07/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2213007120302082	-	-	-	-	-	-	-	-	['Lopinavir', 'Oseltamivir', 'Ritonavir']	['Lopinavir', 'Oseltamivir', 'Ritonavir']
Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19	https://pubmed.ncbi.nlm.nih.gov/32628137/	14/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32628137/	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Bacillus Calmette–Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	09/07/2020	Artigo completo publicado em periódico científico	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis	https://doi.org/10.1186/s13054-020-03117-9	11/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03117-9	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients.  Methods The present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only. The primary outcomes were treatment escalation (intubation, extra-corporeal membrane oxygenation support, or renal replacement therapy) after day 1 until day 28. Secondary outcomes included ventilator-free days at day 28, mortality at day 14 and day 28, treatment safety issues and changes in respiratory tracts, and plasma viral load (as estimated by cycle threshold value) between admission and day 7.  Results Eighty patients were treated during a 4-week period and included in the analysis: 22 (28%) received standard of care only, 20 (25%) patients received lopinavir/ritonavir associated to standard of care, and 38 (47%) patients received hydroxychloroquine and standard of care. Baseline characteristics were well balanced between the 3 groups. Treatment escalation occurred in 9 (41%), 10 (50%), and 15 (39%) patients who received standard of care only, standard of care and lopinavir/ritonavir, and standard of care and hydroxychloroquine, respectively ( p = 0.567). There was no significant difference between groups regarding the number of ventilator-free days at day 28 and mortality at day 14 and day 28. Finally, there was no significant change between groups in viral respiratory or plasma load between admission and day 7.  Conclusion In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28. Further randomized controlled trials are required to demonstrate whether these drugs may be useful in this context.	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
QT prolongation in adiverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin	https://doi.org/10.1007/s10840-020-00822-x	11/07/2020	Artigo completo publicado em periódico científico	10.1007/s10840-020-00822-x	1383-875X	1383875X	JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY (PRINT)	B1	0.680	57	1.96	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine	https://doi.org/10.1007/s12471-020-01462-6	09/07/2020	Artigo completo publicado em periódico científico	10.1007/s12471-020-01462-6	1568-5888	15685888	Netherlands Heart Journal	-	0.753	38	1.55	 Abstract  Background Chloroquine, a quinolone antimalarial drug, is known to potentially inhibit pH-dependent viral replication of the SARS-CoV‑2 infection. Therefore, chloroquine is considered as a treatment option for coronavirus disease 2019 (COVID-19). Chloroquine is known for prolonging the QT interval, but limited data are available on the extent of this QT-prolonging effect.  Objective To assess the QTc-prolonging potential of chloroquine in COVID-19 patients and to evaluate whether this prolongation increases with the cumulative dose of chloroquine and is associated with the peak plasma concentration of chloroquine. Furthermore, the number of patients who prematurely discontinued treatment or had an adjustment in dose due to QTc-interval prolongation was established.  Methods A retrospective, observational study was performed in patients aged over 18 years, hospitalised for a suspected or proven infection with COVID-19, and therefore treated with chloroquine, with a baseline electrocardiogram (ECG) performed prior to the start of treatment and at least one ECG after starting the treatment.  Results In total, 397 patients were included. The mean increase in QTc interval throughout the treatment with chloroquine was 33 ms. Nineteen out of 344 patients unnecessarily had their treatment prematurely discontinued or adjusted due to a prolonged QTc interval based on the computerised interpretation of the ECG.  Conclusion Chloroquine treatment in COVID-19 patients gradually increased the QTc interval. Due to a significant number of overestimated QTc intervals by computer analysis, it is advisable to measure the QTc interval manually before adjusting the dose or withdrawing this potentially beneficial medication.	['Cloroquina']	['Chloroquine']
Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an 1 Open-Label Non-Randomized Clinical Trial: Response to David Spencer (Elsevier)	https://www.mediterranee-infection.com/hydroxychloroquine-and-azithromycin-as-a-treatment-of-covid-19-results-of-an-open-label-non-randomized-clinical-trial-response-to-david-spencer-elsevier/	08/07/2020	Artigo completo publicado em periódico científico	https://www.mediterranee-infection.com/hydroxychloroquine-and-azithromycin-as-a-treatment-of-covid-19-results-of-an-open-label-non-randomized-clinical-trial-response-to-david-spencer-elsevier/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept	https://doi.org/10.15586/jptcp.v27iSP1.689	27/06/2020	Artigo completo publicado em periódico científico	10.15586/jptcp.v27iSP1.689	1710-6222	17106222	CANADIAN JOURNAL OF CLINICAL PHARMACOLOGY (ONLINE)	C	0.350	41	1.39	-	['Anakinra', 'Baricitinibe', 'Canaquinumabe', 'Corticosteroides', 'Heparina', 'Sarilumabe', 'Tocilizumabe', 'Tofacitinibe', 'Vitamina D (25-hidroxivitamina D)']	['Anakinra', 'Baricitinib', 'Canakinumab', 'Corticosteroids', 'Heparin', 'Sarilumab', 'Tocilizumab', 'Tofacitinib', 'Vitamin D (25-hydroxyvitamin D)']
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19	https://link.springer.com/article/10.1007/s40121-020-00318-1	10/07/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00318-1	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Remdesivir']	['Remdesivir']
An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19	https://doi.org/10.1016/S0140-6736(20)31526-9	10/07/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31526-9	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Tocilizumabe']	['Tocilizumab']
Iloprost for COVID-19-related vasculopathy	https://doi.org/10.1016/S2665-9913(20)30232-0	10/07/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30232-0	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Iloprosta']	['Iloprost']
Portal vein thrombosis in a patient with COVID-19	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293484/	13/06/2020	Artigo completo publicado em periódico científico	PMC:PMC7293484/	-	-	-	-	-	-	-	-	['Azitromicina', 'Enoxaparina', 'Hidroxicloroquina']	['Azithromycin', 'Enoxaparin', 'Hydroxychloroquine']
BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)	https://doi.org/10.1073/pnas.2008410117	09/07/2020	Artigo completo publicado em periódico científico	10.1073/pnas.2008410117	0027-8424	00278424	Proceedings of the National Academy of Sciences of the United States of America	-	4.184	805	10.96	 Significance           The COVID-19 pandemic is one of the most devastating in recent history. The bacillus Calmette−Guérin (BCG) vaccine against tuberculosis also confers broad protection against other infectious diseases, and it has been proposed that it could reduce the severity of COVID-19. This epidemiological study assessed the global linkage between BCG vaccination and COVID-19 mortality. Signals of BCG vaccination effect on COVID-19 mortality are influenced by social, economic, and demographic differences between countries. After mitigating multiple confounding factors, several significant associations between BCG vaccination and reduced COVID-19 deaths were observed. This study highlights the need for mechanistic studies behind the effect of BCG vaccination on COVID-19, and for clinical evaluation of the effectiveness of BCG vaccination to protect from severe COVID-19.	['Vacina BCG']	['BCG vaccine']
SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS	https://doi.org/10.1016/j.jinf.2020.07.008	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.07.008	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Tocilizumabe']	['Tocilizumab']
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab	https://doi.org/10.1016/j.jaut.2020.102512	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102512	0896-8411	08968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']
Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysi	https://doi.org/10.1016/j.intimp.2020.106740	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106740	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon recombinante tipo 1']	['Type 1 recombinant interferon']
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living  systematic review	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/full	10/07/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013600.pub2/full	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses	https://doi.org/10.1016/j.intimp.2020.106717	18/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106717	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Agonistas de TLRs', 'AS01B', 'AS03A', 'Delta inulin', 'Hidróxido de alumínio', 'MF59', 'Montanide ISA-51', 'Protollin', 'rOv-ASP-1']	['TLR agonists', 'AS01B', 'AS03A', 'Delta inulin', 'Aluminium hydroxide', 'MF59', 'Montanide ISA-51', 'Protollin', 'rOv-ASP-1']
Role of vitamin D in preventing of COVID-19 infection, progression and severity	https://doi.org/10.1016/j.jiph.2020.06.021	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.06.021	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients	https://www.cureus.com/articles/32778-lithium-toxicity-in-two-coronavirus-disease-2019-covid-19-patients	31/05/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/32778-lithium-toxicity-in-two-coronavirus-disease-2019-covid-19-patients	-	-	-	-	-	-	-	-	['Lítio']	['Lithium']
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal	https://doi.org/10.1002/jmv.26279	09/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26279	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Fingolimode']	['Fingolimod']
COVID-19 among fit patients with CLL treated with venetoclax-based combinations	http://dx.doi.org/10.1038/s41375-020-0941-7	29/06/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-0941-7	0887-6924	08876924	LEUKEMIA	A1	4.030	202	9.5	-	['Venetoclax', 'Venetoclax', 'Venetoclax']	['Venetoclax', 'Venetoclax', 'Venetoclax']
Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases	https://doi.org/10.1016/j.rmcr.2020.101139	23/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rmcr.2020.101139	2213-0071	22130071	RESPIRATORY MEDICINE CASE REPORTS	B2	0.354	19	1.23	-	['Tocilizumabe']	['Tocilizumab']
Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study	https://doi.org/10.1016/S2352-4642(20)30215-7	09/07/2020	Artigo completo publicado em periódico científico	10.1016/S2352-4642(20)30215-7	2352-4642	23524642	THE LANCET CHILD & ADOLESCENT HEALTH (IMPRESSO)	B4	4.385	43	7.82	-	['Esteroides', 'Imunoglobulina', 'Infliximabe', 'Rituximabe', 'Tocilizumabe']	['Steroidal', 'Immunoglobulin', 'Infliximab', 'Rituximab', 'Tocilizumab']
Coronavirus disease 2019 (COVID‑19) in a patient with ankylosing spondylitis treated with secukinumab: a case‑based review	https://doi.org/10.1007/s00296-020-04635-z	26/06/2020	Artigo completo publicado em periódico científico	10.1007/s00296-020-04635-z	0172-8172	01728172	RHEUMATOLOGY INTERNATIONAL (BERLIN. PRINT)	B1	0.747	78	3.1	-	['Secuquinumabe']	['Secukinumab']
Severe refractory COVID-19 patients responding to convalescent plasma; A case series	https://doi.org/10.1016/j.amsu.2020.06.018	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.amsu.2020.06.018	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Plasma convalescente']	['Convalescent Plasma']
Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia	http://www.sciencedirect.com/science/article/pii/S1473050220301725	27/06/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S1473050220301725	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26288	09/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26288	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Treating COVID-19 with Chloroquine	https://academic.oup.com/jmcb/article/12/4/322/5814655	18/05/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/jmcb/article/12/4/322/5814655	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis	https://www.sciencedirect.com/science/article/pii/S1871402120302162	27/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1871402120302162	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Estatina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Statin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Hydroxychloroquine safety: A meta-analysis of randomized controlled trials	https://doi.org/10.1016/j.tmaid.2020.101812	06/07/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101812	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
SARS-CoV-2: Virology, epidemiology, immunology and vaccine development	https://doi.org/10.1016/j.biologicals.2020.06.005	23/06/2020	Artigo completo publicado em periódico científico	10.1016/j.biologicals.2020.06.005	1045-1056	10451056	BIOLOGICALS (LONDON. PRINT)	A4	0.460	60	2.0	-	['Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina Curevac', 'Vacina Curevac', 'Vacina Curevac', 'Vacina Curevac', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine ChAdOx1 nCoV-19', 'Vaccine ChAdOx1 nCoV- 19', 'Vaccina ChAdOx1 nCoV-19', 'Vaccina ChAdOx1 nCoV-19', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina INO-4800', 'Vaccina INO- 4800', 'INO-4800 vaccine', 'INO-4800 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'NVX-CoV2373 vaccine ', 'NVX-CoV2373 vaccine', 'NVX-CoV2373 vaccine', 'NVX-CoV2373 vaccine']
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)	https://www.jstage.jst.go.jp/article/bst/advpub/0/advpub_2020.03072/_article	30/04/2020	Artigo completo publicado em periódico científico	https://www.jstage.jst.go.jp/article/bst/advpub/0/advpub_2020.03072/_article	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions	https://www.mdpi.com/2076-0817/9/6/4266	29/05/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-0817/9/6/4266	-	-	-	-	-	-	-	-	['Cloroquina', 'Emetine', 'Hidroxicloroquina', 'Homoharringtonina (HHT)', 'Interferon recombinante tipo 1', 'Ivermectina', 'Lopinavir', 'Molnupiravir', 'Nitazoxanida', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Emetine', 'Hydroxychloroquine', 'Homoharringtonine (HHT)', 'Recombinant Interferon Type 1', 'Ivermectin', 'Lopinavir', 'Molnupiravir', 'Nitazoxanide', 'Remdesivir', 'Ribavirin' , 'Ritonavir', 'Umifenovir']
Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline	https://www.frontiersin.org/article/10.3389/fimmu.2020.01294	05/06/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fimmu.2020.01294	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir']
Primum non nocere _ Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?	http://www.rsp.fsp.usp.br/artigo/primum-non-nocere-are-chloroquine-and-hydroxychloroquine-safe-prophylactic-treatment-options-for-sars-cov-2-covid-19/?lang=en	26/06/2020	Artigo completo publicado em periódico científico	http://www.rsp.fsp.usp.br/artigo/primum-non-nocere-are-chloroquine-and-hydroxychloroquine-safe-prophylactic-treatment-options-for-sars-cov-2-covid-19/?lang=en	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection	https://doi.org/10.1016/j.medmal.2020.03.006	30/03/2020	Artigo completo publicado em periódico científico	10.1016/j.medmal.2020.03.006	0399-077X	0399077X	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications	https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.14025	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ctr.14025	0902-0063	09020063	CLINICAL TRANSPLANTATION	A4	0.901	80	2.87	-	['Plasma convalescente']	['Convalescent Plasma']
Coronavirus disease 2019 (COVID-19) pneumonia in a hemodialysis patient: A case report	https://journals.lww.com/md-journal/fulltext/2020/07020/coronavirus_disease_2019__covid_19__pneumonia_in_a.82.aspx	02/07/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/md-journal/fulltext/2020/07020/coronavirus_disease_2019__covid_19__pneumonia_in_a.82.aspx	-	-	-	-	-	-	-	-	['Cateter nasal de oxigênio', 'Cloridrato de ambroxol', 'Ganciclovir', 'Interferon alfa', 'Moxifloxacina', 'Prednisona']	['Oxygen nasal catheter', 'Ambroxol hydrochloride', 'Ganciclovir', 'Interferon alpha', 'Moxifloxacin', 'Prednisone']
First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia	https://doi.org/10.1016/j.transci.2020.102866	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102866	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Plasma convalescente']	['Convalescent Plasma']
Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review	https://doi.org/10.3390/tropicalmed5030112	03/07/2020	Artigo completo publicado em periódico científico	10.3390/tropicalmed5030112	2414-6366	24146366	TROPICAL MEDICINE AND INFECTIOUS DISEASE	C	0.924	24	3.61	 COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease continues to pose a major therapeutic challenge. Patient mortality is ultimately caused by acute respiratory distress syndrome (ARDS). Cytokine release syndrome (or “cytokine storm”) is likely to be a contributing factor to ARDS in many patients. Because interleukin 6 (IL-6) is known to play a key role in inflammation, IL-6 receptor inhibitors such as tocilizumab may potentially treat COVID-19 by attenuating cytokine release. We present the case of a 48-year-old male with severe COVID-19, on the verge of meeting intubation requirements, who needed progressive oxygen support for respiratory distress. The patient was treated with a non-weight-based dosage of tocilizumab to prevent the onset of a cytokine storm. We chose to administer an IL-6 inhibitor because of the gradually increasing levels of acute phase reactants identified on serial blood draws, as well as his declining respiratory status. The treatment was well-tolerated in conjunction with standard drug therapies for COVID-19 (hydroxychloroquine, azithromycin, and zinc). The patient subsequently experienced marked improvements in his respiratory symptoms and overall clinical status over the following days. We believe that tocilizumab played a substantial role in his ability to avert clinical decline, particularly the need for mechanical ventilation. Ultimately, the patient was downgraded from the ICU and discharged within days. We highlight the potential of IL-6 inhibitors to prevent the progression of respiratory disease to a point requiring ventilator support. This case underscores the potential importance of early serial measurements of IL-6 and cytokine storm-associated acute phase reactants, such as ferritin, D-dimer, and C-reactive protein, in guiding clinical decision-making in the management of patients with suspected COVID-19. Conclusion: The early, proactive identification of serum acute phase reactants should be implemented in the treatment of COVID-19 in order to screen for a primary contributor to mortality—the cytokine storm. This screening, when followed by aggressive early treatment for cytokine storm, may have optimal therapeutic benefits and obviate the need for mechanical ventilation, thereby decreasing mortality. Additionally, we review current evidence regarding cytokine release syndrome in COVID-19 and the use of IL-6 receptor inhibition as a therapeutic strategy, and examine other reported cases in the literature describing IL-6 antagonist treatment for patients with COVID-19.	['Tocilizumabe']	['Tocilizumab']
Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide	http://www.sciencedirect.com/science/article/pii/S1341321X20302130	01/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S1341321X20302130	-	-	-	-	-	-	-	-	['Ciclesonida']	['Cyclesonide']
Association between angiotensin blockade and COVID-19 severity in Hong Kong	https://www.cmaj.ca/content/192/23/E635.abstract	08/06/2020	Artigo completo publicado em periódico científico	https://www.cmaj.ca/content/192/23/E635.abstract	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era	https://doi.org/10.1016/j.ejim.2020.06.006	06/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.06.006	0953-6205	09536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Apixabana', 'Dabigatrana', 'Edoxabana', 'Heparina', 'Rivaroxabana']	['Apixaban', 'Dabigatran', 'Edoxaban', 'Heparin', 'Rivaroxaban']
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis	http://www.ncbi.nlm.nih.gov/pubmed/32621202%0A	03/07/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32621202%0A	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 Inhibitors' (ACEI 2)', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis	https://doi.org/10.1111/jth.14992	06/07/2020	Artigo completo publicado em periódico científico	10.1111/jth.14992	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Enoxaparina', 'Fondaparinux']	['Enoxaparin', 'Fondaparinux']
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases	https://ard.bmj.com/content/early/2020/06/30/annrheumdis-2020-218054	30/06/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/06/30/annrheumdis-2020-218054	-	-	-	-	-	-	-	-	['Drogas antirreumáticas modificadoras de doenças', 'Hidroxicloroquina', 'Prednisona']	['Disease-modifying anti-rheumatic drugs', 'Hydroxychloroquine', 'Prednisone']
Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy	http://www.ncbi.nlm.nih.gov/pubmed/32634589	04/07/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32634589	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives	https://www.mdpi.com/2077-0383/9/7/2050	30/06/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2077-0383/9/7/2050	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Obstetric Management of COVID-19 in Pregnant Women	https://www.frontiersin.org/article/10.3389/fmicb.2020.01186	26/05/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fmicb.2020.01186	1664-302X	1664302X	FRONTIERS IN MICROBIOLOGY (ONLINE)	A1	1.314	166	6.11	-	['Cloroquina', 'Cloroquina', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']	['Chloroquine', 'Chloroquine', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']
Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature	https://www.tandfonline.com/doi/full/10.1080/08820139.2020.1789655	07/07/2020	Artigo completo publicado em periódico científico	10.1080/08820139.2020.1789655	0882-0139	08820139	IMMUNOLOGICAL INVESTIGATIONS	B2	0.570	50	2.76	-	['Colchicina', 'Colchicina']	['Colchicine', 'Colchicine']
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report	https://doi.org/10.1016/j.msard.2020.102323	21/06/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102323	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Ocrelizumabe']	['Ocrelizumab']
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles	https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e239	06/07/2020	Artigo completo publicado em periódico científico	https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e239	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Mortality and the use of antithrombotic therapies among nursing home residents with COVID ‐19	https://doi.org/10.1111/jgs.16664	07/07/2020	Artigo completo publicado em periódico científico	10.1111/jgs.16664	0002-8614	00028614	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY	A1	2.133	241	4.78	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes']	['Vitamin K antagonists (VKA)', 'Anticoagulants']
Successful use of tPA for thrombolysis in COVID related ARDS: a case series	https://pubmed.ncbi.nlm.nih.gov/32617806	02/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32617806	-	-	-	-	-	-	-	-	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study	http://atm.amegroups.com/article/view/42685/html	08/05/2020	Artigo completo publicado em periódico científico	http://atm.amegroups.com/article/view/42685/html	-	-	-	-	-	-	-	-	['Antibióticos', 'Antivirais', 'Corticosteroides']	['Antibiotics', 'Antivirals', 'Corticosteroids']
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19	http://www.ijmr.org.in/article.asp?issn=0971-5916	01/05/2020	Artigo completo publicado em periódico científico	http://www.ijmr.org.in/article.asp?issn=0971-5916	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)	https://doi.org/10.1016/j.micinf.2020.06.005	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.micinf.2020.06.005	1286-4579	12864579	MICROBES AND INFECTION	A2	1.586	148	6.22	-	['Tocilizumabe']	['Tocilizumab']
An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can’t Get No) Satisfaction	https://doi.org/10.1016/j.ijid.2020.06.095	02/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.095	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study	http://www.sciencedirect.com/science/article/pii/S0924857920302478	04/07/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0924857920302478	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2	https://doi.org/10.3390/vaccines8020293	10/06/2020	Artigo completo publicado em periódico científico	10.3390/vaccines8020293	2076-393X	2076393X	Vaccines	-	1.004	50	4.88	 The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina de adenovírus', 'Vacina de adenovírus', 'Vacina de adenovírus']	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'Vaccine ChAdOx1 nCoV-19', 'Vaccine ChAdOx1 nCoV-19', 'Vaccine ChAdOx1 nCoV-19', 'Adenovirus Vaccine', ' Adenovirus vaccine', 'Adenovirus vaccine']
Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01201/full	27/05/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01201/full	-	-	-	-	-	-	-	-	['Anakinra', 'Emapalumabe', 'Etanercepte', 'Infliximabe', 'Inibidores de proteassoma', 'Micofenolato de mofetila', 'Plerixafor', 'Tocilizumabe']	['Anakinra', 'Emapalumab', 'Etanercept', 'Infliximab', 'Proteasome inhibitors', 'Mycophenolate mofetil', 'Plerixafor', 'Tocilizumab']
Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk	https://doi.org/10.1016/j.hrthm.2020.07.001	02/07/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.07.001	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19	https://www.sciencedirect.com/science/article/pii/S0898656820301832	03/07/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0898656820301832	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.	https://doi.org/10.1016/j.drudis.2020.06.030	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.drudis.2020.06.030	1359-6446	13596446	DRUG DISCOVERY TODAY	A1	1.470	185	8.45	-	['Cloroquina']	['Chloroquine']
A Case of COVID-19 Infection With Delayed Thromboembolic Complication on Warfarin	https://www.cureus.com/articles/35187-a-case-of-covid-19-infection-with-delayed-thromboembolic-complication-on-warfarin	26/06/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/35187-a-case-of-covid-19-infection-with-delayed-thromboembolic-complication-on-warfarin	-	-	-	-	-	-	-	-	['Varfarina']	['Warfarin']
Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19	https://doi.org/10.1016/j.ijid.2020.06.091	30/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.091	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Cloroquina', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']
Serious adverse events associated with hydroxychloroquine amidst COVID-19 pandemic: case series and literature review	https://doi.org/10.7759/cureus.8415	02/06/2020	Artigo completo publicado em periódico científico	10.7759/cureus.8415	2168-8184	21688184	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study	https://doi.org/10.1016/S2665-9913(20)30227-7	03/07/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30227-7	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Corticosteroides', 'Hidroxicloroquina', 'Leflunomida', 'Metotrexato', 'Micofenolato de mofetila']	['Corticosteroids', 'Hydroxychloroquine', 'Leflunomide', 'Methotrexate', 'Mycophenolate mofetil']
Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30151-6/fulltext	15/06/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30151-6/fulltext	-	-	-	-	-	-	-	-	['Amoxicilina', 'Azitromicina', 'Ceftriaxona', 'Esteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Amoxicillin', 'Azithromycin', 'Ceftriaxone', 'Ssteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']
Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: an epidemio-clinical study	https://www.japi.org/v2c474c4/characteristics-treatment-outcomes-and-role-of-hydroxychloroquine-among-522-covid-19-hospitalized-patients-in-jaipur-city-an-epidemio-clinical-study	20/05/2020	Artigo completo publicado em periódico científico	https://www.japi.org/v2c474c4/characteristics-treatment-outcomes-and-role-of-hydroxychloroquine-among-522-covid-19-hospitalized-patients-in-jaipur-city-an-epidemio-clinical-study	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy	https://doi.org/10.1016/j.eplepsyres.2020.106399	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.eplepsyres.2020.106399	0920-1211	09201211	EPILEPSY RESEARCH	A3	0.767	117	3.03	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic	https://pubmed.ncbi.nlm.nih.gov/32603983	20/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32603983	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
RAAS inhibitors do not increase the risk of COVID-19	https://doi.org/10.1038/s41569-020-0401-0	22/06/2020	Artigo completo publicado em periódico científico	10.1038/s41569-020-0401-0	1759-5002	17595002	Nature Reviews Cardiology	-	6.721	145	12.3	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19)	https://pubmed.ncbi.nlm.nih.gov/32618794/	30/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32618794/	-	-	-	-	-	-	-	-	['Remdesivir', 'Tocilizumabe']	['Remdesivir', 'Tocilizumab']
Case reports study of the first five patients COVID-19 treated with remdesivir in France	https://www.sciencedirect.com/science/article/pii/S1201971220305282	30/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1201971220305282	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series	https://doi.org/10.1186/s13054-020-03078-z	03/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03078-z	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir', 'Nafamostato']	['Favipiravir', 'Nafamostat']
A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001	https://doi.org/10.1016/j.jaccas.2020.04.025	03/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaccas.2020.04.025	2666-0849	26660849	JACC: Case Reports	-	0.196	5	0.48	-	['Corticosteroides', 'Fármaco inibidor da aldose redutase (AT-001)', 'Tocilizumabe']	['Corticosteroids', 'Aldose reductase inhibitor drug (AT-001)', 'Tocilizumab']
Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China	http://atm.amegroups.com/article/view/40318/html	08/04/2020	Artigo completo publicado em periódico científico	http://atm.amegroups.com/article/view/40318/html	-	-	-	-	-	-	-	-	['Gamaglobulina', 'Interferon beta', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	['Gammaglobulin', 'Interferon beta', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study	https://doi.org/10.1002/jmv.26260	04/07/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26260	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study	https://pubmed.ncbi.nlm.nih.gov/32620597/	03/07/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32620597/	-	-	-	-	-	-	-	-	['Sarilumabe']	['Sarilumab']
Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19	https://doi.org/10.1016/j.ijid.2020.06.099	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.099	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Hydroxychloroquine as Prophylaxis or Treatment for COVID-19: What Does the Evidence Say?	http://www.ijph.in/article.asp?issn=0019-557X;year=2020;volume=64;issue=6;spage=125;epage=127;aulast=Nina;type=0	05/07/2020	Artigo completo publicado em periódico científico	http://www.ijph.in/article.asp?issn=0019-557X;year=2020;volume=64;issue=6;spage=125;epage=127;aulast=Nina;type=0	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19	https://doi.org/10.1002/sctm.20-0186	11/06/2020	Artigo completo publicado em periódico científico	10.1002/sctm.20-0186	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious—including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis—as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials—including for COVID-19—of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19.                                  <jats:title />               	['Terapia celular']	['Cell Therapy']
Massive Pulmonary Thromboembolism in Patients with COVID-19; Report of Three Cases	http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/748	16/05/2020	Artigo completo publicado em periódico científico	http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/748	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020	https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article	01/07/2020	Artigo completo publicado em periódico científico	https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas	https://doi.org/10.1017/S0950268820001351	22/06/2020	Artigo completo publicado em periódico científico	10.1017/S0950268820001351	0950-2688	09502688	Epidemiology and Infection	-	0.997	114	3.32	 Abstract	['Azitromicina', 'Hidroxicloroquina', 'Plasma convalescente', 'Tocilizumabe']	['Azithromycin', 'Hydroxychloroquine', 'Convalescent Plasma', 'Tocilizumab']
Effects of Hydroxychloroquine Treatment on QT Interval	https://doi.org/10.1016/j.hrthm.2020.06.029	28/06/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.06.029	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis	https://heart.bmj.com/content/early/2020/07/01/heartjnl-2020-317336	01/07/2020	Artigo completo publicado em periódico científico	https://heart.bmj.com/content/early/2020/07/01/heartjnl-2020-317336	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Use of Baricitinib in Patients with Moderate and Severe COVID-19	https://doi.org/10.1093/cid/ciaa879	29/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa879	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.	['Baricitinibe', 'Hidroxicloroquina']	['Baricitinib', 'Hydroxychloroquine']
Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice	http://www.ncbi.nlm.nih.gov/pubmed/32571115	22/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32571115	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Severe COVID-19 Infection While on Long Standing Therapy with Hydroxychloroquine	https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2020&month=June&volume=14&issue=6&page=OD04-OD05&id=13775	01/06/2020	Artigo completo publicado em periódico científico	https://www.jcdr.net/article_fulltext.asp?issn=0973-709x&year=2020&month=June&volume=14&issue=6&page=OD04-OD05&id=13775	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Imatinib for COVID-19: A case report	https://doi.org/10.1016/j.clim.2020.108518	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108518	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Imatinibe']	['Imatinib']
Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with Pglycoprotein inhibitors	https://doi.org/10.1093/cid/ciaa883	28/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa883	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.	['Remdesivir']	['Remdesivir']
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	https://doi.org/10.1016/j.msard.2020.102180	06/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102180	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Fingolimode']	['Fingolimod']
Belatacept, kidney transplantation and COVID-19: successful management of the first reported case within the United Kingdom	https://doi.org/10.1111/ctr.14026	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ctr.14026	0902-0063	09020063	CLINICAL TRANSPLANTATION	A4	0.901	80	2.87	-	['Belatacept']	['Belatacept']
Tratamiento y evolucion del sindrome de tormenta de citoquinas asociados a infeccion por SARS-CoV-2 en pacientes octogenários	https://pubmed.ncbi.nlm.nih.gov/32564984/	03/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32564984/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?	https://doi.org/10.1080/10641963.2020.1783549	22/06/2020	Artigo completo publicado em periódico científico	10.1080/10641963.2020.1783549	1064-1963	10641963	CLINICAL AND EXPERIMENTAL HYPERTENSION (1993, PRINT)	B1	0.481	50	1.96	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry	https://doi.org/10.1016/j.rec.2020.05.018	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rec.2020.05.018	1885-5857	18855857	REVISTA ESPAÑOLA DE CARDIOLOGÍA (INTERNET. ENGLISH ED.)	A4	0.385	7	0.98	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Role of corticosteroid in the management of COVID-19: A systemic review and a clinician’s perspective.	https://doi.org/10.1016/j.dsx.2020.06.054	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.06.054	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Corticosteroides']	['Corticosteroids']
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen	https://doi.org/10.1038/s41429-020-0336-z	12/06/2020	Artigo completo publicado em periódico científico	10.1038/s41429-020-0336-z	0021-8820	00218820	JOURNAL OF ANTIBIOTICS (TOKYO. 1968)	A4	0.514	84	3.09	-	['Ivermectina']	['Ivermectin']
Coronavirus disease-19 and rheumatological disorders: A narrative review	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-618888	01/06/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-618888	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais', 'Antirreumáticos', 'Corticosteroides', 'Esteroides', 'Hidroxicloroquina', 'Ibuprofeno', 'Prednisolona', 'Sulfassalazina']	['Non-steroidal anti-inflammatory drugs', 'Anti-rheumatics', 'Corticosteroids', 'Ssteroids', 'Hydroxychloroquine', 'Ibuprofen', 'Prednisolone', 'Sulfasalazine']
Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment	https://doi.org/10.1007/s11886-020-01327-9	11/06/2020	Artigo completo publicado em periódico científico	10.1007/s11886-020-01327-9	1523-3782	15233782	CURRENT CARDIOLOGY REPORTS (PRINT)	A4	0.916	54	3.55	-	['Heparina', 'Heparina']	['Heparin', 'Heparin']
A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient	https://doi.org/10.1111/tid.13388	25/06/2020	Artigo completo publicado em periódico científico	10.1111/tid.13388	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Favipiravir', 'Tocilizumabe']	['Favipiravir', 'Tocilizumab']
Use of anakinra to prevent mechanical ventilation in severe COVID‐19: a case series	https://doi.org/10.1002/art.41422	30/06/2020	Artigo completo publicado em periódico científico	10.1002/art.41422	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Anakinra']	['Anakinra']
Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatological and rheumatological patients already under treatment	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252077/	01/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7252077/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: an observational study	https://doi.org/10.1111/joim.13145	30/06/2020	Artigo completo publicado em periódico científico	10.1111/joim.13145	0954-6820	09546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Prednisona', 'Tocilizumabe']	['Prednisone', 'Tocilizumab']
Association of Hydroxychloroquine with QTc Interval in Patients	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048476	05/06/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.048476	0009-7322	00097322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593	24/06/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593	-	-	-	-	-	-	-	-	['Colchicina', 'Colchicina', 'Colchicina']	['Colchicine', 'Colchicine', 'Colchicine']
Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial	https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13600	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13600	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Febuxostato']	['Febuxostat']
Nanotechnology for COVID-19: Therapeutics and Vaccine Research	https://doi.org/10.1021/acsnano.0c04006	22/06/2020	Artigo completo publicado em periódico científico	10.1021/acsnano.0c04006	1936-0851	19360851	ACS NANO	A1	4.611	413	17.04	-	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de vírus inativado', 'Vacina de vírus inativado', 'Vacina de vírus inativado', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273']	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'BNT162 Vaccine', 'BNT162 Vaccine', 'BNT162 Vaccine', 'ChAdOx1 Vaccine nCoV-19', 'ChAdOx1 Vaccine nCoV-19', 'ChAdOx1 nCoV-19 vaccine', 'DNA vaccine', 'DNA vaccine', 'DNA vaccine', 'RNA vaccine', 'RNA vaccine', 'RNA vaccine', 'inactivated virus vaccine' , 'Inactivated virus vaccine', 'Inactivated virus vaccine', 'INO-4800 vaccine', 'INO-4800 vaccine', 'INO-4800 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine']
Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?	https://www.frontiersin.org/articles/10.3389/fphar.2020.00791/full	26/06/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.00791/full	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19	https://www.x-mol.com/paper/1276244658808713216	25/06/2020	Artigo completo publicado em periódico científico	https://www.x-mol.com/paper/1276244658808713216	-	-	-	-	-	-	-	-	['Terapia celular']	['Cell Therapy']
A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19	http://www.ncbi.nlm.nih.gov/pubmed/32584474	25/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32584474	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Pneumococcal superinfection in COVID-19 patients: a series of 5 cases	https://doi.org/10.1016/j.medcli.2020.05.022	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.05.022	0025-7753	00257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Anakinra', 'Antibióticos', 'Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Anakinra', 'Antibiotics', 'Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']
Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID‐19 pneumonia	https://doi.org/10.1111/bjh.16978	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16978	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Hidroxicarbamida']	['Hydroxycarbamide']
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents	https://doi.org/10.1056/NEJMoa2021680	29/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021680	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Anakinra', 'Corticosteroides', 'Imunoglobulina', 'Siltuximabe', 'Tocilizumabe']	['Anakinra', 'Corticosteroids', 'Immunoglobulin', 'Siltuximab', 'Tocilizumab']
Prior treatment with immunosuppressants among COVID‐19 inpatients at one hospital in Spain	https://onlinelibrary.wiley.com/doi/10.1111/jdv.16798	28/06/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16798	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Imunossupressores']	['Immunosuppressants']
Multisystem Inflammatory Syndrome in Children in New York State	https://doi.org/10.1056/NEJMoa2021756	29/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021756	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Corticosteroides', 'Imunoglobulina']	['Corticosteroids', 'Immunoglobulin']
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19	https://doi.org/10.1016/j.cmet.2020.06.015	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cmet.2020.06.015	1550-4131	15504131	CELL METABOLISM	A1	9.297	292	22.01	-	['Estatina']	['Statin']
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218152	25/06/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218152	-	-	-	-	-	-	-	-	['Azitromicina', 'Colchicina', 'Drogas antirreumáticas modificadoras de doenças', 'Hidroxicloroquina', 'Inibidores de Janus Kinase (JAK)', 'Prednisona']	['Azithromycin', 'Colchicine', 'Disease-modifying anti-rheumatic drugs', 'Hydroxychloroquine', 'Janus Kinase Inhibitors (JAK)', 'Prednisone']
TB infection and BCG vaccination: are we protected from COVID-19?	https://doi.org/10.1016/j.puhe.2020.05.042	30/05/2020	Artigo completo publicado em periódico científico	10.1016/j.puhe.2020.05.042	0033-3506	00333506	PUBLIC HEALTH (LONDON)	A4	0.973	80	3.65	-	['Vacina BCG']	['BCG vaccine']
Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis	https://doi.org/10.1111/dth.13891	25/06/2020	Artigo completo publicado em periódico científico	10.1111/dth.13891	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Colchicina']	['Colchicine']
A case series of COVID‐19 patients with chronic hepatitis B virus infection	https://doi.org/10.1002/jmv.26201	19/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26201	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Interferon alfa', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis	https://pubmed.ncbi.nlm.nih.gov/32593209/	27/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32593209/	-	-	-	-	-	-	-	-	['Ruxolitinibe']	['Ruxolitinib']
Ruxolitinib for Tocilizumab-Refractory Severe COVID-19 Infection	https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16979	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16979	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Ruxolitinibe']	['Ruxolitinib']
Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome	https://doi.org/10.1111/bjh.16961	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16961	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']
A case of erythema multiforme major in a patient with COVID 19: The role of corticosteroid treatment	https://doi.org/10.1111/dth.13899	26/06/2020	Artigo completo publicado em periódico científico	10.1111/dth.13899	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Prednisona']	['Prednisone']
Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery	https://doi.org/10.1111/bjh.16981	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16981	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Plasma convalescente']	['Convalescent Plasma']
A case of Covid-19 patient with acute limb ischemia and heparin resistance	https://doi.org/10.1016/j.avsg.2020.06.046	23/06/2020	Artigo completo publicado em periódico científico	10.1016/j.avsg.2020.06.046	0890-5096	08905096	ANNALS OF VASCULAR SURGERY (PRINT)	A4	0.511	75	1.53	-	['Heparina']	['Heparin']
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis	https://doi.org/10.1016/j.tmaid.2020.101791	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101791	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1968	26/06/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1968	0009-9236	00099236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review	https://www.frontiersin.org/article/10.3389/fpubh.2020.00252	29/06/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fpubh.2020.00252	2296-2565	22962565	FRONTIERS IN PUBLIC HEALTH	A3	1.298	64	5.87	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world	https://doi.org/10.1016/j.nmni.2020.100709	06/06/2020	Artigo completo publicado em periódico científico	10.1016/j.nmni.2020.100709	2052-2975	20522975	NEW MICROBES NEW INFECT	B2	0.737	33	3.44	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment	https://link.springer.com/article/10.1007/s40264-020-00966-9	23/06/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40264-020-00966-9	0114-5916	01145916	Drug Safety	-	1.268	131	4.42	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Short-Term Dexamethasone in Sars-CoV-2 Patients	http://rimed.org/rimedicaljournal/2020/08/2020-08-39-extra-case-selvaraj.pdf	28/06/2020	Artigo completo publicado em periódico científico	http://rimed.org/rimedicaljournal/2020/08/2020-08-39-extra-case-selvaraj.pdf	-	-	-	-	-	-	-	-	['Dexametasona']	['Dexamethasone']
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)	https://doi.org/10.1038/s41375-020-0907-9	17/06/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-0907-9	0887-6924	08876924	LEUKEMIA	A1	4.030	202	9.5	-	['Ruxolitinibe']	['Ruxolitinib']
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia	https://doi.org/10.1093/cid/ciaa812	23/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa812	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is approved by the Food and Drug Administration for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia.                                                  Methods                   We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations &amp;lt;90% on oxygen support with most intubated. We examined clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment.                                                  Results                   Twenty-seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. Interleukin (IL)-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post-tocilizumab. However, 4 patients did not show rapid CRP declines, of whom 3 had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but 2 deaths (7.4%) occurred that were felt unrelated to tocilizumab.                                                  Conclusions                   Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.               	['Tocilizumabe']	['Tocilizumab']
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab	https://doi.org/10.1016/j.reuma.2020.06.003	17/06/2020	Artigo completo publicado em periódico científico	10.1016/j.reuma.2020.06.003	1699-258X	1699258X	Reumatologia Clinica	-	0.311	29	1.03	-	['Anakinra']	['Anakinra']
Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study	https://pubmed.ncbi.nlm.nih.gov/32584322/	28/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32584322/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study	https://doi.org/10.1007/s40199-020-00353-w	19/06/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00353-w	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Azitromicina', 'Lopinavir', 'Naproxeno', 'Prednisolona', 'Ritonavir']	['Azithromycin', 'Lopinavir', 'Naproxen', 'Prednisolone', 'Ritonavir']
Tocilizumab in patients with severe COVID-19: a retrospective cohort study	https://doi.org/10.1016/S2665-9913(20)30173-9	24/06/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30173-9	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Tocilizumabe']	['Tocilizumab']
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study	https://www.frontiersin.org/articles/10.3389/fphar.2020.00857/full	05/06/2020	Artigo completo publicado em periódico científico	10.3389/fphar.2020.00857/full	-	-	-	-	-	-	-	-	['Eculizumabe', 'Ruxolitinibe']	['Eculizumab', 'Ruxolitinib']
SARS-CoV-2 infection and stem cells: Interaction and intervention.	https://doi.org/10.1016/j.scr.2020.101859	01/06/2020	Artigo completo publicado em periódico científico	10.1016/j.scr.2020.101859	1873-5061	18735061	STEM CELL RESEARCH (AMSTERDAM. PRINT)	A2	0.482	70	1.67	-	['Terapia celular']	['Cell Therapy']
Tocilizumab’s efficacy in COVID-19 patients is determined by the presence of cytokine storm.	https://doi.org/10.1002/jmv.26209	22/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26209	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe', 'Tocilizumabe']	['Tocilizumab', 'Tocilizumab']
Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology.	https://doi.org/10.1093/rheumatology/keaa318	22/06/2020	Artigo completo publicado em periódico científico	10.1093/rheumatology/keaa318	1462-0324	14620324	RHEUMATOLOGY (OXFORD. PRINT)	A1	1.563	181	3.96	-	['Anakinra']	['Anakinra']
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.	https://onlinelibrary.wiley.com/doi/full/10.1111/ijd.15008?af=R	18/06/2020	Artigo completo publicado em periódico científico	10.1111/ijd.15008?af=R	-	-	-	-	-	-	-	-	['Ixequizumab']	['Ixequizumab']
Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis	https://doi.org/10.1007/s10072-020-04522-2	20/06/2020	Artigo completo publicado em periódico científico	10.1007/s10072-020-04522-2	1590-1874	15901874	NEUROLOGICAL SCIENCES (TESTO STAMPATO)	A3	0.847	76	2.69	-	['Rituximabe']	['Rituximab']
Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab	https://www.springermedizin.de/covid-19/rapid-radiological-improvement-of-covid-19-pneumonia-after-treat/180930966	15/06/2020	Artigo completo publicado em periódico científico	https://www.springermedizin.de/covid-19/rapid-radiological-improvement-of-covid-19-pneumonia-after-treat/180930966	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Clinical features and the treatment of children with COVID-19: A case series from Wenzhou, China	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26092	30/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26092	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Interferon alfa']	['Interferon alpha']
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab	https://doi.org/10.1007/s10067-020-05234-w	19/06/2020	Artigo completo publicado em periódico científico	10.1007/s10067-020-05234-w	0770-3198	07703198	CLINICAL RHEUMATOLOGY (PRINTED)	A4	0.873	88	3.38	 Abstract Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA). Tocilizumab was applied and intended to target both COVID-19 and RA. However, disease of this patient aggravated after usage of tocilizumab. After the discussion of a multiple disciplinary team (MDT) including rheumatologists, antimicrobial treatments were applied to target the potential opportunistic infections ( Pneumocystis jirovecii and  Aspergillus fumigatus), which were authenticated several days later via high throughput sequencing. As an important cytokine in immune responses, IL-6 can be a double-edged sword: interference in the IL-6-IL-6 receptor signaling may save patients from cytokine release storm (CRS), but can also weaken the anti-infectious immunity, particularly in rheumatic patients, who may have received a long-term treatment with immunosuppressive/modulatory agents. Thus, we suggest careful considerations before and close monitoring in the administration of tocilizumab in rheumatic patients with COVID-19. Besides tocilizumab, several disease-modifying antirheumatic drugs (DMARDs) can also be applied in the treatment of COVID-19. Therefore, we also reviewed and discussed the application of these DMARDs in COVID-19 condition.	['Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']
Bradycardia in Patients With COVID-19: A Calm Before the Storm?	https://pubmed.ncbi.nlm.nih.gov/32550090	13/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32550090	-	-	-	-	-	-	-	-	['Azitromicina', 'Dexmedetomidina', 'Hidroxicloroquina', 'Propofol']	['Azithromycin', 'Dexmedetomidine', 'Hydroxychloroquine', 'Propofol']
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19	https://doi.org/10.1111/JDV.16761	21/06/2020	Artigo completo publicado em periódico científico	10.1111/JDV.16761	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Acitretina', 'Adalimumabe', 'Apremilast', 'Brodalumabe', 'Certolizumabe Pegol', 'Ciclosporina', 'Etanercepte', 'Guselkumabe', 'Infliximabe', 'Ixequizumab', 'Metotrexato', 'Risankizumabe', 'Secuquinumabe', 'Ustekinumabe']	['Acitretin', 'Adalimumab', 'Apremilast', 'Brodalumab', 'Certolizumab Pegol', 'Cyclosporin', 'Etanercept', 'Guselkumabe', 'Infliximab', 'Ixequizumab', 'Methotrexate', 'Risankizumabe', 'Secukinumab', 'Ustekinumab']
Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion	https://ashpublications.org/blood/article/doi/10.1182/blood.2020007079/461103/Improved-Clinical-Symptoms-and-Mortality-on-Severe	23/06/2020	Artigo completo publicado em periódico científico	10.1182/blood.2020007079/461103/Improved-Clinical-Symptoms-and-Mortality-on-Severe	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
BCG Vaccination in infancy does not protect against COVID‐19. Evidence from a natural experiment in Sweden	https://ssrn.com/abstract=3621167	16/06/2020	Artigo completo publicado em periódico científico	https://ssrn.com/abstract=3621167	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Investigational therapies for the treatment of COVID-19: updates from ongoing clinical trials.	https://doi.org/10.1016/j.euf.2020.05.019	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.euf.2020.05.019	2405-4569	24054569	European Urology Focus	-	1.453	34	4.27	-	['Cloroquina', 'Hidroxicloroquina', 'Inibidores de interleucina-6', 'Plasma convalescente', 'Remdesivir']	['Chloroquine', 'Hydroxychloroquine', 'Interleukin-6 Inhibitors', 'Convalescent Plasma', 'Remdesivir']
Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.	https://doi.org/10.1186/s12985-020-01354-6	19/06/2020	Artigo completo publicado em periódico científico	10.1186/s12985-020-01354-6	1743-422X	1743422X	VIROLOGY JOURNAL	A3	1.091	88	4.9	 Abstract  Background Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time.  Case presentation Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 × 10 9/L) in a 65-year-old Chinese man, who was diagnosed with severe COVID-19. CP was intravenously given twice, and hydroxychloroquine was orally administrated for a week (0.2 g, three times a day). The lactic acid and C-reactive protein levels remained high (2.1 mmol/L and 73.23 mg/L, respectively), while the arterial oxyhemoglobin saturation decreased to 86% with a low oxygenation index (OI, 76 mmHg) on day 4 after CP transfusion. His temperature returned to normal and the OI ascended above 300 on day 11. Moreover, the RNA test remained positive in throat swab, and computed tomography revealed severe pulmonary lesions on day 11 after admission.  Conclusion These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.	['Hidroxicloroquina', 'Plasma convalescente']	['Hydroxychloroquine', 'Convalescent Plasma']
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.	https://www.sciencedirect.com/science/article/pii/S104366182031344X	18/06/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S104366182031344X	-	-	-	-	-	-	-	-	['Cloreto de sódio', 'Ganciclovir', 'Lianhua Qingwen (Medicina Tradicional Chinesa)', 'Lopinavir', 'Oseltamivir', 'Penciclovir', 'Peramivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Sodium chloride', 'Ganciclovir', 'Lianhua Qingwen (Traditional Chinese Medicine)', 'Lopinavir', 'Oseltamivir', 'Penciclovir', 'Peramivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
Vaccine development and therapeutic design for 2019‐ncov/SARS‐cov‐2: challenges and chances.	https://doi.org/10.1002/jcp.29771	18/06/2020	Artigo completo publicado em periódico científico	10.1002/jcp.29771	0021-9541	00219541	JOURNAL OF CELLULAR PHYSIOLOGY (PRINT)	A2	1.308	183	6.77	-	['Vacina']	['Vaccine']
A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.	https://doi.org/10.1002/jcph.1693	18/06/2020	Artigo completo publicado em periódico científico	10.1002/jcph.1693	0091-2700	00912700	JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.687	121	2.9	-	['Tocilizumabe']	['Tocilizumab']
Coagulopathy, thromboembolic complications and the use of heparin in COVID-19 Pneumonia,	https://doi.org/10.1016/j.jvsv.2020.05.018	17/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jvsv.2020.05.018	2213-333X	2213333X	JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS	A3	0.774	34	2.45	-	['Heparina']	['Heparin']
Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes.	https://journal.chestnet.org/article/S0012-3692(20)31670-6/fulltext	15/06/2020	Artigo completo publicado em periódico científico	https://journal.chestnet.org/article/S0012-3692(20)31670-6/fulltext	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
COVID-19 in patients with rheumatic diseases in northern Italy : a single-centre observational and case – control study.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30169-7/fulltext	18/06/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30169-7/fulltext	-	-	-	-	-	-	-	-	['Corticosteroides', 'Drogas antirreumáticas modificadoras de doenças']	['Corticosteroids', 'Disease-modifying anti-rheumatic drugs']
Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital.	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa791/5859555	18/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa791/5859555	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.	https://doi.org/10.1001/jama.2020.11301	19/06/2020	Artigo completo publicado em periódico científico	10.1001/jama.2020.11301	0098-7484	00987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.	https://link.springer.com/article/10.1007/s11606-020-05906-y	17/06/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11606-020-05906-y	0884-8734	08848734	Journal of General Internal Medicine	-	1.537	192	3.25	-	['Antitrombina', 'Ativador do plasminogênio tecidual (tPA)', 'Clopidogrel', 'Heparina']	['Antithrombin', 'Tissue Plasminogen Activator (tPA)', 'Clopidogrel', 'Heparin']
Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.	https://doi.org/10.1016/j.onehlt.2020.100141	19/06/2020	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2020.100141	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Vaccines and Therapies in Development for SARS-CoV-2 Infections	https://pubmed.ncbi.nlm.nih.gov/32560227/	16/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32560227/	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir', 'Remdesivir']
Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.	https://www.cureus.com/articles/32021-anticoagulation-options-for-coronavirus-disease-2019-covid-19-induced-coagulopathy	16/05/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/32021-anticoagulation-options-for-coronavirus-disease-2019-covid-19-induced-coagulopathy	-	-	-	-	-	-	-	-	['Heparina', 'Nafamostato']	['Heparin', 'Nafamostat']
Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.	https://doi.org/10.1111/vox.12973	15/06/2020	Artigo completo publicado em periódico científico	10.1111/vox.12973	0042-9007	00429007	VOX SANGUINIS (BASEL. 1956)	B1	0.643	86	2.47	-	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
Clinical characteristics, diagnosis, and treatment of COVID-19: A case report.	https://www.wjgnet.com/2307-8960/full/v8/i11/2325.htm	06/06/2020	Artigo completo publicado em periódico científico	https://www.wjgnet.com/2307-8960/full/v8/i11/2325.htm	-	-	-	-	-	-	-	-	['Cefoperazona', 'Imunoglobulina', 'Lopinavir', 'Moxifloxacina', 'Oseltamivir', 'Prednisona', 'Ritonavir', 'Zadaxina']	['Cefoperazone', 'Immunoglobulin', 'Lopinavir', 'Moxifloxacin', 'Oseltamivir', 'Prednisone', 'Ritonavir', 'Zadaxine']
A child with a severe multi-system inflammatory syndrome following an asymptomatic COVID-19 infection: a novel management for a new disease?	https://doi.org/10.1002/jmv.26189	17/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26189	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Heparina', 'Prednisona']	['Heparin', 'Prednisone']
COVID-19 in a young man with hypertension: A case study of missed opportunities in intensive progression.	http://www.sciencedirect.com/science/article/pii/S0964339720301014	01/06/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0964339720301014	-	-	-	-	-	-	-	-	['Lopinavir', 'Moxifloxacina', 'Oseltamivir']	['Lopinavir', 'Moxifloxacin', 'Oseltamivir']
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.	https://pubmed.ncbi.nlm.nih.gov/32546029/	17/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32546029/	-	-	-	-	-	-	-	-	['Lenzilumabe', 'Tocilizumabe']	['Lenzilumab', 'Tocilizumab']
COVID-19 in a patient with severe asthma treated with Omalizumab.	http://www.ncbi.nlm.nih.gov/pubmed/32544254	16/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32544254	-	-	-	-	-	-	-	-	['Omalizumabe']	['Omalizumab']
Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13834	15/06/2020	Artigo completo publicado em periódico científico	10.1111/dth.13834	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Use of amantadine in a patient with SARS‐Cov‐2.	https://doi.org/10.1002/jmv.26179	15/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26179	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Amantadina', 'Amantadina']	['Amantadine', 'Amantadine']
Hydroxychloroquine treatment in COVID‐19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China.	https://doi.org/10.1002/jmv.26193	17/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26193	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Tocilizumab in patients with severe COVID-19: a single-center observational analysis.	https://doi.org/10.1002/jmv.26191	17/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26191	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Clinical characteristics of 17 patients with COVID-19and systemic autoimmune diseases: aretrospective study.	https://ard.bmj.com/content/annrheumdis/early/2020/06/15/annrheumdis-2020-217425.full.pdf	25/05/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/annrheumdis/early/2020/06/15/annrheumdis-2020-217425.full.pdf	-	-	-	-	-	-	-	-	[]	[]
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.	http://www.ncbi.nlm.nih.gov/pubmed/32536150	16/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32536150	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.	https://doi.org/10.1002/phar.2438	15/06/2020	Artigo completo publicado em periódico científico	10.1002/phar.2438	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Baricitinibe']	['Baricitinib']
Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.	https://doi.org/10.2147/DDDT.S254354	29/05/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S254354	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Antimaláricos', 'Antivirais']	['Antimalarials', 'Antivirals']
Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.	https://doi.org/10.1177/1753466620933510	16/06/2020	Artigo completo publicado em periódico científico	10.1177/1753466620933510	1753-4666	17534666	THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE	A2	1.219	41	5.26	-	['Óxido nítrico']	['Nitric oxide']
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.	https://europepmc.org/article/pmc/pmc7293467	13/06/2020	Artigo completo publicado em periódico científico	https://europepmc.org/article/pmc/pmc7293467	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Ritonavir']
Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19.	http://dx.doi.org/10.1097/MD.0000000000020481	12/06/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000020481	0025-7974	00257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Antibióticos', 'Interferon alfa', 'Medicina Tradicional Chinesa']	['Antibiotics', 'Interferon alpha', 'Traditional Chinese Medicine']
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.	https://doi.org/10.1016/S2665-9913(20)30170-3	16/06/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30170-3	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Mavrilimumabe']	['Mavrilimumab']
Subcutaneous administrationof interferon beta-1a for COVID-19: A noncontrolled prospective trial.	https://doi.org/10.1016/j.intimp.2020.106688	07/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106688	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon beta']	['Interferon beta']
The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study.	https://jptcp.com/index.php/jptcp/article/view/684	03/06/2020	Artigo completo publicado em periódico científico	https://jptcp.com/index.php/jptcp/article/view/684	-	-	-	-	-	-	-	-	['Azitromicina', 'Lincocin']	['Azithromycin', 'Lincocin']
Vaccination strategies to combat novel corona virus SARS-CoV-2.	https://doi.org/10.1016/j.lfs.2020.117956	12/06/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.117956	0024-3205	00243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Vacina de DNA', 'Vacina de RNA']	['DNA vaccine', 'RNA vaccine']
Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir.	https://doi.org/10.1016/j.ejmech.2020.112527	06/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejmech.2020.112527	0223-5234	02235234	EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY	A1	1.054	175	6.74	-	['Remdesivir']	['Remdesivir']
Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.	https://doi.org/10.1111/TRF.15927	13/06/2020	Artigo completo publicado em periódico científico	10.1111/TRF.15927	0041-1132	00411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.	https://doi.org/10.1016/j.ijantimicag.2020.106053	10/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106053	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina']	['Azithromycin']
Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report.	https://doi.org/10.1186/s13256-020-02396-8	11/06/2020	Artigo completo publicado em periódico científico	10.1186/s13256-020-02396-8	1752-1947	17521947	JOURNAL OF MEDICAL CASE REPORTS	A4	0.289	34	1.13	 Abstract  Background Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, was declared a global pandemic by the World Health Organization in March 2020.  Case presentation We report a case of a 51-year-old Chinese woman who was evacuated from Wuhan, China and diagnosed with coronavirus disease 2019 infection at a Southern California quarantine facility. Her clinical course was notable for high fevers, night sweats, productive cough, transient leukopenia, lymphopenia, thrombocytopenia, and transaminitis. Evolving hypoxia and infiltrates on chest imaging warranted the trial of an investigational antiviral drug - remdesivir. Our patient recovered and was discharged after 2 weeks of hospitalization.  Conclusions This case highlights our patient’s clinical course, including diagnostic work-up, medical management, and challenges in defining non-infectivity in a relatively unknown disease.	['Remdesivir']	['Remdesivir']
Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.	https://www.sciencedirect.com/science/article/pii/S0042682220300933	25/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0042682220300933	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
A Case Series of Patients Coinfected With Influenza and COVID-19.	https://pubmed.ncbi.nlm.nih.gov/32522037/	10/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32522037/	-	-	-	-	-	-	-	-	['Ceftriaxona', 'Hidroxicloroquina', 'Oseltamivir']	['Ceftriaxone', 'Hydroxychloroquine', 'Oseltamivir']
Can steroids reverse the severe COVID-19 induced 'cytokine storm'?	https://pubmed.ncbi.nlm.nih.gov/32530507/	12/06/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32530507/	-	-	-	-	-	-	-	-	['Prednisona']	['Prednisone']
COVID-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role?	https://doi.org/10.1016/j.msard.2020.102250	03/06/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102250	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Natalizumabe']	['Natalizumab']
Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: a multicentre, retrospective study.	https://onlinelibrary.wiley.com/doi/full/10.1111/tbed.13674	12/06/2020	Artigo completo publicado em periódico científico	10.1111/tbed.13674	1865-1674	18651674	Transboundary and Emerging Diseases	-	0.953	70	4.75	-	['Corticosteroides', 'Imunoglobulina', 'Interferon alfa', 'Lopinavir', 'Oseltamivir', 'Ritonavir']	['Corticosteroids', 'Immunoglobulin', 'Interferon alpha', 'Lopinavir', 'Oseltamivir', 'Ritonavir']
Association between renin-angiotensin system inhibitors and COVID-19 complications.	https://academic.oup.com/ehjcvp/article/doi/10.1093/ehjcvp/pvaa062/5856622	12/06/2020	Artigo completo publicado em periódico científico	10.1093/ehjcvp/pvaa062/5856622	-	-	-	-	-	-	-	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Eficacia de los pulsos de corticoides en pacientes con síndrome de liberación de citocinas inducido por infección por SARS-CoV-2.	http://www.sciencedirect.com/science/article/pii/S00257753203028399	27/05/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S00257753203028399	-	-	-	-	-	-	-	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']
Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?	https://doi.org/10.1111/ajt.16141	12/06/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16141	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Ciclosporina']	['Cyclosporin']
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.	https://doi.org/10.1080/1120009X.2020.1775424	12/06/2020	Artigo completo publicado em periódico científico	10.1080/1120009X.2020.1775424	1120-009X	1120009X	JOURNAL OF CHEMOTHERAPY (TESTO STAMPATO)	B1	0.429	52	2.02	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.	https://doi.org/10.1007/s13238-020-00738-2	09/06/2020	Artigo completo publicado em periódico científico	10.1007/s13238-020-00738-2	1674-800X	1674800X	Protein and Cell	-	2.636	74	7.72	 Abstract The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, anti-apoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.	['Terapia celular']	['Cell Therapy']
Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.	https://journals.physiology.org/doi/abs/10.1152/ajplung.00199.2020	10/06/2020	Artigo completo publicado em periódico científico	10.1152/ajplung.00199.2020	1040-0605	10400605	AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY	A1	1.639	169	5.36	  Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy. 	['Heparina']	['Heparin']
Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review	https://www.tandfonline.com/doi/full/10.1080/14767058.2020.1774875	20/05/2020	Artigo completo publicado em periódico científico	10.1080/14767058.2020.1774875	1476-7058	14767058	JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE	B1	0.610	85	2.05	-	['Amoxicilina', 'Azitromicina', 'Betametasona', 'Ceftriaxona', 'Cloroquina', 'Estatina', 'Heparina', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Metformina', 'Pioglitazona', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Amoxicillin', 'Azithromycin', 'Betamethasone', 'Ceftriaxone', 'Chloroquine', 'Statin', 'Heparin', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Metformin', 'Pioglitazone', ' Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.	https://doi.org/10.1111/vox.12968	09/06/2020	Artigo completo publicado em periódico científico	10.1111/vox.12968	0042-9007	00429007	VOX SANGUINIS (BASEL. 1956)	B1	0.643	86	2.47	-	['Plasma convalescente']	['Convalescent Plasma']
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.	https://doi.org/10.1111/jth.14954	11/06/2020	Artigo completo publicado em periódico científico	10.1111/jth.14954	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Heparina']	['Heparin']
COVID-19 in a severe eosinophilic asthmatic receiving benralizumab – a case study.	https://doi.org/10.1080/02770903.2020.1781165	07/06/2020	Artigo completo publicado em periódico científico	10.1080/02770903.2020.1781165	0277-0903	02770903	THE JOURNAL OF ASTHMA	A3	0.554	73	2.11	-	['Benralizumabe']	['Benralizumab']
Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients	https://doi.org/10.1016/j.ijid.2020.06.006	03/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.006	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Zinco']	['Zinc']
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation	https://www.nature.com/articles/s41375-020-0891-0	09/06/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41375-020-0891-0	-	-	-	-	-	-	-	-	['Ruxolitinibe']	['Ruxolitinib']
Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.	https://doi.org/10.1111/all.14452	10/06/2020	Artigo completo publicado em periódico científico	10.1111/all.14452	0105-4538	01054538	ALLERGY (COPENHAGEN)	A1	3.122	183	8.1	-	['Antibióticos', 'Interferon alfa', 'Medicina Tradicional Chinesa']	['Antibiotics', 'Interferon alpha', 'Traditional Chinese Medicine']
Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.	http://dx.doi.org/10.21037/atm-20-3305	08/05/2020	Artigo completo publicado em periódico científico	10.21037/atm-20-3305	2305-5839	23055839	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review.	http://dx.doi.org/10.21037/atm-20-3300	08/05/2020	Artigo completo publicado em periódico científico	10.21037/atm-20-3300	2305-5839	23055839	-	-	-	-	-	-	['Antibióticos']	['Antibiotics']
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.	https://link.springer.com/article/10.1007/s11481-020-09930-x	09/06/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11481-020-09930-x	1557-1890	15571890	JOURNAL OF NEUROIMMUNE PHARMACOLOGY	A2	1.381	77	5.86	-	['Hidroxicloroquina']	['Hydroxychloroquine']
The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.	https://europepmc.org/article/pmc/pmc7276657	08/06/2020	Artigo completo publicado em periódico científico	https://europepmc.org/article/pmc/pmc7276657	-	-	-	-	-	-	-	-	['Agentes para tratamento da insuficiência venosa', 'Agentes para tratamento da insuficiência venosa', 'Anti-inflamatórios', 'Anti-inflamatórios', 'Antibióticos', 'Antibióticos', 'Anticoagulantes', 'Anticoagulantes', 'Antimaláricos', 'Antimaláricos', 'Antineoplásicos', 'Antineoplásicos', 'Antirretrovirais', 'Antirretrovirais', 'Antirreumáticos', 'Antirreumáticos', 'Carrimicina', 'Carrimicina', 'Cloroquina', 'Cloroquina', 'Danoprevir', 'Danoprevir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidor da fosfodiesterase', 'Inibidor da fosfodiesterase', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Sedativo-hipnótico', 'Sedativo-hipnótico', 'Tetrandrina', 'Tetrandrina', 'Umifenovir', 'Umifenovir']	['Agents for the treatment of venous insufficiency', 'Agents for the treatment of venous insufficiency', 'Anti-inflammatory', 'Anti-inflammatory', 'Antibiotics', 'Antibiotics', 'Anticoagulants', 'Anticoagulants', 'Antimalarials' , 'Antimalarials', 'Antineoplastics', 'Antineoplastics', 'Antiretrovirals', 'Antiretrovirals', 'Antirheumatics', 'Antirheumatics', 'Carrimycin', 'Carrimycin', 'Chloroquine', 'Chloroquine', 'Danoprevir', ' Danoprevir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Phosphodiesterase inhibitor', 'Phosphodiesterase inhibitor', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Sedative- hypnotic', 'Sedative-hypnotic', 'Tetrandrine', 'Tetrandrine', 'Umifenovir', 'Umifenovir']
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.	https://doi.org/10.3389/fimmu.2020.01091	19/06/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01091	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Terapia celular']	['Cell Therapy']
COVID-19 related coagulopathy: a distinct entity?	https://doi.org/10.3390/jcm9061651	28/04/2020	Artigo completo publicado em periódico científico	10.3390/jcm9061651	2077-0383	20770383	JOURNAL OF CLINICAL MEDICINE	A1	1.040	75	4.84	 The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.	['Heparina']	['Heparin']
The Current Update of Vaccines for SARS-CoV-2.	https://doi.org/10.29333/ejgm/8233	02/05/2020	Artigo completo publicado em periódico científico	10.29333/ejgm/8233	2516-3507	25163507	Electronic Journal of General Medicine	-	0.297	21	1.74	-	['Vacina ChAdOx1 nCoV-19', 'Vacina Curevac', 'Vacina de adenovírus', 'Vacina de DNA', 'Vacina de RNA', 'Vacina INO-4800', 'Vacina mRNA-1273', 'Vacina NVX-CoV2373']	['ChAdOx1 nCoV-19 vaccine', 'Curevac vaccine', 'Adenovirus vaccine', 'DNA vaccine', 'RNA vaccine', 'INO-4800 vaccine', 'mRNA-1273 vaccine', 'NVX- CoV2373']
A case of Bacillus cereus bacteremia in a COVID-19 patient treated with steroids.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261077/	30/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7261077/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID -19.	https://doi.org/10.1111/bjh.16927	09/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16927	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Argatrobana']	['Argatroban']
Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.	https://doi.org/10.1002/jmv.26149	09/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26149	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19	https://onlinelibrary.wiley.com/doi/full/10.1111/all.14439	08/06/2020	Artigo completo publicado em periódico científico	10.1111/all.14439	0105-4538	01054538	ALLERGY (COPENHAGEN)	A1	3.122	183	8.1	-	['Agentes anti-interleucinas', 'Agentes anti-interleucinas', 'Agentes anti-interleucinas', 'Anti-inflamatórios', 'Anti-inflamatórios', 'Anti-inflamatórios', 'Anticoagulantes', 'Anticoagulantes', 'Anticoagulantes', 'Antiplaquetários', 'Antiplaquetários', 'Antiplaquetários', 'Antivirais', 'Antivirais', 'Antivirais', 'Imunomoduladores', 'Imunomoduladores', 'Imunomoduladores']	['Anti-interleukin agents', 'Anti-interleukin agents', 'Anti-interleukin agents', 'Anti-inflammatory', 'Anti-inflammatory', 'Anti-inflammatory', 'Anticoagulant', 'Anticoagulant', 'Anticoagulant ', 'Antiplatelet agents', 'Antiplatelet agents', 'Antiplatelet agents', 'Antivirals', 'Antivirals', 'Antivirals', 'Immunomodulators', 'Immunomodulators', 'Immunomodulators']
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.	https://doi.org/10.1001/jama.2020.10369	08/06/2020	Artigo completo publicado em periódico científico	10.1001/jama.2020.10369	0098-7484	00987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Anakinra', 'Corticosteroides', 'Imunoglobulina', 'Infliximabe']	['Anakinra', 'Corticosteroids', 'Immunoglobulin', 'Infliximab']
Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City	https://jamanetwork.com/journals/jama/fullarticle/2767207	08/06/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2767207	-	-	-	-	-	-	-	-	['Corticosteroides', 'Imunoglobulina', 'Tocilizumabe']	['Corticosteroids', 'Immunoglobulin', 'Tocilizumab']
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.	https://doi.org/10.1093/ajh/hpaa096	08/06/2020	Artigo completo publicado em periódico científico	10.1093/ajh/hpaa096	0895-7061	08957061	AMERICAN JOURNAL OF HYPERTENSION	A3	0.862	141	2.38	 Abstract                                   BACKGROUND                   The effect of chronic use of renin–angiotensin–aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.                                                  METHODS                   A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.                                                  RESULTS                   All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09–0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17–1.83, P = 0.341).                                                  CONCLUSIONS                   Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A study on clinical effect of Arbidol combined with adjuvant therapy on COVID‐19.	https://doi.org/10.1002/jmv.26142	08/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26142	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Umifenovir']	['Umifenovir']
Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome	https://doi.org/10.1016/j.chest.2020.05.573	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.05.573	0012-3692	00123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Almitrina']	['Almitrine']
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.	http://iv.iiarjournals.org/content/34/3_suppl/1567	20/05/2020	Artigo completo publicado em periódico científico	http://iv.iiarjournals.org/content/34/3_suppl/1567	-	-	-	-	-	-	-	-	['Cobre', 'Cobre', 'Colchicina', 'Colchicina', 'Molnupiravir', 'Molnupiravir', 'N-acetilcisteína', 'N-acetilcisteína', 'Óxido nítrico', 'Óxido nítrico', 'Remdesivir', 'Remdesivir']	['Copper', 'Copper', 'Colchicine', 'Colchicine', 'Molnupiravir', 'Molnupiravir', 'N-Acetylcysteine', 'N-Acetylcysteine', 'Nitric Oxide', 'Nitric Oxide', 'Remdesivir' , 'Remdesivir']
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.	https://doi.org/10.1002/jmv.26141	05/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26141	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Danoprevir', 'Lopinavir', 'Ritonavir']	['Danoprevir', 'Lopinavir', 'Ritonavir']
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19	https://www.intmedpress.com/serveFile.cfm?sUID=375134ca-b54c-4c12-9965-c20565fb4560	04/06/2020	Artigo completo publicado em periódico científico	https://www.intmedpress.com/serveFile.cfm?sUID=375134ca-b54c-4c12-9965-c20565fb4560	-	-	-	-	-	-	-	-	['Interferon alfa', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Tocilizumab in the treatment of a critical COVID-19 patient: a case report.	https://www.europeanreview.org/article/21372	08/06/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/21372	-	-	-	-	-	-	-	-	['Cloroquina', 'Gamaglobulina', 'Prednisona', 'Tocilizumabe', 'Umifenovir']	['Chloroquine', 'Gamaglobulin', 'Prednisone', 'Tocilizumab', 'Umifenovir']
High‐dose, short‐term corticosteroids for ARDS caused by COVID‐19: a case series. Respirology Case Reports.	https://doi.org/10.1002/rcr2.596	04/06/2020	Artigo completo publicado em periódico científico	10.1002/rcr2.596	2051-3380	20513380	Respirology Case Reports	-	0.261	12	0.84	-	['Prednisolona', 'Prednisona']	['Prednisolone', 'Prednisone']
Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.	https://doi.org/10.1111/tid.13348	05/06/2020	Artigo completo publicado em periódico científico	10.1111/tid.13348	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Tocilizumabe']	['Tocilizumab']
Famotidine use and quantitative symptom tracking for COVID-19 in non- hospitalised patients: a case series.	https://gut.bmj.com/content/early/2020/06/10/gutjnl-2020-321852	04/06/2020	Artigo completo publicado em periódico científico	https://gut.bmj.com/content/early/2020/06/10/gutjnl-2020-321852	-	-	-	-	-	-	-	-	['Famotidina', 'Famotidina']	['Famotidine', 'Famotidine']
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report.	https://doi.org/10.1007/s00277-020-04070-x	04/06/2020	Artigo completo publicado em periódico científico	10.1007/s00277-020-04070-x	0939-5555	09395555	ANNALS OF HEMATOLOGY (PRINT)	A4	0.994	84	2.75	-	['Imunoglobulina', 'Prednisona', 'Umifenovir']	['Immunoglobulin', 'Prednisone', 'Umifenovir']
Tocilizumab administration in a refractory case of COVID-19.	https://doi.org/10.1016/j.ijantimicag.2020.106043	02/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106043	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Tocilizumabe']	['Tocilizumab']
Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.	https://doi.org/10.1007/s42399-020-00333-w	29/05/2020	Artigo completo publicado em periódico científico	10.1007/s42399-020-00333-w	2523-8973	25238973	-	-	-	-	-	-	['Antibióticos', 'Azitromicina', 'Cloroquina', 'Cobicistato', 'Darunavir', 'Enoxaparina', 'Hidroxicloroquina', 'Lopinavir', 'Prednisona', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe']	['Antibiotics', 'Azithromycin', 'Chloroquine', 'Cobicistat', 'Darunavir', 'Enoxaparin', 'Hydroxychloroquine', 'Lopinavir', 'Prednisone', 'Remdesivir', 'Ribavirin', 'Ritonavir', ' Tocilizumab']
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.	http://www.ncbi.nlm.nih.gov/pubmed/32496938	04/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32496938	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Anticardiolipin antibodies and COVID-19 - A Case Report from America.	https://doi.org/10.1002/jmv.26135	04/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26135	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Ácido ascórbico', 'Azitromicina', 'Ceftriaxona', 'Enoxaparina', 'Hidroxicloroquina']	['Ascorbic acid', 'Azithromycin', 'Ceftriaxone', 'Enoxaparin', 'Hydroxychloroquine']
Canakinumab in subgroup of patients with COVID-19.	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-526896	07/06/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-526896	-	-	-	-	-	-	-	-	['Canaquinumabe']	['Canakinumab']
Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.	https://www.ijidonline.com/article/S1201-9712(20)30425-2/abstract	01/06/2020	Artigo completo publicado em periódico científico	https://www.ijidonline.com/article/S1201-9712(20)30425-2/abstract	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.	https://onlinelibrary.wiley.com/doi/full/10.1002/ctm2.35	04/06/2020	Artigo completo publicado em periódico científico	10.1002/ctm2.35	2001-1326	20011326	Clinical and Translational Medicine	-	0.130	3	1.0	-	['Prednisona', 'Talidomida']	['Prednisone', 'Thalidomide']
HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern	https://academic.oup.com/jpubhealth/article/doi/10.1093/pubmed/fdaa074/5850534	03/06/2020	Artigo completo publicado em periódico científico	10.1093/pubmed/fdaa074/5850534	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.	https://academic.oup.com/eurheartj/article/41/22/2058/5851436	04/06/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/eurheartj/article/41/22/2058/5851436	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.	https://www.europeanreview.org/article/21373	07/06/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/21373	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.	https://doi.org/10.1016/j.tmaid.2020.101738	05/05/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101738	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.	http://www.cmaj.ca/content/early/2020/06/03/cmaj.200647.1.abstract	06/07/2020	Artigo completo publicado em periódico científico	http://www.cmaj.ca/content/early/2020/06/03/cmaj.200647.1.abstract	-	-	-	-	-	-	-	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
USO DE IVERMECTINA PARA EL TRATAMIENTO DE PACIENTES ADULTOS CON COVID-19	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB17_v02_vermectina.pdf	08/05/2020	Artigo completo publicado em periódico científico	http://www.essalud.gob.pe/ietsi/pdfs/covid_19/RB17_v02_vermectina.pdf	-	-	-	-	-	-	-	-	['Ivermectina']	['Ivermectin']
Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.	https://www.scielo.br/scielo.php?script=sci_abstract&pid=S0037-86822020000100711&lng=pt&nrm=iso&tlng=en	01/06/2020	Artigo completo publicado em periódico científico	https://www.scielo.br/scielo.php?script=sci_abstract&pid=S0037-86822020000100711&lng=pt&nrm=iso&tlng=en	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.	https://doi.org/10.1016/j.transci.2020.102821	29/05/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102821	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Favipiravir', 'Plasma convalescente', 'Tocilizumabe']	['Favipiravir', 'Convalescent plasma', 'Tocilizumab']
The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.	https://doi.org/10.1016/j.crwh.2020.e00221	16/05/2020	Artigo completo publicado em periódico científico	10.1016/j.crwh.2020.e00221	2214-9112	22149112	Case Reports in Women's Health	-	0.318	9	1.38	-	['Plasma convalescente', 'Remdesivir']	['Convalescent Plasma', 'Remdesivir']
Remdesivir and Tocilizumab: Mix or Match.	https://doi.org/10.1002/jmv.26117	03/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26117	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Remdesivir', 'Tocilizumabe']	['Remdesivir', 'Tocilizumab']
Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26127	03/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26127	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Interferon', 'Lopinavir', 'Ritonavir']	['Interferon', 'Lopinavir', 'Ritonavir']
COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.	https://doi.org/10.1002/jmv.26129	03/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26129	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Interferon', 'Oseltamivir', 'Ribavirina', 'Umifenovir']	['Interferon', 'Oseltamivir', 'Ribavirin', 'Umifenovir']
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial	https://jamanetwork.com/journals/jama/article-abstract/2766943	03/06/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/article-abstract/2766943	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	https://doi.org/10.1056/NEJMoa2016638	03/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2016638	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.	https://doi.org/10.1016/j.imr.2020.100426	20/05/2020	Artigo completo publicado em periódico científico	10.1016/j.imr.2020.100426	2213-4220	22134220	INTEGRATIVE MEDICINE RESEARCH	B4	0.397	7	3.17	-	['Agentes imunológicos', 'Agentes imunológicos', 'Anticorpos', 'Anticorpos', 'ASC09F', 'ASC09F', 'Azivudina', 'Azivudina', 'Baloxavir marboxil', 'Baloxavir marboxil', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Danoprevir', 'Danoprevir', 'Darunavir', 'Darunavir', 'Favipiravir', 'Favipiravir', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Oxigenação por membrana extracorpórea (ECMO)', 'Oxigenação por membrana extracorpórea (ECMO)', 'Oxigenoterapia', 'Oxigenoterapia', 'Plasma convalescente', 'Plasma convalescente', 'Ribavirina', 'Ribavirina', 'Ritonavir', 'Ritonavir', 'Sangue do cordão umbilical', 'Sangue do cordão umbilical', 'Terapia celular', 'Terapia celular', 'Terapia de inalação hidrogênio-oxigênio', 'Terapia de inalação hidrogênio-oxigênio', 'Terapia de inalação óxido nítrico', 'Terapia de inalação óxido nítrico', 'Terapia psicológica', 'Terapia psicológica', 'Triazavirina', 'Triazavirina', 'Umifenovir', 'Umifenovir', 'Vitaminas', 'Vitaminas']	['Immune agents', 'Immune agents', 'Antibodies', 'Antibodies', 'ASC09F', 'ASC09F', 'Azivudine', 'Azivudine', 'Baloxavir marboxil', 'Baloxavir marboxil', 'Chloroquine', ' Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Danoprevir', 'Danoprevir', 'Darunavir', 'Darunavir', 'Favipiravir', 'Favipiravir', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir' , 'Extracorporeal membrane oxygenation (ECMO)', 'Extracorporeal membrane oxygenation (ECMO)', 'Oxygen therapy', 'Oxygen therapy', 'Convalescent plasma', 'Convalescent plasma', 'Ribavirin', 'Ribavirin', 'Ritonavir' , 'Ritonavir', 'Umbilical cord blood', 'Umbilical cord blood', 'Cell therapy', 'Cell therapy', 'Hydrogen-oxygen inhalation therapy', 'Hydrogen-oxygen inhalation therapy', 'Hydrogen-oxygen 'Nitric oxide inhalation therapy', 'Nitric oxide inhalation therapy', 'Psychological therapy', 'Psychological therapy', 'Triazavirin', 'Triazavirin', 'Umifenovir', 'Umifenovir', 'Vitamins', 'Vitamins']
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.	http://www.ncbi.nlm.nih.gov/pubmed/32474885	30/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32474885	-	-	-	-	-	-	-	-	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Imunoglobulina', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Immunoglobulin', 'Tocilizumab']
COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.	https://doi.org/10.1007/s40122-020-00173-5	24/05/2020	Artigo completo publicado em periódico científico	10.1007/s40122-020-00173-5	2193-8237	21938237	Pain and Therapy	-	0.651	26	3.74	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Use of corticosteroids in asthma and COPD patients with or without COVID-19.	https://doi.org/10.1016/j.rmed.2020.106045	24/05/2020	Artigo completo publicado em periódico científico	10.1016/j.rmed.2020.106045	0954-6111	09546111	RESPIRATORY MEDICINE	A2	1.112	127	3.99	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients.	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26111	26/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26111	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Persisting SARS-CoV-2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature.	https://doi.org/10.1111/bjh.16896	01/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16896	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Rituximabe']	['Rituximab']
Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251409/	27/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7251409/	-	-	-	-	-	-	-	-	['Dexmedetomidina']	['Dexmedetomidine']
Covid-19 infection in psoriasis patients treated with cyclosporin.	https://doi.org/10.1111/dth.13739	01/06/2020	Artigo completo publicado em periódico científico	10.1111/dth.13739	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Ciclosporina']	['Cyclosporin']
Feasibility of Tocilizumab in ICU patients with COVID-19.	https://doi.org/10.1002/jmv.26110	02/06/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26110	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.	https://doi.org/10.1111/jce.14594	02/06/2020	Artigo completo publicado em periódico científico	10.1111/jce.14594	1045-3873	10453873	JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (PRINT)	A3	1.019	143	2.1	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.	https://doi.org/10.1016/j.ejim.2020.05.021	01/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.05.021	0953-6205	09536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Tocilizumabe']	['Tocilizumab']
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.	https://doi.org/10.1053/j.gastro.2020.05.066	23/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.066	0016-5085	00165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Corticosteroides']	['Corticosteroids']
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.	https://doi.org/10.1016/j.phrs.2020.104872	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104872	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Cloroquina', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence	https://doi.org/10.1016/j.therap.2020.05.010	23/05/2020	Artigo completo publicado em periódico científico	10.1016/j.therap.2020.05.010	0040-5957	00405957	Therapie	-	0.442	36	1.73	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Trials and tribulations: so many potential treatments, so few answers	https://link.springer.com/article/10.1007/s00264-020-04625-7	24/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s00264-020-04625-7	0341-2695	03412695	INTERNATIONAL ORTHOPAEDICS	A2	0.956	96	3.4	-	['Antimaláricos']	['Antimalarials']
Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.	https://doi.org/10.1016/j.hrthm.2020.04.0466	04/05/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.04.0466	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.	https://doi.org/10.1111/bjh.16901	01/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16901	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']
Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring	https://doi.org/10.1101/2020.04.22.20075671	25/04/2020	Artigo completo publicado em periódico científico	10.1101/2020.04.22.20075671	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19.	https://doi.org/10.1111/liv.14516	17/05/2020	Artigo completo publicado em periódico científico	10.1111/liv.14516	1478-3223	14783223	LIVER INTERNATIONAL (PRINT)	A2	2.064	118	6.49	-	['Tocilizumabe']	['Tocilizumab']
Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2.	https://doi.org/10.1111/ajt.16080	31/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16080	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']
Successful use of methylprednisolone for treating severe COVID-19.	https://doi.org/10.1016/j.jaci.2020.05.021	28/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.021	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Prednisona']	['Prednisone']
Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.	http://www.ncbi.nlm.nih.gov/pubmed/32470602%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7250091	26/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32470602%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7250091	-	-	-	-	-	-	-	-	['Nafamostato']	['Nafamostat']
The association between treatment with heparin and survival in patients with Covid-19.	http://www.ncbi.nlm.nih.gov/pubmed/32476080	02/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32476080	-	-	-	-	-	-	-	-	['Heparina', 'Heparina']	['Heparin', 'Heparin']
Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission—A Preliminary Report of a Retrospective Cohort Study.	https://doi.org/10.1007/s11596-020-2203-3	30/05/2020	Artigo completo publicado em periódico científico	10.1007/s11596-020-2203-3	2096-5230	20965230	Current Medical Science	-	0.538	32	2.61	-	['Umifenovir']	['Umifenovir']
Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.	https://doi.org/10.1186/s13613-020-00678-4	24/05/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00678-4	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.	http://www.ncbi.nlm.nih.gov/pubmed/32451823	02/06/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32451823	-	-	-	-	-	-	-	-	['Profilaxia para tromboembolismo']	['Prophylaxis for thromboembolism']
Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment	https://doi.org/10.1007/s40264-020-00952-1	28/05/2020	Artigo completo publicado em periódico científico	10.1007/s40264-020-00952-1	0114-5916	01145916	Drug Safety	-	1.268	131	4.42	-	['Remdesivir']	['Remdesivir']
Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient	https://doi.org/10.1002/jmv.26086	29/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26086	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Corticosteroides']	['Corticosteroids']
Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.	https://doi.org/10.1186/s13287-020-01725-4	27/05/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01725-4	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton’s jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People’s Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.	['Terapia celular']	['Cell Therapy']
Treatment of COVID-19 Patients with Convalescent Plasma	https://doi.org/10.1016/j.ajpath.2020.05.014	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ajpath.2020.05.014	0002-9440	00029440	THE AMERICAN JOURNAL OF PATHOLOGY (PRINT)	A1	1.619	289	4.82	-	['Plasma convalescente']	['Convalescent Plasma']
A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois	https://www.liebertpub.com/doi/10.1089/APC.2020.0103	29/05/2020	Artigo completo publicado em periódico científico	10.1089/APC.2020.0103	1087-2914	10872914	AIDS PATIENT CARE AND STDS	A1	2.544	87	4.91	-	['Azitromicina', 'Cefalosporina', 'Hidroxicloroquina']	['Azithromycin', 'Cephalosporin', 'Hydroxychloroquine']
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.	https://www.journalofinfection.com/article/S0163-4453(20)30318-2/fulltext	27/05/2020	Artigo completo publicado em periódico científico	https://www.journalofinfection.com/article/S0163-4453(20)30318-2/fulltext	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study	https://doi.org/10.1016/j.phrs.2020.104965	29/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104965	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Ácido acetilsalicílico', 'Anticoagulantes']	['Acetylsalicylic acid', 'Anticoagulants']
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort	https://doi.org/10.1016/S2352-3018(20)30164-8	28/05/2020	Artigo completo publicado em periódico científico	10.1016/S2352-3018(20)30164-8	2352-3018	23523018	THE LANCET HIV	A1	5.296	62	4.76	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Anakinra for severe forms of COVID-19 : a cohort study	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	29/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome	https://doi.org/10.1016/j.jinf.2020.05.056	28/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.05.056	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, singleblind, randomized controlled trial	https://doi.org/10.1016/j.jaci.2020.05.019	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.019	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Ruxolitinibe']	['Ruxolitinib']
Ramipril in High Risk Patients with COVID-19	https://doi.org/10.1016/j.jacc.2020.05.040	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jacc.2020.05.040	0735-1097	07351097	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (PRINT)	A1	9.756	451	9.53	-	['Ramipril']	['Ramipril']
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review	https://doi.org/10.1016/j.cmi.2020.05.016	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.05.016	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome	https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0146	29/05/2020	Artigo completo publicado em periódico científico	10.1002/sctm.20-0146	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.                                  <jats:title />                   Significance statement The potential benefits of mesenchymal stromal cell (MSC) therapy for patients with COVID-19 acute respiratory distress syndrome support the rapid commencement of clinical trials, as well as the compassionate use of MSCs that already have documented safety profiles from FDA-approved studies.               	['Terapia celular']	['Cell Therapy']
Remdesivir para el tratamiento de infeccion por Covid-19. Informe de Revisión Rápida	http://www.med.unlp.edu.ar/index.php/news/43-generales/gen-home/2438-informe-del-cufar	18/05/2020	Artigo completo publicado em periódico científico	http://www.med.unlp.edu.ar/index.php/news/43-generales/gen-home/2438-informe-del-cufar	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease‑19 (COVID‑19)	https://doi.org/10.1007/s40261-020-00927-1	28/05/2020	Artigo completo publicado em periódico científico	10.1007/s40261-020-00927-1	1173-2563	11732563	CLINICAL DRUG INVESTIGATION	A4	0.718	60	2.86	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Pharmacological treatment for the Novel Coronavirus Disease 2019 (COVID-19 Infection)	https://pharmacy.mahidol.ac.th/journal/journalabstract.php?jvol=47&jpart=2&jconnum=1	29/05/2020	Artigo completo publicado em periódico científico	https://pharmacy.mahidol.ac.th/journal/journalabstract.php?jvol=47&jpart=2&jconnum=1	-	-	-	-	-	-	-	-	['Cloroquina', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sofosbuvir', 'Umifenovir']	['Chloroquine', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sofosbuvir', 'Umifenovir']
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?	https://doi.org/10.1016/j.phrs.2020.104906	13/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104906	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']
Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis	https://doi.org/10.1093/aje/kwaa093	27/05/2020	Artigo completo publicado em periódico científico	10.1093/aje/kwaa093	0002-9262	00029262	AMERICAN JOURNAL OF EPIDEMIOLOGY	A1	1.831	267	3.68	 Abstract More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it. High-risk patients with progressing symptomatic disease currently have only hospitalization treatment, with its high mortality, available to them. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir and hydroxychloroquine (HCQ) + azithromycin (AZ). Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials in outpatients have been registered. HCQ + AZ has been widely misrepresented in both clinical reports and public media, and results of outpatient trials are not expected until September. Early outpatient illness is very different from later florid disease requiring hospitalization, and the treatments differ. Evidence about use of HCQ alone, or of HCQ + AZ in inpatients, is irrelevant with regard to the efficacy of HCQ + AZ in early high-risk outpatient disease. Five studies, including 2 controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. HCQ + AZ has been used as the standard of care in more than 300,000 older adults with multiple comorbid conditions; the estimated proportion of such patients diagnosed with cardiac arrhythmia attributable to the medications is 47 per 100,000 users, among whom estimated mortality is less than 20% (9/100,000 users), as compared with the 10,000 Americans now dying each week. These medications need to be made widely available and promoted immediately for physicians to prescribe.	['Azitromicina', 'Hidroxicloroquina', 'Remdesivir']	['Azithromycin', 'Hydroxychloroquine', 'Remdesivir']
Can Zn Be a Critical Element in COVID-19 Treatment?	https://link.springer.com/article/10.1007/s12011-020-02194-9	26/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s12011-020-02194-9	0163-4984	01634984	BIOLOGICAL TRACE ELEMENT RESEARCH	A3	0.649	88	4.18	-	['Zinco']	['Zinc']
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments	http://www.ncbi.nlm.nih.gov/pubmed/32460133	12/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32460133	-	-	-	-	-	-	-	-	['Atazanavir', 'Cloroquina', 'Hidroxicloroquina', 'Ivermectina', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Atazanavir', 'Chloroquine', 'Hydroxychloroquine', 'Ivermectin', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?	https://www.frontiersin.org/articles/10.3389/fimmu.2020.00970/full	08/05/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.00970/full	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma	https://pubmed.ncbi.nlm.nih.gov/32467007/	21/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32467007/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a	https://doi.org/10.1016/j.idcr.2020.e00837	22/05/2020	Artigo completo publicado em periódico científico	10.1016/j.idcr.2020.e00837	2214-2509	22142509	ID CASES	B3	0.392	19	1.61	-	['Peginterferon alfa 2a']	['Peginterferon alpha 2a']
Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes.	https://doi.org/10.1111/dom.14097	28/05/2020	Artigo completo publicado em periódico científico	10.1111/dom.14097	1462-8902	14628902	DIABETES, OBESITY AND METABOLISM (PRINT)	A1	2.356	135	6.08	-	['Inibidores da DPP-4']	['DPP-4 Inhibitors']
QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin	https://doi.org/10.1016/j.hrthm.2020.05.014	11/05/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.05.014	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine']
Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence	https://doi.org/10.1111/ijcp.13557	27/05/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13557	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Ácido acetilsalicílico', 'Brometo de ipratrópio', 'Claritromicina', 'Ibuprofeno', 'Interferon alfa', 'Naproxeno', 'Oseltamivir', 'Paracetamol']	['Acetylsalicylic acid', 'Ipratropium bromide', 'Clarithromycin', 'Ibuprofen', 'Interferon alpha', 'Naproxen', 'Oseltamivir', 'Paracetamol']
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review	http://www.ncbi.nlm.nih.gov/pubmed/32462545	27/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32462545	-	-	-	-	-	-	-	-	['Azitromicina', 'Favipiravir', 'Ganciclovir', 'Heparina', 'Hidroxicloroquina', 'Imunoglobulina', 'Interferon alfa-beta', 'Lopinavir', 'Moxifloxacina', 'Oseltamivir', 'Prednisona', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Azithromycin', 'Favipiravir', 'Ganciclovir', 'Heparin', 'Hydroxychloroquine', 'Immunoglobulin', 'Interferon alpha-beta', 'Lopinavir', 'Moxifloxacin', 'Oseltamivir', 'Prednisone', 'Ribavirin ', 'Ritonavir', 'Umifenovir']
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID‐19	https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14929	27/05/2020	Artigo completo publicado em periódico científico	10.1111/jth.14929	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Profilaxia para tromboembolismo']	['Prophylaxis for thromboembolism']
Compassionate use of hzVSF-v13 in two patients with severe COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26063	26/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26063	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['hzVSF-v13']	['hzVSF-v13']
A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics	https://doi.org/10.1111/jdv.16664	26/05/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16664	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Azitromicina', 'Cefditoren', 'Ceftriaxona', 'Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Cefditoren', 'Ceftriaxone', 'Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']
Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab	https://onlinelibrary.wiley.com/doi/10.1002/art.41380	26/05/2020	Artigo completo publicado em periódico científico	10.1002/art.41380	2326-5191	23265191	Arthritis and Rheumatology	-	3.205	328	7.06	-	['Rituximabe']	['Rituximab']
Early tocilizumab treatment could improve survival among COVID-19 patients	https://www.clinexprheumatol.org/article.asp?a=15835	29/05/2020	Artigo completo publicado em periódico científico	https://www.clinexprheumatol.org/article.asp?a=15835	-	-	-	-	-	-	-	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']
COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults	https://onlinelibrary.wiley.com/doi/full/10.1111/jgs.16623	22/05/2020	Artigo completo publicado em periódico científico	10.1111/jgs.16623	0002-8614	00028614	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY	A1	2.133	241	4.78	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	https://doi.org/10.1056/NEJMoa2015301	27/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2015301	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature	https://escholarship.org/content/qt9z6961f2/qt9z6961f2_noSplash_b327bee3f796b6e836dd7b0aecb3ce76.pdf	20/05/2020	Artigo completo publicado em periódico científico	https://escholarship.org/content/qt9z6961f2/qt9z6961f2_noSplash_b327bee3f796b6e836dd7b0aecb3ce76.pdf	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension: A Meta-Analysis	https://pubmed.ncbi.nlm.nih.gov/32458694/	27/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32458694/	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review	https://www.acpjournals.org/doi/10.7326/M20-2496	27/05/2020	Artigo completo publicado em periódico científico	10.7326/M20-2496	0003-4819	00034819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic	https://doi.org/10.1016/j.ijantimicag.2020.106028	22/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106028	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26053	25/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26053	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Azitromicina', 'Cloroquina', 'Cobicistato', 'Elvitegravir', 'Emtricitabina', 'Enoxaparina', 'Gentamicina', 'Levofloxacina', 'Meropenem', 'Oseltamivir', 'Piperacilina-tazobactam', 'Tenofovir', 'Vancomicina']	['Azithromycin', 'Chloroquine', 'Cobicistat', 'Elvitegravir', 'Emtricitabine', 'Enoxaparin', 'Gentamicin', 'Levofloxacin', 'Meropenem', 'Oseltamivir', 'Piperacylin-tazobactam', 'Tenofovir' , 'Vancomycin']
Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury	https://doi.org/10.1186/s13287-020-01699-3	24/05/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01699-3	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.	['Terapia celular']	['Cell Therapy']
Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review	https://link.springer.com/article/10.1007/s10067-020-05172-7	25/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10067-020-05172-7	0770-3198	07703198	CLINICAL RHEUMATOLOGY (PRINTED)	A4	0.873	88	3.38	-	['Prednisona']	['Prednisone']
Efficacy of therapeutic plasma exchange in severe COVID-19 patients	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16890	26/05/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16890	0007-1048	00071048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Plasmaferese']	['Plasmapheresis']
Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient	https://doi.org/10.1111/dth.13668	24/05/2020	Artigo completo publicado em periódico científico	10.1111/dth.13668	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Apremilast']	['Apremilast']
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab	https://doi.org/10.1111/tid.13334	25/05/2020	Artigo completo publicado em periódico científico	10.1111/tid.13334	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Esteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Steroidal', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']
Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19	https://pubmed.ncbi.nlm.nih.gov/32425661/	16/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32425661/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
COVID-19 and systemic lupus erythematosus: a case series	https://doi.org/10.1016/S2665-9913(20)30161-2	25/05/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30161-2	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Cloroquina', 'Esteroides', 'Hidroxicloroquina', 'Imunossupressores']	['Chloroquine', 'Ssteroids', 'Hydroxychloroquine', 'Immunosuppressants']
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19	https://doi.org/10.1007/s00405-020-06067-8	24/05/2020	Artigo completo publicado em periódico científico	10.1007/s00405-020-06067-8	0937-4477	09374477	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY	A3	0.926	76	3.14	-	['Ácido acético']	['Acetic Acid']
A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26040	21/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26040	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Ozonioterapia']	['Ozone Therapy']
COVID-19 and Liver Transplantation: lessons learned from three reported cases	https://doi.org/10.1111/TID.13335	21/05/2020	Artigo completo publicado em periódico científico	10.1111/TID.13335	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Corticosteroides', 'Imunossupressores']	['Corticosteroids', 'Immunosuppressants']
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients	https://doi.org/doi:10.1016/j.diabet.2020.05.005	21/05/2020	Artigo completo publicado em periódico científico	doi:10.1016/j.diabet.2020.05.005	1262-3636	12623636	DIABETES & METABOLISM	A2	1.834	94	4.51	-	['Tocilizumabe']	['Tocilizumab']
Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0375	26/05/2020	Artigo completo publicado em periódico científico	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0375	0002-9637	00029637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Metformina']	['Metformin']
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin	https://doi.org/10.1016/j.ijcard.2020.05.036	18/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.05.036	0167-5273	01675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238991/	20/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7238991/	-	-	-	-	-	-	-	-	['Interferon alfa', 'Umifenovir']	['Interferon alpha', 'Umifenovir']
Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis	http://www.cmaj.ca/content/early/2020/05/22/cmaj.200642.abstract	01/05/2020	Artigo completo publicado em periódico científico	http://www.cmaj.ca/content/early/2020/05/22/cmaj.200642.abstract	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease	https://www.jacionline.org/article/S0091-6749(20)30634-5/abstract	10/05/2020	Artigo completo publicado em periódico científico	https://www.jacionline.org/article/S0091-6749(20)30634-5/abstract	-	-	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases	https://doi.org/10.1016/j.dsx.2020.05.023	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.023	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Plasma convalescente']	['Convalescent Plasma']
Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2429	23/05/2020	Artigo completo publicado em periódico científico	10.1002/phar.2429	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
COVID-19 vaccines: knowing the unknown	https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048663	21/05/2020	Artigo completo publicado em periódico científico	10.1002/eji.202048663	0014-2980	00142980	EUROPEAN JOURNAL OF IMMUNOLOGY	A2	1.831	209	4.89	-	['Vacina', 'Vacina']	['Vaccine', 'Vaccine']
Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019	https://doi.org/10.1111/jcpt.13170	25/05/2020	Artigo completo publicado em periódico científico	10.1111/jcpt.13170	0269-4727	02694727	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (PRINT)	B1	0.517	76	2.22	-	['Antibióticos', 'Antivirais', 'Corticosteroides', 'Imunomoduladores', 'Medicamentos sintomáticos de suporte', 'Medicina tradicional chinesa']	['Antibiotics', 'Antivirals', 'Corticosteroids', 'Immunomodulators', 'Symptomatic Support Drugs', 'Traditional Chinese Medicine']
COVID-19 and QT interval prolongation: more than just drug toxicity?	https://academic.oup.com/europace/article/doi/10.1093/europace/euaa145/5842075	22/05/2020	Artigo completo publicado em periódico científico	10.1093/europace/euaa145/5842075	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Heparin resistance in COVID-19 patients in the intensive care unit	https://doi.org/10.1007/s11239-020-02145-0	22/05/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02145-0	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Heparina']	['Heparin']
Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes	https://www.sciencedirect.com/science/article/pii/S1386653220301670	07/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1386653220301670	-	-	-	-	-	-	-	-	['Azitromicina', 'Cefalosporina', 'Interferon alfa-beta', 'Medicina Tradicional Chinesa', 'Oseltamivir', 'Ribavirina', 'Umifenovir']	['Azithromycin', 'Cephalosporin', 'Interferon alpha-beta', 'Traditional Chinese Medicine', 'Oseltamivir', 'Ribavirin', 'Umifenovir']
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy [published online ahead of print	https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(20)30196-5	21/05/2020	Artigo completo publicado em periódico científico	https://linkinghub.elsevier.com/retrieve/pii/S0953-6205(20)30196-5	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study	https://doi.org/10.1093/cid/ciaa624	22/05/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa624	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Renin-angiotensin-aldosterone system (RAAS) inhibitors may facilitate host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or attenuate organ injury via RAAS blockade. We aimed to assess the associations between prior use of RAAS inhibitors and clinical outcomes among Korean patients with coronavirus disease 2019 (COVID-19).                                                  Methods                   We performed a nationwide population-based cohort study using the Korean Health Insurance Review and Assessment database. Claim records were screened for 69 793 individuals who were tested for COVID-19 until 8 April 2020. Adjusted odds ratios (ORs) were used to compare the clinical outcomes between RAAS inhibitor users and nonusers.                                                  Results                   Among 5179 confirmed COVID-19 cases, 762 patients were RAAS inhibitor users and 4417 patients were nonusers. Relative to nonusers, RAAS inhibitor users were more likely to be older, male, and have comorbidities. Among 1954 hospitalized patients with COVID-19, 377 patients were RAAS inhibitor users, and 1577 patients were nonusers. In-hospital mortality was observed for 33 RAAS inhibitor users (9%) and 51 nonusers (3%) (P &amp;lt; .001). However, after adjustment for age, sex, Charlson comorbidity index, immunosuppression, and hospital type, the use of RAAS inhibitors was not associated with a higher risk of mortality (adjusted OR, 0.88; 95% confidence interval, 0.53–1.44; P = .60). No significant differences were observed between RAAS inhibitor users and nonusers in terms of vasopressor use, modes of ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and acute cardiac events.                                                  Conclusions                   Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Remdesivir for the Treatment of Covid-19 — Preliminary Report	https://doi.org/10.1056/NEJMoa2007764	22/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review	https://doi.org/10.1016/j.hrthm.2020.05.008	10/05/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.05.008	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy	https://doi.org/10.3389/fcvm.2020.00078	30/04/2020	Artigo completo publicado em periódico científico	10.3389/fcvm.2020.00078	2297-055X	2297055X	FRONTIERS IN CARDIOVASCULAR MEDICINE	B4	1.443	44	5.5	-	['Anakinra', 'Canaquinumabe', 'Etanercepte', 'Infliximabe', 'Terapia celular', 'Tocilizumabe']	['Anakinra', 'Canakinumab', 'Etanercept', 'Infliximab', 'Cell therapy', 'Tocilizumab']
Hepatic complications of COVID‐19 and its treatment	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26036	21/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26036	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Lopinavir', 'Ritonavir', 'Umifenovir']	['Lopinavir', 'Ritonavir', 'Umifenovir']
Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26047	21/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26047	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
The immunology of COVID-19: is immune modulation an option for treatment?	https://doi.org/10.1016/S2665-9913(20)30120-X	21/05/2020	Artigo completo publicado em periódico científico	10.1016/S2665-9913(20)30120-X	2665-9913	26659913	Lancet Rheumatology, The	-	6.633	28	9.58	-	['Imunomoduladores']	['Immunomodulators']
Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines	https://doi.org/10.1186/s40779-020-00251-x	05/05/2020	Artigo completo publicado em periódico científico	10.1186/s40779-020-00251-x	2054-9369	20549369	Military Medical Research	-	2.277	25	15.59	 Abstract The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.	['Cloroquina', 'Corticosteroides', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Terapia celular', 'Tocilizumabe', 'Umifenovir']	['Chloroquine', 'Corticosteroids', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Cell therapy', 'Tocilizumab', 'Umifenovir']
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019	https://journals.lww.com/ccejournal/Fulltext/2020/04000/Rationale_for_Prolonged_Corticosteroid_Treatment.18.aspx	24/05/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/ccejournal/Fulltext/2020/04000/Rationale_for_Prolonged_Corticosteroid_Treatment.18.aspx	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids']
Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236913/	22/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7236913/	-	-	-	-	-	-	-	-	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Extracorporeal Membrane Oxygenation as Treatment of Severe COVID-19 Infection: A Case Report	https://www.cureus.com/articles/30774-extracorporeal-membrane-oxygenation-as-treatment-of-severe-covid-19-infection-a-case-report	17/04/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/30774-extracorporeal-membrane-oxygenation-as-treatment-of-severe-covid-19-infection-a-case-report	-	-	-	-	-	-	-	-	['Oxigenação por membrana extracorpórea (ECMO)']	['Extracorporeal membrane oxygenation (ECMO)']
Baricitinib: a chance to treat COVID‐19?	https://onlinelibrary.wiley.com/doi/10.1002/jmv.26033	21/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26033	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Baricitinibe']	['Baricitinib']
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	https://nn.neurology.org/content/7/4/e753	05/05/2020	Artigo completo publicado em periódico científico	https://nn.neurology.org/content/7/4/e753	-	-	-	-	-	-	-	-	['Fingolimode', 'Hidroxicloroquina', 'Oseltamivir', 'Piperacilina-tazobactam']	['Fingolimod', 'Hydroxychloroquine', 'Oseltamivir', 'Piperacillin-tazobactam']
Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases	https://journals.lww.com/jtrauma/Abstract/9000/Early_Outcomes_with_Utilization_of_Tissue.97876.aspx	14/05/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/jtrauma/Abstract/9000/Early_Outcomes_with_Utilization_of_Tissue.97876.aspx	-	-	-	-	-	-	-	-	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?	https://care.diabetesjournals.org/content/early/2020/05/15/dc20-0723	19/05/2020	Artigo completo publicado em periódico científico	https://care.diabetesjournals.org/content/early/2020/05/15/dc20-0723	-	-	-	-	-	-	-	-	['Insulina']	['Insulin']
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	https://doi.org/10.1016/S0140-6736(20)31180-6	22/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31180-6	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Cloroquina', 'Hidroxicloroquina', 'Macrolídeos']	['Chloroquine', 'Hydroxychloroquine', 'Macrolides']
Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection	https://doi.org/10.1183/13993003.00799-2020	08/05/2020	Artigo completo publicado em periódico científico	10.1183/13993003.00799-2020	0903-1936	09031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background The duration of viral shedding is central to the guidance of decisions about isolation precautions and antiviral treatment. However, studies regarding the risk factors associated with prolonged shedding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the impact of lopinavir/ritonavir (LPV/r) treatment on viral shedding remain scarce.  Methods Data were collected from all SARS-CoV-2 infected patients who were admitted to isolation wards and had reverse transcription PCR conversion at the No. 3 People's Hospital of Hubei province, China, between 31 January and 9 March 2020. We compared clinical characteristics and SARS-CoV-2 RNA shedding between patients initiated with LPV/r treatment and those without. Logistic regression analysis was employed to evaluate the risk factors associated with prolonged viral shedding.  Results Of 120 patients, the median age was 52 years, 54 (45%) were male and 78 (65%) received LPV/r treatment. The median duration of SARS-CoV-2 RNA detection from symptom onset was 23 days (interquartile range 18–32 days). Older age (OR 1.03, 95% CI 1.00–1.05; p=0.03) and the lack of LPV/r treatment (OR 2.42, 95% CI 1.10–5.36; p=0.029) were independent risk factors for prolonged SARS-CoV-2 RNA shedding. Patients who initiated LPV/r treatment within 10 days from symptom onset, but not initiated from day 11 onwards, had significantly shorter viral shedding duration compared with those without LPV/r treatment (median 19 days  versus 28.5 days; log-rank p&lt;0.001).  Conclusion Older age and the lack of LPV/r treatment were independently associated with prolonged SARS-CoV-2 RNA shedding in patients with coronavirus disease 2019 (COVID-19). Earlier administration of LPV/r treatment could shorten viral shedding duration.	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
SARS2-CoV-2 and Stroke in a New York Healthcare System	https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.030335	20/05/2020	Artigo completo publicado em periódico científico	10.1161/STROKEAHA.120.030335	0039-2499	00392499	STROKE (DALLAS. 1970)	A1	3.245	330	6.52	              Background and Purpose:             With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.                                  Methods:             We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).                                  Results:                           During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%,               P              =0.003) and historical controls (25.0%,               P              &lt;0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.                                              Conclusions:             We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.          	['Anticoagulantes']	['Anticoagulants']
Adjuvant corticosteroid therapy for critically ill patients with COVID-19	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02964-w	19/05/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02964-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Corticosteroides']	['Corticosteroids']
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	https://doi.org/10.1016/S0140-6736(20)31208-3	22/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31208-3	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Ad5-nCoV']	['Ad5-nCoV']
Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwhomdl-32432527	15/05/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwhomdl-32432527	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review	https://doi.org/10.1002/jmv.26038	21/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26038	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Hydroxychloroquine for COVID-19: A review and a debate based on available clinical trials/case studies	http://dx.doi.org/10.22270/jddt.v10i3.4110	21/05/2020	Artigo completo publicado em periódico científico	10.22270/jddt.v10i3.4110	2250-1177	22501177	-	-	-	-	-	 Hydroxychloroquine (HCQ) as a drug grabbed serious attention of whole world in dealing with COVID-19 pandemic. Recently some in-vitro and in-vivo study showing possible inhibition of SARS-CoV-2 by use of HCQ. However at the same time, some case studies showing NO clinical benefit/ poor clinical outcome with substantial detrimental adverse effects by use of HCQ in treatment of coronavirus disease-2019. Thus, the HCQ use (in COVID-19 treatment) is of current international interest, although a consensus has not yet been reached. More evidences are still required to prove efficacy of HCQ against COVID-19. In view of this, the present review highlights the current ongoing research related to use of HCQ in treatment coronavirus disease-2019. The present review will discuss the possible anti-viral mechanism of HCQ, prophylaxis strategy and effect of HCQ against SARS-CoV-2 virus in-vitro study. Further this review also summarizes and debates all available clinical trials/ case studies of HCQ use against COVID-19 (with clinical outcome). Finally possible detrimental adverse effects are also discussed considering the public health and pharmacovigilance concern.&#x0D;Keywords: Potency of hydroxychloroquine; COVID-19; Coronavirus disease-2019; Clinical trials; SARS-CoV-2; Adverse effects of hydroxychloroquine; Pharmacovigilance concern	['Hidroxicloroquina']	['Hydroxychloroquine']
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225250/	15/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7225250/	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Ibuprofeno', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Ibuprofen', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Thrombotic risk in COVID-19: a case series and case–control study	https://www.rcpjournals.org/content/clinmedicine/early/2020/05/18/clinmed.2020-0228	18/05/2020	Artigo completo publicado em periódico científico	https://www.rcpjournals.org/content/clinmedicine/early/2020/05/18/clinmed.2020-0228	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Therapy for probable COVID-19 associated erythema pernio-like lesions in pediatric age. Case report	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32424851	18/05/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32424851	-	-	-	-	-	-	-	-	['Furoato de mometasona', 'Heparina']	['Mometasone Furoate', 'Heparin']
Pericarditis aguda secundaria a COVID-19	https://pesquisa.bvsalud.org/portal/resource/es/ibc-ET2-5100	21/05/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/portal/resource/es/ibc-ET2-5100	-	-	-	-	-	-	-	-	['Ácido acetilsalicílico', 'Azitromicina', 'Colchicina', 'Interferon beta', 'Lopinavir', 'Ritonavir']	['Acetylsalicylic acid', 'Azithromycin', 'Colchicine', 'Interferon beta', 'Lopinavir', 'Ritonavir']
Successful Intravenous Immunoglobulin Treatment in Severe COVID-19 Pneumonia	https://www.sciencedirect.com/science/article/pii/S2214250920301025	16/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2214250920301025	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?	https://www.sciencedirect.com/science/article/pii/S2211034820302728	16/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2211034820302728	-	-	-	-	-	-	-	-	['Interferon beta']	['Interferon beta']
Effective Use of Angiotensin II in Coronavirus Disease 19–Associated Mixed Shock State: A Case Report	https://europepmc.org/article/pmc/pmc7172437	15/04/2020	Artigo completo publicado em periódico científico	https://europepmc.org/article/pmc/pmc7172437	-	-	-	-	-	-	-	-	['Angiotensina II']	['Angiotensin II']
Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series	https://dspace.mit.edu/handle/1721.1/125345	21/05/2020	Artigo completo publicado em periódico científico	https://dspace.mit.edu/handle/1721.1/125345	-	-	-	-	-	-	-	-	['Alteplase']	['Alteplase']
The potential role of TNFα in 2019 novel coronavirus pneumonia	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215148/	12/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7215148/	-	-	-	-	-	-	-	-	['Antagonistas de TNF']	['TNF Antagonists']
Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry	https://doi.org/10.1053/j.gastro.2020.05.032	18/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.032	0016-5085	00165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Antagonistas de TNF', 'Azatioprina', 'Corticosteroides', 'Mercaptopurina', 'Metotrexato']	['TNF antagonists', 'Azathioprine', 'Corticosteroids', 'Mercaptopurine', 'Methotrexate']
Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome	https://doi.org/10.1161/CIRCULATIONAHA.120.046702	18/05/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.046702	0009-7322	00097322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	              Background:             To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center.                                  Methods:             We studied a total of 143 patients with COVID-19 from January 29, 2020 to February 29, 2020. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities, and outcome variables were obtained, and comparisons were made between groups with and without DVT.                                  Results:                           Of the 143 patients hospitalized with COVID-19 (age 63±14 years, 74 [51.7%] men), 66 patients developed lower extremity DVT (46.1%: 23 [34.8%] with proximal DVT and 43 [65.2%] with distal DVT). Compared with patients who did not have DVT, patients with DVT were older and had a lower oxygenation index, a higher rate of cardiac injury, and worse prognosis, including an increased proportion of deaths (23 [34.8%] versus 9 [11.7%];               P              =0.001) and a decreased proportion of patients discharged (32 [48.5%] versus 60 [77.9%];               P              &lt;0.001). Multivariant analysis showed an association only between CURB-65 (confusion status, urea, respiratory rate, and blood pressure) score 3 to 5 (odds ratio, 6.122;               P              =0.031), Padua prediction score ≥4 (odds ratio, 4.016;               P              =0.04), D-dimer &gt;1.0 μg/mL (odds ratio, 5.818;               P              &lt;0.014), and DVT in this cohort, respectively. The combination of a CURB-65 score 3 to 5, a Padua prediction score ≥4, and D-dimer &gt;1.0 μg/mL has a sensitivity of 88.52% and a specificity of 61.43% for screening for DVT. In the subgroup of patients with a Padua prediction score ≥4 and whose ultrasound scans were performed &gt;72 hours after admission, DVT was present in 18 (34.0%) patients in the subgroup receiving venous thromboembolism prophylaxis versus 35 (66.0%) patients in the nonprophylaxis group (               P              =0.010).                                              Conclusions:             The prevalence of DVT is high and is associated with adverse outcomes in hospitalized patients with COVID-19. Prophylaxis for venous thromboembolism may be protective in patients with a Padua protection score ≥4 after admission. Our data seem to suggest that COVID-19 is probably an additional risk factor for DVT in hospitalized patients.          	['Antagonistas do Receptor da Angiotensina II', 'Antivirais', 'Heparina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Antivirals', 'Heparin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care	https://doi.org/10.1016/j.jcv.2020.104444	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jcv.2020.104444	1386-6532	13866532	JOURNAL OF CLINICAL VIROLOGY	A3	3.355	114	10.59	-	['Tocilizumabe']	['Tocilizumab']
The Effect of Potential Therapeutic Agents on QT Interval in Patients With COVID-19 Infection: The Importance of Close Monitoring and Correction of Electrolytes	https://pubmed.ncbi.nlm.nih.gov/32460209/	16/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32460209/	-	-	-	-	-	-	-	-	['Magnésio', 'Potássio']	['Magnesium', 'Potassium']
Early Short Course Corticosteroids in Hospitalized Patients with COVID-19	https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa601/5840526	19/05/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa601/5840526	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients	http://www.journaljpri.com/index.php/JPRI/article/view/30455	18/05/2020	Artigo completo publicado em periódico científico	http://www.journaljpri.com/index.php/JPRI/article/view/30455	-	-	-	-	-	-	-	-	['Lopinavir', 'Oseltamivir', 'Prednisona', 'Ritonavir', 'Umifenovir']	['Lopinavir', 'Oseltamivir', 'Prednisone', 'Ritonavir', 'Umifenovir']
Antivirals for COVID-19	https://doi.org/10.3949/ccjm.87a.ccc030	27/05/2020	Artigo completo publicado em periódico científico	10.3949/ccjm.87a.ccc030	0891-1150	08911150	Cleveland Clinic Journal of Medicine	-	0.500	65	1.44	-	['Favipiravir', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!	https://pubmed.ncbi.nlm.nih.gov/32418917/	11/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32418917/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection	https://pubmed.ncbi.nlm.nih.gov/32418728/	07/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32418728/	-	-	-	-	-	-	-	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']
Chloroquine and hydroxychloroquine during pregnancy: What do we know?	https://pubmed.ncbi.nlm.nih.gov/32418732/	11/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32418732/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease	https://www.mdpi.com/2076-3425/10/5/284	08/05/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-3425/10/5/284	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']
Cutaneous Sıde-Effects of the Potentıal Covıd-19 Drugs	https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13476	01/05/2020	Artigo completo publicado em periódico científico	10.1111/dth.13476	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Antimaláricos', 'Azitromicina', 'Colchicina', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Antimalarials', 'Azithromycin', 'Colchicine', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
Recovery from COVID-19 in two patients with coexisted HIV infection	http://www.ncbi.nlm.nih.gov/pubmed/32401359	13/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32401359	-	-	-	-	-	-	-	-	['Antibióticos', 'Oseltamivir', 'Ribavirina', 'Umifenovir']	['Antibiotics', 'Oseltamivir', 'Ribavirin', 'Umifenovir']
Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?	https://doi.org/10.1016/j.jdermsci.2020.05.002	16/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jdermsci.2020.05.002	0923-1811	09231811	JOURNAL OF DERMATOLOGICAL SCIENCE (AMSTERDAM)	A2	1.097	99	3.97	-	['Ampicilina', 'Anti-inflamatórios não esteroidais', 'Claritromicina', 'Levofloxacina', 'Prednisolona', 'Sulbactam']	['Ampicillin', 'Non-steroidal anti-inflammatory drugs', 'Clarithromycin', 'Levofloxacin', 'Prednisolone', 'Sulbactam']
COVID-19 Managed With Early Non-Invasive Ventilation and a Bundle Pharmacotherapy: A Case Report	https://www.wjgnet.com/2307-8960/full/v8/i9/1705.htm	06/05/2020	Artigo completo publicado em periódico científico	https://www.wjgnet.com/2307-8960/full/v8/i9/1705.htm	-	-	-	-	-	-	-	-	['Corticosteroides', 'Heparina', 'Interferon alfa', 'Lopinavir', 'Medicina Tradicional Chinesa', 'Prednisona', 'Ritonavir', 'Timosina', 'Ventilação não invasiva precoce']	['Corticosteroids', 'Heparin', 'Interferon alpha', 'Lopinavir', 'Traditional Chinese Medicine', 'Prednisone', 'Ritonavir', 'Thymosin', 'Early non-invasive ventilation']
Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series	https://academic.oup.com/neurosurgery/article/doi/10.1093/neuros/nyaa198/5840444	19/05/2020	Artigo completo publicado em periódico científico	10.1093/neuros/nyaa198/5840444	-	-	-	-	-	-	-	-	['Oxigenação por membrana extracorpórea (ECMO)']	['Extracorporeal membrane oxygenation (ECMO)']
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report	https://doi.org/10.1016/j.ijid.2020.05.050	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.05.050	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Anakinra', 'Remdesivir', 'Remdesivir']	['Anakinra', 'Anakinra', 'Remdesivir', 'Remdesivir']
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir	https://www.frontiersin.org/article/10.3389/fmed.2020.00241	19/05/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fmed.2020.00241	2296-858X	2296858X	FRONTIERS IN MEDICINE	C	1.179	54	5.1	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
‘‘Off-label’’ use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers	https://doi.org/10.1016/j.therap.2020.05.002	07/05/2020	Artigo completo publicado em periódico científico	10.1016/j.therap.2020.05.002	0040-5957	00405957	Therapie	-	0.442	36	1.73	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects	https://doi.org/10.1016/j.jinf.2020.05.020	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.05.020	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Terapia celular']	['Cell Therapy']
Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048360	17/05/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.048360	0009-7322	00097322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	              Background:             Cardiac injury and myocarditis have been described in adults with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children is typically minimally symptomatic. We report a series of febrile pediatric patients with acute heart failure potentially associated with SARS-CoV-2 infection and the multisystem inflammatory syndrome in children as defined by the US Centers for Disease Control and Prevention.                                  Methods:             Over a 2-month period, contemporary with the SARS-CoV-2 pandemic in France and Switzerland, we retrospectively collected clinical, biological, therapeutic, and early outcomes data in children who were admitted to pediatric intensive care units in 14 centers for cardiogenic shock, left ventricular dysfunction, and severe inflammatory state.                                  Results:             Thirty-five children were identified and included in the study. Median age at admission was 10 years (range, 2–16 years). Comorbidities were present in 28%, including asthma and overweight. Gastrointestinal symptoms were prominent. Left ventricular ejection fraction was &lt;30% in one-third; 80% required inotropic support with 28% treated with extracorporeal membrane oxygenation. Inflammation markers were suggestive of cytokine storm (interleukin-6 median, 135 pg/mL) and macrophage activation (D-dimer median, 5284 ng/mL). Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL). Thirty-one of 35 patients (88%) tested positive for SARS-CoV-2 infection by polymerase chain reaction of nasopharyngeal swab or serology. All patients received intravenous immunoglobulin, with adjunctive steroid therapy used in one-third. Left ventricular function was restored in the 25 of 35 of those discharged from the intensive care unit. No patient died, and all patients treated with extracorporeal membrane oxygenation were successfully weaned.                                  Conclusions:             Children may experience an acute cardiac decompensation caused by severe inflammatory state after SARS-CoV-2 infection (multisystem inflammatory syndrome in children). Treatment with immunoglobulin appears to be associated with recovery of left ventricular systolic function.          	['Imunoglobulina']	['Immunoglobulin']
Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids	https://doi.org/10.1016/j.intimp.2020.106560	08/05/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106560	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Anticorpos', 'Corticosteroides', 'Imunoglobulina', 'Interferon recombinante tipo 1', 'Plasma convalescente', 'Tocilizumabe']	['Antibodies', 'Corticosteroids', 'Immunoglobulin', 'Recombinant Interferon Type 1', 'Convalescent Plasma', 'Tocilizumab']
SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc	https://www.sciencedirect.com/science/article/pii/S2590153220300094	14/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2590153220300094	-	-	-	-	-	-	-	-	['Inibidores de interleucina-6']	['Interleukin-6 inhibitors']
Is COVID-19 a New Hematologic Disease?	https://doi.org/10.1007/s12015-020-09987-4	12/05/2020	Artigo completo publicado em periódico científico	10.1007/s12015-020-09987-4	2629-3269	26293269	Stem Cell Reviews and Reports	-	1.078	77	5.92	-	['Terapia celular']	['Cell Therapy']
Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases	https://doi.org/10.1016/j.biopha.2020.110230	13/05/2020	Artigo completo publicado em periódico científico	10.1016/j.biopha.2020.110230	0753-3322	07533322	BIOMEDICINE & PHARMACOTHERAPY	A2	1.194	109	7.17	-	['Antagonistas do Receptor da Angiotensina II', 'Antiarrítmicos', 'Antifúngicos', 'Azitromicina', 'Corticosteroides', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Levofloxacina', 'Lopinavir', 'Moxifloxacina', 'Prednisona', 'Remdesivir', 'Ritonavir']	['Angiotensin II Receptor Antagonists', 'Antiarrhythmics', 'Antifungals', 'Azithromycin', 'Corticosteroids', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Levofloxacin', 'Lopinavir', 'Moxifloxacin ', 'Prednisone', 'Remdesivir', 'Ritonavir']
A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?	https://doi.org/10.1111/jdv.16633	18/05/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16633	0926-9959	09269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Anti-histamínicos', 'Antibióticos', 'Anticoagulantes', 'Antivirais', 'Esteroides']	['Antihistamines', 'Antibiotics', 'Anticoagulants', 'Antivirals', 'Steroidal']
Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report	https://onlinelibrary.wiley.com/doi/10.1111/ajt.15985	02/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15985	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']
COVID-19 infection in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab	https://doi.org/10.1016/j.jaci.2020.05.005	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.005	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Dupilumabe']	['Dupilumab']
Early experience with remdesivir in SARS-CoV-2 pneumonia	https://link.springer.com/article/10.1007/s15010-020-01448-x	16/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s15010-020-01448-x	0300-8126	03008126	INFECTION	A4	1.119	80	4.01	-	['Remdesivir']	['Remdesivir']
Coronavirus disease 2019 in renal transplant recipients: report of two cases	https://doi.org/10.1111/tid.13329	16/05/2020	Artigo completo publicado em periódico científico	10.1111/tid.13329	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Prednisona']	['Prednisone']
Coronavirus Disease 2019 in Heart Transplant Recipients in Southeastern Michigan – Case Series	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224667/	14/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7224667/	-	-	-	-	-	-	-	-	['Corticosteroides', 'Hidroxicloroquina', 'Tocilizumabe']	['Corticosteroids', 'Hydroxychloroquine', 'Tocilizumab']
A Case of Coronavirus Disease 2019 Treated With Ciclesonide	https://doi.org/10.1016/j.mayocp.2020.04.007	15/04/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.04.007	0025-6196	00256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Ciclesonida']	['Cyclesonide']
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran	https://doi.org/10.1016/j.msard.2020.102195	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102195	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Imunomoduladores', 'Imunomoduladores', 'Imunossupressores', 'Imunossupressores']	['Immunomodulators', 'Immunomodulators', 'Immunosuppressants', 'Immunosuppressants']
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study	https://doi.org/10.1111/ajt.16062	15/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16062	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data	https://www.bmj.com/content/369/bmj.m1844	14/05/2020	Artigo completo publicado em periódico científico	https://www.bmj.com/content/369/bmj.m1844	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Complement activation in patientswith COVID-19: A novel therapeutictarget	https://doi.org/10.1016/j.jaci.2020.05.006	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.006	0091-6749	00916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Sistema complemento']	['Add-on system']
The role of passive immunization in the age of SARS‑CoV‑2: an update	https://doi.org/10.1186/s40001-020-00414-5	13/05/2020	Artigo completo publicado em periódico científico	10.1186/s40001-020-00414-5	2047-783X	2047783X	EUROPEAN JOURNAL OF MEDICAL RESEARCH	A3	0.725	60	3.84	 Abstract The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19	http://doi.org/10.1016/j.msard.2020.102182	07/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102182	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Tocilizumabe']	['Tocilizumab']
Appearance of Skin Rash in Pediatric Patients with COVID-19: Three Case Presentations	https://onlinelibrary.wiley.com/doi/10.1111/dth.13594	15/05/2020	Artigo completo publicado em periódico científico	10.1111/dth.13594	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia	https://doi.org/10.1002/jmv.26016	15/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26016	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765633	01/05/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765633	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19	https://doi.org/10.1007/s11427-020-1732-2	15/05/2020	Artigo completo publicado em periódico científico	10.1007/s11427-020-1732-2	1674-7305	16747305	Science China Life Sciences	-	1.403	60	6.51	-	['Hidroxicloroquina']	['Hydroxychloroquine']
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic	https://doi.org/10.1016/j.sapharm.2020.04.031	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.sapharm.2020.04.031	1551-7411	15517411	RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY	A3	0.674	54	2.88	-	['Amoxicilina', 'Azitromicina', 'Cloroquina']	['Amoxicillin', 'Azithromycin', 'Chloroquine']
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103-X/fulltext	13/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31103-X/fulltext	-	-	-	-	-	-	-	-	['Imunoglobulina', 'Prednisona']	['Immunoglobulin', 'Prednisone']
Nifedipine and Amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19	http://doi.org/10.7759/cureus.8069	12/05/2020	Artigo completo publicado em periódico científico	10.7759/cureus.8069	2168-8184	21688184	-	-	-	-	-	-	['Anlodipina', 'Nifedipino']	['Amlodipine', 'Nifedipine']
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19	http://www.ncbi.nlm.nih.gov/pubmed/32359035	01/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32359035	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China	https://doi.org/10.1007/s11096-020-01031-2	14/05/2020	Artigo completo publicado em periódico científico	10.1007/s11096-020-01031-2	2210-7703	22107703	INTERNATIONAL JOURNAL OF CLINICAL PHARMACY	A4	0.501	63	2.41	-	['Corticosteroides', 'Fluoroquinolona', 'Interferon alfa', 'Lopinavir', 'Novaferon', 'Ritonavir']	['Corticosteroids', 'Fluoroquinolone', 'Interferon alpha', 'Lopinavir', 'Novaferon', 'Ritonavir']
Compassionate  remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status	https://doi.org/10.1016/j.phrs.2020.104899	11/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104899	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Remdesivir']	['Remdesivir']
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?	https://doi.org/10.7326/M20-1998	18/05/2020	Artigo completo publicado em periódico científico	10.7326/M20-1998	0003-4819	00034819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213073/	30/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7213073/	-	-	-	-	-	-	-	-	['Favipiravir']	['Favipiravir']
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies	https://doi.org/10.1016/j.dsx.2020.05.018	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.018	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Remdesivir']	['Remdesivir']
Combating COVID-19 with Mesenchymal Stem Cell therapy	https://doi.org/10.1016/j.btre.2020.e00467	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.btre.2020.e00467	2215-017X	2215017X	BIOTECHNOLOGY REPORTS	A2	0.854	43	6.09	-	['Terapia celular']	['Cell Therapy']
A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials	https://www.sciencedirect.com/science/article/pii/S0024320520305233	11/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0024320520305233	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine	https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13565	13/05/2020	Artigo completo publicado em periódico científico	10.1111/dth.13565	1396-0296	13960296	Dermatologic Therapy	-	0.598	72	2.18	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19	https://doi.org/10.1002/jmv.26004	13/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.26004	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Tolicizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome	https://www.ejcrim.com/index.php/EJCRIM/article/view/1675	22/04/2020	Artigo completo publicado em periódico científico	https://www.ejcrim.com/index.php/EJCRIM/article/view/1675	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Allogeneic cardiosphere‐derived cells (CAP‐1002) in critically ill COVID‐19 patients: compassionate‐use case series	https://doi.org/10.1007/s00395-020-0795-1	12/05/2020	Artigo completo publicado em periódico científico	10.1007/s00395-020-0795-1	0300-8428	03008428	BASIC RESEARCH IN CARDIOLOGY (PRINT)	A1	1.615	100	11.01	 Abstract There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients ( n = 6; age range 19–75 years, 1 female) required ventilatory support (invasive mechanical ventilation,  n = 5) with PaO 2/FiO 2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients ( n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43–2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89–1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26–0.82 × 10 3/µl) but had increased in three of these five patients at last follow-up (range 0.23–1.02 × 10 3/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.	['Terapia celular']	['Cell Therapy']
Use of anakinra in severe COVID-19: a case report	https://doi.org/10.1016/j.ijid.2020.05.026	10/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.05.026	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra']	['Anakinra']
Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis	https://doi.org/10.1016/j.chom.2020.05.007	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.chom.2020.05.007	1931-3128	19313128	CELL HOST & MICROBE	A1	9.373	201	19.72	-	['Anakinra', 'Anakinra', 'Anakinra']	['Anakinra', 'Anakinra', 'Anakinra']
Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	https://doi.org/10.1016/S0140-6736(20)31030-8	14/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31030-8	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Interferon-α2b Treatment for COVID-19. 2020	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full	15/05/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01061/full	-	-	-	-	-	-	-	-	['Interferon alfa', 'Umifenovir']	['Interferon alpha', 'Umifenovir']
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219361/	13/05/2020	Artigo completo publicado em periódico científico	PMC:PMC7219361/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)	https://pubmed.ncbi.nlm.nih.gov/32397399/	09/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32397399/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial	https://www.bmj.com/content/369/bmj.m1849	14/05/2020	Artigo completo publicado em periódico científico	https://www.bmj.com/content/369/bmj.m1849	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600/full	14/05/2020	Artigo completo publicado em periódico científico	10.1002/14651858.CD013600/full	-	-	-	-	-	-	-	-	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']
Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis	https://doi.org/10.1016/j.dsx.2020.05.017	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.017	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Should azithromycin be used to treat COVID-19? A rapid review	https://bjgpopen.org/content/4/2/bjgpopen20X101094/tab-article-info	12/05/2020	Artigo completo publicado em periódico científico	https://bjgpopen.org/content/4/2/bjgpopen20X101094/tab-article-info	-	-	-	-	-	-	-	-	['Azitromicina']	['Azithromycin']
SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions	https://www.mdpi.com/1999-4915/12/5/526	10/05/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1999-4915/12/5/526	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de RNA']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors' , 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Convalescent Plasma', 'Convalescent Plasma' , 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'DNA vaccine', 'Vaccine ', 'DNA vaccine', 'RNA vaccine', 'RNA vaccine', 'RNA vaccine']
SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors	https://doi.org/10.1016/S2213-2600(20)30224-1	13/05/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30224-1	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults	https://jamanetwork.com/journals/jama/fullarticle/2766182	13/05/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2766182	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance	https://www.sciencedirect.com/science/article/pii/S2052297520300366	22/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2052297520300366	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin']
Perspectives for repurposing drugs for the coronavirus disease 2019	http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2020;volume=151;issue=2;spage=160;epage=171;aulast=Cherian	28/04/2020	Artigo completo publicado em periódico científico	http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2020;volume=151;issue=2;spage=160;epage=171;aulast=Cherian	-	-	-	-	-	-	-	-	['Baricitinibe', 'Cloroquina', 'Cobicistato', 'Darunavir', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Baricitinib', 'Chloroquine', 'Cobicistat', 'Darunavir', 'Favipiravir', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']
The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms	https://www.mdpi.com/2076-0817/9/5/331	29/04/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-0817/9/5/331	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Baricitinibe', 'Cloroquina', 'Darunavir', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Angiotensin II Receptor Antagonists', 'Baricitinib', 'Chloroquine', 'Darunavir', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury	https://www.nejm.org/doi/full/10.1056/NEJMcpc2002418	13/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMcpc2002418	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Anticoagulantes', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Remdesivir', 'Tocilizumabe']	['Anticoagulants', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Remdesivir', 'Tocilizumab']
2019 Novel Coronavirus Pneumonia With Onset of Dizziness: a Case Report	http://dx.doi.org/10.21037/atm.2020.03.89	04/03/2020	Artigo completo publicado em periódico científico	10.21037/atm.2020.03.89	2305-5839	23055839	-	-	-	-	-	-	['Oseltamivir', 'Umifenovir']	['Oseltamivir', 'Umifenovir']
COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients	https://doi.org/10.1007/s15010-020-01438-z	11/05/2020	Artigo completo publicado em periódico científico	10.1007/s15010-020-01438-z	0300-8126	03008126	INFECTION	A4	1.119	80	4.01	-	['Darunavir', 'Emtricitabina', 'Lamivudina', 'Ritonavir', 'Tenofovir']	['Darunavir', 'Emtricitabine', 'Lamivudine', 'Ritonavir', 'Tenofovir']
Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report	https://doi.org/10.1186/s13037-020-00245-7	08/05/2020	Artigo completo publicado em periódico científico	10.1186/s13037-020-00245-7	1754-9493	17549493	PATIENT SAFETY IN SURGERY	B1	0.845	26	2.9	 Abstract  Background The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease.  Case presentation A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient’s condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28.  Conclusion This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients.	['Oxigenação por membrana extracorpórea (ECMO)', 'Remdesivir']	['Extracorporeal membrane oxygenation (ECMO)', 'Remdesivir']
COVID-19 vaccines: breaking record times to first-in-human trials	https://www.nature.com/articles/s41541-020-0188-3	30/04/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41541-020-0188-3	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']
The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension	http://dx.doi.org/10.21037/atm.2020.03.229	30/03/2020	Artigo completo publicado em periódico científico	10.21037/atm.2020.03.229	2305-5839	23055839	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
A global treatments for coronaviruses including COVID-19	https://doi.org/10.1002/jcp.29785	11/05/2020	Artigo completo publicado em periódico científico	10.1002/jcp.29785	0021-9541	00219541	JOURNAL OF CELLULAR PHYSIOLOGY (PRINT)	A2	1.308	183	6.77	-	['Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Teicoplanina', 'Umifenovir']	['Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Teicoplanin', 'Umifenovir']
Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?	http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7202902	07/05/2020	Artigo completo publicado em periódico científico	http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7202902	-	-	-	-	-	-	-	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']
Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019	https://www.sciencedirect.com/science/article/pii/S1054880720300326	17/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1054880720300326	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Ritonavir', 'Ritonavir', 'Terapia celular', 'Terapia celular', 'Terapia com ervas', 'Terapia com ervas', 'Tocilizumabe', 'Tocilizumabe']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Chloroquine', 'Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Angiotensin Converting Enzyme Inhibitors 2 (ACEI 2)', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir', 'Lopinavir', 'Convalescent Plasma', 'Convalescent Plasma', 'Ritonavir', 'Ritonavir', 'Cell Therapy' ', 'Cell therapy', 'Herbal therapy', 'Herbal therapy', 'Tocilizumab', 'Tocilizumab']
A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis	https://www.frontiersin.org/articles/10.3389/fneur.2020.00296/full	22/04/2020	Artigo completo publicado em periódico científico	10.3389/fneur.2020.00296/full	-	-	-	-	-	-	-	-	['Cefoperazona', 'Prednisona', 'Sulbactam', 'Umifenovir']	['Cefoperazone', 'Prednisone', 'Sulbactam', 'Umifenovir']
Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series	https://doi.org/10.1016/j.bbi.2020.05.022	07/05/2020	Artigo completo publicado em periódico científico	10.1016/j.bbi.2020.05.022	0889-1591	08891591	BRAIN, BEHAVIOR, AND IMMUNITY	A1	3.046	170	12.52	-	['Plasmaferese']	['Plasmapheresis']
A Hemodialysis Patient with Severe COVID-19 Pneumonia	https://www.cureus.com/articles/31511-a-hemodialysis-patient-with-severe-covid-19-pneumonia	06/05/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/31511-a-hemodialysis-patient-with-severe-covid-19-pneumonia	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Meropenem', 'Oseltamivir', 'Ribavirina', 'Ritonavir', 'Vancomicina']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Meropenem', 'Oseltamivir', 'Ribavirin', 'Ritonavir', 'Vancomycin']
Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units	https://doi.org/10.1001/jamapediatrics.2020.1948	11/05/2020	Artigo completo publicado em periódico científico	10.1001/jamapediatrics.2020.1948	2168-6203	21686203	JAMA PEDIATRICS (PRINT)	A1	3.450	196	5.81	-	['Azitromicina', 'Hidroxicloroquina', 'Plasma convalescente', 'Remdesivir', 'Tocilizumabe']	['Azithromycin', 'Hydroxychloroquine', 'Convalescent Plasma', 'Remdesivir', 'Tocilizumab']
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study	https://www.eymj.org/DOIx.php?id=10.3349/ymj.2020.61.5.431	24/04/2020	Artigo completo publicado em periódico científico	https://www.eymj.org/DOIx.php?id=10.3349/ymj.2020.61.5.431	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
COVID-19 cases are less prevalent in countries where malaria is endemic, suggesting a role for anti-malarial drugs as prophylaxis	https://www.eyereports.org/index.php/eyereports/article/view/100	13/05/2020	Artigo completo publicado em periódico científico	https://www.eyereports.org/index.php/eyereports/article/view/100	-	-	-	-	-	-	-	-	['Antimaláricos', 'Antimaláricos']	['Antimalarials', 'Antimalarials']
Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study	https://pubmed.ncbi.nlm.nih.gov/32391519/	08/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32391519/	-	-	-	-	-	-	-	-	['Anticoagulantes', 'Esteroides', 'Hidroxicloroquina', 'Plasma convalescente', 'Remdesivir']	['Anticoagulants', 'Ssteroids', 'Hydroxychloroquine', 'Convalescent Plasma', 'Remdesivir']
Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature	https://www.frontiersin.org/articles/10.3389/fmed.2020.00170/full	24/04/2020	Artigo completo publicado em periódico científico	10.3389/fmed.2020.00170/full	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids', 'Corticosteroids']
COVID-19 and diabetes mellitus: An unholy interaction of two pandemics	https://www.sciencedirect.com/science/article/pii/S1871402120301144	06/05/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1871402120301144	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Cobicistato', 'Corticosteroides', 'Darunavir', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Chloroquine', 'Cobicistat', 'Corticosteroids', 'Darunavir', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
A comparison analysis on Remdesivir, Favipiravir, Hydroxychloroquine, Chloroquine and Azithromycin in the treatment of corona virus disease 2019 (Covid-19) - A Review	https://www.researchgate.net/publication/341070360_A_COMPARISON_ANALYSIS_ON_REMDESIVIR_FAVIPIRAVIR_HYDROXYCHLOROQUINE_CHLOROQUINE_AND_AZITHROMYCIN_IN_THE_TREATMENT_OF_CORONA_VIRUS_DISEASE_2019_COVID-19_-A_REVIEW	12/05/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/341070360_A_COMPARISON_ANALYSIS_ON_REMDESIVIR_FAVIPIRAVIR_HYDROXYCHLOROQUINE_CHLOROQUINE_AND_AZITHROMYCIN_IN_THE_TREATMENT_OF_CORONA_VIRUS_DISEASE_2019_COVID-19_-A_REVIEW	-	-	-	-	-	-	-	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Remdesivir', 'Remdesivir', 'Remdesivir']
Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19	https://www.researchgate.net/publication/341101811_Adverse_Cardiac_Events_Related_to_Hydroxychloroquine_Prophylaxis_and_Treatment_of_COVID-19	12/05/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/341101811_Adverse_Cardiac_Events_Related_to_Hydroxychloroquine_Prophylaxis_and_Treatment_of_COVID-19	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir	https://doi.org/10.5114/ada.2020.95029	08/05/2020	Artigo completo publicado em periódico científico	10.5114/ada.2020.95029	1642-395X	1642395X	Postepy Dermatologii I Alergologii	-	0.450	29	1.6	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach	https://doi.org/10.1016/j.msard.2020.102165	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102165	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Natalizumabe']	['Natalizumab']
Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection.	https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12797	08/04/2020	Artigo completo publicado em periódico científico	10.1111/cts.12797	1752-8054	17528054	Clinical and Translational Science	-	1.162	48	4.64	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State	https://jamanetwork.com/journals/jama/fullarticle/2766117	11/05/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2766117	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients	http://www.ncbi.nlm.nih.gov/pubmed/32387320	06/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32387320	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019	http://www.sciencedirect.com/science/article/pii/S0025619620303153	04/04/2020	Artigo completo publicado em periódico científico	http://www.sciencedirect.com/science/article/pii/S0025619620303153	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19	https://pubmed.ncbi.nlm.nih.gov/32384798/	06/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32384798/	-	-	-	-	-	-	-	-	['Ozonioterapia']	['Ozone Therapy']
COVID-19: treating and managing severe cases	https://doi.org/10.1038/s41422-020-0329-2	29/04/2020	Artigo completo publicado em periódico científico	10.1038/s41422-020-0329-2	1001-0602	10010602	Cell Research	-	7.804	183	20.2	-	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options	https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.15982	07/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15982	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Hidroxicloroquina', 'Imunoglobulina', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Hydroxychloroquine', 'Immunoglobulin', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']
Novel coronavirus 2019 (COVID-19): A case report and review of treatments. Medicine (Baltimore)	https://journals.lww.com/md-journal/Fulltext/2020/05080/Novel_coronavirus_2019__COVID_19___A_case_report.93.aspx	11/05/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/md-journal/Fulltext/2020/05080/Novel_coronavirus_2019__COVID_19___A_case_report.93.aspx	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Azitromicina', 'Hidroxicloroquina', 'Remdesivir', 'Tocilizumabe']	['Ascorbic acid', 'Azithromycin', 'Hydroxychloroquine', 'Remdesivir', 'Tocilizumab']
Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with Novel Coronavirus Disease (COVID-19) Treated with Hydroxychloroquine	https://pubmed.ncbi.nlm.nih.gov/32383430/	07/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32383430/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	https://pubmed.ncbi.nlm.nih.gov/32380315/	04/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32380315/	-	-	-	-	-	-	-	-	['Colchicina', 'Colchicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Colchicine', 'Colchicine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	https://doi.org/10.1016/j.autrev.2020.102568	03/05/2020	Artigo completo publicado em periódico científico	10.1016/j.autrev.2020.102568	1568-9972	15689972	AUTOIMMUNITY REVIEWS	A1	3.168	130	11.48	-	['Tocilizumabe']	['Tocilizumab']
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	07/05/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	-	-	-	-	-	-	-	-	['Anakinra', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Anakinra', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial	http://dx.doi.org/10.1016/S0140-6736(20)31042-4	08/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31042-4	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Interferon beta', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Interferon beta', 'Lopinavir', 'Ribavirin', 'Ritonavir']
Rapid review for the anti-coronavirus effect of remdesivir	https://pubmed.ncbi.nlm.nih.gov/32378648/	11/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32378648/	-	-	-	-	-	-	-	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol	https://journals.sagepub.com/doi/full/10.1177/2048872620922784	06/05/2020	Artigo completo publicado em periódico científico	10.1177/2048872620922784	2048-8726	20488726	European Heart Journal: Acute Cardiovascular Care	-	1.467	40	4.82	 More than 2,000,000 individuals worldwide have had coronavirus 2019 disease infection (COVID-19), yet there is no effective medical therapy. Multiple off-label and investigational drugs, such as chloroquine and hydroxychloroquine, have gained broad interest due to positive pre-clinical data and are currently used for treatment of COVID-19. However, some of these medications have potential cardiac adverse effects. This is important because up to one-third of patients with COVID-19 have cardiac injury, which can further increase the risk of cardiomyopathy and arrhythmias. Adverse effects of chloroquine and hydroxychloroquine on cardiac function and conduction are broad and can be fatal. Both drugs have an anti-arrhythmic property and are proarrhythmic. The American Heart Association has listed chloroquine and hydroxychloroquine as agents which can cause direct myocardial toxicity. Similarly, other investigational drugs such as favipiravir and lopinavir/ritonavir can prolong QT interval and cause Torsade de Pointes. Many antibiotics commonly used for the treatment of patients with COVID-19, for instance azithromycin, can also prolong QT interval. This review summarizes evidenced-based data regarding potential cardiac adverse effects due to off-label and investigational drugs including chloroquine and hydroxychloroquine, antiviral therapy, monoclonal antibodies, as well as common antibiotics used for the treatment of COVID-19. The article focuses on practical points and offers a point-of-care protocol for providers who are taking care of patients with COVID-19 in an inpatient and outpatient setting. The proposed protocol is taking into consideration that resources during the pandemic are limited.	['Azitromicina', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Sarilumabe', 'Tocilizumabe']	['Azithromycin', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Sarilumab', 'Tocilizumab']
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19	https://www.europeanreview.org/article/21038	10/05/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/21038	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
A new era for the therapeutic management of the ongoing COVID-19 pandemic	https://doi.org/10.31925/farmacia.2020.2.1	10/05/2020	Artigo completo publicado em periódico científico	10.31925/farmacia.2020.2.1	0014-8237	00148237	Farmacia	-	0.265	27	1.27	-	['Baricitinibe', 'Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Metformina', 'Plasma convalescente', 'Remdesivir', 'Tocilizumabe']	['Baricitinib', 'Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Metformin', 'Convalescent Plasma', 'Remdesivir', 'Tocilizumab']
Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight	https://pubmed.ncbi.nlm.nih.gov/32362051/	02/05/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32362051/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Tocilizumab for the Treatment of Severe COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25964	05/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25964	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/nejmoa2012410	07/05/2020	Artigo completo publicado em periódico científico	10.1056/nejmoa2012410	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.	https://www.nature.com/articles/s41375-020-0848-3	05/05/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41375-020-0848-3	-	-	-	-	-	-	-	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2	https://doi.org/10.1111/bph.15092	05/05/2020	Artigo completo publicado em periódico científico	10.1111/bph.15092	0007-1188	00071188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Antagonistas do Receptor da Angiotensina II', 'Camostato', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Medicina Tradicional Chinesa', 'Meplazumabe', 'Metuximabe', 'Metuzumabe', 'Plasma convalescente', 'Proteína spike', 'Ribavirina', 'Ritonavir', 'Soro convalescente', 'Tocilizumabe', 'Vacina']	['Angiotensin II Receptor Antagonists', 'Camostat', 'Transmembrane Serine Protease Inhibitor 2 (TMPRSS2)', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir', 'Traditional Chinese Medicine', 'Meplazumab', 'Metuximab', 'Metuzumab', 'Convalescent plasma', 'Spike protein', 'Ribavirin', 'Ritonavir', 'Convalescent serum', 'Tocilizumab', 'Vaccine']
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061cases in Marseille, France	https://doi.org/10.1016/j.tmaid.2020.101738	05/05/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101738	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report	https://academic.oup.com/qjmed/article/doi/10.1093/qjmed/hcaa153/5828942	04/05/2020	Artigo completo publicado em periódico científico	10.1093/qjmed/hcaa153/5828942	-	-	-	-	-	-	-	-	['Cloroquina', 'Tocilizumabe']	['Chloroquine', 'Tocilizumab']
Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases	https://www.sciencedirect.com/science/article/pii/S1341321X20301318	16/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1341321X20301318	-	-	-	-	-	-	-	-	['Ciclesonida']	['Cyclesonide']
Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for Coronavirus Disease 2019 (COVID-19)	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765695	05/05/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765695	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Cytokine storm intervention in the early stages of COVID-19 pneumonia	https://www.sciencedirect.com/science/article/pii/S1359610120300484	25/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1359610120300484	-	-	-	-	-	-	-	-	['Anticorpos', 'Corticosteroides', 'Imunoterapia', 'Interferon']	['Antibodies', 'Corticosteroids', 'Immunotherapy', 'Interferon']
Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic	https://www.sciencedirect.com/science/article/pii/S0887796320300250	23/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0887796320300250	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19	https://academic.oup.com/ofid/article/7/4/ofaa130/5820538	15/04/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/ofid/article/7/4/ofaa130/5820538	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']
Candidate drugs against SARS-CoV-2 and COVID-19	https://pubmed.ncbi.nlm.nih.gov/32360480/	29/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32360480/	-	-	-	-	-	-	-	-	['Camostato', 'Camostato', 'Cefarantina', 'Cefarantina', 'Cloridrato de mefloquina', 'Cloridrato de mefloquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da protease SARS-CoV-2 Mpro (3Clpro)', 'Inibidores da protease SARS-CoV-2 Mpro (3Clpro)', 'Lopinavir', 'Lopinavir', 'Nafamostato', 'Nafamostato', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Selamectina', 'Selamectina', 'Umifenovir', 'Umifenovir']	['Camostat', 'Camostat', 'Cepharantine', 'Cepharantine', 'Mefloquine hydrochloride', 'Mefloquine hydrochloride', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'SARS-CoV-2 Protease Inhibitors Mpro (3Clpro)', 'Protease Inhibitors SARS-CoV-2 Mpro (3Clpro)', 'Lopinavir', 'Lopinavir', 'Nafamostat', 'Nafamostat', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Selamectin', 'Selamectin' , 'Umifenovir', 'Umifenovir']
Quadruple therapy for asymptomatic COVID-19 infection patients	http://www.ncbi.nlm.nih.gov/pubmed/32362193	03/05/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32362193	-	-	-	-	-	-	-	-	['Interferon alfa', 'Lianhua Qingwen (Medicina Tradicional Chinesa)', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lianhua Qingwen (Traditional Chinese Medicine)', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again	https://www.magonlinelibrary.com/doi/full/10.12968/hmed.2020.0156	05/05/2020	Artigo completo publicado em periódico científico	10.12968/hmed.2020.0156	1750-8460	17508460	British journal of hospital medicine (London, England : 2005)	-	0.227	29	0.65	-	['Interferon alfa', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ribavirin', 'Ritonavir']
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101	https://www.sciencedirect.com/science/article/pii/S1521661620303314	29/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1521661620303314	-	-	-	-	-	-	-	-	['AMY-101 - inibidor do complemento C3']	['AMY-101 - C3 complement inhibitor']
Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial	https://www.cell.com/pb-assets/products/coronavirus/MEDJ1.pdf	30/04/2020	Artigo completo publicado em periódico científico	https://www.cell.com/pb-assets/products/coronavirus/MEDJ1.pdf	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir', 'Umifenovir']	['Lopinavir', 'Ritonavir', 'Umifenovir']
Evidence for Use or Disuse of Renin–Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder	https://journals.sagepub.com/doi/10.1177/1074248420921720	30/04/2020	Artigo completo publicado em periódico científico	10.1177/1074248420921720	1074-2484	10742484	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS	A2	0.685	52	2.63	  Coronavirus disease 19 (COVID-19) originated in Wuhan, China, in December 2019 has been declared pandemic by World Health Organization due to an exponential rise in the number of infected and deceased persons across the globe. Emerging reports suggest that susceptibility and mortality rates are higher in patients with certain comorbidities when compared to the average population. Cardiovascular diseases and diabetes are important risk factors for a lethal outcome of COVID-19. Extensive research ensuing the outbreak of coronavirus-related severe acute respiratory syndrome in the year 2003, and COVID-19 recently revealed a role of renin–angiotensin system (RAS) components in the entry of coronavirus wherein angiotensin-converting enzyme 2 (ACE2) had garnered the significant attention. This raises the question whether the use of RAS inhibitors, the backbone of treatment of cardiovascular, neurovascular, and kidney diseases could increase the susceptibility for coronavirus infection or unfortunate outcomes of COVID-19. Thus, currently, there is a lack of consensus regarding the effects of RAS inhibitors in such patients. Moreover, expert bodies like American Heart Association, American College of Cardiology, and so on have now released official statements that RAS inhibitors must be continued, unless suggested otherwise by a physician. In this brief review, we will elaborate on the role of RAS and ACE2 in pathogenesis of COVID-19. Moreover, we will discuss the potential effect of the use and disuse of RAS inhibitors in patients having COVID-19 with cardiometabolic comorbidities. 	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Rethinking the role of hydroxychloroquine in the treatment of COVID-19	https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202000919	29/04/2020	Artigo completo publicado em periódico científico	10.1096/fj.202000919	0892-6638	08926638	THE FASEB JOURNAL	A1	1.385	287	5.11	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?	https://www.researchgate.net/publication/340879850_Efetividade_e_toxicidade_da_cloroquina_e_da_hidroxicloroquina_associada_ou_nao_a_azitromicina_para_tratamento_da_COVID-19_O_que_sabemos_ate_o_momento	04/05/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/340879850_Efetividade_e_toxicidade_da_cloroquina_e_da_hidroxicloroquina_associada_ou_nao_a_azitromicina_para_tratamento_da_COVID-19_O_que_sabemos_ate_o_momento	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19	https://www.mdpi.com/1999-4915/12/5/486	26/04/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1999-4915/12/5/486	-	-	-	-	-	-	-	-	['Vesículas extracelulares contendo inibidores de protease']	['Extracellular vesicles containing protease inhibitors']
COVID-19: Immunology and treatment options	https://doi.org/10.1016/j.clim.2020.108448	27/04/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108448	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Azitromicina', 'Corticosteroides', 'Enzima Conversora de Angiotensina 2 recombinante', 'Hidroxicloroquina', 'Imunoglobulina', 'Inibidores de Janus Kinase (JAK)', 'Interferon recombinante tipo 1', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Corticosteroids', 'Recombinant Angiotensin 2 Converting Enzyme', 'Hydroxychloroquine', 'Immunoglobulin', 'Janus Kinase (JAK) Inhibitors', 'Recombinant Interferon Type 1', 'Lopinavir', 'Convalescent Plasma ', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
COVID-19: Therapeutics and Their Toxicities	https://doi.org/10.1007/s13181-020-00777-5	30/04/2020	Artigo completo publicado em periódico científico	10.1007/s13181-020-00777-5	1556-9039	15569039	Journal of Medical Toxicology	-	0.535	52	2.12	-	['Azitromicina', 'Cloroquina', 'Enzima Conversora de Angiotensina 2 recombinante', 'Favipiravir', 'Hidroxicloroquina', 'Leronlimab', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir']	['Azithromycin', 'Chloroquine', 'Recombinant Angiotensin 2 Converting Enzyme', 'Favipiravir', 'Hydroxychloroquine', 'Leronlimab', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir']
Convalescent plasma: possible therapy for novel coronavirus disease 2019	https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15797	02/05/2020	Artigo completo publicado em periódico científico	10.1111/trf.15797	0041-1132	00411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']
A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine	https://www.cureus.com/articles/29732-a-coronavirus-disease-2019-covid-19-patient-with-multifocal-pneumonia-treated-with-hydroxychloroquine	30/03/2020	Artigo completo publicado em periódico científico	https://www.cureus.com/articles/29732-a-coronavirus-disease-2019-covid-19-patient-with-multifocal-pneumonia-treated-with-hydroxychloroquine	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2007621	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007621	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2006923	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2006923	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effective treatment of severe COVID-19 patients with tocilizumab	https://www.pnas.org/content/117/20/10970	29/04/2020	Artigo completo publicado em periódico científico	https://www.pnas.org/content/117/20/10970	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19	https://doi.org/10.1056/NEJMoa2008975	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2008975	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonista de β-adrenérgico', 'Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Diuréticos', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['β-Adrenergic Antagonist', 'Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Diuretics', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Chloroquine-induced QTc prolongation in COVID-19 patients	https://doi.org/10.1007/s12471-020-01429-7	29/04/2020	Artigo completo publicado em periódico científico	10.1007/s12471-020-01429-7	1568-5888	15685888	Netherlands Heart Journal	-	0.753	38	1.55	 Abstract  Background In the battle against the SARS-CoV‑2 pandemic, chloroquine has emerged as a new potential therapeutic option for the treatment of infected patients. A safety consideration for the application of chloroquine is its QTc-prolonging potential. Thus far, no data are available on the QTc-prolonging potential of chloroquine in COVID-19 patients.  Objective To assess the degree of chloroquine-induced QTc prolongation in hospitalised COVID-19 patients.  Methods A baseline electrocardiogram (ECG) and ECGs recorded during chloroquine treatment were retrospectively collected in patients suspected of having COVID-19. The QTc interval was calculated by computerised and manual interpretation. Baseline and follow-up QTc intervals were compared using the paired samples  t-test.  Results A total of 95 patients had a baseline ECG recording and at least one ECG recording during chloroquine therapy. Chloroquine treatment resulted in a mean QTc prolongation of 35 ms (95% CI 28–43 ms) using computerised interpretation and 34 ms (95% CI 25–43 ms) using manual interpretation. No torsade de pointes was observed during chloroquine treatment. After manual review, 22 patients (23%) had a QTc interval exceeding 500 ms during chloroquine treatment. None of these patients had a prolonged QTc interval prior to the initiation of chloroquine treatment.  Conclusions Chloroquine significantly prolongs the QTc interval in a clinically relevant matter. This highlights the need for ECG monitoring when prescribing chloroquine to COVID-19 patients.	['Cloroquina']	['Chloroquine']
Convalescent plasma transfusion for the treatment of COVID-19: Systematic review	https://doi.org/10.1002/jmv.25961	01/05/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25961	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1111/acem.14005	02/05/2020	Artigo completo publicado em periódico científico	10.1111/acem.14005	1069-6563	10696563	ACADEMIC EMERGENCY MEDICINE	A1	1.374	130	3.05	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review	https://doi.org/10.1016/j.jcv.2020.104380	21/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jcv.2020.104380	1386-6532	13866532	JOURNAL OF CLINICAL VIROLOGY	A3	3.355	114	10.59	-	['Tocilizumabe']	['Tocilizumab']
Coronavirus Infections in Children Including COVID-19	https://journals.lww.com/pidj/fulltext/2020/05000/coronavirus_infections_in_children_including.1.aspx	03/05/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/pidj/fulltext/2020/05000/coronavirus_infections_in_children_including.1.aspx	-	-	-	-	-	-	-	-	['Anticorpos', 'Cloroquina', 'Corticosteroides', 'Imunoglobulina', 'Inibidores da síntese de RNA', 'Inibidores de protease', 'Interferon alfa', 'Lopinavir', 'Ritonavir']	['Antibodies', 'Chloroquine', 'Corticosteroids', 'Immunoglobulin', 'RNA synthesis inhibitors', 'Protease inhibitors', 'Interferon alpha', 'Lopinavir', 'Ritonavir']
The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis of patients in advanced disease state: A review	https://doi.org/10.1016/j.medidd.2020.100033	04/04/2020	Artigo completo publicado em periódico científico	10.1016/j.medidd.2020.100033	2590-0986	25900986	Medicine in Drug Discovery	-	0.306	5	3.33	-	['Resiniferatoxina']	['Resiniferatoxin']
Treatment for emerging viruses: Convalescent plasma and COVID-19	https://doi.org/10.1016/j.transci.2020.102790	20/04/2020	Artigo completo publicado em periódico científico	10.1016/j.transci.2020.102790	1473-0502	14730502	TRANSFUSION AND APHERESIS SCIENCE	B1	0.583	57	1.86	-	['Plasma convalescente']	['Convalescent Plasma']
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMsr2005760	23/04/2020	Artigo completo publicado em periódico científico	10.1056/NEJMsr2005760	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']
Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report	https://www.sciencedirect.com/science/article/pii/S2214250920300706	20/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2214250920300706	-	-	-	-	-	-	-	-	['Azitromicina', 'Ceftriaxona', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Ceftriaxone', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study	https://doi.org/10.1161/HYPERTENSIONAHA.120.15143	01/05/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15143	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             With the capability of inducing elevated expression of ACE2 (angiotensin-converting enzyme 2), the cellular receptor for severe acute respiratory syndrome coronavirus 2, angiotensin II receptor blockers (ARBs) or ACE inhibitors treatment may have a controversial role in both facilitating virus infection and reducing pathogenic inflammation. We aimed to evaluate the effects of ARBs/ACE inhibitors on coronavirus disease 2019 (COVID-19) in a retrospective, single-center study. One hundred twenty-six patients with COVID-19 and preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine in Wuhan from January 5 to February 22, 2020, were retrospectively allocated to ARBs/ACE inhibitors group (n=43) and non-ARBs/ACE inhibitors group (n=83) according to their antihypertensive medication. One hundred twenty-five age- and sex-matched patients with COVID-19 without hypertension were randomly selected as nonhypertension controls. In addition, the medication history of 1942 patients with hypertension that were admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from November 1 to December 31, 2019, before the COVID-19 outbreak were also reviewed for external comparison. Epidemiological, demographic, clinical, and laboratory data were collected, analyzed, and compared between these groups. The frequency of ARBs/ACE inhibitors usage in patients with hypertension with or without COVID-19 were comparable. Among patients with COVID-19 and hypertension, those received either ARBs/ACE inhibitors or non-ARBs/ACE inhibitors had comparable blood pressure. However, ARBs/ACE inhibitors group had significantly lower concentrations of hs-CRP (high-sensitivity C-reactive protein;             P            =0.049) and PCT (procalcitonin,             P            =0.008). Furthermore, a lower proportion of critical patients (9.3% versus 22.9%;             P            =0.061) and a lower death rate (4.7% versus 13.3%;             P            =0.216) were observed in ARBs/ACE inhibitors group than non-ARBs/ACE inhibitors group, although these differences failed to reach statistical significance. Our findings thus support the use of ARBs/ACE inhibitors in patients with COVID-19 and preexisting hypertension.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients	https://doi.org/10.1093/infdis/jiaa228	29/04/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa228	0022-1899	00221899	THE JOURNAL OF INFECTIOUS DISEASES	A1	2.509	261	5.29	 Abstract                Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.	['Plasma convalescente']	['Convalescent Plasma']
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study	https://doi.org/10.1016/j.eng.2020.03.007	18/03/2020	Artigo completo publicado em periódico científico	10.1016/j.eng.2020.03.007	2095-8099	20958099	Engineering	-	1.614	59	10.19	-	['Favipiravir']	['Favipiravir']
Will the antimalarial drug take over to combat COVID-19?	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189021/	29/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7189021/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina', 'Remdesivir']	['Chloroquine', 'Hydroxychloroquine', 'Remdesivir']
Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19	https://www.nature.com/articles/s41440-020-0455-8	27/04/2020	Artigo completo publicado em periódico científico	https://www.nature.com/articles/s41440-020-0455-8	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?	https://www.researchgate.net/publication/340178205_Can_early_and_high_intravenous_dose_of_vitamin_C_prevent_and_treat_coronavirus_disease_2019_COVID-19	05/03/2020	Artigo completo publicado em periódico científico	https://www.researchgate.net/publication/340178205_Can_early_and_high_intravenous_dose_of_vitamin_C_prevent_and_treat_coronavirus_disease_2019_COVID-19	-	-	-	-	-	-	-	-	['Ácido ascórbico']	['Ascorbic acid']
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development	https://doi.org/10.1016/j.ebiom.2020.102768	26/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ebiom.2020.102768	2352-3964	23523964	EBIOMEDICINE	A1	2.663	79	7.76	-	['Plasma convalescente', 'Vacina']	['Convalescent Plasma', 'Vaccine']
Darunavir does not prevent SARS-CoV-2 infection in HIV patients	https://pubmed.ncbi.nlm.nih.gov/32325127/	20/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32325127/	-	-	-	-	-	-	-	-	['Darunavir']	['Darunavir']
Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report	https://doi.org/10.1016/j.chest.2020.04.0244	25/04/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.04.0244	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis	https://www.sciencedirect.com/science/article/pii/S221425092030086X	27/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S221425092030086X	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study	https://doi.org/10.1016/j.cmi.2020.04.026	25/04/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.04.026	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Umifenovir']	['Umifenovir']
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext	29/04/2020	Artigo completo publicado em periódico científico	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32299202	29/04/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32299202	-	-	-	-	-	-	-	-	['Anakinra', 'Anakinra', 'Anti-inflamatórios não esteroidais', 'Anti-inflamatórios não esteroidais', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Imunoglobulina', 'Imunoglobulina', 'Inibidores de Janus Kinase (JAK)', 'Inibidores de Janus Kinase (JAK)', 'Mavrilimumabe', 'Mavrilimumabe', 'Micofenolato de mofetila', 'Micofenolato de mofetila', 'Tocilizumabe', 'Tocilizumabe']	['Anakinra', 'Anakinra', 'Non-steroidal anti-inflammatory drugs', 'Non-steroidal anti-inflammatory drugs', 'Chloroquine', 'Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Immunoglobulin', 'Immunoglobulin', 'Janus Kinase (JAK) Inhibitors', 'Janus Kinase (JAK) Inhibitors', 'Mavrilimumab', 'Mavrilimumab', 'Mycophenolate mofetil', 'Mycophenolate mofetil', 'Tocilizumab' , 'Tocilizumab']
Pharmacotherapy in COVID-19; A narrative review for emergency providers	https://www.sciencedirect.com/science/article/pii/S0735675720302631	15/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0735675720302631	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Azitromicina', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Ibuprofeno', 'Indometacina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sarilumabe', 'Tocilizumabe']	['Angiotensin II Receptor Antagonists', 'Azithromycin', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Ibuprofen', 'Indomethacin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir ', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sarilumab', 'Tocilizumab']
COVID-19: An update on diagnostic and therapeutic approaches	https://pubmed.ncbi.nlm.nih.gov/32336317/	29/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32336317/	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Plasma convalescente']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Convalescent Plasma', 'Convalescent Plasma']
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status	https://www.sciencedirect.com/science/article/pii/S1567134820301581	19/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1567134820301581	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Darunavir', 'Darunavir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Ivermectina', 'Ivermectina', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Darunavir', 'Darunavir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Ivermectin', 'Ivermectin', 'Lopinavir', 'Lopinavir', ' Convalescent plasma', 'Convalescent plasma', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab']
Treatment of SARS-CoV-2: How far have we reached?	https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_2020.03008/_article	21/04/2020	Artigo completo publicado em periódico científico	https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_2020.03008/_article	-	-	-	-	-	-	-	-	['Cloroquina', 'Darunavir', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Sarilumabe', 'Umifenovir']	['Chloroquine', 'Darunavir', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Sarilumab', 'Umifenovir']
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs	https://pubmed.ncbi.nlm.nih.gov/32314010/	20/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32314010/	-	-	-	-	-	-	-	-	['Famotidina', 'Hidroxicloroquina', 'Leflunomida', 'Lopinavir', 'Meloxicam', 'Prednisona', 'Ritonavir']	['Famotidine', 'Hydroxychloroquine', 'Leflunomide', 'Lopinavir', 'Meloxicam', 'Prednisone', 'Ritonavir']
Two distinct cases with COVID-19 in kidney transplant recipients	https://doi.org/10.1111/ajt.15947	26/04/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15947	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia	https://doi.org/10.1007/s40261-020-00917-3	26/04/2020	Artigo completo publicado em periódico científico	10.1007/s40261-020-00917-3	1173-2563	11732563	CLINICAL DRUG INVESTIGATION	A4	0.718	60	2.86	-	['Tocilizumabe']	['Tocilizumab']
Combating Devastating COVID -19 by Drug Repurposing	https://doi.org/10.1016/j.ijantimicag.2020.105984	20/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105984	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19	https://www.sciencedirect.com/science/article/pii/S0924857920301539	23/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0924857920301539	-	-	-	-	-	-	-	-	['Glicirrizina']	['Glycyrrhizin']
Update on treatment of COVID-19: ongoing studies between promising and disappointing results	https://pubmed.ncbi.nlm.nih.gov/32335561/	22/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32335561/	-	-	-	-	-	-	-	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Imunoglobulina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Immunoglobulin', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir', 'Tocilizumab']
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality	https://pubmed.ncbi.nlm.nih.gov/32234467/	29/03/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32234467/	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Current status of potential therapeutic candidates for the COVID-19 crisis	https://www.sciencedirect.com/science/article/pii/S0889159120305894	22/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0889159120305894	-	-	-	-	-	-	-	-	['Ácido ascórbico', 'Ácido ascórbico', 'Anti-inflamatórios não esteroidais', 'Anti-inflamatórios não esteroidais', 'Anticoagulantes', 'Anticoagulantes', 'Anticorpos', 'Anticorpos', 'Azitromicina', 'Azitromicina', 'Baricitinibe', 'Baricitinibe', 'Cloroquina', 'Cloroquina', 'Corticosteroides', 'Corticosteroides', 'Favipiravir', 'Favipiravir', 'Gamaglobulina', 'Gamaglobulina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Molnupiravir', 'Molnupiravir', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Sarilumabe', 'Sarilumabe', 'Terapia celular', 'Terapia celular', 'Tocilizumabe', 'Tocilizumabe', 'Vacina', 'Vacina', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Zinco', 'Zinco']	['Ascorbic acid', 'Ascorbic acid', 'Non-steroidal anti-inflammatory drugs', 'Non-steroidal anti-inflammatory drugs', 'Anticoagulants', 'Anticoagulants', 'Antibodies', 'Antibodies', 'Azithromycin', 'Azithromycin' , 'Baricitinib', 'Baricitinib', 'Chloroquine', 'Chloroquine', 'Corticosteroids', 'Corticosteroids', 'Favipiravir', 'Favipiravir', 'Gamaglobulin', 'Gamaglobulin', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Molnupiravir', 'Molnupiravir', 'Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', ' Sarilumab', 'Sarilumab', 'Cell therapy', 'Cell therapy', 'Tocilizumab', 'Tocilizumab', 'Vaccine', 'Vaccine', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25- hydroxyvitamin D)', 'Zinc', 'Zinc']
The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment	https://www.mdpi.com/1660-4601/17/7/2323	30/03/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/1660-4601/17/7/2323	-	-	-	-	-	-	-	-	['Carbapenêmicos', 'Carbapenêmicos', 'Carbapenêmicos', 'Cefalosporina', 'Cefalosporina', 'Cefalosporina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Ganciclovir', 'Ganciclovir', 'Ganciclovir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Nafamostato', 'Nafamostato', 'Nafamostato', 'Nitazoxanida', 'Nitazoxanida', 'Nitazoxanida', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Penciclovir', 'Penciclovir', 'Penciclovir', 'Proteínas de fusão', 'Proteínas de fusão', 'Proteínas de fusão', 'Quinolonas', 'Quinolonas', 'Quinolonas', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de RNA']	['Carbapenems', 'Carbapenems', 'Carbapenems', 'Cephalosporin', 'Cephalosporin', 'Cephalosporin', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', ' Ganciclovir', 'Ganciclovir', 'Ganciclovir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Nafamostat', 'Nafamostat', 'Nafamostat', 'Nitazoxanide', 'Nitazoxanide', 'Nitazoxanide', 'Oseltamivir' , 'Oseltamivir', 'Oseltamivir', 'Penciclovir', 'Penciclovir', 'Penciclovir', 'Fusion proteins', 'Fusion proteins', 'Fusion proteins', 'Quinolones', 'Quinolones', 'Quinolones' , 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Cell therapy', 'Cell therapy', 'Cell therapy ', 'RNA vaccine', 'RNA vaccine', 'RNA vaccine']
A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15082	24/04/2020	Artigo completo publicado em periódico científico	10.1111/bph.15082	0007-1188	00071188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
COVID-19: lambda interferon against viral load and hyperinflammation	https://www.embopress.org/doi/10.15252/emmm.202012465	25/04/2020	Artigo completo publicado em periódico científico	10.15252/emmm.202012465	1757-4676	17574676	EMBO MOLECULAR MEDICINE	A1	4.039	119	10.64	-	['Interferon lambda']	['Interferon lambda']
Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin	https://pubmed.ncbi.nlm.nih.gov/32331519/	24/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32331519/	-	-	-	-	-	-	-	-	['Claritromicina', 'Cloroquina']	['Clarithromycin', 'Chloroquine']
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	https://ard.bmj.com/content/79/6/837	27/04/2020	Artigo completo publicado em periódico científico	https://ard.bmj.com/content/79/6/837	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thromobolytic drugs to treat COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14872	23/04/2020	Artigo completo publicado em periódico científico	10.1111/jth.14872	1538-7933	15387933	Journal of Thrombosis and Haemostasis	-	3.815	191	10.86	-	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Current pharmacological treatments for COVID-19: what’s next?	https://doi.org/10.1111/bph.15072	24/04/2020	Artigo completo publicado em periódico científico	10.1111/bph.15072	0007-1188	00071188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Umifenovir']
SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options	https://www.europeanreview.org/article/20871	26/04/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/20871	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Azitromicina', 'Azitromicina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidor de protease vinil sulfona', 'Inibidor de protease vinil sulfona', 'Lopinavir', 'Lopinavir', 'Peptídeo baseado em ECA 2', 'Peptídeo baseado em ECA 2', 'Proteína spike', 'Proteína spike', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Azithromycin', 'Azithromycin', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Vinyl Sulfone Protease Inhibitor' , 'Vinyl sulfone protease inhibitor', 'Lopinavir', 'Lopinavir', 'ACE-based peptide 2', 'ACE-based peptide 2', 'Spike protein', 'Spike protein', 'Remdesivir', 'Remdesivir' , 'Ritonavir', 'Ritonavir']
Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1863	22/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1863	0009-9236	00099236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future	http://www.ijo.in/article.asp?issn=0301-4738;year=2020;volume=68;issue=5;spage=693;epage=702;aulast=Shetty	28/03/2020	Artigo completo publicado em periódico científico	http://www.ijo.in/article.asp?issn=0301-4738;year=2020;volume=68;issue=5;spage=693;epage=702;aulast=Shetty	-	-	-	-	-	-	-	-	['Anakinra', 'Azitromicina', 'Baricitinibe', 'Camostato', 'Corticosteroides', 'Emodina', 'Hidroxicloroquina', 'Imunoglobulina', 'Interferon alfa', 'Interferon beta', 'Lopinavir', 'Medicina Tradicional Indiana', 'Nafamostato', 'Nelfinavir', 'Oseltamivir', 'Plasma convalescente', 'Promazina', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Ruxolitinibe', 'Sofosbuvir', 'Tocilizumabe', 'Upadacitinibe', 'Zanamivir']	['Anakinra', 'Azithromycin', 'Baricitinib', 'Camostat', 'Corticosteroids', 'Emodin', 'Hydroxychloroquine', 'Immunoglobulin', 'Interferon alpha', 'Interferon beta', 'Lopinavir', 'Traditional Medicine Indiana', 'Nafamostat', 'Nelfinavir', 'Oseltamivir', 'Convalescent Plasma', 'Promazine', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Ruxolitinib', 'Sofosbuvir', 'Tocilizumab', 'Upadacitinib ', 'Zanamivir']
The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164894/	17/03/2020	Artigo completo publicado em periódico científico	PMC:PMC7164894/	-	-	-	-	-	-	-	-	['Antagonistas de TNF', 'Anti-inflamatórios não esteroidais', 'Cloroquina', 'Colchicina', 'Corticosteroides', 'Fator estimulador de colônias de granulócitos-monócitos (GM-FEC)', 'Hidroxicloroquina', 'Imunoglobulina', 'Inibidores de Janus Kinase (JAK)', 'Leflunomida', 'Metotrexato', 'Micofenolato de mofetila', 'Tocilizumabe']	['TNF antagonists', 'Non-steroidal anti-inflammatory drugs', 'Chloroquine', 'Colchicine', 'Corticosteroids', 'Granulocyte-monocyte colony-stimulating factor (GM-FEC)', 'Hydroxychloroquine', 'Immunoglobulin' , 'Janus Kinase (JAK) inhibitors', 'Leflunomide', 'Methotrexate', 'Mycophenolate mofetil', 'Tocilizumab']
Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival	https://link.springer.com/article/10.1007/s40588-020-00140-w	20/04/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40588-020-00140-w	2196-5471	21965471	Current Clinical Microbiology Reports	-	0.839	22	3.78	-	['Deferasirox', 'Deferiprona', 'Deferoxamina']	['Deferasirox', 'Deferiprone', 'Deferoxamine']
Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience	https://www.europeanreview.org/article/20875	26/04/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/20875	-	-	-	-	-	-	-	-	['Eculizumabe']	['Eculizumab']
A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report	https://doi.org/10.1016/j.jiac.2020.03.018	18/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jiac.2020.03.018	1341-321X	1341321X	JOURNAL OF INFECTION AND CHEMOTHERAPY	A4	0.588	64	2.23	-	['Lopinavir', 'Oxigenação por membrana extracorpórea (ECMO)', 'Ritonavir']	['Lopinavir', 'Extracorporeal membrane oxygenation (ECMO)', 'Ritonavir']
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049	23/04/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes	https://doi.org/10.1016/S0140-6736(20)30912-0	23/04/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)30912-0	0140-6736	01406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Hidrocortisona']	['Hydrocortisone']
Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1866	23/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1866	0009-9236	00099236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Cloroquina', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Lopinavir', 'Ritonavir', 'Umifenovir']
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients	http://www.ncbi.nlm.nih.gov/pubmed/32320517	26/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32320517	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19	https://www.sciencedirect.com/science/article/pii/S2211383520305529	20/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2211383520305529	-	-	-	-	-	-	-	-	['Dipiridamol']	['Dipyridamole']
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2001282	18/03/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2001282	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0290	26/04/2020	Artigo completo publicado em periódico científico	http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0290	0002-9637	00029637	American Journal of Tropical Medicine and Hygiene	-	1.013	157	2.87	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
COVID-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine	http://www.ncbi.nlm.nih.gov/pubmed/32324331	26/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32324331	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency	https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13432	23/04/2020	Artigo completo publicado em periódico científico	10.1111/ejh.13432	0902-4441	09024441	EUROPEAN JOURNAL OF HAEMATOLOGY	A3	1.057	88	3.2	-	['Hidroxicloroquina']	['Hydroxychloroquine']
A Case of SARS-CoV-2-pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant	http://www.ncbi.nlm.nih.gov/pubmed/32319218	26/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32319218	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166303/	23/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7166303/	-	-	-	-	-	-	-	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']
Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database	https://pubmed.ncbi.nlm.nih.gov/32321905/	26/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32321905/	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499	24/04/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499	-	-	-	-	-	-	-	-	['Cloroquina']	['Chloroquine']
Emerging Therapeutic Strategies for COVID-19 patients	https://pubmed.ncbi.nlm.nih.gov/32309622/	12/03/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32309622/	-	-	-	-	-	-	-	-	['Anticorpos', 'Cloroquina', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Terapia celular', 'Umifenovir', 'Vacina']	['Antibodies', 'Chloroquine', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Cell therapy', 'Umifenovir', 'Vaccine']
Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1710019	21/04/2020	Artigo completo publicado em periódico científico	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1710019	0340-6245	03406245	THROMBOSIS AND HAEMOSTASIS	A1	1.745	195	5.58	 Abstract Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.	['Anticoagulantes', 'Anticoagulantes']	['Anticoagulants', 'Anticoagulants']
Janus Kinase inhibitor baricitinib is not an ideal option for management of COVID-19	https://www.sciencedirect.com/science/article/pii/S0924857920301242	04/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0924857920301242	-	-	-	-	-	-	-	-	['Baricitinibe']	['Baricitinib']
PAK1-blockers: Potential Therapeutics against COVID-19	http://www.ncbi.nlm.nih.gov/pubmed/32313880%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7166201	19/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32313880%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7166201	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina', 'Melatonina', 'Pimenta de Sichuan', 'Própolis', 'Proteínas quinases PKA', 'Triptolide']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin', 'Melatonin', 'Sichuan pepper', 'Propolis', 'PKA protein kinases', 'Triptolide']
COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164888/	17/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7164888/	-	-	-	-	-	-	-	-	['Cloroquina', 'Corticosteroides', 'Favipiravir', 'Hidroxicloroquina', 'Inibidores de interleucina-6', 'Interferon alfa-beta', 'Interferon beta', 'Interferon gama', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sarilumabe', 'Siltuximabe', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Favipiravir', 'Hydroxychloroquine', 'Interleukin-6 inhibitors', 'Interferon alpha-beta', 'Interferon beta', 'Interferon gamma', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sarilumab', 'Siltuximab', 'Tocilizumab']
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?	https://pubmed.ncbi.nlm.nih.gov/32315980/	15/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32315980/	-	-	-	-	-	-	-	-	['Ocrelizumabe']	['Ocrelizumab']
Points to consider in the preparation and transfusion of COVID-19 convalescent plasma	https://onlinelibrary.wiley.com/doi/full/10.1111/vox.12939	22/04/2020	Artigo completo publicado em periódico científico	10.1111/vox.12939	0042-9007	00429007	VOX SANGUINIS (BASEL. 1956)	B1	0.643	86	2.47	-	['Plasma convalescente']	['Convalescent Plasma']
Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19)	https://pubmed.ncbi.nlm.nih.gov/32314698/	17/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32314698/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Therapeutic strategies for critically ill patients with COVID-19	https://doi.org/10.1186/s13613-020-00661-z	20/04/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00661-z	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	 Abstract Since the 2019 novel coronavirus disease (COVID-19) outbreak originated from Wuhan, Hubei Province, China, at the end of 2019, it has become a clinical threat to the general population worldwide. Among people infected with the novel coronavirus (2019-nCoV), the intensive management of the critically ill patients in intensive care unit (ICU) needs substantial medical resource. In the present article, we have summarized the promising drugs, adjunctive agents, respiratory supportive strategies, as well as circulation management, multiple organ function monitoring and appropriate nutritional strategies for the treatment of COVID-19 in the ICU based on the previous experience of treating other viral infections and influenza. These treatments are referable before the vaccine and specific drugs are available for COVID-19.	['Ciclosporina', 'Corticosteroides', 'Favipiravir', 'Gamaglobulina', 'Interferon', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Timosina', 'Tocilizumabe', 'Umifenovir']	['Cyclosporin', 'Corticosteroids', 'Favipiravir', 'Gamaglobulin', 'Interferon', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Thymosin', 'Tocilizumab', 'Umifenovir']
A short review on antibody therapy for COVID-19	https://doi.org/10.1016/j.nmni.2020.100682	20/04/2020	Artigo completo publicado em periódico científico	10.1016/j.nmni.2020.100682	2052-2975	20522975	NEW MICROBES NEW INFECT	B2	0.737	33	3.44	-	['Anticorpos', 'Plasma convalescente']	['Antibodies', 'Convalescent Plasma']
Treatment options for COVID-19: The reality and challenges	https://doi.org/10.1016/j.jmii.2020.03.034	04/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jmii.2020.03.034	1684-1182	16841182	JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION	A4	1.748	63	7.83	-	['Azitromicina', 'Cloroquina', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Prednisona', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Azithromycin', 'Chloroquine', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent Plasma', 'Prednisone', 'Remdesivir', 'Ribavirin', 'Ritonavir']
Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data	https://doi.org/10.1002/ptr.6700	04/04/2020	Artigo completo publicado em periódico científico	10.1002/ptr.6700	0951-418X	0951418X	PTR. PHYTOTHERAPY RESEARCH	A2	1.046	140	7.29	-	['Produtos naturais', 'Produtos naturais', 'Produtos naturais']	['Natural products', 'Natural products', 'Natural products']
Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China	https://cmjournal.biomedcentral.com/articles/10.1186/s13020-020-00317-x	15/04/2020	Artigo completo publicado em periódico científico	https://cmjournal.biomedcentral.com/articles/10.1186/s13020-020-00317-x	1749-8546	17498546	Chinese Medicine	-	0.833	45	5.88	 Abstract  Background A novel coronavirus was identified in December, 2019 in Wuhan, China, and traditional Chinese medicine (TCM) played an active role in combating the novel coronavirus pneumonia (NCP) caused by this fast-spreading virus COVID-19. Thus, we aimed to explore TCM characteristics of clinical efficacy to NCP, as well as to optimize Qingfei Paidu decoction (QFPDD) and the recommended formulas to NCP by National Health Commission (NHC).  Methods Chinese medical sciences theory and clinical application of TCM were analyzed. A total of 54 NCP patients were observed in a hospital from Wuhan, whose clinical characteristics and utilization of Chinese Medicines (CMs) were described. Paired t test was used to measure the change of patients’ hemogram during hospitalization period, indicating the effect of CMs. Multiple linear regression analysis was applied to explore the factors affecting the length of hospital stay. Network pharmacology analysis was applied to figure out the performance of NHC-recommended formulas of five disease stages at levels of compounds, targets and pathways.  Result The average length of hospital stay was 8.96 days. Patients over 45 stayed 9.79 days in hospital in average, longer than 7.64 days of patients under 45. Comparing the hemograms between admission and discharge of hospital, the number of leukocytes, neutrophil, lymphocyte and platelet increased, while the numbers of erythrocytes, hemoglobin concentration and hematocrit decreased. According to the standard coefficients of regression, the factor affecting the length of stay for the most was CMs in category of invigorating spleen and removing dampness (ISRD), followed by administrating CMs, male, and cough. Thirty-two CMs were screened after deleting duplication from QFPDD and NHC-recommended formulas. Compound quercetin, luteolin, kaempferol, acacetin etc., were all involved in the treatment of various disease stages on the compound level both in generality and individuality.  Conclusion TCM has a systemic theoretical understanding on the pathological evolution and a positive clinical efficacy on NCP. The CMs of ISRD improved patients’ recovery, suggesting the importance of regulating intestinal function and keeping microenvironmental balance in TCM treatment of NCP. The active compounds from QFPDD and NHC-recommended formulas contribute to recovery of varied disease progresses during TCM treating NCP.	['Medicina Tradicional Chinesa']	['Traditional Chinese medicine']
Antiviral Therapy in Man-agement of COVID-19: a Systematic Review on Current Evidence	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156260/	06/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7156260/	-	-	-	-	-	-	-	-	[]	[]
Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies	https://doi.org/10.1016/j.ijantimicag.2020.105982	16/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105982	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Hidroxicloroquina', 'Prednisona', 'Tocilizumabe', 'Ulinastatina']	['Chloroquine', 'Hydroxychloroquine', 'Prednisone', 'Tocilizumab', 'Ulinastatin']
American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States	https://doi.org/10.1016/j.bbmt.2020.04.005	16/04/2020	Artigo completo publicado em periódico científico	10.1016/j.bbmt.2020.04.005	1083-8791	10838791	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION	A1	1.397	126	4.17	-	['Cloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Ruxolitinibe', 'Terapia celular', 'Tocilizumabe']	['Chloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Ruxolitinib', 'Cell therapy', 'Tocilizumab']
Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment	http://www.ncbi.nlm.nih.gov/pubmed/32306836	21/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32306836	-	-	-	-	-	-	-	-	['Anticorpos', 'Anticorpos', 'Anticorpos', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Ebselen', 'Ebselen', 'Ebselen', 'Ivermectina', 'Ivermectina', 'Ivermectina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Antibodies', 'Antibodies', 'Antibodies', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Ebselen', 'Ebselen', 'Ebselen', 'Ivermectin', 'Ivermectin', 'Ivermectin', ' Lopinavir', 'Lopinavir', 'Lopinavir', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir']
COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139268/	08/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7139268/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Progress and Prospects on Vaccine Development against SARS-CoV-2	https://www.mdpi.com/2076-393X/8/2/153	29/03/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2076-393X/8/2/153	-	-	-	-	-	-	-	-	['Vacina contra SARS-CoV-2', 'Vacina contra SARS-CoV-2']	['SARS-CoV-2 vaccine', 'SARS-CoV-2 vaccine']
Clinical Implications of SARS-CoV-2 Interaction with Renin Angiotensin System	https://doi.org/10.1016/j.jacc.2020.04.028	09/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jacc.2020.04.028	0735-1097	07351097	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (PRINT)	A1	9.756	451	9.53	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19	https://doi.org/10.1016/j.nmni.2020.100680	14/04/2020	Artigo completo publicado em periódico científico	10.1016/j.nmni.2020.100680	2052-2975	20522975	NEW MICROBES NEW INFECT	B2	0.737	33	3.44	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage	https://pubmed.ncbi.nlm.nih.gov/32251732/	03/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32251732/	-	-	-	-	-	-	-	-	['Amodiaquina', 'Lopinavir', 'Nelfinavir', 'Ritonavir']	['Amodiaquine', 'Lopinavir', 'Nelfinavir', 'Ritonavir']
Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19	https://doi.org/10.1016/j.redar.2020.03.004	14/04/2020	Artigo completo publicado em periódico científico	10.1016/j.redar.2020.03.004	0034-9356	00349356	Revista Espanola de Anestesiologia y Reanimacion	-	0.258	25	0.94	-	['Ácido ascórbico', 'Ozonioterapia']	['Ascorbic acid', 'Ozone therapy']
Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046988	16/04/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.046988	0009-7322	00097322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Antagonista de P2Y12', 'Heparina', 'Ticagrelor']	['P2Y12 antagonist', 'Heparin', 'Ticagrelor']
Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers	http://www.ncbi.nlm.nih.gov/pubmed/32283499%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7144598	09/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32283499%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7144598	-	-	-	-	-	-	-	-	['Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists']
Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19	https://pubmed.ncbi.nlm.nih.gov/32301957/	17/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32301957/	-	-	-	-	-	-	-	-	['Interferon lambda']	['Interferon lambda']
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1857	17/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1857	0009-9236	00099236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Azitromicina']	['Azithromycin']
Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2	https://journals.lww.com/cardiovascularpharm/Fulltext/9000/Cardiovascular_Pharmacology_in_the_Time_of.98409.aspx	19/04/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/cardiovascularpharm/Fulltext/9000/Cardiovascular_Pharmacology_in_the_Time_of.98409.aspx	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32302280	31/03/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32302280	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Remdesivir']	['Chloroquine', 'Hydroxychloroquine', 'Convalescent Plasma', 'Remdesivir']
Antiviral treatment of COVID-19	https://doi.org/10.3906/sag-2004-145	15/04/2020	Artigo completo publicado em periódico científico	10.3906/sag-2004-145	1303-6165	13036165	Turkish Journal of Medical Sciences	-	0.440	32	2.32	-	['Cloroquina', 'Favipiravir', 'Ivermectina', 'Lopinavir', 'Nitazoxanida', 'Remdesivir', 'Ritonavir']	['Chloroquine', 'Favipiravir', 'Ivermectin', 'Lopinavir', 'Nitazoxanide', 'Remdesivir', 'Ritonavir']
A Review of SARS-CoV-2 and the Ongoing Clinical Trials	http://www.ncbi.nlm.nih.gov/pubmed/32290293	10/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32290293	-	-	-	-	-	-	-	-	['Favipiravir', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Favipiravir', 'Hydroxychloroquine', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir', 'Remdesivir', 'Ritonavir']
Coronavirus Disease 2019 (COVID-19) Pneumonia in a Hemodialysis Patient	https://www.sciencedirect.com/science/article/pii/S2590059520300492	12/03/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S2590059520300492	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
The epidemiology and clinical information about COVID-19	https://doi.org/10.1007/s10096-020-03874-z	04/04/2020	Artigo completo publicado em periódico científico	10.1007/s10096-020-03874-z	0934-9723	09349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Cloroquina', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']
COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies	https://doi.org/10.1016/j.jacbts.2020.04.002	10/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jacbts.2020.04.002	2452-302X	2452302X	JACC: Basic to Translational Science	-	2.879	40	5.48	-	['Antagonistas do Receptor da Angiotensina II', 'Anti-inflamatórios', 'Azitromicina', 'Baricitinibe', 'Camostato', 'Cloroquina', 'Corticosteroides', 'Emapalumabe', 'Hidroxicloroquina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores de fusão', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Sinvastatina', 'Tocilizumabe', 'Vacina contra SARS-CoV-2']	['Angiotensin II Receptor Antagonists', 'Anti-inflammatories', 'Azithromycin', 'Baricitinib', 'Camostat', 'Chloroquine', 'Corticosteroids', 'Emapalumab', 'Hydroxychloroquine', 'Inhibitors of the Angiotensin 2 (ACEI 2)', 'Fusion inhibitors', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Simvastatin', 'Tocilizumab', 'SARS-CoV-2 vaccine']
Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection	https://doi.org/10.1016/j.ijantimicag.2020.105974	13/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105974	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Imunoglobulina', 'Plasmaferese']	['Immunoglobulin', 'Plasmapheresis']
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25882	15/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25882	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
Evaluation of Antiviral Therapies for Coronavirus Disease 2019 (COVID-19) Pneumonia in Shanghai, China	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25893	16/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25893	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Darunavir', 'Interferon alfa', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Darunavir', 'Interferon alpha', 'Lopinavir', 'Ritonavir', 'Umifenovir']
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment	https://doi.org/10.1002/jia2.25489	26/03/2020	Artigo completo publicado em periódico científico	10.1002/jia2.25489	1758-2652	17582652	JOURNAL OF THE INTERNATIONAL AIDS SOCIETY	A1	2.162	69	4.42	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Hydroxychloroquine and covid-19	http://www.ncbi.nlm.nih.gov/pubmed/32296259%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7158785	15/04/2020	Artigo completo publicado em periódico científico	http://www.ncbi.nlm.nih.gov/pubmed/32296259%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7158785	-	-	-	-	-	-	-	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']
An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.	https://doi.org/10.1016/j.hrcr.2020.03.016	01/04/2020	Artigo completo publicado em periódico científico	10.1016/j.hrcr.2020.03.016	2214-0271	22140271	HeartRhythm Case Reports	-	0.331	14	0.88	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina', 'Lidocaína']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine', 'Lidocaine']
Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis	https://onlinelibrary.wiley.com/doi/10.1002/jmv.25898	16/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25898	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152693/	13/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7152693/	-	-	-	-	-	-	-	-	['Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options	https://doi.org/10.1093/ofid/ofaa105	04/04/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa105	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Nitazoxanida', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Nitazoxanide', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Tocilizumab']
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?	https://www.sciencedirect.com/science/article/pii/S0896841120300676	10/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0896841120300676	-	-	-	-	-	-	-	-	['Antivirais', 'Corticosteroides', 'Inibidores de interleucina-6', 'Tocilizumabe']	['Antivirals', 'Corticosteroids', 'Interleukin-6 Inhibitors', 'Tocilizumab']
Remdesivir, la esperanza antiviral frente al SARS-CoV-2	https://pubmed.ncbi.nlm.nih.gov/32239125/	01/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32239125/	-	-	-	-	-	-	-	-	['Remdesivir']	['Remdesivir']
Mesenchymal stem cells and management of COVID-19 pneumonia	http://dx.doi.org/10.1016/j.medidd.2020.100019	19/03/2020	Artigo completo publicado em periódico científico	10.1016/j.medidd.2020.100019	2590-0986	25900986	Medicine in Drug Discovery	-	0.306	5	3.33	-	['Terapia celular']	['Cell Therapy']
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study	https://doi.org/10.1016/j.tmaid.2020.101663	11/04/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101663	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Cytokine Storm in COVID-19 and Treatment	https://doi.org/10.1016/j.jinf.2020.03.037	10/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.037	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Anakinra', 'Antagonistas de TNF', 'Cloroquina', 'Corticosteroides', 'Imunoglobulina', 'Inibidores de IFN-αβ', 'Interferon lambda', 'Tocilizumabe', 'Ulinastatina']	['Anakinra', 'TNF Antagonists', 'Chloroquine', 'Corticosteroids', 'Immunoglobulin', 'IFN-αβ Inhibitors', 'Interferon lambda', 'Tocilizumab', 'Ulinastatin']
Can Hepatitis A Vaccine Provide Protection Against COVID-19?	https://pubmed.ncbi.nlm.nih.gov/32279655/	15/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32279655/	-	-	-	-	-	-	-	-	['Vacina Hepatite A']	['Hepatitis A Vaccine']
Mesenchymal Stem Cell Therapy for COVID-19: Present or Future	https://doi.org/10.1007/s12015-020-09973-w	13/04/2020	Artigo completo publicado em periódico científico	10.1007/s12015-020-09973-w	2629-3269	26293269	Stem Cell Reviews and Reports	-	1.078	77	5.92	-	['Terapia celular']	['Cell Therapy']
Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)	https://pubmed.ncbi.nlm.nih.gov/32283223/	10/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32283223/	-	-	-	-	-	-	-	-	['Inibidores da via Rho quinase']	['Rho kinase pathway inhibitors']
Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19	https://www.sciencedirect.com/science/article/pii/S0163445320301882	10/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0163445320301882	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir', 'Umifenovir']	['Lopinavir', 'Ritonavir', 'Umifenovir']
Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19	https://doi.org/10.1016/j.jinf.2020.03.039	14/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.039	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Prednisona']	['Prednisone']
The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis	https://pubmed.ncbi.nlm.nih.gov/32283144/	10/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32283144/	-	-	-	-	-	-	-	-	['Corticosteroides']	['Corticosteroids']
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19	https://doi.org/10.1016/j.jinf.2020.03.044	10/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.044	0163-4453	01634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Imunoglobulina']	['Immunoglobulin']
COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25870	13/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25870	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Plasma convalescente']	['Convalescent Plasma']
Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea	https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e149	13/04/2020	Artigo completo publicado em periódico científico	https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e149	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157945/	12/04/2020	Artigo completo publicado em periódico científico	PMC:PMC7157945/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)	https://jamanetwork.com/journals/jama/fullarticle/2764727	13/04/2020	Artigo completo publicado em periódico científico	https://jamanetwork.com/journals/jama/fullarticle/2764727	-	-	-	-	-	-	-	-	['Cloroquina', 'Corticosteroides', 'Favipiravir', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Favipiravir', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Tocilizumab']
Traditional Chinese medicine for treatment of coronavirus disease 2019: a review.	https://www.tmrjournals.com/tmr/EN/10.12032/TMR20200222165	14/04/2020	Artigo completo publicado em periódico científico	https://www.tmrjournals.com/tmr/EN/10.12032/TMR20200222165	-	-	-	-	-	-	-	-	['Medicina Tradicional Chinesa']	['Traditional Chinese medicine']
Drug repositioning an alternative for the treatment of coronavirus COVID-19	https://doi.org/10.1016/j.ijantimicag.2020.105969	09/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105969	0924-8579	09248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Hidroxicloroquina', 'Metformina', 'Nitazoxanida', 'Remdesivir', 'Teicoplanina', 'Vancomicina']	['Chloroquine', 'Hydroxychloroquine', 'Metformin', 'Nitazoxanide', 'Remdesivir', 'Teicoplanin', 'Vancomycin']
Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.	https://doi.org/10.1002/phar.2403	13/04/2020	Artigo completo publicado em periódico científico	10.1002/phar.2403	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Remdesivir']	['Remdesivir']
The possible of immunotherapy for COVID-19: A systematic review	https://www.sciencedirect.com/science/article/pii/S1567576920309127	14/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S1567576920309127	-	-	-	-	-	-	-	-	['Anticorpos', 'Vacina']	['Antibodies', 'Vaccine']
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32243501	14/04/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32243501	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']
Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab	https://doi.org/10.1016/j.diii.2020.03.010	31/03/2020	Artigo completo publicado em periódico científico	10.1016/j.diii.2020.03.010	2211-5684	22115684	Diagnostic and interventional imaging	-	1.093	43	4.01	-	['Tocilizumabe']	['Tocilizumab']
COVID-19: A promising cure for the global panic	https://www.sciencedirect.com/science/article/pii/S0048969720317903	04/04/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0048969720317903	-	-	-	-	-	-	-	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Interferon alfa', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Medicamentos homeopáticos', 'Medicamentos homeopáticos', 'Medicamentos homeopáticos', 'Medicina Tradicional Indiana', 'Medicina Tradicional Indiana', 'Medicina Tradicional Indiana', 'Naturopatia', 'Naturopatia', 'Naturopatia', 'Oseltamivir', 'Oseltamivir', 'Oseltamivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ribavirina', 'Ribavirina', 'Ribavirina', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Sofosbuvir', 'Sofosbuvir', 'Sofosbuvir']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Interferon alfa', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Lopinavir ', 'Homeopathic Medicines', 'Homeopathic Medicines', 'Homeopathic Medicines', 'Traditional Indian Medicine', 'Traditional Indian Medicine', 'Traditional Indian Medicine', 'Naturopathy', 'Naturopathy', 'Naturopathy', 'Oseltamivir' , 'Oseltamivir', 'Oseltamivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ribavirin', 'Ribavirin', 'Ribavirin', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Sofosbuvir', ' Sofosbuvir', 'Sofosbuvir']
Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats	https://www.mdpi.com/2073-4409/9/4/909	21/03/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2073-4409/9/4/909	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina', 'Ruxolitinibe', 'Tocilizumabe']	['Azithromycin', 'Hydroxychloroquine', 'Ruxolitinib', 'Tocilizumab']
Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society	https://pubmed.ncbi.nlm.nih.gov/32278018/	08/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32278018/	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)	https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.13286	12/04/2020	Artigo completo publicado em periódico científico	10.1111/tid.13286	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Cobicistato', 'Darunavir', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tacrolimus']	['Cobicistat', 'Darunavir', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tacrolimus']
Síntesis rápida: Tratamiento farmacológico de la infección por COVID-19 en adultos (Pharmacological interventions for adults with COVID-19 infection: Rapid Synthesis – Up to date)	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1087643	25/03/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1087643	-	-	-	-	-	-	-	-	['Cloroquina', 'Corticosteroides', 'Ganciclovir', 'Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Oxigenoterapia', 'Plasma convalescente', 'Remdesivir', 'Ressuscitação com fluidoterapia', 'Ritonavir', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Ganciclovir', 'Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Oxygen Therapy', 'Convalescent Plasma', 'Remdesivir', 'Resuscitation with Fluid Therapy', 'Ritonavir', 'Tocilizumab ']
Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience	https://doi.org/10.1016/j.sapharm.2020.03.027	03/04/2020	Artigo completo publicado em periódico científico	10.1016/j.sapharm.2020.03.027	1551-7411	15517411	RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY	A3	0.674	54	2.88	-	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Tocilizumab', 'Umifenovir']
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	https://doi.org/10.1016/j.clim.2020.108409	07/04/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108409	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Zinco', 'Zinco', 'Zinco', 'Zinco', 'Zinco', 'Zinco']	['Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Antibodies', 'Antibodies', 'Antibodies', 'Antibodies', 'Antibodies' , 'Antibodies', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', ' Darunavir', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Herbs with chymotrypsin-like 3 protease inhibitory activity', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin protease inhibitory activity 3' -like 3', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychlor oquina', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Inhibitor of transmembrane serine protease 2 (TMPRSS2)', 'Transmembrane serine protease inhibitor 2 (TMPRSS2)', 'Transmembrane serine protease inhibitor 2 (TMPRSS2)', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', ' Lopinavir', 'Lopinavir', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Promazine', 'Promazine', 'Promazine', ' Promazine', 'Promazine', 'Promazine', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir' , 'Ritonavir', 'Ritonavir', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Viperine', 'Viperine', 'Viperine', 'Viperine', ' Viperina', 'Viperina', 'Vitami in A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)' , 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Zinc', ' Zinc', 'Zinc', 'Zinc', 'Zinc', 'Zinc']
Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?	https://www.europeanreview.org/article/20715	31/03/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/20715	-	-	-	-	-	-	-	-	['Mio-inositol', 'Tocilizumabe']	['Myo-inositol', 'Tocilizumab']
Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report	https://www.europeanreview.org/article/20705	19/01/2020	Artigo completo publicado em periódico científico	https://www.europeanreview.org/article/20705	-	-	-	-	-	-	-	-	['Oxigenação por membrana extracorpórea (ECMO)']	['Extracorporeal membrane oxygenation (ECMO)']
Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25839	08/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25839	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Eritropoetina humana recombinante (rhEPO)']	['Recombinant human erythropoietin (rhEPO)']
Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)	https://onlinelibrary.wiley.com/doi/full/10.5694/mja2.50577	08/04/2020	Artigo completo publicado em periódico científico	10.5694/mja2.50577	0025-729X	0025729X	Medical Journal of Australia	-	1.302	137	2.97	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19	https://doi.org/10.1093/qjmed/hcaa121	10/04/2020	Artigo completo publicado em periódico científico	10.1093/qjmed/hcaa121	1460-2725	14602725	QJM (OXFORD. 1994. PRINT)	A2	0.755	123	2.1	 Abstract                                   Background                   Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin and ‘ground-glass’ opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection.                                                  Aim                   We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19.                                                  Design                   Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen.                                                  Methods                   Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by computed tomography scanning images and patient monitor.                                                  Results                   After plasminogen inhalation, conditions of lung lesions in five clinically moderate patients have quickly improved, shown as the decreased range and density of ‘ground glass’ opacity. Improvements of oxygen saturation were observed in six clinically severe patients. In the two patients with critical conditions, the oxygen levels have significantly increased from 79–82% to 91% just about 1 h after the first inhalation. In 8 of 13 patients, the heart rates had slowed down. For the five clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed.                                                  Conclusion                   Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.               	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']
Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019	https://pubmed.ncbi.nlm.nih.gov/32271456/	24/03/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32271456/	-	-	-	-	-	-	-	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']
Compassionate Use of Remdesivir for Patients with Severe Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2007016	10/04/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007016	0028-4793	00284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome	https://onlinelibrary.wiley.com/doi/full/10.1002/acr2.11135	08/04/2020	Artigo completo publicado em periódico científico	10.1002/acr2.11135	2578-5745	25785745	-	-	-	-	-	-	['Anakinra']	['Anakinra']
Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)	https://doi.org/10.1101/2020.03.22.20040949	27/03/2020	Artigo completo publicado em periódico científico	10.1101/2020.03.22.20040949	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review	https://bjgpopen.org/content/4/2/bjgpopen20X101069/tab-article-info	01/04/2020	Artigo completo publicado em periódico científico	https://bjgpopen.org/content/4/2/bjgpopen20X101069/tab-article-info	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A Quasi-Randomized Comparative Study	https://bibliovid.org/en/clinical-outcomes-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19-a-302	12/04/2020	Artigo completo publicado em periódico científico	https://bibliovid.org/en/clinical-outcomes-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19-a-302	-	-	-	-	-	-	-	-	['Hidroxicloroquina']	['Hydroxychloroquine']
Tratamento precoce de 1061 pacientes COVID-19 com hidroxicloroquina e azitromicina, Marselha, França	https://www.mediterranee-infection.com/pre-prints-ihu/	12/04/2020	Artigo completo publicado em periódico científico	https://www.mediterranee-infection.com/pre-prints-ihu/	-	-	-	-	-	-	-	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses	https://doi.org/10.1016/j.onehlt.2020.100128	27/03/2020	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2020.100128	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Remdesivir']	['Remdesivir']
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?	https://doi.org/10.3332/ecancer.2020.1023	30/03/2020	Artigo completo publicado em periódico científico	10.3332/ecancer.2020.1023	1754-6605	17546605	ECANCER MEDICAL JOURNAL	B1	0.665	37	2.9	-	['Anti-inflamatórios não esteroidais', 'Corticosteroides']	['Non-steroidal anti-inflammatory drugs', 'Corticosteroids']
Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths	https://www.mdpi.com/2072-6643/12/4/988	02/04/2020	Artigo completo publicado em periódico científico	https://www.mdpi.com/2072-6643/12/4/988	-	-	-	-	-	-	-	-	['Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)']
Metronidazole; a Potential Novel Addition to the COVID-19 Regimen	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114714/	30/03/2020	Artigo completo publicado em periódico científico	PMC:PMC7114714/	-	-	-	-	-	-	-	-	['Metronidazol']	['Metronidazole']
Tocilizumab treatment in COVID-19: a single center experience	https://onlinelibrary.wiley.com/doi/10.1002/jmv.25801	06/04/2020	Artigo completo publicado em periódico científico	10.1002/jmv.25801	0146-6615	01466615	JOURNAL OF MEDICAL VIROLOGY (PRINT)	B1	2.656	137	14.76	-	['Tocilizumabe']	['Tocilizumab']
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019	https://pubmed.ncbi.nlm.nih.gov/32258207/	07/03/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32258207/	-	-	-	-	-	-	-	-	['Imunoglobulina']	['Immunoglobulin']
Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32233816	01/04/2020	Artigo completo publicado em periódico científico	https://pesquisa.bvsalud.org/controlecancer/resource/pt/mdl-32233816	-	-	-	-	-	-	-	-	['Amicacina', 'Medidas de suporte', 'Oseltamivir', 'Vancomicina']	['Amicacin', 'Support measures', 'Oseltamivir', 'Vancomycin']
Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia	http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml	13/03/2020	Artigo completo publicado em periódico científico	http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml	-	-	-	-	-	-	-	-	['Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular', 'Terapia celular']	['Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy', 'Cell therapy']
Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence	https://doi.org/10.3332/ecancer.2020.1022	27/03/2020	Artigo completo publicado em periódico científico	10.3332/ecancer.2020.1022	1754-6605	17546605	ECANCER MEDICAL JOURNAL	B1	0.665	37	2.9	-	['Imunossupressores']	['Immunosuppressants']
Deployment of convalescent plasma for the prevention and treatment of COVID-19	https://pubmed.ncbi.nlm.nih.gov/32254064/	07/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32254064/	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Effectiveness of convalescent plasma therapy in severe COVID-19 patients	https://www.pnas.org/content/117/17/9490	06/04/2020	Artigo completo publicado em periódico científico	https://www.pnas.org/content/117/17/9490	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019	https://doi.org/10.1002/phar.2398	07/02/2020	Artigo completo publicado em periódico científico	10.1002/phar.2398	0277-0008	02770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Baricitinibe', 'Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon alfa', 'Lopinavir', 'Nelfinavir', 'Nitazoxanida', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Tocilizumabe']	['Baricitinib', 'Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon alfa', 'Lopinavir', 'Nelfinavir', 'Nitazoxanide', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Tocilizumab' ]
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses	https://www.frontiersin.org/articles/10.3389/fmicb.2020.00298/full	28/02/2020	Artigo completo publicado em periódico científico	10.3389/fmicb.2020.00298/full	-	-	-	-	-	-	-	-	['Vacina']	['Vaccine']
Current Drugs with Potential for Treatment of COVID-19: A Literature Review	https://pubmed.ncbi.nlm.nih.gov/32251618/	08/04/2020	Artigo completo publicado em periódico científico	PUBMED_ID:32251618/	-	-	-	-	-	-	-	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']
Estudo Preliminar de Sintomas e Medicamentos Prevalentes do “Gênio Pandêmico” da Pandemia de Covid-19 no Brasil	https://amhb.org.br/wp-content/uploads/2020/04/Estudo-Preliminar-do-Ge%CC%82nio-Epide%CC%82mico-capa-e-timbre-AMHB.pdf	03/04/2020	Artigo completo publicado em periódico científico	https://amhb.org.br/wp-content/uploads/2020/04/Estudo-Preliminar-do-Ge%CC%82nio-Epide%CC%82mico-capa-e-timbre-AMHB.pdf	-	-	-	-	-	-	-	-	['Medicamentos homeopáticos']	['Homeopathic Medicines']
The potential of low molecular weight heparin to mitigatie cytokine storm in severe covid-19 patients: a retrospective clinical study	https://doi.org/10.1101/2020.03.28.20046144	01/04/2020	Artigo completo publicado em periódico científico	10.1101/2020.03.28.20046144	-	-	-	-	-	-	-	-	['Heparina']	['Heparin']
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations	https://doi.org/10.1016/S2213-2600(20)30161-2	06/04/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30161-2	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', ' Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir' , 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir ', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']
Infuenza and obesity: its odd relationship and the lessons for COVID‑19 pandemic	https://doi.org/10.1007/s00592-020-01522-8	05/04/2020	Artigo completo publicado em periódico científico	10.1007/s00592-020-01522-8	0940-5429	09405429	ACTA DIABETOLOGICA (PRINT)	A2	1.048	73	3.71	-	['Metformina', 'Pioglitazona']	['Metformin', 'Pioglitazone']
Diference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2	https://doi.org/10.1007/s11239-020-02105-8	03/04/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02105-8	0929-5305	09295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Heparina']	['Heparin']
Potential therapeutic agents against COVID-19: What we know so far	https://journals.lww.com/jcma/fulltext/2020/06000/potential_therapeutic_agents_against_covid_19_.8.aspx	04/04/2020	Artigo completo publicado em periódico científico	https://journals.lww.com/jcma/fulltext/2020/06000/potential_therapeutic_agents_against_covid_19_.8.aspx	-	-	-	-	-	-	-	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sarilumabe', 'Tocilizumabe']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sarilumab', 'Tocilizumab']
Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1844	04/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1844	0009-9236	00099236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Favipiravir']	['Favipiravir']
Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how	https://onlinelibrary.wiley.com/doi/full/10.1111/vox.12926	02/04/2020	Artigo completo publicado em periódico científico	10.1111/vox.12926	0042-9007	00429007	VOX SANGUINIS (BASEL. 1956)	B1	0.643	86	2.47	-	['Plasma convalescente']	['Convalescent Plasma']
Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection	https://www.sciencedirect.com/science/article/pii/S0012369220305717	31/03/2020	Artigo completo publicado em periódico científico	https://www.sciencedirect.com/science/article/pii/S0012369220305717	-	-	-	-	-	-	-	-	['Plasma convalescente']	['Convalescent Plasma']
Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, Chin	https://academic.oup.com/cid/article/71/15/748/5814897	13/03/2020	Artigo completo publicado em periódico científico	https://academic.oup.com/cid/article/71/15/748/5814897	-	-	-	-	-	-	-	-	['Carbapenêmicos', 'Cefalosporina', 'Imunoglobulina', 'Lopinavir', 'Oseltamivir', 'Prednisona', 'Quinolonas', 'Umifenovir']	['Carbapenems', 'Cephalosporin', 'Immunoglobulin', 'Lopinavir', 'Oseltamivir', 'Prednisone', 'Quinolones', 'Umifenovir']